{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.13654"}, {"@name": "filename", "#text": "19697_clarissa_cunha_ioc_dout_2017.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "MINIST\u00c9RIO DA SA\u00daDE \nFUNDA\u00c7\u00c3O OSWALDO CRUZ \nINSTITUTO OSWALDO CRUZ \n\n \nDoutorado pelo Programa de P\u00f3s-Gradua\u00e7\u00e3o em Biologia Parasit\u00e1ria \n\n \n \n \n \n \n \n\nPARTICIPA\u00c7\u00c3O DAS POPULA\u00c7\u00d5ES CELULARES CITOT\u00d3XICAS NA \nIMUNOPATOGENIA DA LEISHMANIOSE CUT\u00c2NEA HUMANA \n\nCAUSADA POR Leishmania (V.) braziliensis:  \nAVALIA\u00c7\u00d5ES NA FASE ATIVA DA DOEN\u00c7A, DURANTE E AP\u00d3S A \n\nTERAPIA ANTIMONIAL E EM EPIS\u00d3DIOS DE FALHA TERAP\u00caUTICA. \n  \n \n \n \n \n \n \n\nCLARISSA FERREIRA CUNHA \n \n \n \n \n \n \n \n \n\n \n\n \n \n \n \n \n \n \n \n \n \n\nRio de Janeiro \nJulho de 2017 \n\n\n\nii \n\n \n\n \n\n \n\nINSTITUTO OSWALDO CRUZ \n\nPrograma de P\u00f3s-Gradua\u00e7\u00e3o em Biologia Parasit\u00e1ria \n\n \n \n \n \n \n \n\nCLARISSA FERREIRA CUNHA \n\n \n \n\nPARTICIPA\u00c7\u00c3O DAS POPULA\u00c7\u00d5ES CELULARES CITOT\u00d3XICAS NA \n\nIMUNOPATOGENIA DA LEISHMANIOSE CUT\u00c2NEA HUMANA CAUSADA POR \n\nLeishmania (V.) braziliensis: AVALIA\u00c7\u00d5ES NA FASE ATIVA DA DOEN\u00c7A, \n\nDURANTE E AP\u00d3S A TERAPIA ANTIMONIAL E EM EPIS\u00d3DIOS DE FALHA \n\nTERAP\u00caUTICA. \n\n \n\n \n \n \n \n\nTese apresentada ao Instituto Oswaldo Cruz \n\ncomo parte dos requisitos para obten\u00e7\u00e3o do t\u00edtulo \n\nde Doutor em Ci\u00eancias. \n\n \n \n \n \n\nOrientador (es): Prof. Dr.  \u00c1lvaro Luiz Bertho dos Santos \n \n\nProf. Dra. Alda Maria da Cruz \n \n \n \n \n  \n\nRIO DE JANEIRO \n\nJulho de 2017 \n\n\n\nFERREIRA CUNHA, CLARISSA .\n\nPARTICIPA\u00c7\u00c3O  DAS  POPULA\u00c7\u00d5ES  CELULARES  CITOT\u00d3XICAS  NA\nIMUNOPATOGENIA  DA  LEISHMANIOSE  CUT\u00c2NEA  HUMANA  CAUSADA\nPOR  Leishmania  (V.)  braziliensis  :  AVALIA\u00c7\u00d5ES  NA  FASE  ATIVA  DA\nDOEN\u00c7A, DURANTE E AP\u00d3S A TERAPIA ANTIMONIAL E EM EPIS\u00d3DIOS DE\nFALHA  TERAP\u00caUTICA  /  CLARISSA  FERREIRA  CUNHA.  -  Rio  de  janeiro,\n2017.\n      202 f.\n\nTese (Doutorado) \u2013 Instituto Oswaldo Cruz, P\u00f3s-Gradua\u00e7\u00e3o em Biologia\nParasit\u00e1ria, 2017.\n\nOrientador: ALVARO LUIZ BERTHO DOS SANTOS.\nCo-orientadora: ALDA MARIA DA CRUZ.\n\nBibliografia: f. 108-128\n\n1.  LEISHMANIOSE  TEGUMENTAR.  2.  CITOTOXICIDADE.  3.\nLINFOCITOS.  4.  NK.  5.  NKT.  I.  T\u00edtulo.\n\nElaborada pelo Sistema de Gera\u00e7\u00e3o Autom\u00e1tica de Ficha Catalogr\u00e1fica da Biblioteca de Manguinhos/ICICT com os dados\nfornecidos pelo(a) autor(a).\n\n\n\niv \n\n \n\n \n\nINSTITUTO OSWALDO CRUZ \nPrograma de P\u00f3s-Gradua\u00e7\u00e3o em Biologia Parasit\u00e1ria \n\n \n \n \nCLARISSA FERREIRA CUNHA:  \n\n \n\n  \n\nPARTICIPA\u00c7\u00c3O DAS POPULA\u00c7\u00d5ES CELULARES CITOT\u00d3XICAS NA \n\nIMUNOPATOGENIA DA LEISHMANIOSE CUT\u00c2NEA HUMANA CAUSADA POR  \n\nLeishmania (V.) braziliensis: AVALIA\u00c7\u00d5ES NA FASE ATIVA DA DOEN\u00c7A, \n\nDURANTE E AP\u00d3S A TERAPIA ANTIMONIAL E EM EPIS\u00d3DIOS DE FALHA \n\nTERAP\u00caUTICA. \n\n \n \n\nORIENTADOR (ES): Prof. Dr. \u00c1lvaro Luiz Bertho dos Santos \nProf. Dra. Alda Maria da Cruz \n\n \n\n \n\nAprovada em: _____/_____/_____ \n \n\n \n\n \n\nEXAMINADORES:  \n \n\nDra. K\u00e1tia da Silva Calabrese \u2013 Laborat\u00f3rio de Imunomodula\u00e7\u00e3o e Protozoologia, \nInstituto Oswaldo Cruz/ FIOCRUZ. \nDra. Walderez Ornelas Dutra \u2013 Laborat\u00f3rio de Biologia das Intera\u00e7\u00f5es Celulares, \nInstituto de Ci\u00eancias Biol\u00f3gicas/ UFMG. \nDra. Carmem Beatriz Wagner Giacoia Gripp \u2013 Laborat\u00f3rio de AIDS e Imunologia \nMolecular, Instituto Oswaldo Cruz/ FIOCRUZ. \nDra. Joanna Reis Santos de Oliveira \u2013 Instituto Federal de Educa\u00e7\u00e3o, Ci\u00eancia e \nTecnologia do Rio de Janeiro/ IFRJ. \nDra. Andrea Henriques Pons \u2013 Laborat\u00f3rio de Inova\u00e7\u00f5es em Terapias, Ensino e \nBioprodutos, Instituto Oswaldo Cruz/ FIOCRUZ. \n \n\nRio de Janeiro, 14 de julho de 2017   \n\n\n\nvi \n\n \n\n \n\nAos meus pais, que sempre \nacreditaram em mim e se dedicaram \nna realiza\u00e7\u00e3o dos meus sonhos.  \n\n\n\nvii \n\nAGRADECIMENTOS \n\nAos meus orientadores, que me apoiaram e permitiram que eu chegasse at\u00e9 \n\naqui. Obrigada Dr. \u00c1lvaro, pela oportunidade concedida, por todos os ensinamentos, \n\npela confian\u00e7a, por me ajudar a trilhar uma carreira e ser a base para meu \n\ncrescimento profissional e pessoal. Obrigada Dra. Alda, por todo o apoio e carinho \n\nnestes anos. Muito obrigada! \n\n\u00c0 Raquel Ferraz, amiga que fiz desde o primeiro dia de laborat\u00f3rio. Obrigada \n\npela amizade, pelo companheirismo, pelas li\u00e7\u00f5es, por todos os minutos de trabalho, \n\nde cumplicidade, de tristeza, de frusta\u00e7\u00f5es e alegrias compartilhadas. \n\nAos meus pais, pelo amor e apoio incondicionais. Voc\u00eas s\u00e3o meu ch\u00e3o, meu \n\nporto seguro. Obrigada por sempre acreditarem em mim. Faltam-me palavras para \n\nexpressar a minha eterna gratid\u00e3o. Aos meus irm\u00e3os, Felippe e Clara, pelo amor e \n\npela alegria! Cada passo dado \u00e9 impulsionado por voc\u00eas.   \n\nAo Victor, pelo amor acima de tudo, pela paci\u00eancia e apoio durante todos \n\nesses anos.  \n\n\u00c0 toda a minha gigante e linda fam\u00edlia, pelo zelo de sempre! Em especial ao \n\ntio Z\u00e9, tia Sueli e tia Beta, pessoas maravilhosas sem as quais eu n\u00e3o teria \n\ncompletado esta jornada.  \n\n\u00c0 todos os meus amigos, t\u00e3o fundamentais em toda a minha vida! Obrigada \n\npor estarem presentes mesmo quando distantes. Em especial \u00e0 Marina, por dividir \n\ncomigo a rotina, as horas dif\u00edceis, as noites de estudo e luz acesa e, principalmente, \n\nos dias de sucesso e as felicidades. Em especial tamb\u00e9m aos meus \u201cpresentes de \n\nOswaldo\u201d: obrigada Marcela, Nath\u00e1lia e Carol! Pela amizade di\u00e1ria e por tornarem \n\nestes anos t\u00e3o felizes!   \n\n\u00c0 toda a equipe do LIP! Em especial \u00e0 Dra. L\u00e9a e ao Dr. Josu\u00e9, pelos \n\nensinamentos e carinho; \u00e0 Aline, Virg\u00ednia e Dr. Juan, pela amizade, companheirismo \n\ne por estarem sempre presentes me apoiando. \n\n\u00c0 toda a equipe do VigiLeish e ao Ambulat\u00f3rio do INI, pela preciosa \n\ncolabora\u00e7\u00e3o, em especial ao Dr. Armando Schubach, Dr. Marcelo Rosandisky Lyra, \n\nDra. Maria In\u00eas Pimentel,  Michelle Moreira e Liliane Ant\u00f4nio, pessoas que confiaram \n\nno meu trabalho e estiveram \u00e0 disposi\u00e7\u00e3o para toda a ajuda necess\u00e1ria.  \n\nAos pacientes e aos volunt\u00e1rios que aceitaram participar deste estudo. \n\n\n\nviii \n\n\u00c0 Plataforma Multiusu\u00e1rio de Citometria de Fluxo do IOC, N\u00facleo de \n\nPurifica\u00e7\u00e3o Celular, em especial ao Alessandro Marins e Thaize Quiroga, por \n\ncompartilharem os dias, os trabalhos e os ensinamentos. \u00c0 Plataforma de Citometria \n\nde Fluxo do PDTIS, em especial \u00e0 Dra. \u00cdris Marins Peixoto. \n\n\u00c0 equipe da P\u00f3s-gradua\u00e7\u00e3o em Biologia Parasit\u00e1ria e aos professores que \n\nenriqueceram minha jornada profissional. Em especial \u00e0 Rita, que esteve sempre \n\ndispon\u00edvel e auxiliando nestes anos.  \n\n\u00c0 Funda\u00e7\u00e3o Oswaldo Cruz e ao IOC, este lugar maravilhoso que aumentou \n\nminha alegria em trabalhar e delineou meu crescimento profissional. \n\nAo CNPq pela concess\u00e3o da bolsa de estudos e oportunidade de alcan\u00e7ar \n\neste t\u00e3o sonhado t\u00edtulo. \n\n \n\n \n\n\n\nix \n\n \n\n\u201cA mais importante busca humana \u00e9 esfor\u00e7ar-se pela moralidade em nossa a\u00e7\u00e3o.\n\nNosso equilibrio interno, inclusive da exist\u00eancia, depende disso. Somente a\n\nmoralidade em nossas a\u00e7\u00f5es pode dar beleza e dignidade \u00e0 vida.\u201d\n\nAlbert Einstein\n\n\n\nx \n\n\u00cdNDICE  \n\n1. INTRODU\u00c7\u00c3O 19 \n\n1.1. Aspectos epidemiol\u00f3gicos 19 \n\n1.2. Ciclo de vida do protozo\u00e1rio 24 \n\n1.3. Formas cl\u00ednicas da Leishmaniose Tegumentar Americana 26 \n\n1.3.1. Leishmaniose Cut\u00e2nea Inaparente ou Subcl\u00ednica 26 \n\n1.3.2. Leishmaniose Cut\u00e2nea Localizada (LCL) 26 \n\n1.3.3. Leishmaniose Recidiva C\u00fatis (LRC) 27 \n\n1.3.4. Leishmaniose Disseminada (Ldiss) 27 \n\n1.3.5. Leishmaniose Cut\u00e2nea Difusa (LCD) 28 \n\n1.3.6. Leishmaniose Mucosa (LM) 28 \n\n1.4. Diagn\u00f3stico e tratamento da Leishmaniose Tegumentar Americana 29 \n\n1.5. Imunopatogenia da Leishmaniose Tegumentar Americana 32 \n\n2. JUSTIFICATIVA 44 \n\n3. OBJETIVO GERAL 45 \n\n3.1. Objetivos Espec\u00edficos 45 \n\n4. MATERIAL E M\u00c9TODOS 47 \n\n4.1. Casu\u00edstica 47 \n\n4.2. Coleta do Material Biol\u00f3gico 49 \n\n4.3. Obten\u00e7\u00e3o, Criopreserva\u00e7\u00e3o e Recupera\u00e7\u00e3o das C\u00e9lulas \n\nMononucleares do Sangue Perif\u00e9rico (CMSP) 49 \n\n4.4. Parte 1 \u2013 Ensaios ex vivo 50 \n\n4.4.1. Citometria de Fluxo 52 \n\n4.5. Parte 2 \u2013 Ensaios in vitro 53 \n\n4.5.1. Citometria de Fluxo 55 \n\n4.5.2. Cin\u00e9tica de padroniza\u00e7\u00e3o do tempo de cultivo in vitro 56 \n\n4.5.3. Preparo do ant\u00edgeno particulado de L. (V.) braziliensis (Lb-Ag) 57 \n\n4.6. Parte 3 58 \n\n4.6.1. Experimentos in vitro 58 \n\n4.6.1.1.Express\u00e3o de CLA                                                                               58 \n\n4.6.1.2.Grupo de Pacientes com Falha Terap\u00eautica (FT)\n\n                                                                                                               58 \n\n4.6.2. Quantifica\u00e7\u00e3o de IL-15 59 \n\n\n\nxi \n\n4.7. An\u00e1lise Estat\u00edstica 60 \n\n5. RESULTADOS 61 \n\n5.1. Parte 1 \u2013 Artigo I (Publicado; anexo 2) 61 \n\n5.1.1. Frequencia de linf\u00f3citos T CD8+ e T CD4+, c\u00e9lulas NK e NKT. 61 \n\n5.1.2. Express\u00e3o de CD107a pelos linf\u00f3citos T CD8+ e T CD4+, c\u00e9lulas NK e \n\nNKT.                                                                                                               63 \n\n5.1.3. Densidade de express\u00e3o de CD8. 65 \n\n5.1.4. Densidade de express\u00e3o de CD56. 66 \n\n5.1.5. Subpopula\u00e7\u00f5es de c\u00e9lulas NKT 66 \n\n5.2. Parte 2 \u2013 Artigo II (Submetido; anexo 3) 69 \n\n5.2.1. Caracter\u00edsticas dos pacientes. 69 \n\n5.2.2. Os ant\u00edgenos de L. (V.) braziliensis induzem expans\u00e3o das c\u00e9lulas T \n\nCD8+, NK e CD3+ CD56+ NKT e contra\u00e7\u00e3o de linf\u00f3citos T CD4+ em pacientes \n\nde LC.                                                                                                               69 \n\n5.2.3. A maioria das c\u00e9lulas NKT CD3+CD56+ n\u00e3o expresa TCR invariante. 72 \n\n5.2.4. Os ant\u00edgenos de L. (V.) braziliensis induzem aumento de c\u00e9lulas T \n\nCD4+, NK e NKT CD3+CD56+ ativadas e em degranula\u00e7\u00e3o em todos os \n\ngrupos de pacientes de LC. 73 \n\n5.2.5. Os ant\u00edgenos de L. (V.) braziliensis induzem a exaust\u00e3o de c\u00e9lulas NK \n\nnos pacientes de LC. 76 \n\n5.2.6. Os linf\u00f3citos T CD4+ representam a maior propor\u00e7\u00e3o de c\u00e9lulas que \n\nexpressam os biomarcadores CD107a, CD38 e CD279. 76 \n\n5.3. Parte 3 80 \n\n5.3.1. Express\u00e3o de CLA 80 \n\n5.3.2. Grupo de Pacientes com Falha Terap\u00eautica (FT) 89 \n\n5.3.3. Quantifica\u00e7\u00e3o de IL-15 90 \n\n6. DISCUSS\u00c3O 93 \n\n7. CONCLUS\u00d5ES 107 \n\n8. REFER\u00caNCIAS BIBLIOGR\u00c1FICAS 108 \n\n9. ANEXOS 129 \n\n9.1. ANEXO 1 129 \n\n9.2. ANEXO 2 130 \n\n\n\nxii \n\n9.3. ANEXO 3 142 \n\n9.4. ANEXO 4 178 \n\n9.5. ANEXO 5 191 \n\n \n\n\n\nxiii \n\n\u00cdNDICE DE FIGURAS \n\n \n\nFigura 1: Mapa da endemicidade mundial da Leishmaniose Tegumentar ............... 20 \n\nFigura 2: Densidade de casos de Leishmaniose Tegumentar Americana ............... 21 \n\nFigura 3: Distribui\u00e7\u00e3o dos casos de Leishmaniose Tegumentar por unidade \n\nfederada do territ\u00f3rio brasileiro .................................................................................. 22 \n\nFigura 4: Ciclo de vida de Leishmania spp. .............................................................. 25 \n\nFigura 5. Experimento de cin\u00e9tica ............................................................................ 57 \n\nFigura 6. Protocolo citofluorim\u00e9trico representativo .................................................. 62 \n\nFigura 7. Frequ\u00eancias de linf\u00f3citos T CD8+ , linf\u00f3citos T CD4+ e c\u00e9lulas NK ........... 63 \n\nFigura 8. Express\u00e3o de CD107a pelos linf\u00f3citos T CD8+, linf\u00f3citos T CD4+, c\u00e9lulas \n\nNK e c\u00e9lulas NKT ...................................................................................................... 64 \n\nFigura 9. Distribui\u00e7\u00e3o de linf\u00f3citos T CD8+ e T CD4+, c\u00e9lulas NK e NKT a partir do \n\ngate de c\u00e9lulas CD107a+. .......................................................................................... 65 \n\nFigura 10. An\u00e1lise da frequ\u00eancia e express\u00e3o de CD107a de subpopula\u00e7\u00f5es de \n\nc\u00e9lulas NKT ............................................................................................................... 68 \n\nFigura 11. Protocolo citofluorim\u00e9trico representativo ................................................ 71 \n\nFigura 12. Compara\u00e7\u00e3o entre as c\u00e9lulas estimuladas com ant\u00edgeno de L. (V.) \n\nbraziliensis (Lb-Ag) e n\u00e3o estimuladas (background \u2013 BG) ...................................... 72 \n\nFigura 13. Compara\u00e7\u00e3o da express\u00e3o de CD107a pelas c\u00e9lulas T CD4+, NK e NKT \n\nCD3+CD56+ estimuladas (Lb-Ag) e n\u00e3o estimuladas (BG \u2013 background) ................. 74 \n\nFigura 14. Compara\u00e7\u00e3o entre as culturas estimuladas (Lb-Ag) e n\u00e3o estimuladas \n\n(BG \u2013 background) em rela\u00e7\u00e3o \u00e0 express\u00e3o de CD38 .............................................. 75 \n\nFigura 15. Compara\u00e7\u00e3o da express\u00e3o de CD279 entre as c\u00e9lulas estimuladas (Lb-\n\nAg) e n\u00e3o estimuladas (BG \u2013 background) ............................................................... 78 \n\nFigura 16. Express\u00e3o total de CD107a, CD38 e CD279 .......................................... 79 \n\nFigura 17. Percentual de linf\u00f3citos T CD4+ CLA+ nas culturas n\u00e3o estimuladas (BG: \n\nbackground) e estimuladas com ant\u00edgenos de L. braziliensis (Lb-Ag) ...................... 81 \n\nFigura 18. Percentual de linf\u00f3citos T CD8+ CLA+ nas culturas n\u00e3o estimuladas (BG: \n\nbackground) e estimuladas com ant\u00edgenos de L. braziliensis (Lb-Ag) ...................... 82 \n\n\n\nxiv \n\nFigura 19. Percentual de c\u00e9lulas NK CLA+ nas culturas n\u00e3o estimuladas (BG: \n\nbackground) e estimuladas com ant\u00edgenos de L. braziliensis (Lb-Ag) ...................... 82 \n\nFigura 20. Percentual de c\u00e9lulas NKT CLA+ nas culturas n\u00e3o estimuladas (BG: \n\nbackground) e estimuladas com ant\u00edgenos de L. braziliensis (Lb-Ag) ...................... 83 \n\nFigura 21. Distribui\u00e7\u00e3o das popula\u00e7\u00f5es celulares a partir da express\u00e3o total de CLA \n\nem pacientes com leishmaniose cut\u00e2nea ativa ......................................................... 85 \n\nFigura 22. Distribui\u00e7\u00e3o das popula\u00e7\u00f5es celulares a partir da express\u00e3o total de CLA \n\nem pacientes sob a terapia antimonial ...................................................................... 86 \n\nFigura 23. Distribui\u00e7\u00e3o das popula\u00e7\u00f5es celulares a partir da express\u00e3o total de CLA \n\nem pacientes com cura cl\u00ednica .................................................................................. 87 \n\nFigura 24. Distribui\u00e7\u00e3o das popula\u00e7\u00f5es celulares a partir da express\u00e3o total de CLA \n\nem indiv\u00edduos sadios ................................................................................................. 88 \n\nFigura 25. Avalia\u00e7\u00e3o da express\u00e3o de CD107a espec\u00edfica ao Lb-Ag ....................... 89 \n\nFigura 26. Compara\u00e7\u00e3o da concentra\u00e7\u00e3o de IL-15 no sobrenadante das culturas de \n\nCMSP estimuladas com ant\u00edgenos de L. braziliensis (Lb-Ag) e das culturas n\u00e3o \n\nestimuladas (BG: background) .................................................................................. 91 \n\nFigura 27. Concentra\u00e7\u00e3o de IL-15 no sobrenadante das culturas de CMSP ............ 91 \n\nFigura 28. Concentra\u00e7\u00e3o de IL-15 plasm\u00e1tica .......................................................... 92 \n\nFigura 29. Concentra\u00e7\u00e3o de IL-15 no sobrenadante de macerado de amostras de \n\nbiopsia de les\u00e3o ........................................................................................................ 92 \n\n \n\n\n\nxv \n\nLISTA DE TABELAS \n\n \n\nTabela 1. Casos confirmados no Brasil por forma cl\u00ednica segundo unidade federada \n\nde notifica\u00e7\u00e3o no ano de 2015. ................................................................................. 23 \n\nTabela 2. Caracter\u00edsticas cl\u00ednicas e epidemiol\u00f3gicas dos pacientes de LC .............. 48 \n\nTabela 3: Combina\u00e7\u00e3o de anticorpos monoclonais utilizados como marcadores para \n\navaliar diferentes caracter\u00edsticas celulares por citometria de fluxo nos ensaios \n\nexperimentais ex vivo. ............................................................................................... 52 \n\nTabela 4: Combina\u00e7\u00e3o de anticorpos monoclonais utilizados como marcadores para \n\navaliar diferentes caracter\u00edsticas celulares por citometria de fluxo nos ensaios \n\nexperimentais in vitro ................................................................................................ 55 \n\nTabela 5. Principais caracter\u00edsticas cl\u00ednico-epidemiol\u00f3gicas dos pacientes inclu\u00eddos \n\nna segunda etapa do estudo. .................................................................................... 70 \n\n\n\nxvi \n\nLISTA DE SIGLAS E ABREVIATURAS \n\n \n\n7AAD \u2013 7 aminoactinomicina D  \n\nAcMo \u2013 anticorpo monoclonal \n\nAD \u2013 pacientes com a doen\u00e7a ativa, do ingl\u00eas active disease \n\nADCC \u2013 do ingl\u00eas Antibody-dependent cell cytotoxicity (citotoxicidade cellular \ndependente de anticorpo) \n\nAPCs \u2013 do ingl\u00eas Antigen-Presenting Cells (c\u00e9lulas apresentadoras de ant\u00edgenos) \n\nBG \u2013 do ingl\u00eas background (c\u00e9lulas cultivadas sem est\u00edmulo) \n\nBT \u2013 pacientes antes do in\u00edcio da terapia antimonial, do ingl\u00eas Before Treatment \n\nCC \u2013 pacientes com cura cl\u00ednica recente, do ingl\u00eas Clinically Cured \n\nCD \u2013 do ingl\u00eas Cluster of Differentiation (grupamento de diferencia\u00e7\u00e3o) \n\nCEP \u2013 Comit\u00ea de \u00c9tica em Pesquisa  \n\nCLA \u2013 do ingl\u00eas Cutaneous Lymphocyte-associated Antigen (receptor ant\u00edgeno \nlinfocit\u00e1rio cut\u00e2neo) \n\nCMSP \u2013 C\u00e9lulas Mononucleares de Sangue Perif\u00e9rico \n\nDMSO \u2013 Dimetilsulf\u00f3xido \n\nDN \u2013 duplo-negativas \n\nDP \u2013 duplo-positivas \n\nDT \u2013 pacientes durante o tratamento antimonial, do ingl\u00eas During Treatment \n\nELISA \u2013 do ingl\u00eas Enzyme-Linked Immunosorbent Assay (ensaio imunoenzim\u00e1tico) \n\nFas-L \u2013 receptor Fas ligante \n\nFIOCRUZ \u2013 Funda\u00e7\u00e3o Oswaldo Cruz \n\nFMO \u2013 do ingl\u00eas Fluorescence Minus One \n\nFSC \u2013 do ingl\u00eas Forward Scatter (par\u00e2metro que avalia o tamanho celular) \n\nFT \u2013 pacientes com Falha Terap\u00eautica \n\nGIPLs \u2013 glico-inositol-fosfolip\u00eddeos  \n\nGM-CSF \u2013 do ingl\u00eas Granulocyte-Macrophage Colony-Stimulating Factor (fator \nestimulador de col\u00f4nias de granul\u00f3citos e macr\u00f3fagos) \n\nGPI \u2013 glicosil-fosfatidil-inositol  \n\nHEPES \u2013 \u00c1cido 2-[4-(2-hidroxietil)1-piperazinil]-etanosulf\u00f3nico \n\nHI \u2013 indiv\u00edduos sadios, do ingl\u00eas Healthy Individuals \n\nHIV \u2013 do ingl\u00eas Human Immunodeficiency V\u00edrus (v\u00edrus da imunodefici\u00eancia humana) \n\nICAM \u2013 do ingl\u00eas Intercellular Adhesion Molecule (mol\u00e9cula de ades\u00e3o intercelular) \n\nIDRM \u2013 Intradermorrea\u00e7\u00e3o de Montenegro \n\nIFI \u2013 Imunofluoresc\u00eancia Indireta \n\n\n\nxvii \n\nIFN-? \u2013 Interferon-gamma \n\nIgG \u2013 Imunoglobulina G \n\nIL \u2013 Interleucina \n\nINI \u2013 Instituto Nacional de Infectologia \n\niNKT \u2013 c\u00e9lulas Natural Killer T invariantes \n\nIOC \u2013 Instituto Oswaldo Cruz \n\nKIR \u2013 do ingl\u00eas Killer Immunoglobulin-like Receptors \n\nL. \u2013 Leishmania \n\nLAMP \u2013 do ingl\u00eas Lysosomal-Associated Membrane Proteins (prote\u00ednas de \nmembrana associadas \u00e0 lisossomos) \n\nLb-Ag \u2013 ant\u00edgenos particulados de L. (V.) braziliensis  \n\nLC \u2013 Leishmaniose Cut\u00e2nea \n\nLCD \u2013 Leishmaniose Cut\u00e2nea Difusa \n\nLCL \u2013 Leishmaniose Cut\u00e2nea Localizada \n\nLdiss \u2013 Leishmaniose Disseminada \n\nLFA \u2013 do ingl\u00eas Lymphocyte Function-Associated Antigen (ant\u00edgeno associado \u00e0 \nfun\u00e7\u00e3o leucocit\u00e1ria) \n\nLIT \u2013 Meio de cultura Liver Infusion Triptose \n\nLM \u2013 Leishmaniose Mucosa \n\nLPG \u2013 Lipofosfoglicano  \n\nLRC \u2013 Leishmaniose Recidiva C\u00fatis \n\nLT \u2013 Leishmaniose Tegumentar \n\nLTA \u2013 Leishmaniose Tegumentar Americana \n\nLu. \u2013 Lutzomyia \n\nLV \u2013 Leishmaniose Visceral \n\nMHC \u2013 do ingl\u00eas Major Histocompatibility Complex (complexo principal de \nhistocompatibilidade) \n\nMIP \u2013 do ingl\u00eas Macrophage Inflammatory Protein (prote\u00edna inflamat\u00f3ria de \nmacr\u00f3fagos) \n\nMS \u2013 Minist\u00e9rio da Sa\u00fade \n\nn.d. \u2013 n\u00e3o determinado \n\nNETs \u2013 do ingl\u00eas Neutrophil Extracellular Traps \n\nNK \u2013 c\u00e9lulas Natural Killer \n\nNKT \u2013 c\u00e9lulas Natural Killer T \n\nNNN \u2013 Meio de cultura Neal, Novy, Nicolle \n\nNO \u2013 do ingl\u00eas Nitric oxide (\u00f3xido n\u00edtrico) \n\nNR \u2013 doen\u00e7a n\u00e3o-relacionada \n\nOMS \u2013 Organiza\u00e7\u00e3o Mundial da Sa\u00fade \n\n\n\nxviii \n\nOX40L \u2013 OX40 ligante \n\nPAMPs \u2013 do ingl\u00eas Pathogen-Associated Molecular Patterns (padr\u00f5es moleculares \nassociados a pat\u00f3genos) \n\nPBS \u2013 do ingl\u00eas Phosphate Buffered Saline (tamp\u00e3o fosfato-salino)  \n\nPD-1 \u2013 do ingl\u00eas Programmed Death-1 (receptor de morte programada-1) \n\nPDTIS \u2013 Plataforma de Citometria de Fluxo da Rede de Plataformas Tecnol\u00f3gicas \ndo Programa de Desenvolvimento Tecnol\u00f3gico em Insumos para Sa\u00fade \n\nPFA \u2013 Paraformalde\u00eddo \n\nPHA \u2013 do ingl\u00eas Phytohemagglutinin (fitohemaglutinina) \n\nRANTES \u2013 do ingl\u00eas Regulated on Activation, Normal T Cell Expressed and \nSecreted (regulada por ativa\u00e7\u00e3o expressa e secretada por c\u00e9lulas T normais) \n\nROS \u2013 do ingl\u00eas Reactive Oxygen Species (esp\u00e9cies reativas de oxig\u00eanio) \n\nrpm \u2013 Rota\u00e7\u00f5es por Minuto \n\nRPMI \u2013 do ingl\u00eas Roswell Park Memorial Institute medium \n\nSb+5 \u2013 antim\u00f4nio pentavalente \n\nSFB \u2013 Soro Fetal Bovino \n\nSSC \u2013 do ingl\u00eas Side Scatter (par\u00e2metro que avalia a granularidade celular) \n\nSVS \u2013 Secretaria de Vigil\u00e2ncia em Sa\u00fade \n\nTCR \u2013 do ingl\u00eas T-Cell Receptor (receptor de c\u00e9lulas T) \n\nTfh \u2013 c\u00e9lulas T foliculares \n\nTGF-? \u2013 do ingl\u00eas Transforming Growth Factor Beta (Fator de transforma\u00e7\u00e3o do \ncrescimento beta) \n\nTh \u2013 do ingl\u00eas T helper (linf\u00f3citos T auxiliares) \n\nTIA-1 \u2013 do ingl\u00eas T-cell Intracytoplasmic Antigen (ant\u00edgeno intracitoplasm\u00e1tico de \nc\u00e9lulas T) \n\nTLRs \u2013 do ingl\u00eas Toll-like Receptors (receptores do tipo Toll) \n\nTNF \u2013 do ingl\u00eas Tumor Necrosis Factor (fator de necrose tumoral) \n\nTreg \u2013 c\u00e9lulas T reguladoras \n\nV.  \u2013 Viannia \n\nVigiLeish \u2013 Laborat\u00f3rio de Vigil\u00e2ncia em Leishmanioses \n\nvNKT \u2013 c\u00e9lulas Natural Killer T variantes \n\n?GalCer - alfa-galactosilceramida  \n\n \n\n\n\n19 \n\n1. INTRODU\u00c7\u00c3O \n\nAs leishmanioses s\u00e3o um grupo de doen\u00e7as causadas por diversas esp\u00e9cies \n\nde protozo\u00e1rios do g\u00eanero Leishmania que possuem uma grande variabilidade de \n\nesp\u00e9cies de vetores e reservat\u00f3rios envolvidos em sua transmiss\u00e3o (1). Constituem \n\num importante problema de sa\u00fade p\u00fablica, com incid\u00eancia crescente na \u00faltima \n\nd\u00e9cada e est\u00e1 relacionada \u00e0 pobreza, mas fatores sociais, ambientais e \n\nclimatol\u00f3gicos influenciam diretamente a epidemiologia da doen\u00e7a (2). As \n\nleishmanioses s\u00e3o classificadas pela Organiza\u00e7\u00e3o Mundial da Sa\u00fade (OMS) como \n\ndoen\u00e7as tropicais negligenciadas e s\u00e3o classificadas em duas formas principais: \n\nLeishmaniose Tegumentar (LT) e Leishmaniose Visceral (LV), que variam em \n\ngravidade desde les\u00f5es da pele a desfigura\u00e7\u00f5es graves e infec\u00e7\u00e3o sist\u00eamica fatal \n\n(3).  \n\n \n\n1.1. Aspectos epidemiol\u00f3gicos \n\nAs leishmanioses s\u00e3o end\u00eamicas em mais de 90 pa\u00edses, os quais apresentam \n\numa estimativa de 0,2 a 0,4 milh\u00f5es de novos casos de LV e 0,7 a 1,2 milh\u00f5es de \n\ncasos de LT por ano (3). A LV registra altas taxas de morbidade e mortalidade, com \n\nepidemias recorrentes principalmente na \u00c1frica Oriental (Eti\u00f3pia, Qu\u00eania, Sud\u00e3o do \n\nSul e Sud\u00e3o). Da mesma forma, grandes epidemias de LT t\u00eam afetado diferentes \n\npartes do mundo, mas a maioria dos novos casos se concentra em apenas seis \n\npa\u00edses: Afeganist\u00e3o, Arg\u00e9lia, Brasil, Col\u00f4mbia, Rep\u00fablica Isl\u00e2mica do Ir\u00e3 e Rep\u00fablica \n\n\u00c1rabe S\u00edria (3). \u00c9 dif\u00edcil a obten\u00e7\u00e3o de n\u00fameros precisos sobre a incid\u00eancia da \n\ndoen\u00e7a. Acredita-se que a subnotifica\u00e7\u00e3o seja resultante de diversos fatores, como a \n\nescassez de t\u00e9cnicas diagn\u00f3sticas precisas e simplificadas, grande parte dos \n\npacientes residir em locais de dif\u00edcil acesso, a doen\u00e7a n\u00e3o ser de notifica\u00e7\u00e3o \n\ncompuls\u00f3ria em muitos pa\u00edses e tamb\u00e9m devido a muitos casos serem subcl\u00ednicos \n\n(4,5).  \n\n\n\n20 \n\nApesar de mais de dois ter\u00e7os dos casos de LT se concentrarem em apenas \n\nseis pa\u00edses, a distribui\u00e7\u00e3o da doen\u00e7a \u00e9 ampla. Normalmente os surtos s\u00e3o \n\ndetectados em cidades densamente povoadas, associados \u00e0 migra\u00e7\u00e3o de \n\npopula\u00e7\u00f5es (6). A figura 1 ilustra o mapa de distribui\u00e7\u00e3o mundial da LT referente aos \n\ndados epidemiol\u00f3gicos do ano de 2015 (7). A LT \u00e9 end\u00eamica em quase todo o \n\ncontinente Americano, aonde \u00e9 denominada Leishmaniose Tegumentar Americana \n\n(LTA), e se registram casos desde o sul dos Estados Unidos at\u00e9 o norte da \n\nArgentina, com exce\u00e7\u00e3o do Chile, Uruguai e El Salvador (9,10) (Figura 2). A \n\nepidemiologia da LTA \u00e9 complexa devido a varia\u00e7\u00f5es intra e interespec\u00edficas nos \n\nciclos de transmiss\u00e3o: diversidade de hospedeiros reservat\u00f3rios e vetores, m\u00faltiplas \n\nesp\u00e9cies de Leishmania circulantes na mesma \u00e1rea geogr\u00e1fica, al\u00e9m de ampla \n\nvariedade de manifesta\u00e7\u00f5es cl\u00ednicas e diferentes perfis de resposta \u00e0 terapia (6). \n\n \n\n \n\nFigura 1: Mapa da endemicidade mundial da Leishmaniose Tegumentar baseada em dados \nreferentes ao ano de 2015. Adaptado de WHO, 2016 (7). \n\n \n\nNo Brasil, a LTA era inicialmente considerada uma zoonose de animais \n\nsilvestres, devido \u00e0 detec\u00e7\u00e3o de casos restrita \u00e0s pessoas em contato com florestas. \n\nEntretanto, com os processos de migra\u00e7\u00e3o e urbaniza\u00e7\u00e3o das \u00faltimas d\u00e9cadas, o \n\npadr\u00e3o epidemiol\u00f3gico da doen\u00e7a se modificou (8). Tr\u00eas perfis epidemiol\u00f3gicos \n\nprincipais s\u00e3o observados no pa\u00eds: silvestre, no qual a transmiss\u00e3o est\u00e1 relacionada \n\n\n\n21 \n\napenas \u00e0s \u00e1reas de matas e os animais silvestres s\u00e3o os reservat\u00f3rios envolvidos; \n\nocupacional ou de lazer, que \u00e9 o perfil associado \u00e0s atividades de com\u00e9rcio, \n\ndesmatamento, urbaniza\u00e7\u00e3o e ecoturismo; e rural ou periurbano, onde s\u00e3o \n\ndetectados animais dom\u00e9sticos participando do ciclo (8). A LTA representa um \n\ngrande problema de sa\u00fade p\u00fablica do Brasil e sua incid\u00eancia gera reflexos no campo \n\nsocial e econ\u00f4mico, devido ao risco de ocorr\u00eancia de deformidades f\u00edsicas e \n\npsicol\u00f3gicas (8).  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 2: Densidade de casos de Leishmaniose Tegumentar Americana em 2014. Adaptado de \nPAHO, 2016 (9). \n\n \n\nNos \u00faltimos anos, v\u00eam sendo notificados casos de LTA em todos os estados \n\nbrasileiros, com um registro de 20.161 casos em 2015 (11,12). As regi\u00f5es Norte e \n\nNordeste s\u00e3o as regi\u00f5es mais end\u00eamicas, com registro em 2015 de 9.664 (45,66%) \n\ne 5.671 (26,79%) casos, respectivamente (12). Apesar de n\u00fameros mais baixos de \n\ncasos registrados na regi\u00e3o Sudeste, o estado do Rio de Janeiro \u00e9 considerado \n\nend\u00eamico, apresentando uma incid\u00eancia de 30 casos em 2015. A figura 3 ilustra o \n\nmapa de distribui\u00e7\u00e3o de casos de LT por estado no Brasil (13) e a tabela 1 \n\n\n\n22 \n\ndiscrimina o n\u00famero de casos registrados em cada unidade federada referentes ao \n\nano de 2015 (12). \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 3: Distribui\u00e7\u00e3o dos casos de Leishmaniose Tegumentar por unidade federada do territ\u00f3rio \nbrasileiro baseada em dados do ano de 2015. Adaptado de SVS/MS, 2016 (13). \n\n\n\n23 \n\nTabela 1. Casos confirmados no Brasil por forma cl\u00ednica segundo unidade federada de notifica\u00e7\u00e3o no \nano de 2015. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nUF: unidade federada; Ign: ignorado. \n\n \n\nAtualmente, 53 esp\u00e9cies de Leishmania s\u00e3o conhecidas e pelo menos 21 \n\nesp\u00e9cies s\u00e3o patog\u00eanicas ao ser humano (14). De acordo com a classifica\u00e7\u00e3o \n\ntaxon\u00f4mica mais utilizada, as esp\u00e9cies de Leishmania s\u00e3o divididas em dois \n\nsubg\u00eaneros: Leishmania e Viannia (15). Os agentes etiol\u00f3gicos da LTA pertencem \n\naos dois subg\u00eaneros, em contrataste com a leishmaniose cut\u00e2nea do Velho Mundo, \n\nonde apenas o subg\u00eanero Leishmania est\u00e1 representado (14). Nas regi\u00f5es do pa\u00eds \n\nem que a LTA \u00e9 end\u00eamica, a esp\u00e9cie mais envolvida \u00e9 a Leishmania (Viannia) \n\nbraziliensis, que est\u00e1 presente tanto em \u00e1reas de coloniza\u00e7\u00e3o antigas quanto \n\nrecentes (8,16,17). Pelo menos sete esp\u00e9cies patog\u00eanicas ao homem j\u00e1 foram \n\n\n\n24 \n\nidentificadas no pa\u00eds, sendo seis do subg\u00eanero Viannia [L. (V.) braziliensis; L. (V.) \n\nguyanensis; L. (V.) lainsoni; L. (V.) naiffi; L. (V.) lindenberg; e L. (V.) shawi] e uma do \n\nsubg\u00eanero Leishmania [L. (L.) amazonensis] (8). Com exce\u00e7\u00e3o das esp\u00e9cies L. (V.) \n\nbraziliensis e L. (L.) amazonensis, que apresentam ampla distribui\u00e7\u00e3o no territ\u00f3rio \n\nnacional, as outras esp\u00e9cies s\u00e3o encontradas em regi\u00f5es caracter\u00edsticas. No estado \n\ndo Rio de Janeiro s\u00e3o descritos casos desde o in\u00edcio do s\u00e9culo XX (18) e s\u00e3o \n\nassociados a um perfil rural e periurbano de transmiss\u00e3o, causados pela esp\u00e9cie L. \n\n(V.) braziliensis (19,20). S\u00e3o encontrados focos da doen\u00e7a principalmente em \n\nregi\u00f5es dos munic\u00edpios do Rio de Janeiro, Paraty, Mesquita, Ilha Grande e \n\nParacambi (8,21\u201323). \n\n \n\n1.2. Ciclo de vida do protozo\u00e1rio \n\nA Leishmania \u00e9 um protozo\u00e1rio parasito unicelular pertencente ao g\u00eanero \n\nLeishmania (Trypanosomatida: Trypanosomatidae) (24). Sua morfologia varia de \n\nacordo com a fase do ciclo biol\u00f3gico e se apresenta sob duas formas evolutivas \n\nprincipais: amastigota, encontrada nos tecidos dos hospedeiros vertebrados; e \n\npromastigota, observada no tubo digestivo do inseto vetor (8). A divis\u00e3o nos \n\nsubg\u00eaneros Viannia ou Leishmania foi definida de acordo com a localiza\u00e7\u00e3o em que \n\nse desenvolvem no intestino do hospedeiro invertebrado (15). As esp\u00e9cies do \n\nsubg\u00eanero Viannia colonizam a regi\u00e3o posterior do est\u00f4mago do flebotom\u00edneos, \n\nenquanto as esp\u00e9cies do subg\u00eanero Leishmania colonizam a por\u00e7\u00e3o anterior (15).   \n\nOs hospedeiros invertebrados, ou vetores, s\u00e3o as f\u00eameas hemat\u00f3fagas de \n\nflebotom\u00edneos (Diptera: Psychodidae: Phlebotominae), que podem ser do g\u00eanero \n\nLutzomyia, no Novo Mundo, ou do g\u00eanero Phlebotomus, no Velho Mundo (25). S\u00e3o \n\nmais de 500 esp\u00e9cies de flebotom\u00edneos identificadas e, destas, cerca de 40 \n\nesp\u00e9cies participam do ciclo da Leishmania como vetores, indicando que as \n\nesp\u00e9cies de Leishmania parecem ter prefer\u00eancia por esp\u00e9cies particulares de \n\nvetores (22,26). A L. (V.) braziliensis \u00e9 transmitida por diferentes esp\u00e9cies de \n\nflebotom\u00edneos, principalmente Lutzomyia intermedia, Lu. whitmani e Lu. wellcomei, e \n\nseus grandes reservat\u00f3rios potenciais s\u00e3o os animais dom\u00e9sticos (27\u201329). Os \n\nhospedeiros vertebrados incluem o homem; animais dom\u00e9sticos, como c\u00e3es, gatos e \n\nequinos; e animais silvestres, como marsupiais, roedores, pregui\u00e7as, tamandu\u00e1s \n\n(15,30,31). \n\n\n\n25 \n\nO ciclo tem in\u00edcio quando f\u00eameas de flebotom\u00edneos transmitem a forma \n\ninfectante de Leishmania (promastigota metac\u00edclica) ao hospedeiro vertebrado \n\ndurante o repasto sangu\u00edneo. As promastigotas, que s\u00e3o formas alongadas e com \n\nflagelo livre, s\u00e3o ent\u00e3o fagocitadas por macr\u00f3fagos e c\u00e9lulas dendr\u00edticas. No interior \n\ndestas c\u00e9lulas, as promastigotas se localizam em vac\u00faolos parasit\u00f3foros, onde se \n\ndiferenciam em amastigotas (formas ovoides e com flagelo interiorizado). As \n\namastigotas se multiplicam por divis\u00e3o bin\u00e1ria, levando \u00e0 lise celular, quando s\u00e3o \n\nent\u00e3o liberadas, permitindo a infec\u00e7\u00e3o de outras c\u00e9lulas. Quando um fleb\u00f3tomo \n\nrealiza o repasto sangu\u00edneo em um hospedeiro infectado, ingere, juntamente com o \n\nsangue, macr\u00f3fagos infectados com as formas amastigotas. Estas amastigotas se \n\ndiferenciam em promastigotas no intestino do hospedeiro invertebrado, se \n\nmultiplicam por divis\u00e3o bin\u00e1ria e passam por um processo de metaciclog\u00eanese, onde \n\ndeixam de se reproduzir e tornam-se infectantes. Nesta forma evolutiva, a \n\nLeishmania perde a capacidade de ades\u00e3o ao epit\u00e9lio do intestino e realiza \n\nmigra\u00e7\u00e3o para a prob\u00f3scida do inseto, onde permanece apta a infectar um novo \n\nhospedeiro vertebrado, reiniciando seu ciclo (32,33) (Figura 4). A infec\u00e7\u00e3o tamb\u00e9m \n\npode ser transmitida atrav\u00e9s do compartilhamento de agulhas, transfus\u00e3o de sangue \n\ncom produtos sangu\u00edneos infectados e at\u00e9 via transplacent\u00e1ria, embora estes tipos \n\nde transmiss\u00e3o sejam raros (34,35). \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 4: Ciclo de vida de Leishmania spp.. Adaptado de Kaye &amp; Scott, 2011 (36). \n \n\n\n\n26 \n\n \n1.3. Formas cl\u00ednicas da Leishmaniose Tegumentar Americana \n\nA LTA apresenta uma variedade de manifesta\u00e7\u00f5es cl\u00ednicas, altera\u00e7\u00f5es \n\nhistopatol\u00f3gicas e imunol\u00f3gicas que caracterizam as diferentes formas desta \n\ndoen\u00e7a: leishmaniose cut\u00e2nea localizada (LCL), leishmaniose recidiva c\u00fatis (LRC), \n\nleishmaniose disseminada (Ldiss), leishmaniose cut\u00e2nea difusa (LCD) e \n\nleishmaniose mucosa (LM) (8,37). O amplo espectro de formas e de gravidade da \n\ndoen\u00e7a s\u00e3o reflexos da contribui\u00e7\u00e3o de diferentes fatores de virul\u00eancia do parasito e \n\nrespostas do hospedeiro, alguns dos quais atuam de maneira a proteger o \n\nhospedeiro, enquanto outros exacerbam a doen\u00e7a (10). Apesar de algumas \n\nmanifesta\u00e7\u00f5es cl\u00ednicas serem mais frequentemente associadas a uma determinada \n\nesp\u00e9cie ou subg\u00eanero, nenhuma \u00e9 \u00fanica para uma esp\u00e9cie (38). Felizmente, uma \n\nparte substancial das infec\u00e7\u00f5es \u00e9 assintom\u00e1tica (forma subcl\u00ednica) e a cura \n\nespont\u00e2nea \u00e9 comum. Em contrapartida, uma resposta imunol\u00f3gica inadequada \n\nresulta em uma replica\u00e7\u00e3o descontrolada do parasito e a subsequentes formas n\u00e3o \n\ncurativas (5). \n\n \n\n1.3.1. Leishmaniose Cut\u00e2nea Inaparente ou Subcl\u00ednica \n\nEm \u00e1reas end\u00eamicas de leishmaniose s\u00e3o observados indiv\u00edduos infectados \n\npor Leishmania que n\u00e3o apresentam manifesta\u00e7\u00f5es cl\u00ednicas aparentes, sendo \n\ncapazes de controlar a infec\u00e7\u00e3o, dispensando assim o tratamento medicamentoso \n\n(39,40). Em \u00e1reas end\u00eamicas de L. (V.) braziliensis, aproximadamente 10% dos \n\nindiv\u00edduos possuem teste intrad\u00e9rmico positivo, mas nenhuma hist\u00f3ria pr\u00e9via de \n\nleishmaniose ou les\u00f5es t\u00edpicas, caracterizando a forma subcl\u00ednica da leishmaniose \n\n(39). Os indiv\u00edduos com esta forma da doen\u00e7a geralmente apresentam positividade \n\ntamb\u00e9m nos testes sorol\u00f3gicos (39). \n\n \n\n1.3.2. Leishmaniose Cut\u00e2nea Localizada (LCL) \n\nA LCL, comumente denominada apenas leishmaniose cut\u00e2nea (LC), \u00e9 a \n\nforma mais prevalente e pode ser causada por todas as esp\u00e9cies dermotr\u00f3picas de \n\nLeishmania. \u00c9 caracterizada por les\u00f5es \u00fanicas ou escassas (no m\u00e1ximo 10 les\u00f5es) \n\nulceradas na pele, com bordas bem delimitadas, margens em relevo e fundo \n\ngranuloso (19,41,42). As \u00falceras s\u00e3o tipicamente indolores, exceto quando h\u00e1 \n\n\n\n27 \n\ninfec\u00e7\u00e3o bacteriana ou f\u00fangica secund\u00e1ria. A linfadenopatia regional \u00e9 frequente e \n\ngeralmente associada \u00e0 apresenta\u00e7\u00e3o inicial, mas pode persistir mesmo ap\u00f3s as \n\nles\u00f5es cut\u00e2neas terem cicatrizado (42). A doen\u00e7a geralmente evolui de forma \n\ncr\u00f4nica e a les\u00e3o cicatriza ap\u00f3s a terapia, podendo cicatrizar de forma espont\u00e2nea \n\nem alguns casos (10,43). Em casu\u00edstica no estado do Rio de Janeiro, durante um \n\nper\u00edodo de um ano, 8% dos pacientes evolu\u00edram para a cura espont\u00e2nea (44). \n\nAs les\u00f5es cicatrizadas s\u00e3o em geral lisas, finas e hipopigmentadas e a \n\nocorr\u00eancia de traumatismo na cicatriz pode conduzir a um ressurgimento da les\u00e3o \n\nleishmani\u00f3tica, levando \u00e0 reativa\u00e7\u00e3o da infec\u00e7\u00e3o, provavelmente devido \u00e0 \n\npersist\u00eancia do parasito ap\u00f3s o tratamento cl\u00ednico (42,45,46). Nesta forma da \n\ndoen\u00e7a, geralmente a intradermorrea\u00e7\u00e3o de Montenegro (IDRM) e os testes \n\nsorol\u00f3gicos s\u00e3o positivos (8). A infec\u00e7\u00e3o prim\u00e1ria pode ainda evoluir para a forma \n\nmucosa, mesmo ap\u00f3s a cura cl\u00ednica (47).  \n\n \n\n1.3.3. Leishmaniose Recidiva C\u00fatis (LRC) \n\nA LRC \u00e9 um quadro de recidiva da LCL, que \u00e9 raro e apresenta \n\ncaracter\u00edsticas cl\u00ednicas e evolu\u00e7\u00e3o espec\u00edficas (48). \u00c9 mais prevalente no Velho \n\nMundo, onde est\u00e1 associada com a infec\u00e7\u00e3o por L. (L.) tropica, mas tamb\u00e9m \u00e9 \n\nobservada no Novo Mundo, associada com infec\u00e7\u00e3o por L. (V.) braziliensis e L. (L.) \n\namazonensis no Brasil; e L. (V.) panamensis no Equador (48\u201350). Ap\u00f3s um per\u00edodo \n\nvari\u00e1vel de tempo, a cicatriz clinicamente curada de LCL apresenta complica\u00e7\u00f5es \n\npelo desenvolvimento perif\u00e9rico de placas infiltradas e crostosas, mimetizando \n\nclinicamente e histologicamente a infec\u00e7\u00e3o por lupus vulgaris (51,52). \u00c9 considerada \n\numa forma hiper\u00e9rgica de leishmaniose cut\u00e2nea devido aos pacientes apresentarem \n\nforte resposta na IDRM e uma rea\u00e7\u00e3o granulomatosa bem organizada \n\nhistologicamente, com parasitos escassos ou ausentes (53). A persist\u00eancia do \n\nparasito por muito tempo, mesmo ap\u00f3s a cura cl\u00ednica, \u00e9 uma explica\u00e7\u00e3o plaus\u00edvel \n\npara os casos de recorr\u00eancia de LRC (45,46,54). \n\n \n\n1.3.4. Leishmaniose Disseminada (Ldiss) \n\nA forma disseminada \u00e9 uma rara manifesta\u00e7\u00e3o da LT que acomete cerca de \n\n2% dos casos e \u00e9 clinicamente caracterizada pela presen\u00e7a de m\u00faltiplas les\u00f5es \n\npleom\u00f3rficas (mais de dez les\u00f5es) em duas ou mais \u00e1reas n\u00e3o cont\u00edguas do corpo, \n\n\n\n28 \n\nque s\u00e3o provavelmente causadas por dissemina\u00e7\u00e3o linf\u00e1tica ou hematog\u00eanica \n\n(55,56). As les\u00f5es podem ser acneiformes, nodulares, papulares, verrucosas e \n\nulceradas, podendo sofrer necrose central e formar crosta (55,57). Sintomas \n\nconstitucionais como febre, astenia e mal-estar est\u00e3o presentes em alguns pacientes \n\nno in\u00edcio da dissemina\u00e7\u00e3o das les\u00f5es e em quase 29% dos casos \u00e9 observado \n\nacometimento da mucosa (55,58). Os pacientes geralmente apresentam resposta \n\npositiva na IDRM e aos testes de prolifera\u00e7\u00e3o linfocit\u00e1ria (37), entretanto h\u00e1 relatos \n\nde pacientes com Ldiss causada por L. (L.) amazonensis que apresentaram \n\nresposta negativa a estes testes (55). No Brasil, a incid\u00eancia desta forma \u00e9 de 2,4%, \n\nsendo atribu\u00edda principalmente \u00e0 infec\u00e7\u00e3o por L. (V.) braziliensis, embora j\u00e1 tenha \n\nsido observada associa\u00e7\u00e3o com L. (L.) amazonensis e L (V.) guyanensis (21,55,58\u2013\n\n60).  \n\n \n\n1.3.5. Leishmaniose Cut\u00e2nea Difusa (LCD) \n\nA LCD \u00e9 uma manifesta\u00e7\u00e3o cl\u00ednica grave e rara da LC. \u00c9 caracterizada pela \n\npresen\u00e7a de m\u00faltiplas les\u00f5es nodulares n\u00e3o-ulcerativas, ricas em formas \n\namastigotas, difundidas por quase todo o corpo (61). Imunologicamente parece \n\nhaver uma falha na resposta imune celular aos ant\u00edgenos de Leishmania, levando ao \n\ncrescimento descontrolado do parasito (62). Deste modo, os pacientes an\u00e9rgicos \n\napresentam uma evolu\u00e7\u00e3o cr\u00f4nica, IDRM negativa devido \u00e0 fraca resposta celular e \n\nm\u00e1 resposta ao tratamento (55,63). Les\u00f5es \u00f3sseas como osteopenia, les\u00f5es \n\nosteol\u00edticas ou osteomielite podem ocorrer (64). Esta forma da doen\u00e7a \u00e9 associada \n\ncom a infec\u00e7\u00e3o por L. (L.) amazonensis e L. (L.) mexicana no Novo Mundo e L. (L.) \n\naethiopica no Velho Mundo (38).  \n\n \n\n1.3.6. Leishmaniose Mucosa (LM) \n\nA LM pode apresentar acometimento unicamente mucoso, surgindo \n\ngeralmente meses ou anos ap\u00f3s uma les\u00e3o cut\u00e2nea inicial, ou ocorrer \n\nsimultaneamente com a LC, sendo usualmente denominada leishmaniose \n\nmucocut\u00e2nea (8). \u00c9 uma forma agressiva da doen\u00e7a, com curso cr\u00f4nico, \n\ncaracterizada por m\u00faltiplas ou extensas les\u00f5es destrutivas na cavidade oral ou \n\nnasofar\u00edngea, podendo ainda afetar laringe e traqueia, causando severa deforma\u00e7\u00e3o \n\nfacial e dist\u00farbios respirat\u00f3rios (65,66). Tal patog\u00eanese tem sido associada a uma \n\n\n\n29 \n\nhiperatividade da resposta imune celular mediada por linf\u00f3citos T, com uma forte e \n\nprogressiva resposta inflamat\u00f3ria, que resultam em dano tecidual (67). Os pacientes \n\napresentam uma intensa resposta na IDRM, denotando uma hipersensibilidade aos \n\nant\u00edgenos de Leishmania (37). Os pacientes de LM n\u00e3o curam espontaneamente, \n\napresentam comumente co-infec\u00e7\u00f5es bacterianas e maiores \u00edndices de falha \n\nterap\u00eautica e recidiva s\u00e3o detectados (68). A L. (V.) braziliensis \u00e9 a principal esp\u00e9cie \n\nrespons\u00e1vel pela LM no Novo Mundo, embora casos por L. (L.) amazonensis, L. (V.) \n\npanamensis e L. (V.) guyanensis tamb\u00e9m sejam descritos (65,69\u201372). \n\n \n\n1.4. Diagn\u00f3stico e tratamento da Leishmaniose Tegumentar Americana \n\nA complexidade das leishmanioses imp\u00f5e que o diagn\u00f3stico seja baseado em \n\ncrit\u00e9rios que considerem dados epidemiol\u00f3gicos, cl\u00ednicos e laboratoriais. Os dados \n\nepidemiol\u00f3gicos s\u00e3o importantes no aux\u00edlio ao diagn\u00f3stico tanto de indiv\u00edduos que \n\nresidem em \u00e1reas end\u00eamicas, como de viajantes que n\u00e3o residem nestas \u00e1reas (73\u2013\n\n75). O diagn\u00f3stico cl\u00ednico \u00e9 realizado a partir das caracter\u00edsticas cl\u00ednicas (les\u00f5es \n\nleishmani\u00f3ticas t\u00edpicas e localiza\u00e7\u00e3o destas) apresentadas pelos pacientes. \n\nEntretanto, a confirma\u00e7\u00e3o do diagn\u00f3stico por m\u00e9todos laboratoriais \u00e9 essencial e de \n\nextrema import\u00e2ncia, tendo em vista as muitas doen\u00e7as que fazem diagn\u00f3stico \n\ndiferencial com a LTA, como paracoccidioidomicose, carcinoma epiderm\u00f3ide, \n\ncarcinoma basocelular, linfomas, rinofima, rinosporidiose, entomoftoromicose, \n\nhansen\u00edase, s\u00edfilis terci\u00e1ria, perfura\u00e7\u00e3o septal, rinite al\u00e9rgica, sinusite, sarcoidose, \n\ngranulomatose de Wegner e outras doen\u00e7as mais raras (8,41,76). \n\nO \u201cpadr\u00e3o-ouro\u201d de diagn\u00f3stico laboratorial para LTA ainda s\u00e3o os exames \n\nparasitol\u00f3gicos diretos e indiretos para demonstra\u00e7\u00e3o do parasito (8). Os exames \n\ndiretos constituem em escarifica\u00e7\u00e3o e bi\u00f3psia de les\u00e3o. Entretanto, a possibilidade \n\nde encontro do parasito \u00e9 diminu\u00edda com o tempo de evolu\u00e7\u00e3o, ficando a \n\nsensibilidade destes testes entre 15 e 30% apenas, principalmente devido aos \n\nfrequentes casos cr\u00f4nicos e de LM (8,77,78). Os exames indiretos constituem em \n\nisolamento do parasito em cultivo in vitro, onde fragmentos obtidos por bi\u00f3psia da \n\nles\u00e3o s\u00e3o cultivados em meios apropriados (geralmente NNN ou LIT), e in vivo, onde \n\no fragmento \u00e9 triturado em solu\u00e7\u00e3o salina est\u00e9ril e inoculado por via intrad\u00e9rmica em \n\nhamster (Mesocricetus auratus). Entretanto, apesar de uma maior sensibilidade, este \n\n\u00faltimo \u00e9 pouco utilizado devido \u00e0 sua dificuldade de manuseio e manuten\u00e7\u00e3o (8). \n\n\n\n30 \n\nTestes imunol\u00f3gicos (IDRM e testes sorol\u00f3gicos) tamb\u00e9m s\u00e3o comumente \n\nrealizados. A IDRM \u00e9 realizada rotineiramente e fundamenta-se na visualiza\u00e7\u00e3o da \n\nresposta de hipersensibilidade celular tardia. Neste, uma prepara\u00e7\u00e3o de ant\u00edgenos \n\nde Leishmania (a esp\u00e9cie utilizada varia em diferentes laborat\u00f3rios e localidades) \u00e9 \n\ninoculada no antebra\u00e7o do indiv\u00edduo com suspeita de leishmaniose e, ap\u00f3s 48-72h, \n\na rea\u00e7\u00e3o \u00e9 avaliada e considerada positiva quando a \u00e1rea de endurecimento for \n\nigual ou maior do que 5 mm (8,79). Por\u00e9m, este teste n\u00e3o diferencia se a infec\u00e7\u00e3o \u00e9 \n\natual ou antiga, podendo se manter positivo mais de dois anos ap\u00f3s cura cl\u00ednica. A \n\nIDRM pode tamb\u00e9m ser positiva em indiv\u00edduos moradores de \u00e1reas end\u00eamicas, al\u00e9m \n\nde apresentar diferen\u00e7as de positividade entre as diferentes formas cl\u00ednicas, como \n\ndiscutido anteriormente (39,80\u201382). Os testes sorol\u00f3gicos detectam anticorpos anti-\n\nLeishmania circulantes no soro dos pacientes e s\u00e3o realizados pelas t\u00e9cnicas de \n\nimunofluoresc\u00eancia indireta (IFI) ou ensaio imunoenzim\u00e1tico (ELISA) (8). A \n\nsensibilidade destes testes tamb\u00e9m varia de acordo com a forma cl\u00ednica (83,84) e \n\ncom a esp\u00e9cie de Leishmania respons\u00e1vel pela infec\u00e7\u00e3o (85,86).  \n\nDesta forma, devido \u00e0 variabilidade de sensibilidade e falta de m\u00e9todos \n\ndevidamente padronizados, indiv\u00edduos com diagn\u00f3stico cl\u00ednico sugestivo de LTA e \n\ncom IDRM positiva s\u00e3o normalmente submetidos ao tratamento medicamentoso, \n\nmesmo sem a confirma\u00e7\u00e3o parasitol\u00f3gica (8). Assim, existe a necessidade do \n\nemprego de m\u00e9todos diagn\u00f3sticos mais eficazes. Os m\u00e9todos moleculares v\u00eam \n\nsurgindo para este fim por serem altamente espec\u00edficos, sens\u00edveis e r\u00e1pidos; por\u00e9m \n\nsua alta complexidade e custo elevado impedem sua utiliza\u00e7\u00e3o rotineira (79). \n\nAtualmente, s\u00e3o v\u00e1rios os alvos e m\u00e9todos moleculares em estudo para a detec\u00e7\u00e3o \n\nde Leishmania e distin\u00e7\u00e3o das diferentes esp\u00e9cies. Entretanto, ainda \u00e9 necess\u00e1ria a \n\npadroniza\u00e7\u00e3o dos protocolos e alvos moleculares, a fim de se obter resultados \n\ncompar\u00e1veis e confi\u00e1veis (24). \n\nMesmo com a grande preval\u00eancia das leishmanioses e com os \n\nconhecimentos atuais sobre a rela\u00e7\u00e3o entre o parasito e o hospedeiro, poucos \n\navan\u00e7os foram obtidos no tratamento da doen\u00e7a. Inicialmente foi empregado o \n\nantimonial trivalente para o tratamento das leishmanioses, que foi introduzido no \n\nBrasil em 1912 por Gaspar Vianna. Somente entre a d\u00e9cada de 1935 e 1945 foram \n\nrealizados os primeiros estudos cl\u00ednicos com estes f\u00e1rmacos (87,88). Atualmente, a \n\ndroga de primeira escolha \u00e9 o antimonial pentavalente (Sb+5), administrado por via \n\nintramuscular ou intravenosa. Dois tipos de antimoniais pentavalentes podem ser \n\n\n\n31 \n\nutilizados: o antimoniato de N-metilglucamina e o estibogluconato de s\u00f3dio. No Brasil \n\n\u00e9 utilizado somente o antimoniato de N-metilglucamina (Glucantime \u00ae Rhodia), que \n\nvem sendo produzido no pa\u00eds desde 2007 pela Sanofi-Aventis, e distribu\u00eddo para a \n\nrede p\u00fablica de sa\u00fade pela Secretaria de Vigil\u00e2ncia em Sa\u00fade do Minist\u00e9rio da \n\nSa\u00fade (SVS/MS) (8). A dose recomendada pelo MS varia de 10 a 20 mg Sb+5/kg/dia \n\npor um per\u00edodo m\u00ednimo de 20 dias (8,89,90). Entretanto, estudos t\u00eam sido realizados \n\nna tentativa de diminuir a dose administrada devido \u00e0 alta toxidade do medicamento. \n\nNo Rio de Janeiro, a equipe do Laborat\u00f3rio de Vigil\u00e2ncia em Leishmanioses \n\n(VigiLeish), do Instituto Nacional de Infectologia (INI/FIOCRUZ), tem demonstrado \n\nefic\u00e1cia satisfat\u00f3ria na utiliza\u00e7\u00e3o de esquema de tratamento com baixa dose de \n\nantim\u00f4nio pentavalente (5 mg Sb5+/kg/dia) por um per\u00edodo mais prolongado (30 dias) \n\n(91\u201396).  \n\nOs principais efeitos colaterais est\u00e3o associados \u00e0 toxidade hep\u00e1tica e renal, \n\ne diversos sintomas s\u00e3o frequentes, como mialgias e artralgias, dist\u00farbios \n\ngastrointestinais, dores de cabe\u00e7a, anorexia, fadiga, febre, rea\u00e7\u00f5es cut\u00e2neas, \n\naltera\u00e7\u00f5es comportamentais e altera\u00e7\u00f5es cardiovasculares e respirat\u00f3rias (97). \n\nEmbora os antimoniais pentavalentes sejam utilizados h\u00e1 d\u00e9cadas, seu mecanismo \n\nde a\u00e7\u00e3o ainda n\u00e3o foi totalmente esclarecido. Faltam elucidar detalhes da a\u00e7\u00e3o \n\nleishmanicida dessas drogas ap\u00f3s sua convers\u00e3o in vivo (95). Existe, ainda, o \n\nproblema de resist\u00eancia a estes f\u00e1rmacos, que \u00e9 cada vez mais crescente, tendo \n\nsua administra\u00e7\u00e3o j\u00e1 limitada em algumas \u00e1reas devido \u00e0 falta de efic\u00e1cia (98). Nos \n\ncasos de resist\u00eancia ou impedimento do emprego de antimoniais, outras classes de \n\nmedicamentos s\u00e3o aplicadas no tratamento de segunda escolha, como anfotericina \n\nB, pentamidinas e miltefosina (8,97,99). Em outros pa\u00edses, s\u00e3o utilizadas ainda \n\noutras drogas, como paromomicina, sitamaquina e az\u00f3is (100).  \n\nO tratamento com antimonial pentavalente \u00e9 eficaz na maioria dos casos e as \n\nles\u00f5es geralmente evoluem para a cura cl\u00ednica com forma\u00e7\u00e3o de cicatriz atr\u00f3fica. \n\nEntretanto, a efic\u00e1cia varia de acordo com a forma cl\u00ednica da leishmaniose e a \n\nesp\u00e9cie do parasito (101,102). No estado do Rio de Janeiro, onde o agente \n\netiol\u00f3gico \u00e9 a L. (V.) braziliensis, o tempo decorrido entre o in\u00edcio da terapia \n\nantimonial e a cura cl\u00ednica da LC leva em torno de cem dias em m\u00e9dia e h\u00e1 relato de \n\ntaxas de cura de 75% a 95% (95,103). A cura cl\u00ednica \u00e9 considerada com a \n\ncicatriza\u00e7\u00e3o das les\u00f5es, que \u00e9 caracterizada pela total reconstitui\u00e7\u00e3o do epit\u00e9lio \n\nlesionado e aus\u00eancia de hiperemia ou edema (104). \u00c9 determinado, entretanto, que \n\n\n\n32 \n\nesta cura pode ocorrer somente sob o ponto de vista cl\u00ednico, pois a persist\u00eancia \n\nparasit\u00e1ria j\u00e1 foi observada mesmo anos ap\u00f3s a cicatriza\u00e7\u00e3o da les\u00e3o \n\n(45,46,77,105). \n\nMuitos s\u00e3o os esfor\u00e7os para desenvolver uma vacina eficaz contra as \n\nleishmanioses, entretanto at\u00e9 o momento esse objetivo n\u00e3o foi alcan\u00e7ado. Fatores \n\ncomo as caracter\u00edsticas gen\u00e9ticas do hospedeiro e do parasito, virul\u00eancia, cen\u00e1rios \n\nepidemiol\u00f3gicos e, principalmente, diferentes perfis de resposta imune \n\ndesencadeados pelas esp\u00e9cies de Leishmania tornam a realiza\u00e7\u00e3o desse objetivo \n\numa tarefa complexa (106). Al\u00e9m disso, a maior parte do conhecimento envolvendo \n\no desenvolvimento de vacinas para LC prov\u00e9m do modelo de infec\u00e7\u00e3o por L. (L.) \n\nmajor, que n\u00e3o pode ser totalmente aplicado \u00e0 leishmaniose do Novo Mundo (106). \n\nO fato de ainda n\u00e3o existir um tratamento satisfat\u00f3rio e uma vacina eficaz contra a \n\nleishmaniose leva \u00e0 conclus\u00e3o de que ainda \u00e9 necess\u00e1rio uma melhor compreens\u00e3o \n\nda resposta imune na patog\u00eanese da infec\u00e7\u00e3o e dos mecanismos relacionados \u00e0 \n\ncura e prote\u00e7\u00e3o.  \n\n \n\n1.5. Imunopatogenia da Leishmaniose Tegumentar Americana \n\nO espectro de manifesta\u00e7\u00f5es cl\u00ednicas observado na leishmaniose \u00e9 \n\ndeterminado em grande parte pelo tipo e magnitude da resposta imune do \n\nhospedeiro (107). A resposta desencadeada na LTA se caracteriza por uma rea\u00e7\u00e3o \n\nde hipersensibilidade tardia, que se inicia com o reconhecimento do pat\u00f3geno, \n\ngerando inicialmente uma resposta imune inata e indu\u00e7\u00e3o da produ\u00e7\u00e3o de citocinas \n\npr\u00f3-inflamat\u00f3rias e mol\u00e9culas co-estimulat\u00f3rias (108,109). Assim, ap\u00f3s a infec\u00e7\u00e3o \n\npor Leishmania, a a\u00e7\u00e3o coordenada de c\u00e9lulas da imunidade inata e adaptativa \u00e9 \n\ndeterminante para o desenvolvimento de uma resposta imune protetora.  \n\nQuando as promastigotas s\u00e3o injetadas na pele do hospedeiro atrav\u00e9s do \n\nrepasto sangu\u00edneo dos flebotom\u00edneos, v\u00e1rios tipos de c\u00e9lulas fagoc\u00edticas s\u00e3o \n\nrecrutados para o local e iniciam sua atividade de fagocitose de promastigotas. \n\nDurante a infec\u00e7\u00e3o natural, fatores adicionais presentes na saliva do flebotom\u00edneo \n\ns\u00e3o juntamente introduzidos na pele do hospedeiro e podem influenciar respostas \n\nimunes precoces (110). Dentro do fagolisossomo das c\u00e9lulas fagoc\u00edticas, as \n\npromastigotas se transformam ent\u00e3o em formas amastigotas. Embora os \n\nmacr\u00f3fagos sejam a principal c\u00e9lula hospedeira para a Leishmania, mon\u00f3citos, \n\nc\u00e9lulas dendr\u00edticas e neutr\u00f3filos recrutados para o local da infec\u00e7\u00e3o podem tornar-se \n\n\n\n33 \n\ninfectados e desempenhar pap\u00e9is importantes e distintos na forma\u00e7\u00e3o da resposta \n\nimune \u00e0 infec\u00e7\u00e3o (107). An\u00e1lises histopatol\u00f3gicas da les\u00e3o prim\u00e1ria em modelo \n\nmurino evidenciaram alta frequ\u00eancia de eosin\u00f3filos e mast\u00f3citos nas fases iniciais da \n\ninfec\u00e7\u00e3o (111). Os diferentes tipos celulares da resposta imune inata interagem com \n\nmol\u00e9culas do parasito (denominadas \u201cPAMPs\u201d \u2013 padr\u00f5es moleculares associados a \n\npat\u00f3genos) atrav\u00e9s dos receptores do tipo Toll (TLRs). Estas intera\u00e7\u00f5es s\u00e3o \n\nimportantes no direcionamento da resposta imune na infec\u00e7\u00e3o por Leishmania por \n\nfornecerem est\u00edmulos necess\u00e1rios para ativa\u00e7\u00e3o da transcri\u00e7\u00e3o de genes nas c\u00e9lulas \n\ndo sistema imune inato, que s\u00e3o respons\u00e1veis pela produ\u00e7\u00e3o de citocinas pr\u00f3-\n\ninflamat\u00f3rias e mol\u00e9culas co-estimulat\u00f3rias (112). \n\nOs neutr\u00f3filos s\u00e3o rapidamente recrutados para o local da inocula\u00e7\u00e3o e \n\npossuem papel importante nos momentos iniciais da infec\u00e7\u00e3o. Eles atuam na \n\ntentativa de impedir a sobreviv\u00eancia dos parasitos, atrav\u00e9s de mecanismos \n\noxidantes e dependentes de proteases; e ao interagir com mon\u00f3citos, macr\u00f3fagos, \n\nc\u00e9lulas dendriticas e linf\u00f3citos T e B, direcionando as respostas inflamat\u00f3rias \n\nenvolvidas na defesa do hospedeiro e na repara\u00e7\u00e3o tecidual (113). Alguns estudos \n\nmostram a contribui\u00e7\u00e3o de NETs (neutrophil extracellular traps) na indu\u00e7\u00e3o de morte \n\nda Leishmania, mas ainda n\u00e3o \u00e9 bem determinado se as NETs possuem papel \n\nprotetor in vivo (114,115). Neutr\u00f3filos necr\u00f3ticos podem ser fagocitados por \n\nmacr\u00f3fagos, induzindo a ativa\u00e7\u00e3o destes atrav\u00e9s da produ\u00e7\u00e3o de mediadores pr\u00f3-\n\ninflamat\u00f3rios. Entretanto, a coopera\u00e7\u00e3o entre macr\u00f3fagos e neutr\u00f3filos pode \n\ncontribuir para a susceptibilidade ap\u00f3s infec\u00e7\u00e3o por L. (L.) amazonensis e L. (L.) \n\nmajor, limitando a ativa\u00e7\u00e3o das c\u00e9lulas fagoc\u00edticas, o que leva a uma melhor \n\nsobreviv\u00eancia do parasito (116\u2013118). Os neutr\u00f3filos tamb\u00e9m influenciam na \n\ndiminui\u00e7\u00e3o da ativa\u00e7\u00e3o de c\u00e9lulas dendr\u00edticas, reduzindo a resposta do tipo Th1 e \n\ninibindo a apresenta\u00e7\u00e3o cruzada para a ativa\u00e7\u00e3o dos linf\u00f3citos T CD8+ (119,120).  \n\nEmbora as formas amastigotas possam ser rapidamente encontradas no \n\ninterior de neutr\u00f3filos ap\u00f3s a infec\u00e7\u00e3o, no interior de fag\u00f3citos mononucleares a \n\nLeishmania encontra um ambiente mais adequado para sua replica\u00e7\u00e3o e \n\nsobreviv\u00eancia a longo prazo. Mon\u00f3citos inflamat\u00f3rios e c\u00e9lulas dendr\u00edticas \n\nrecrutados ao local de inocula\u00e7\u00e3o apresentam amastigotas em seu interior poucas \n\nhoras ap\u00f3s a infec\u00e7\u00e3o e, ao longo dos primeiros dias, passam a ser as popula\u00e7\u00f5es \n\ndominantemente infectadas com os parasitos de Leishmania (119,121,122). A \n\nconsequ\u00eancia da infec\u00e7\u00e3o de mon\u00f3citos \u00e9 distinta da infec\u00e7\u00e3o de macr\u00f3fagos. Os \n\n\n\n34 \n\nmon\u00f3citos exibem um intenso burst respirat\u00f3rio imediatamente ap\u00f3s a infec\u00e7\u00e3o, \n\nlevando a um controle parasit\u00e1rio inicial, enquanto os macr\u00f3fagos necessitam de \n\nativa\u00e7\u00e3o por IFN-? para destruir os parasitos (122). Os macr\u00f3fagos s\u00e3o as c\u00e9lulas \n\nmais importantes do sistema imune inato na infec\u00e7\u00e3o por Leishmania, por \n\ndesempenharem um papel triplo: como c\u00e9lulas hospedeiras, como c\u00e9lulas \n\napresentadoras de ant\u00edgenos (APCs) e como c\u00e9lulas efetoras (123). Os macr\u00f3fagos \n\nativados classicamente secretam IL-2 e produzem esp\u00e9cies reativas de oxig\u00eanio \n\n(ROS), geradas no burst respirat\u00f3rio durante a fagocitose, e \u00f3xido n\u00edtrico (NO), \n\nresultante da ativa\u00e7\u00e3o via IFN-?, as quais s\u00e3o capazes de eliminar os parasitos de \n\nforma eficaz (107). Os parasitos do g\u00eanero Leishmania s\u00e3o sens\u00edveis \u00e0s ROS, mas o \n\nburst respirat\u00f3rio que ocorre em macr\u00f3fagos n\u00e3o-ativados \u00e9 insuficiente para matar \n\nos parasitos. A ativa\u00e7\u00e3o via IFN-? \u00e9 capaz de aumentar o burst respirat\u00f3rio nos \n\nmacr\u00f3fagos, levando \u00e0 destrui\u00e7\u00e3o mais eficaz do parasito (124). As citocinas IFN-? e \n\nfator de necrose tumoral (TNF) atuam sinergicamente promovendo a ativa\u00e7\u00e3o \u00f3tima \n\nde macr\u00f3fagos, que induz a produ\u00e7\u00e3o de NO e consequente elimina\u00e7\u00e3o da \n\nLeishmania (125). Em condi\u00e7\u00f5es alternativas ou desfavor\u00e1veis, por\u00e9m, os \n\nmacr\u00f3fagos ativados preferencialmente ativam a via da arginase para produzir \n\npoliaminas, mecanismo este que favorece a replica\u00e7\u00e3o do parasito (126\u2013128). \n\nMacr\u00f3fagos infectados atuam ainda como APCs e apresentam o ant\u00edgeno \n\nprocessado ao receptor de c\u00e9lulas T (TCR) dos linf\u00f3citos Th0 CD4+ atrav\u00e9s do \n\ncomplexo principal de histocompatibilidade (MHC) classe II. O TCR reconhece o \n\ncomplexo pept\u00eddeo-MHC II e, simultaneamente, mol\u00e9culas co-estimulat\u00f3rias, como \n\nB7-1/B7-2, ICAM-1 e LFA-3 no macr\u00f3fago s\u00e3o reconhecidas por seus receptores \n\n(CD28, LFA-1 e CD2, respectivamente) na superf\u00edcie dos linf\u00f3citos, promovendo \n\nent\u00e3o a ativa\u00e7\u00e3o destes (36,41,129). A presen\u00e7a de citocinas \u00e9 fundamental para os \n\nprocessos de ativa\u00e7\u00e3o e controle da dissemina\u00e7\u00e3o parasit\u00e1ria e estas s\u00e3o \n\ninicialmente produzidas por c\u00e9lulas do sistema imune inato. No entanto, ap\u00f3s esta \n\nresposta inicial inespec\u00edfica, uma resposta imune adquirida, espec\u00edfica aos \n\nant\u00edgenos de Leishmania, determina o curso da infec\u00e7\u00e3o. \n\nO desenvolvimento da les\u00e3o e a evolu\u00e7\u00e3o da doen\u00e7a s\u00e3o determinados pela \n\nnatureza e magnitude da resposta imune mediada por linf\u00f3citos T. A atividade \n\nefetora m\u00fatua e a coopera\u00e7\u00e3o entre os linf\u00f3citos T CD4+ e T CD8+ parecem definir o \n\ncurso da doen\u00e7a, respons\u00e1vel pela imunopatogenia da LTA (130). Ap\u00f3s serem \n\nativados, os linf\u00f3citos T CD4+ passam a ser respons\u00e1veis por orquestrar e direcionar \n\na resposta imune adaptativa. Em modelo murino de infec\u00e7\u00e3o por L. (L.) major foi \n\n\n\n35 \n\nevidenciado que uma resposta do tipo 1, com produ\u00e7\u00e3o de citocinas pr\u00f3-\n\ninflamat\u00f3rias como IL-2 e IFN-?, est\u00e1 associada a um bom progn\u00f3stico e evolu\u00e7\u00e3o \n\npara a cura; enquanto uma resposta do tipo 2, com produ\u00e7\u00e3o de citocinas anti-\n\ninflamat\u00f3rias como IL-4 e IL-5, \u00e9 relacionada a uma anergia celular e progress\u00e3o da \n\ndoen\u00e7a (131). Entretanto, esta resposta de linf\u00f3citos T CD4+ polarizada n\u00e3o \u00e9 \n\nevidente na leishmaniose humana e a import\u00e2ncia da IL-4 como mediador prim\u00e1rio \n\nde susceptibilidade \u00e0 infec\u00e7\u00e3o n\u00e3o \u00e9 corroborada nos ensaios cl\u00ednicos (132). Na \n\ninfec\u00e7\u00e3o humana por L. (V.) braziliensis \u00e9 sugerido que elevados percentuais de \n\nlinf\u00f3citos T CD4+ ativados produtores de IFN-? s\u00e3o associados com maiores les\u00f5es e \n\nque uma resposta Th1 exacerbada \u00e9 relacionada ao polo hiper\u00e9rgico da doen\u00e7a, \n\nsendo observada em pacientes de LM (132,133).  \n\nNeste contexto, \u00e9 bem determinado que os linf\u00f3citos T CD4+ s\u00e3o essenciais \n\npara o controle da Leishmania e seus perfis de citocinas v\u00eam sendo bastante \n\nestudados. Estes linf\u00f3citos s\u00e3o divididos em subpopula\u00e7\u00f5es com base no perfil de \n\ncitocinas produzidas e fatores de transcri\u00e7\u00e3o envolvidos, induzindo assim respostas \n\nespec\u00edficas: Th1 secretam principalmente IFN-? e s\u00e3o importantes contra infec\u00e7\u00f5es \n\ncausadas por pat\u00f3genos intracelulares; Th2 secretam principalmente IL-4 e IL-5 e \n\nfornecem prote\u00e7\u00e3o contra pat\u00f3genos extracelulares; Th17 secretam principalmente \n\nIL-17 e s\u00e3o importantes em infec\u00e7\u00f5es f\u00fangicas, na regula\u00e7\u00e3o da inflama\u00e7\u00e3o durante \n\ninfec\u00e7\u00f5es e na autoimunidade; T reguladoras (Treg) secretam IL-10 e TGF-? e \n\natuam na toler\u00e2ncia perif\u00e9rica e na regula\u00e7\u00e3o de respostas ap\u00f3s infec\u00e7\u00f5es; e T \n\nfoliculares (Tfh) secretam principalmente IL-21 e s\u00e3o especializadas em interagir \n\ncom as c\u00e9lulas B (134\u2013137). Ainda, em adi\u00e7\u00e3o a estas fun\u00e7\u00f5es auxiliares, os \n\nlinf\u00f3citos T CD4+ s\u00e3o capazes de exercer um papel citot\u00f3xico, com a habilidade de \n\nlisar diretamente c\u00e9lulas infectadas ou alteradas (138). Entretanto, o papel da \n\ncitotoxicidade na leishmaniose ainda n\u00e3o foi elucidado e tem sido frequentemente \n\nassociado ao dano tecidual (130,139\u2013144). \n\nA fun\u00e7\u00e3o citot\u00f3xica dos linf\u00f3citos T CD4+ vem sendo observada h\u00e1 muitos \n\nanos, tanto em humanos quanto em camundongos, mas tais relatos eram isolados e \n\ngeralmente associados a longos per\u00edodos de cultura, sendo ent\u00e3o considerados por \n\nalguns autores como artefatos (145\u2013150). Atualmente, s\u00e3o reconhecidos como uma \n\nsubpopula\u00e7\u00e3o especializada de linf\u00f3citos T CD4+, poss\u00edvel de ser identificada por \n\nalgumas prote\u00ednas marcadoras espec\u00edficas ou fatores de transcri\u00e7\u00e3o (151). Linf\u00f3citos \n\nT CD4+ citot\u00f3xicos s\u00e3o detectados e estudados principalmente em infec\u00e7\u00f5es virais \n\n\n\n36 \n\n(152), mas tamb\u00e9m t\u00eam sido descritos em respostas antitumorais e inflamat\u00f3rias, \n\ncomo doen\u00e7as autoimunes e infec\u00e7\u00f5es parasit\u00e1rias, associados tanto \u00e0 infec\u00e7\u00f5es \n\nagudas como cr\u00f4nicas (153\u2013157). Entretanto, pouco ainda \u00e9 conhecido sobre o \n\npapel dos linf\u00f3citos T CD4+ citot\u00f3xicos nas infec\u00e7\u00f5es n\u00e3o-virais e os fatores que \n\nlevam \u00e0 gera\u00e7\u00e3o desta popula\u00e7\u00e3o.  \n\nUm marcador espec\u00edfico para os linf\u00f3citos T CD4+ citot\u00f3xicos ainda n\u00e3o foi \n\ndeterminado, mas alguns marcadores relacionados \u00e0 fun\u00e7\u00e3o citot\u00f3xica podem ser \n\nempregados (158). Os linf\u00f3citos T CD4+, assim como outras c\u00e9lulas citot\u00f3xicas \n\ncl\u00e1ssicas (como os linf\u00f3citos T CD8+ e c\u00e9lulas NK) exercem sua fun\u00e7\u00e3o citot\u00f3xica \n\nefetora principalmente atrav\u00e9s da via de exocitose de gr\u00e2nulos l\u00edticos (159\u2013161). Por \n\nesta via, ap\u00f3s a ativa\u00e7\u00e3o das c\u00e9lulas citot\u00f3xicas, se inicia uma cascata de \n\nsinaliza\u00e7\u00e3o intracelular que rapidamente direciona os gr\u00e2nulos secret\u00f3rios dispersos \n\nno citoplasma para o s\u00edtio da sinapse imunol\u00f3gica formada com a c\u00e9lula-alvo e \n\nliberam seu conte\u00fado t\u00f3xico (162,163). Estes gr\u00e2nulos secret\u00f3rios possuem um \n\ndenso n\u00facleo onde s\u00e3o armazenadas prote\u00ednas que, cooperativamente, causam a \n\nmorte da c\u00e9lula-alvo. Destas, as principais s\u00e3o perforinas e granzimas, mas tamb\u00e9m \n\nest\u00e3o presentes granulisina e catepsinas (164,165). Na superf\u00edcie dos gr\u00e2nulos \n\nl\u00edticos s\u00e3o expressas prote\u00ednas de membrana associadas \u00e0 lisossomos (LAMPs \u2013 \n\nlysosomal-associated membrane proteins), incluindo CD107a (LAMP-1), CD107b \n\n(LAMP-2) e CD63 (LAMP-3). Essas mol\u00e9culas s\u00e3o encontradas na membrana \n\ninterna dos gr\u00e2nulos e s\u00e3o expostas na superf\u00edcie das c\u00e9lulas citot\u00f3xicas durante o \n\nprocesso de degranula\u00e7\u00e3o, que \u00e9 um pr\u00e9-requisito para a lise das c\u00e9lulas-alvo \n\nmediada por gr\u00e2nulos (166,167). Estas mol\u00e9culas t\u00eam sido empregadas como \n\nmarcadores de degranula\u00e7\u00e3o (167,168) e podem, desta forma, serem utilizadas para \n\na identificar os linf\u00f3citos T CD4+ citot\u00f3xicos (158). Outros receptores caracter\u00edsticos \n\nde c\u00e9lulas citot\u00f3xicas cl\u00e1ssicas, como NKG2A e NKG2D, tamb\u00e9m s\u00e3o expressos \n\npelos linf\u00f3citos T CD4+ citot\u00f3xicos, indicando similaridade de caracter\u00edsticas e \n\nfun\u00e7\u00f5es (169\u2013171). Podem ainda produzir citocinas com perfil Th1, como IFN-?, \n\nprincipalmente, TNF e IL-2 (172\u2013174). Entretanto, apesar de compartilharem esta \n\ncaracter\u00edstica com os linf\u00f3citos Th1, uma condi\u00e7\u00e3o polarizada por citocinas com este \n\nperfil n\u00e3o \u00e9 ideal para a gera\u00e7\u00e3o de T CD4+ citot\u00f3xicos, sendo melhores induzidos \n\nna presen\u00e7a de IL-2, IL-12 e IL-15 (151,175) . \n\nOs linf\u00f3citos T CD8+ desempenham dois pap\u00e9is principais na resposta imune \n\nadaptativa: como c\u00e9lulas citot\u00f3xicas e produtoras de citocinas. Atrav\u00e9s de seu TCR, \n\n\n\n37 \n\nos linf\u00f3citos T CD8+ reconhecem os pept\u00eddeos que s\u00e3o apresentados no contexto \n\nMHC classe I. Geralmente, estes pept\u00eddeos s\u00e3o de origem end\u00f3gena, entretanto \n\ntamb\u00e9m pode ocorrer via TCR a apresenta\u00e7\u00e3o de pept\u00eddeos ex\u00f3genos por um \n\nmecanismo de \u201capresenta\u00e7\u00e3o cruzada\u201d, como observado com ant\u00edgenos de \n\nLeishmania (176). Ainda n\u00e3o \u00e9 completamente compreendido como os linf\u00f3citos T \n\nCD8+ s\u00e3o ativados na leishmaniose, mas \u00e9 bem estabelecido que eles respondem \n\nespecificamente durante a infec\u00e7\u00e3o por Leishmania. Entretanto, se as fun\u00e7\u00f5es que \n\nestas c\u00e9lulas adquirem ap\u00f3s sua ativa\u00e7\u00e3o s\u00e3o relacionadas a um papel protetor, \n\npatol\u00f3gico ou irrelevante na infec\u00e7\u00e3o tem sido discutido (177).  \n\nJ\u00e1 est\u00e1 claro que, ap\u00f3s a ativa\u00e7\u00e3o, os linf\u00f3citos T CD8+ se diferenciam em \n\nc\u00e9lulas efetoras e adquirem capacidade citot\u00f3xica e de produ\u00e7\u00e3o de citocinas, \n\nprincipalmente IFN-?, TNF-? e IL-2, mas tamb\u00e9m IL-4, IL-5, IL-10, IL-17 e TGF-? \n\n(129,178,179). Seu papel protetor tem sido associado principalmente \u00e0 sua \n\ncapacidade de produzir n\u00edveis elevados de IFN-? (180\u2013185). Foi sugerido que, em \n\nadi\u00e7\u00e3o \u00e0 produ\u00e7\u00e3o de IFN-?, a produ\u00e7\u00e3o de perforina por linf\u00f3citos T CD8+ tamb\u00e9m \u00e9 \n\ncrucial para a imunidade induzida por vacina contra L. (L.) amazonensis (186). \n\nAlguns estudos sugeriram um papel protetor e ben\u00e9fico dos linf\u00f3citos T CD8+ \n\ntamb\u00e9m na infec\u00e7\u00e3o por L. (V.) braziliensis (40,187\u2013190). Entretanto, estudos mais \n\nrecentes v\u00eam relacionando a fun\u00e7\u00e3o citot\u00f3xica dos linf\u00f3citos T CD8+ ao dano \n\ntecidual e exacerba\u00e7\u00e3o da doen\u00e7a, principalmente nas infec\u00e7\u00f5es por L. (V.) \n\nbraziliensis. A caracteriza\u00e7\u00e3o gen\u00f4mica de les\u00f5es de pacientes de LC confirmou que \n\na citotoxicidade \u00e9 a principal caracter\u00edstica de les\u00f5es de L. braziliensis (142). A \n\nexpress\u00e3o de genes associados \u00e0 fun\u00e7\u00e3o citot\u00f3xica e dos genes envolvidos na \n\nfun\u00e7\u00e3o de barreira cut\u00e2nea foram negativamente correlacionadas, sugerindo que a \n\ncitotoxicidade e a perda de integridade da pele ocorrem concomitante na LC (142). A \n\npresen\u00e7a de linf\u00f3citos T CD8+ e c\u00e9lulas NK com forte express\u00e3o de TIA-1 (uma \n\nmol\u00e9cula associada com citotoxicidade) foi observada em les\u00f5es de pacientes de \n\nLC, sugerindo a participa\u00e7\u00e3o destas c\u00e9lulas na patogenia da doen\u00e7a, podendo ser \n\ntanto na tentativa de eliminar o parasito, quanto estar contribuindo para o \n\ndesenvolvimento da les\u00e3o (140). Linf\u00f3citos T CD8+ de pacientes de LC em est\u00e1gio \n\ntardio apresentam maior express\u00e3o de granzima A que pacientes em est\u00e1gio inicial. \n\nEsta express\u00e3o foi positivamente correlacionada com a intensidade do infiltrado \n\ninflamat\u00f3rio nos pacientes em est\u00e1gio tardio, mas n\u00e3o nos pacientes em est\u00e1gio \n\ninicial, sugerindo que h\u00e1 um recrutamento de linf\u00f3citos T CD8+ com perfil citot\u00f3xico \n\npara a les\u00e3o, que foi associado com a progress\u00e3o da infec\u00e7\u00e3o (Faria et al, 2009). \n\n\n\n38 \n\nLinf\u00f3citos T CD8+ em degranula\u00e7\u00e3o foram observados em les\u00f5es cut\u00e2neas, o que foi \n\nassociado com promo\u00e7\u00e3o de dano tecidual (142,143). A associa\u00e7\u00e3o da a\u00e7\u00e3o \n\ncitot\u00f3xica com o dano tecidual tamb\u00e9m foi observada em pacientes de LM \n\n(139,191,192). Neste contexto, os linf\u00f3citos T CD8+ parecem desempenhar pap\u00e9is \n\ndistintos em diferentes fases da leishmaniose e nas diferentes formas cl\u00ednicas, \n\nsendo necess\u00e1rios mais estudos no intuito de desvendar os fatores que determinam \n\nquando esta resposta \u00e9 protetora e quando contribui para a manuten\u00e7\u00e3o da infec\u00e7\u00e3o \n\n(177).  \n\n\u00c9 conhecido que c\u00e9lulas NK representam uma das primeiras linhas de defesa \n\ncontra a Leishmania e que sofrem uma ativa\u00e7\u00e3o r\u00e1pida e transiente nos momentos \n\niniciais da infec\u00e7\u00e3o (193,194). Entretanto, o papel desempenhado por estas c\u00e9lulas \n\nao longo da infec\u00e7\u00e3o n\u00e3o \u00e9 bem definido (195). As c\u00e9lulas NK s\u00e3o uma popula\u00e7\u00e3o \n\nde linf\u00f3citos granulares componentes da resposta imune inata, mas que interagem \n\ncom a resposta imune adaptativa, e est\u00e3o envolvidas na resposta imune em v\u00e1rios \n\ntipos de tumores e infec\u00e7\u00f5es por pat\u00f3genos, com capacidade de limilitar sua \n\npropaga\u00e7\u00e3o e o dano tecidual subsequente (196,197). Fenotipicamente, podem ser \n\ndefinidas por sua express\u00e3o de CD56 e CD16 e aus\u00eancia de CD3 (198). Ap\u00f3s \n\nativa\u00e7\u00e3o, as c\u00e9lulas NK adquirem a capacidade de exercer suas fun\u00e7\u00f5es efetoras: \n\nprodu\u00e7\u00e3o de citocinas e quimiocinas; express\u00e3o de ligantes co-estimulat\u00f3rios; e \n\nmecanismos de citoxicidade. As c\u00e9lulas NK s\u00e3o especializadas na produ\u00e7\u00e3o de IFN-\n\n? e TNF, que contribuem para o desenvolvimento de uma resposta tipo 1 e ativa\u00e7\u00e3o \n\nde macr\u00f3fagos para execu\u00e7\u00e3o de mecanismos antimicrobicidas (125,199). Podem \n\nproduzir tamb\u00e9m GM-CSF, IL-5, IL-13, MIP-1 e RANTES (200\u2013202). Ainda, c\u00e9lulas \n\nNK adquirem capacidade de produzir IL-10 durante infec\u00e7\u00f5es sist\u00eamicas, atuando \n\ncomo reguladores da resposta imune atrav\u00e9s da inibi\u00e7\u00e3o de IL-12, como \n\ndemonstrado em modelo experimental de infec\u00e7\u00e3o por L. (L.) donovani, agente \n\netiol\u00f3gico da LV (203). A express\u00e3o de ligantes co-estimulat\u00f3rios pelas c\u00e9lulas NK, \n\ncomo CD40L e OX40L, para linf\u00f3citos T ou B, representa uma liga\u00e7\u00e3o direta entre a \n\nimunidade inata e adaptativa. As APCs estimulam c\u00e9lulas NK, que, por sua vez, \n\nfornecem sinais co-estimulat\u00f3rios para os linf\u00f3citos (204,205). C\u00e9lulas NK s\u00e3o \n\nconsideradas c\u00e9lulas citot\u00f3xicas cl\u00e1ssicas, sendo seu principal mecanismo de \n\ncitoxicidade a via de exocitose de gr\u00e2nulos l\u00edticos (206). Ainda, as c\u00e9lulas NK \n\npossuem a capacidade de lisar diretamente c\u00e9lulas revestidas por anticorpos, \n\natrav\u00e9s de um mecanismo denominado citotoxicidade anticorpo-dependente (ADCC \n\n\n\n39 \n\n\u2013 Antibody-dependent cell cytotoxicity), por meio da ativa\u00e7\u00e3o do receptor CD16 \n\n(207).  \n\nA intera\u00e7\u00e3o entre Leishmania, macr\u00f3fagos e a resposta imune adaptativa tem \n\nsido bastante estudada, contudo a informa\u00e7\u00e3o sobre as c\u00e9lulas NK e NKT na \n\ninfec\u00e7\u00e3o permanece escassa (208). Embora os linf\u00f3citos T CD8+, T CD4+ e c\u00e9lulas \n\nNK, assim como as c\u00e9lulas NKT, exer\u00e7am atividade citot\u00f3xica comum, os \n\nmecanismos de reconhecimento s\u00e3o diferentes. Os linf\u00f3citos T CD8+ e CD4+ \n\ncitot\u00f3xicos induzem apoptose da c\u00e9lula-alvo ap\u00f3s o reconhecimento antig\u00eanico \n\nespec\u00edfico atrav\u00e9s do MHC classe I e classe II, respectivamente. C\u00e9lulas NKT, por \n\nsua vez, reconhecem ant\u00edgenos apresentados preferencialmente pela glicoprote\u00edna \n\nCD1d. J\u00e1 as c\u00e9lulas NK s\u00e3o ativadas e destroem c\u00e9lulas-alvo atrav\u00e9s de \n\nmecanismos independentes de apresenta\u00e7\u00e3o antig\u00eanica espec\u00edfica (209). Suas \n\nfun\u00e7\u00f5es s\u00e3o reguladas pela integra\u00e7\u00e3o de sinais de receptores de ativa\u00e7\u00e3o e \n\nreceptores inibit\u00f3rios que reconhecem ligantes na superf\u00edcie de c\u00e9lulas-alvo \n\npotenciais. A regula\u00e7\u00e3o positiva de ligantes para receptores de ativa\u00e7\u00e3o na c\u00e9lula \n\nNK (por exemplo, NKG2D) ou a regula\u00e7\u00e3o negativa de ligantes para receptores de \n\ninibi\u00e7\u00e3o (por exemplo, CD94-NKG2A) j\u00e1 s\u00e3o est\u00edmulos relevantes para a ativa\u00e7\u00e3o \n\ndestas c\u00e9lulas (210\u2013212). Muitos dos receptores inibit\u00f3rios expressos pelas c\u00e9lulas \n\nNK, como os KIR (Killer Immunoglobulin-like Receptors), reconhecem mol\u00e9culas de \n\nMHC classe I. Deste modo, a aus\u00eancia ou altera\u00e7\u00e3o da express\u00e3o de MHC classe I, \n\ngeralmente observada em c\u00e9lulas infectadas, impede a liga\u00e7\u00e3o do sinal inibit\u00f3rio, \n\nresultando na ativa\u00e7\u00e3o das c\u00e9lulas NK (210,213,214). \n\nAlguns estudos apontam para um papel protetor das c\u00e9lulas NK na LT. \n\nC\u00e9lulas NK de indiv\u00edduos curados ou indiv\u00edduos sadios moradores de \u00e1rea end\u00eamica \n\ns\u00e3o capazes de uma prolifera\u00e7\u00e3o mais acentuada e maior produ\u00e7\u00e3o de IFN-? ap\u00f3s \n\nestimula\u00e7\u00e3o in vitro com ant\u00edgenos de Leishmania quando comparados com \n\npacientes com LC ativa (215,216). Experimentos in vitro demonstraram a \n\nimport\u00e2ncia das c\u00e9lulas NK devido a sua a\u00e7\u00e3o citot\u00f3xica, lisando macr\u00f3fagos \n\ninfectados e induzindo a morte de promastigotas extracelulares; e de produ\u00e7\u00e3o de \n\ncitocinas, direcionando a resposta imune para um perfil Th1 e ativando macr\u00f3fagos \n\n(194,217\u2013223). Foi poss\u00edvel detectar a atividade citot\u00f3xica e de produ\u00e7\u00e3o de IFN-? \n\ndas c\u00e9lulas NK em linfonodos perif\u00e9ricos logo no primeiro dia de infec\u00e7\u00e3o por L. (L.) \n\nmajor em modelos experimentais de LC com cura espont\u00e2nea (194,218). Entretanto, \n\nalguns estudos sugerem que o papel citot\u00f3xico das c\u00e9lulas NK na LT n\u00e3o seja \n\n\n\n40 \n\nprotetor, contribuindo para a progress\u00e3o da les\u00e3o e gravidade da doen\u00e7a (139,140). \n\nEm resumo, as c\u00e9lulas NK s\u00e3o componentes importantes na resposta imune contra \n\npat\u00f3genos intracelulares, como a Leishmania, seja por sua a\u00e7\u00e3o citot\u00f3xica, pela \n\nprodu\u00e7\u00e3o de citocinas ou por suas fun\u00e7\u00f5es regulat\u00f3rias, sendo capazes de modular \n\nrespostas imunes. Entretanto, ainda \u00e9 necess\u00e1rio definir qual o papel destas c\u00e9lulas \n\nna infec\u00e7\u00e3o por Leishmania e se estas contribuem para cura ou progress\u00e3o da \n\npatologia (224\u2013226). \n\nAs c\u00e9lulas NKT s\u00e3o subtipos de linf\u00f3citos que expressam receptores de \n\nsuperf\u00edcie caracter\u00edsticos de linf\u00f3citos T (CD3) e de c\u00e9lulas NK (CD56 e CD16), \n\npromovendo uma intera\u00e7\u00e3o entre o sistema imune inato e adaptativo (227). Apesar \n\nde apresentarem TCR, como os linf\u00f3citos T convencionais, nas c\u00e9lulas NKT estes \n\nreceptores interagem com uma variedade limitada de ant\u00edgenos, similarmente aos \n\nPAMPs da imunidade inata. Estes ant\u00edgenos s\u00e3o de natureza lip\u00eddica ou glicolip\u00eddica \n\ne s\u00e3o apresentados exclusivamente pela glicoprote\u00edna CD1d, uma mol\u00e9cula \n\nsemelhante ao MHC I, \u00e0s c\u00e9lulas NKT. A CD1d \u00e9 expressa predominantemente por \n\nc\u00e9lulas hematopoi\u00e9ticas e mais abundantes nas APCs, tim\u00f3citos CD4+CD8+ (duplo-\n\npositivos) e linf\u00f3citos B de zona marginal (228\u2013230,227,231\u2013233). A maioria das \n\nc\u00e9lulas NKT \u00e9 denominada tipo I ou invariante (iNKT) e expressam um TCR semi-\n\ninvariante composto das cadeias V?24J?18 e V?11 em humanos (227,234\u2013236). O \n\noutro subtipo, denominadas NKT variantes (vNKT) ou do tipo II, expressam TCRs \n\nmais diversos e frequentemente possuem fun\u00e7\u00e3o oposta ou regulat\u00f3ria \u00e0s c\u00e9lulas \n\niNKT (237). Outro par\u00e2metro que \u00e9 comumente utilizado para definir as c\u00e9lulas iNKT \n\n\u00e9 sua habilidade de reconhecer e ser fortemente ativada por ?-galactosilceramida \n\n(?GalCer) (227), que \u00e9 um glicolip\u00eddeo com potentes efeitos anti-tumorais em \n\ncamundongos (238). As c\u00e9lulas vNKT tamb\u00e9m s\u00e3o restritas \u00e0 apresenta\u00e7\u00e3o \n\nantig\u00eanica por CD1d, por\u00e9m n\u00e3o possuem TCR semi-invariante e n\u00e3o s\u00e3o capazes \n\nde reconhecer ?GalCer (227,239). As c\u00e9lulas vNKT expressam um repert\u00f3rio de \n\nTCR mais diverso, que \u00e9 pouco conhecido, e s\u00e3o capazes de reconhecer uma \n\nvariedade de ant\u00edgenos hidrof\u00f3bicos, incluindo sulfatide, lisofosfatidilcolina e \n\npequenas mol\u00e9culas arom\u00e1ticas (n\u00e3o-lip\u00eddicas) (240\u2013244).  \n\nAs c\u00e9lulas NKT se assemelham mais \u00e0s c\u00e9lulas do sistema imune inato \n\nfuncionalmente por exercerem suas fun\u00e7\u00f5es efetoras rapidamente ap\u00f3s ativa\u00e7\u00e3o \n\n(245). S\u00e3o capazes de exercer fun\u00e7\u00f5es citot\u00f3xicas, mas s\u00e3o mais estudadas por sua \n\npotente capacidade de produ\u00e7\u00e3o de citocinas variadas, tanto pr\u00f3- quanto anti-\n\n\n\n41 \n\ninflamat\u00f3rias, desempenhando principalmente papel regulador em uma ampla gama \n\nde respostas imunes (227,232,246). As c\u00e9lulas NKT humanas podem ser CD4+, \n\nCD8+ ou duplo-negativas (DN), apesar de se desenvolverem independente de \n\nsinaliza\u00e7\u00e3o de MHC I ou II. Diferen\u00e7as funcionais t\u00eam sido observadas entre estes \n\nsubtipos e existem evid\u00eancias de que a mol\u00e9cula CD4 \u00e9 a respons\u00e1vel por estas \n\ndiferen\u00e7as (247\u2013251). As c\u00e9lulas NKT CD4+ produzem n\u00edveis mais elevados de IL-4, \n\nIL-13, GM-CSF e IL-2 do que as c\u00e9lulas NKT que n\u00e3o expressam CD4, enquanto a \n\nprodu\u00e7\u00e3o de TNF e IFN-? \u00e9 elevada em todos os subtipos. As c\u00e9lulas NKT CD8+ \n\nexibem atividade citot\u00f3xica mais potente do que as c\u00e9lulas NKT DN e CD4neg, \n\nrespectivamente (247,248,252). C\u00e9lulas NKT murinas s\u00e3o bastante distintas das \n\nc\u00e9lulas NKT humanas, n\u00e3o sendo observadas subpopula\u00e7\u00f5es com express\u00e3o de \n\nCD8, al\u00e9m das iNKT apresentarem um TCR distinto (251,253). \n\nAs c\u00e9lulas NKT est\u00e3o envolvidas em processos imunol\u00f3gicos em diversas \n\ndoen\u00e7as, como c\u00e2ncer e doen\u00e7as auto-imunes, rejei\u00e7\u00e3o a transplantes e imunidade \n\ncontra agentes infecciosos, como a Leishmania (232). Na leishmaniose, \u00e9 sugerido \n\nque estas c\u00e9lulas sejam capazes de sofrer ativa\u00e7\u00e3o por ant\u00edgenos do glicoc\u00e1lix de \n\nLeishmania apresentados via CD1d, devido \u00e0 sua semelhan\u00e7a com ?-GalCer. \n\nExemplos destes ant\u00edgenos s\u00e3o o lipofosfoglicano (LPG) de L. (L.) donovani, glico-\n\ninositol-fosfolip\u00eddeos (GIPLs) e glicosil-fosfatidil-inositol (GPI) (254,255). Outra via de \n\nativa\u00e7\u00e3o \u00e9 de forma indireta, atrav\u00e9s de citocinas como IL-12 ou IL-18 produzidas \n\npor APCs (256,257). Foi demonstrado que c\u00e9lulas NKT s\u00e3o capazes de produzir \n\nIFN-? ap\u00f3s incuba\u00e7\u00e3o com c\u00e9lulas dendr\u00edticas previamente ativadas por L. (L.) \n\nmexicana (208). Na infec\u00e7\u00e3o por L. (L.) major, c\u00e9lulas NKT apresentam ativa\u00e7\u00e3o \n\ndiminu\u00edda, devido \u00e0 capacidade do parasito de inibir a express\u00e3o de CD1d nas \n\nc\u00e9lulas dendr\u00edticas (258). Ainda assim, estas c\u00e9lulas t\u00eam sido associadas a um \n\npapel crucial nos est\u00e1gios iniciais da resposta imune protetora e no direcionamento \n\npara um perfil de resposta Th1 ou Th2 em infec\u00e7\u00f5es por L. (L.) major (259,260). \n\nEntretanto, os estudos sobre a atividade das c\u00e9lulas NKT na LT humana s\u00e3o ainda \n\nmuitos escassos (261). \n\nNeste contexto, os linf\u00f3citos T CD8+, T CD4+, c\u00e9lulas NK e NKT compartilham \n\na capacidade de atuarem como c\u00e9lulas citot\u00f3xicas, tendo como principal via a de \n\nexocitose de gr\u00e2nulos l\u00edticos (161). Entretanto, na LT, a fun\u00e7\u00e3o citot\u00f3xica ainda n\u00e3o \n\n\u00e9 bem elucidada e v\u00e1rios estudos v\u00eam tentando compreender tal fun\u00e7\u00e3o e sua \n\nrela\u00e7\u00e3o com a cura ou a progress\u00e3o da doen\u00e7a (107). Juntamente com a fun\u00e7\u00e3o \n\n\n\n42 \n\ncitot\u00f3xica, \u00e9 de fundamental import\u00e2ncia tentar entender os perfis de ativa\u00e7\u00e3o das \n\npopula\u00e7\u00f5es celulares. \u00c9 conhecido que a persist\u00eancia parasit\u00e1ria cr\u00f4nica tem \n\nprofundo impacto na capacidade efetora de c\u00e9lulas T ant\u00edgeno-espec\u00edficas, \n\ninduzindo uma perda gradual de fun\u00e7\u00e3o (262). A imunorregula\u00e7\u00e3o via receptores \n\ninibit\u00f3rios \u00e9 uma das principais vias de exaust\u00e3o celular, que \u00e9 um estado definido \n\npor pobre fun\u00e7\u00e3o efetora, express\u00e3o sustentada de receptores inibit\u00f3rios e estado \n\ntranscricional distinto das c\u00e9lulas efetoras ou de mem\u00f3ria funcionais (262). O \n\nreceptor inibit\u00f3rio CD279, tamb\u00e9m chamado receptor de morte programada-1 (PD-1 \n\n\u2013 programmed death-1), \u00e9 o principal receptor inibit\u00f3rio envolvido na exaust\u00e3o de \n\nc\u00e9lulas T (262). A identifica\u00e7\u00e3o da via regulat\u00f3ria \u00e9 importante para distinguir a \n\nexaust\u00e3o de c\u00e9lulas T de outros tipos de defeitos, como a regula\u00e7\u00e3o negativa de \n\nCD3 ou de TCR (263,264). Linf\u00f3citos T CD8+ e T CD4+ exaustos s\u00e3o comumente \n\ndetectados em infec\u00e7\u00f5es virais cr\u00f4nicas e agudas. A perda de fun\u00e7\u00e3o normalmente \n\nocorre de maneira gradual e as c\u00e9lulas podem perder completamente a habilidade \n\nde produzir citocinas e de degranular (265\u2013268). Similarmente aos linf\u00f3citos T, \n\nc\u00e9lulas NK e NKT com express\u00e3o de CD279 foram detectadas em infec\u00e7\u00f5es virais e \n\nbacterianas e em tumores, nas quais apresentaram caracter\u00edsticas de perda de \n\nfun\u00e7\u00e3o (269\u2013274). \n\nAinda, \u00e9 necess\u00e1rio a compreens\u00e3o da rela\u00e7\u00e3o dos fen\u00f4menos que ocorrem \n\nsistemicamente e no s\u00edtio da infec\u00e7\u00e3o pela Leishmania. A migra\u00e7\u00e3o dos linf\u00f3citos da \n\ncircula\u00e7\u00e3o para a les\u00e3o \u00e9 um processo complexo que envolve muitas mol\u00e9culas que \n\nos direcionam especificamente. Selectinas e integrinas s\u00e3o fam\u00edlias de mol\u00e9culas de \n\nades\u00e3o que medeiam este processo de migra\u00e7\u00e3o e direcionam as c\u00e9lulas para os \n\ncompartimentos apropriados (275). Para acesso ao compartimento de pele, as \n\nc\u00e9lulas utilizam um \"c\u00f3digo\" de pele denominado receptor ant\u00edgeno linfocit\u00e1rio \n\ncut\u00e2neo (CLA \u2013 cutaneous lymphocyte-associated antigen), que \u00e9 um membro da \n\nfam\u00edlia das selectinas expresso em c\u00e9lulas T de mem\u00f3ria e que se liga ao receptor \n\nde E-selectina nas c\u00e9lulas endoteliais da pele inflamada (276). O CLA tem sido \n\nreconhecido como uma das mais importantes mol\u00e9culas de homing para pele e sua \n\nexpress\u00e3o em linf\u00f3citos ativados pode afetar a composi\u00e7\u00e3o celular do infiltrado \n\ninflamat\u00f3rio (276). Consequentemente, o CLA tem sido associado \u00e0 patog\u00eanese ou \n\ngravidade de muitas doen\u00e7as inflamat\u00f3rias da pele, como dermatites e tamb\u00e9m na \n\nleishmaniose cut\u00e2nea (277\u2013279). O detalhamento dos processos de migra\u00e7\u00e3o \n\ncelular e forma\u00e7\u00e3o do infiltrado inflamat\u00f3rio auxilia na compreens\u00e3o dos eventos \n\n\n\n43 \n\nimunopatog\u00eanicos que ocorrem in situ, que s\u00e3o determinantes para a progress\u00e3o ou \n\nresolu\u00e7\u00e3o da les\u00e3o. \n\n\n\n44 \n\n2. JUSTIFICATIVA \n\nA leishmaniose cut\u00e2nea (LC) \u00e9 uma das doen\u00e7as negligenciadas de maior \n\nimport\u00e2ncia para a sa\u00fade p\u00fablica, com registro de cerca de 20.000 novos casos \n\nanualmente no Brasil, a maioria causada pela esp\u00e9cie Leishmania (Viannia) \n\nbraziliensis, que \u00e9 a esp\u00e9cie respons\u00e1vel pela infec\u00e7\u00e3o no estado do Rio de Janeiro. \n\nO desfecho cl\u00ednico da doen\u00e7a \u00e9 determinado principalmente pela resposta imune \n\ndesencadeada pelo hospedeiro. A obten\u00e7\u00e3o de sucesso na cura de pacientes de LC \n\nparece estar associada ao desencadeamento de uma resposta imune eficaz o \n\nsuficiente para levar \u00e0 cicatriza\u00e7\u00e3o da les\u00e3o, em contraste com a impotente resposta \n\nimune desenvolvida por pacientes que apresentam quadros de falha terap\u00eautica. \n\nApesar dos esfor\u00e7os dos grupos de pesquisa por todo o mundo, ainda n\u00e3o existe \n\numa vacina eficaz contra as leishmanioses e os esquemas terap\u00eauticos empregados \n\napresentam taxas vari\u00e1veis de cura e elevada toxidade. Neste contexto, \u00e9 urgente a \n\nnecessidade da compreens\u00e3o dos fen\u00f4menos imunol\u00f3gicos envolvidos na \n\npatog\u00eanese da infec\u00e7\u00e3o, bem como no desenvolvimento de cura e prote\u00e7\u00e3o.  \n\nA resposta imune mediada por c\u00e9lulas T \u00e9 determinante no curso da infec\u00e7\u00e3o, \n\nentretanto n\u00e3o \u00e9 bem estabelecido qual o perfil de c\u00e9lulas efetoras \u00e9 respons\u00e1vel por \n\nlevar \u00e0 cura da doen\u00e7a. Uma forte resposta inflamat\u00f3ria e a presen\u00e7a de c\u00e9lulas \n\ncitot\u00f3xicas na les\u00e3o s\u00e3o caracter\u00edsticas da infec\u00e7\u00e3o por L. (V.) braziliensis. Sendo \n\nassim, com intuito de obter um maior entendimento acerca do papel das popula\u00e7\u00f5es \n\ncelulares potencialmente citot\u00f3xicas na imunopatogenia da LC, o desenho \n\nexperimental deste trabalho visa avaliar a frequ\u00eancia e os perfis de degranula\u00e7\u00e3o, \n\nativa\u00e7\u00e3o, exaust\u00e3o e endere\u00e7amento para a les\u00e3o dos linf\u00f3citos T CD8+, T CD4+, \n\nc\u00e9lulas NK e NKT em um estudo de pacientes de LC na evolu\u00e7\u00e3o para a cura cl\u00ednica \n\ne em epis\u00f3dios de falha terap\u00eautica. As informa\u00e7\u00f5es obtidas atrav\u00e9s das an\u00e1lises \n\nfenot\u00edpico-funcionais das popula\u00e7\u00f5es celulares citot\u00f3xicas certamente resultar\u00e3o em \n\nnovas perspectivas para estudos vacinais e terapias mais eficientes e menos \n\nagressivas. \n\n\n\n45 \n\n3.  OBJETIVO GERAL \n\nDelinear os perfis imunol\u00f3gicos das popula\u00e7\u00f5es celulares potencialmente \n\ncitot\u00f3xicas (linf\u00f3citos T CD8+, T CD4+, c\u00e9lulas NK e NKT) na resposta imune de \n\npacientes de leishmaniose cut\u00e2nea, da fase ativa at\u00e9 a cura cl\u00ednica e em epis\u00f3dios \n\nde falha terap\u00eautica.  \n\n \n\n3.1. Objetivos Espec\u00edficos \n\n- Determinar a distribui\u00e7\u00e3o das popula\u00e7\u00f5es de linf\u00f3citos T CD8+, T CD4+, \n\nc\u00e9lulas NK e NKT no sangue perif\u00e9rico de pacientes com forma ativa da \n\nleishmaniose cut\u00e2nea, durante a terapia e clinicamente curados;  \n\n- Verificar a atividade de degranula\u00e7\u00e3o de linf\u00f3citos T CD8+, T CD4+, c\u00e9lulas \n\nNK e NKT do sangue perif\u00e9rico de pacientes com a forma ativa da leishmaniose \n\ncut\u00e2nea, durante a terapia e clinicamente curados;  \n\n- Estabelecer os perfis de distribui\u00e7\u00e3o e de citotoxicidade das diferentes \n\nsubpopula\u00e7\u00f5es de linf\u00f3citos T CD8+ (T CD8dim e T CD8bright), c\u00e9lulas NK (NK CD56dim \n\ne NK CD56bright) e NKT (NK CD8+, NKT CD4+, NKT CD8negCD4neg, NKT CD8+CD4+) \n\ndo sangue perif\u00e9rico de pacientes com a forma ativa da leishmaniose cut\u00e2nea, \n\ndurante a terapia e clinicamente curados;  \n\n- Avaliar a resposta de linf\u00f3citos T CD8+, T CD4+, c\u00e9lulas NK e NKT do \n\nsangue perif\u00e9rico de pacientes com a forma ativa da leishmaniose cut\u00e2nea, durante \n\na terapia e clinicamente curados, quando estimulados com ant\u00edgenos particulados \n\nde L. (V.) braziliensis;  \n\n- Analisar o efeito do ant\u00edgeno de L. (V.) braziliensis na frequ\u00eancia, ativa\u00e7\u00e3o e \n\natividade citot\u00f3xica de linf\u00f3citos T CD8+, T CD4+, c\u00e9lulas NK e NKT obtidos do \n\nsangue perif\u00e9rico de pacientes com a forma ativa da leishmaniose cut\u00e2nea, durante \n\na terapia e clinicamente curados; \n\n- Detectar um potencial comprometimento da funcionalidade dos linf\u00f3citos T \n\nCD8+, linf\u00f3citos T CD4+, c\u00e9lulas NK e NKT no sangue perif\u00e9rico de pacientes com a \n\nforma ativa da leishmaniose cut\u00e2nea, durante a terapia e clinicamente curados \n\ninduzido pelo ant\u00edgeno de L. (V.) braziliensis; \n\n- Verificar a influ\u00eancia do ant\u00edgeno L. (V.) braziliensis nos perfis de \n\nendere\u00e7amento para a les\u00e3o dos linf\u00f3citos T CD8+, linf\u00f3citos T CD4+, c\u00e9lulas NK e \n\n\n\n46 \n\nNKT do sangue perif\u00e9rico de pacientes com a forma ativa da leishmaniose cut\u00e2nea, \n\ndurante a terapia e clinicamente curados; \n\n- Correlacionar os dados cl\u00ednicos dos pacientes (tempo de evolu\u00e7\u00e3o da \n\ndoen\u00e7a, reatividade ao teste de Montenegro, n\u00famero e tamanho das les\u00f5es) com os \n\nperfis de distribui\u00e7\u00e3o, citotoxicidade, ativa\u00e7\u00e3o, exaust\u00e3o e migra\u00e7\u00e3o para a pele dos \n\nlinf\u00f3citos T CD8+, linf\u00f3citos T CD4+, c\u00e9lulas NK e NKT do sangue perif\u00e9rico; \n\n- Comparar a resposta antig\u00eanica quanto \u00e0s caracter\u00edsticas de distribui\u00e7\u00e3o, \n\ncitotoxicidade, ativa\u00e7\u00e3o, exaust\u00e3o e migra\u00e7\u00e3o para a pele dos linf\u00f3citos T CD8+, \n\nlinf\u00f3citos T CD4+, c\u00e9lulas NK e NKT do sangue perif\u00e9rico de pacientes que \n\nevolu\u00edram para a cura ap\u00f3s a terapia com aqueles que apresentam quadro de falha \n\nterap\u00eautica;  \n\n- Determinar a concentra\u00e7\u00e3o de IL-15 produzida em resposta ao ant\u00edgeno de \n\nL. (V.) braziliensis, correlacionando com o processo de doen\u00e7a e de cura cl\u00ednica; \n\n- Correlacionar a concentra\u00e7\u00e3o de IL-15 com os perfis de distribui\u00e7\u00e3o, \n\ncitotoxicidade, ativa\u00e7\u00e3o, exaust\u00e3o e migra\u00e7\u00e3o para a les\u00e3o dos linf\u00f3citos T CD8+, \n\nlinf\u00f3citos T CD4+, c\u00e9lulas NK e NKT do sangue perif\u00e9rico de pacientes com a forma \n\nativa da leishmaniose cut\u00e2nea, durante a terapia e clinicamente curados; \n\n- Determinar a concentra\u00e7\u00e3o de IL-15 no plasma sangu\u00edneo e sua rela\u00e7\u00e3o \n\ncom o processo de doen\u00e7a e evolu\u00e7\u00e3o para a cura cl\u00ednica; \n\n- Comparar a concentra\u00e7\u00e3o de IL-15 no microambiente da les\u00e3o de \n\nleishmaniose cut\u00e2nea com a concentra\u00e7\u00e3o observada em doen\u00e7as n\u00e3o-\n\nrelacionadas, como a esporotricose. \n\n \n\n\n\n47 \n\n4. MATERIAL E M\u00c9TODOS \n\n4.1. Casu\u00edstica \n\nForam inclu\u00eddos neste estudo um total de trinta e dois pacientes de LC e \n\ncatorze indiv\u00edduos sadios, com idade entre dezoito e setenta anos. Os indiv\u00edduos \n\nsadios n\u00e3o possu\u00edam hist\u00f3rico pr\u00e9vio de leishmaniose e n\u00e3o residiam em \u00e1reas \n\nend\u00eamicas da doen\u00e7a. Os pacientes eram residentes no estado do Rio de Janeiro e \n\nforam atendidos e diagnosticados para LC no Laborat\u00f3rio de Vigil\u00e2ncia em \n\nLeishmanioses do INI/FIOCRUZ. O diagn\u00f3stico foi confirmado ap\u00f3s serem \n\nrealizadas as devidas avalia\u00e7\u00f5es da hist\u00f3ria cl\u00ednica e epidemiol\u00f3gica dos pacientes; \n\nIDRM; isolamento e caracteriza\u00e7\u00e3o do parasito; e diagn\u00f3stico diferencial com outras \n\ndoen\u00e7as atrav\u00e9s de exame micol\u00f3gico e bacteriol\u00f3gico. Os crit\u00e9rios de exclus\u00e3o \n\nforam: idade inferior a dezoito anos e superior a setenta anos, presen\u00e7a de \n\ncomorbidade e gravidez, tratamento pr\u00e9vio com drogas leishmanicidas e visita pr\u00e9via \n\n\u00e0 \u00e1rea end\u00eamica fora do Estado do Rio de Janeiro. \n\nTodos os pacientes diagnosticados positivamente para LC foram ent\u00e3o \n\nsubmetidos a um ensaio cl\u00ednico de tratamento, randomizado e duplo cego, com \n\nantimoniato de N-metilglucamina (Glucantime\u00ae). O crit\u00e9rio de cura cl\u00ednica foi definido \n\npor epiteliza\u00e7\u00e3o total das les\u00f5es ap\u00f3s conclus\u00e3o do esquema terap\u00eautico (8). Em \n\ncaso de aus\u00eancia de cicatriza\u00e7\u00e3o completa ap\u00f3s uso do Glucantime\u00ae, o tratamento \n\nfoi considerado insatisfat\u00f3rio, ou seja, determinado como \u201cfalha terap\u00eautica\u201d, sendo, \n\nnestes casos, necess\u00e1rio um esquema terap\u00eautico alternativo ou a repeti\u00e7\u00e3o de um \n\nciclo da mesma terapia antimonial. A tabela 2 mostra as principais caracter\u00edsticas \n\ncl\u00ednicas e epidemiol\u00f3gicas dos pacientes inclu\u00eddos no estudo.  \n\nO presente estudo segue a resolu\u00e7\u00e3o 196/96 do Conselho Nacional de Sa\u00fade \n\nque trata das diretrizes e normas de pesquisas envolvendo seres humanos. O \n\ndesenho experimental e o Termo de Consentimento Livre e Esclarecido (anexo 1) \n\nforam aprovados pelo Comit\u00ea de \u00c9tica em Pesquisa do INI (CEP-INI)/FIOCRUZ sob \n\no n\u00famero 029/2012. \n\n \n\n\n\n48 \n\nTabela 2. Caracter\u00edsticas cl\u00ednicas e epidemiol\u00f3gicas dos pacientes de LC. \n\nPaciente Idade (anos) Sexo \nN\u00famero de \n\nles\u00f5es \n\nTamanho \n\nda les\u00e3o \n\n(maior \n\ndi\u00e2metro) \n\n(mm)\na \n\nTempo de \n\nevolu\u00e7\u00e3o \n\nat\u00e9 in\u00edcio do \n\ntratamento \n\nIDRM\nb\n \n\n(mm) \nDesfecho \n\n1 22 M\nc \n\n1 34 40 24 Cura cl\u00ednica \n\n2 56 F\nd \n\n1 36 60 36 Cura cl\u00ednica \n\n3 24 M 1 45 90 n.d.\ne \n\nCura cl\u00ednica \n\n4 28 M 1 20 30 11 Cura cl\u00ednica \n\n5 44 M 1 28 120 n.d. Cura cl\u00ednica \n\n6 29 M 1 50 120 n.d. Cura cl\u00ednica \n\n7 70 M 1 n.d. 15 25 Cura cl\u00ednica \n\n8 46 M 4 75 180 27 Cura cl\u00ednica \n\n9 52 M 1 24 90 47 Cura cl\u00ednica \n\n10 51 F 1 40 60 n.d. Cura cl\u00ednica \n\n11 70 M 7 n.d. 210 10 Cura cl\u00ednica \n\n12 32 F 1 130 120 n.d. Cura cl\u00ednica \n\n13 59 M 1 20 60 12 Cura cl\u00ednica \n\n14 30 M 5 n.d. 45 20 Cura cl\u00ednica \n\n15 52 M 1 22 120 n.d. Cura cl\u00ednica \n\n16 31 M 1 47 330 n.d. Cura cl\u00ednica \n\n17 59 M 1 60 120 11 Cura cl\u00ednica \n\n18 23 F 1 35 120 n.d. Cura cl\u00ednica \n\n19 43 M 2 37 90 17 Cura cl\u00ednica \n\n20 31 M 1 58 150 19 Cura cl\u00ednica \n\n21 19 M 1 22 60 18 Cura cl\u00ednica \n\n22 26 M 4 n.d. 60 n.d. Cura cl\u00ednica \n\n23 47 M 1 45 30 14 Cura cl\u00ednica \n\n24 18 F 1 50 60 pos\nf \n\nCura cl\u00ednica \n\n25 19 M 1 30 30 22 Cura cl\u00ednica \n\n26 30 M 4 n.d. 120 n.d. Cura cl\u00ednica \n\n27 25 M 1 14 n.d. n.d. Cura cl\u00ednica \n\n28 57 F 1 21 60 n.d. Cura cl\u00ednica \n\n29 42 F 1 35 90 10 Cura cl\u00ednica \n\n30* 48 M 9 24 180 n.d. Falha terap\u00eautica \n\n31* 31 M 3 50 180 n.d. Falha terap\u00eautica \n\n32* 38 M 1 70 40 3 Falha terap\u00eautica \n\n \n\namm: mil\u00edmetros;  \nbIDRM: Intradermorrea\u00e7\u00e3o de Montenegro;  \ncM: masculino;  \ndF: feminino;  \nen.d.: n\u00e3o determinado; \nfpos: positivo. \n\n \n\n\n\n49 \n\n4.2. Coleta do Material Biol\u00f3gico \n\nAmostras de sangue perif\u00e9rico foram obtidas por pun\u00e7\u00e3o venosa em tubos \n\nheparinizados (Becton, Dickinson and Company \u2013 BD, Franklin Lakes, NJ, E.U.A.) \n\nem um volume m\u00e1ximo de 40 mL de cada indiv\u00edduo, no Setor de Coleta no INI e \n\nenviadas ao Laborat\u00f3rio de Imunoparasitologia (IOC/FIOCRUZ) para \n\nprocessamento. O tempo m\u00e1ximo entre a coleta do material biol\u00f3gico e o \n\nprocessamento do mesmo foi de vinte e quatro horas e durante este per\u00edodo os \n\ntubos com sangue ficaram \u00e0 temperatura ambiente (20 \u00b1 2oC) em agitador orbital \n\nsob homogeneiza\u00e7\u00e3o (Arsec, S\u00e3o Paulo, SP, Brasil). \n\n \n\n4.3. Obten\u00e7\u00e3o, Criopreserva\u00e7\u00e3o e Recupera\u00e7\u00e3o das C\u00e9lulas Mononucleares \n\ndo Sangue Perif\u00e9rico (CMSP) \n\nAs CMSP foram obtidas atrav\u00e9s de centrifuga\u00e7\u00e3o em gradiente de densidade \n\nFicoll-Hypaque (Histopaque\u00ae 1077; Sigma-Aldrich, St. Louis, MO, E.U.A.), como \n\ndescrito a seguir. O sangue heparinizado foi dilu\u00eddo na propor\u00e7\u00e3o 1:1 em meio de \n\ncultura RPMI 1640 (Gibco, Carlsbad, CA, E.U.A.), suplementado com HEPES \n\n(10mM; Sigma-Aldrich), 2-mercaptoetanol (1mM; Gibco), L-glutamina (1,5mM; \n\nSigma-Aldrich), penicilina (200UI; Sigma-Aldrich) e estreptomicina (200mg/mL; \n\nSigma-Aldrich). O sangue dilu\u00eddo foi ent\u00e3o depositado cuidadosamente sobre o \n\nFicoll-Hypaque, numa propor\u00e7\u00e3o 2:1, em tubo de polipropileno de fundo c\u00f4nico \n\n(Corning Inc., Tewksbury, MA, E.U.A.). Posteriormente, esta amostra foi submetida a \n\numa centrifuga\u00e7\u00e3o a 400 giros por 30 minutos a 20\u00baC, sem acelera\u00e7\u00e3o e sem freio \n\n(Fisher Scientific, Pittsburgh, PA, E.U.A.). As CMSP foram coletadas do anel de \n\nc\u00e9lulas formado na interface entre o soro e o Ficoll, sendo em seguida submetidas a \n\ntr\u00eas lavagens por centrifuga\u00e7\u00e3o (10 minutos/ 250 giros/ 20\u00b0C, com acelera\u00e7\u00e3o e \n\nfreio) em meio RPMI suplementado. \n\nAp\u00f3s a \u00faltima lavagem, as CMSP obtidas foram ressuspendidas em soro fetal \n\nbovino (SFB; Sigma-Aldrich) e contadas em c\u00e2mara de Neubauer (Laboroptik Ltd., \n\nLancing, GBR) com aux\u00edlio de microsc\u00f3pio \u00f3ptico (Carl Zeiss Inc., Thornwood, NY, \n\nE.U.A.). A viabilidade das c\u00e9lulas foi determinada atrav\u00e9s da dilui\u00e7\u00e3o em corante \n\nAzul de Trypan (Sigma-Aldrich) e a concentra\u00e7\u00e3o de c\u00e9lulas vi\u00e1veis foi ajustada para \n\n1x107/mL de solu\u00e7\u00e3o de criopreserva\u00e7\u00e3o, que consiste em SFB com 10% de \n\ndimetilsulf\u00f3xido (DMSO; Sigma-Aldrich). Cada 1 mL desta suspens\u00e3o de c\u00e9lulas foi \n\nacondicionado em um tubo de criopreserva\u00e7\u00e3o (criotubo; Nunc A/S, Kamstrupvej, \n\n\n\n50 \n\nRoskilde, DNK), que foi colocado em recipiente pr\u00f3prio para congelamento (5100 \n\nCryo 1\u00b0C Freezing Container \u2013 \u201cMr. Frosty\u201d; Nalgene, Rochester, NY, E.U.A.) e \n\nmantido overnight \u00e0 temperatura de 80\u00b0C negativos. Ap\u00f3s este tempo, os criotubos \n\nforam transferidos para containers de nitrog\u00eanio l\u00edquido, onde foram armazenados \n\nat\u00e9 sua utiliza\u00e7\u00e3o. \n\nPara a realiza\u00e7\u00e3o dos ensaios experimentais, as CMSP criopreservadas \n\nforam descongeladas em banho-maria (VWR, Radnor, PA, E.U.A.) a 37\u00b0C, e \n\nvertidas em 10 mL de meio RPMI suplementado acrescido de 20% de SFB (Sigma-\n\nAldrich). Ap\u00f3s homogeneiza\u00e7\u00e3o, foram realizadas duas lavagens por centrifuga\u00e7\u00e3o \n\n(1500 rpm/10 min/ 4\u00baC/ com acelera\u00e7\u00e3o e freio) e as CMSP foram ressuspendidas \n\nem meio RPMI suplementado. A recupera\u00e7\u00e3o e viabilidade foram determinadas \n\natrav\u00e9s da contagem em c\u00e2mara de Neubauer (Laboroptik Ltd) com a utiliza\u00e7\u00e3o do \n\ncorante Azul de Trypan (Sigma-Aldrich) e somente foram utilizadas amostras cuja \n\nviabilidade foi superior a 85%.  \n\n \n\n4.4. Parte 1 \u2013 Ensaios ex vivo \n\nA primeira parte do estudo resultou na publica\u00e7\u00e3o do artigo I (anexo 2) e \n\ncompreendeu avalia\u00e7\u00f5es de ensaios ex vivo de pacientes de LC, assim como de \n\nindiv\u00edduos sadios (inclu\u00eddos como grupo controle). A casu\u00edstica dessa parte do \n\ntrabalho incluiu catorze pacientes de LC oriundos do estado do Rio de Janeiro, os \n\nquais apresentaram cura cl\u00ednica em sua totalidade, al\u00e9m de onze indiv\u00edduos sadios. \n\nOs pacientes de LC foram divididos em tr\u00eas grupos: \n\n- Pacientes antes do in\u00edcio da terapia antimonial (BT, do ingl\u00eas before \n\ntreatment) \u2013 avaliados ap\u00f3s a confirma\u00e7\u00e3o do diagn\u00f3stico, momento no qual \n\nos pacientes apresentavam a doen\u00e7a ativa e presen\u00e7a de les\u00e3o \n\nleishmani\u00f3tica (n= 8). \n\n- Pacientes durante a terapia antimonial (DT, do ingl\u00eas during therapy) \u2013 \n\navaliados no vig\u00e9simo dia ap\u00f3s o in\u00edcio da terapia antimonial, momento no \n\nqual os pacientes apresentavam les\u00f5es ainda n\u00e3o totalmente cicatrizadas \n\n(n=8). \n\n- Pacientes com cura cl\u00ednica recente (CC, do ingl\u00eas clinical cure) \u2013 avaliados no \n\noctog\u00e9simo dia ap\u00f3s o in\u00edcio da terapia antimonial, momento no qual as \n\nterapias j\u00e1 haviam sido conclu\u00eddas e os pacientes foram considerados \n\n\n\n51 \n\nclinicamente curados de acordo com crit\u00e9rios definidos pela equipe m\u00e9dica do \n\nINI/ FIOCRUZ (n=8). \n\n \n\nComo alguns pacientes foram repetidos nos grupos, o n\u00famero de amostras \n\nde sangue perif\u00e9rico de pacientes processadas foi igual a oito por grupo, totalizando \n\nvinte e quatro amostras de pacientes inclu\u00eddas no estudo. \n\nAs CMSP recuperadas foram dispostas em placas de 96 po\u00e7os de fundo \u201cU\u201d \n\n(Corning Inc.) em uma concentra\u00e7\u00e3o de 3,0 X 105 c\u00e9lulas/100 \u00b5L em meio RPMI \n\nsuplementado acrescido de 10% de SFB (Sigma-Aldrich). As placas foram \n\nincubadas a 37\u00b0C em atmosfera \u00famida de 5% de CO2 (Panasonic Healthcare \n\nCompany of North America, Wood Dale, IL, E.U.A.) na presen\u00e7a do anticorpo \n\nmonoclonal (AcMo) anti-CD107a (BD Biosciences) por uma hora, quando foi \n\nadicionada monensina (BD Golgi-StopTM, BD Biosciences) (6 ?g/mL) e acrescidas \n\nmais cinco horas de incuba\u00e7\u00e3o, como descrito na literatura (167) e confirmado por \n\nexperimentos anteriores no nosso laborat\u00f3rio (280). A monensina \u00e9 importante para \n\nprevenir a acidifica\u00e7\u00e3o de ves\u00edculas endoc\u00edticas, evitando a degrada\u00e7\u00e3o de prote\u00ednas \n\nCD107a reinternalizadas. Ap\u00f3s incuba\u00e7\u00e3o total de seis horas, as c\u00e9lulas foram \n\nlavadas por centrifuga\u00e7\u00e3o (2000 rpm/ 5 min.) em meio RPMI suplementado e \n\nressuspendidas em 50 ?L de uma solu\u00e7\u00e3o tamp\u00e3o fosfato-salino (PBS) contendo \n\n0,1% de azida s\u00f3dica (Merck, Frankfurter Str., Darmstadt, Alemanha) e 2% de SFB \n\n(Sigma-Aldrich) (PBS azida). As CMSP foram ent\u00e3o submetidas \u00e0 marca\u00e7\u00e3o com os \n\nseguintes AcMo: anti-CD3, anti-CD4, anti-CD8 e anti-CD56 (BD Biosciences; \n\nBeckman Coulter, BREA, CA, E.U.A.). Ap\u00f3s incuba\u00e7\u00e3o por 20 minutos a 4\u00baC \n\nprotegidas da luz, as c\u00e9lulas foram lavadas por centrifuga\u00e7\u00e3o (2000 rpm/ 5min.) em \n\nPBS azida, e fixadas em paraformalde\u00eddo (PFA; Sigma-Aldrich) a 1% e mantidas a \n\n4\u00baC, protegidas da luz, por um per\u00edodo m\u00e1ximo de at\u00e9 24 horas para aquisi\u00e7\u00e3o em \n\ncit\u00f4metro de fluxo.  \n\nA combina\u00e7\u00e3o de marcadores utilizados nas an\u00e1lises citofluorim\u00e9tricas para \n\navaliar as caracter\u00edsticas celulares est\u00e1 descrita na Tabela 3. \n\n \n\n\n\n52 \n\nTabela 3: Combina\u00e7\u00e3o de anticorpos monoclonais utilizados como marcadores para avaliar diferentes \ncaracter\u00edsticas celulares por citometria de fluxo nos ensaios experimentais ex vivo. \n \n\n \n\nAn\u00e1lise Citofluorim\u00e9trica Caracter\u00edstica Celular \n\nCD56negCD3+CD4+ Linf\u00f3citos T CD4+ \n\nCD56negCD3+CD8+ Linf\u00f3citos T CD8+ \n\nCD56negCD3+CD8dim Linf\u00f3citos T CD8dim \n\nCD56neg CD3+CD8bright Linf\u00f3citos T CD8bright \n\nCD3negCD56+ C\u00e9lulas NK \n\nCD3negCD56dim C\u00e9lulas NK CD56dim \n\nCD3negCD56bright C\u00e9lulas NK CD56bright \n\nCD3+CD56+ C\u00e9lulas NKT \n\nCD3+CD56+ CD8+CD4+ C\u00e9lulas NKT DP \n\nCD3+CD56+ CD8negCD4+ C\u00e9lulas NKT CD4+ \n\nCD3+CD56+ CD8+CD4neg C\u00e9lulas NKT CD8+ \n\nCD3+CD56+ CD8negCD4neg C\u00e9lulas NKT DN \n\nCD107a+ C\u00e9lulas em degranula\u00e7\u00e3o \n\n \n\nneg: negativo; \n\nbright: c\u00e9lulas que apresentam alta intensidade de fluoresc\u00eancia;  \n\ndim: c\u00e9lulas que apresentam baixa intensidade de fluoresc\u00eancia. \n\n \n\n \n\n4.4.1. Citometria de Fluxo \n\nNesta parte do estudo, foram utilizados dois cit\u00f4metros de fluxo: MoFlo \n\nAstrios (Beckman Coulter), da Plataforma Multiusu\u00e1rios de Citometria de Fluxo do \n\nIOC, N\u00facleo de Purifica\u00e7\u00e3o Celular (Cell Sorting); e FACS Aria II (BD Biosciences), \n\nda Plataforma de Citometria de Fluxo da Rede de Plataformas Tecnol\u00f3gicas do \n\nPrograma de Desenvolvimento Tecnol\u00f3gico em Insumos para Sa\u00fade (PDTIS), \n\nFIOCRUZ. As amostras foram adquiridas em um total de 50 mil eventos dentro de \n\numa regi\u00e3o criada de acordo com as caracter\u00edsticas morfol\u00f3gicas de tamanho e \n\ngranularidade das c\u00e9lulas e as an\u00e1lises citofluorim\u00e9tricas foram realizadas utilizando \n\no programa computacional espec\u00edfico Kaluza 1.2 (Beckman Coulter). \n\n\n\n53 \n\nAcMo isot\u00edpicos anti-IgG, conjugados aos mesmos fluorocromos usados nos \n\nensaios ex vivo, foram empregados como controles negativos de marca\u00e7\u00e3o e para o \n\najuste da voltagem ideal. Amostras com marca\u00e7\u00e3o simples para cada fluorocromo \n\nutilizado foram aplicadas para a compensa\u00e7\u00e3o de cores. Foi tamb\u00e9m empregada a \n\nestrat\u00e9gia de FMO (do ingl\u00eas Fluorescence Minus One), que cont\u00e9m todos os \n\nfluorocromos do painel, exceto aquele que est\u00e1 sendo avaliado. Realizados ent\u00e3o \n\ntodos os controles e ajustes, as amostras foram adquiridas em cit\u00f4metro de fluxo.  \n\n \n\n4.5. Parte 2 \u2013 Ensaios in vitro \n\nA segunda parte do estudo resultou no desenvolvimento do artigo II  \n\n(anexo 3) e compreendeu avalia\u00e7\u00f5es de ensaios in vitro de pacientes de LC, assim \n\ncomo de indiv\u00edduos sadios (inclu\u00eddos como grupo controle). A casu\u00edstica dessa parte \n\ndo trabalho incluiu vinte e quatro pacientes de LC oriundos do estado do Rio de \n\nJaneiro, os quais apresentaram cura cl\u00ednica em sua totalidade, al\u00e9m de sete \n\nindiv\u00edduos sadios. Os pacientes de LC foram divididos em tr\u00eas grupos: \n\n- Pacientes com a doen\u00e7a ativa (AD, do ingl\u00eas active disease) \u2013 avaliados ap\u00f3s \n\na confirma\u00e7\u00e3o do diagn\u00f3stico de LC, antes do in\u00edcio da terapia antimonial; \n\nmomento no qual os pacientes apresentavam les\u00e3o leishmani\u00f3tica (n= 17).  \n\n- Pacientes durante a terapia antimonial (DT, do ingl\u00eas during therapy) \u2013 \n\navaliados entre o d\u00e9cimo quinto e o vig\u00e9simo dia ap\u00f3s o in\u00edcio da terapia \n\nantimonial, momento no qual os pacientes apresentavam les\u00f5es ainda n\u00e3o \n\ntotalmente cicatrizadas (n=16). \n\n- Pacientes com cura cl\u00ednica recente (CC, do ingl\u00eas clinical cure) \u2013 avaliados no \n\noctog\u00e9simo dia ap\u00f3s o in\u00edcio da terapia antimonial, momento no qual as \n\nterapias j\u00e1 haviam sido conclu\u00eddas e os pacientes foram considerados \n\nclinicamente curados de acordo com crit\u00e9rios definidos pela equipe m\u00e9dica do \n\nINI/ FIOCRUZ (n=10). \n\n \n\nComo alguns pacientes foram repetidos nos grupos, o n\u00famero de amostras \n\nde sangue perif\u00e9rico de pacientes processadas foi vari\u00e1vel em cada grupo, \n\ntotalizando quarenta e tr\u00eas amostras de pacientes no estudo.  \n\nPara os ensaios in vitro, as CMSP recuperadas foram ajustadas para a \n\nconcentra\u00e7\u00e3o de 3,0 X 105 c\u00e9lulas/100 \u00b5L em meio RPMI suplementado acrescido \n\n\n\n54 \n\nde 10% de SFB e dispostas em placas de 96 po\u00e7os de fundo \u201cU\u201d (Corning Inc.) em \n\num volume final de 200 \u00b5L/po\u00e7o. As placas foram incubadas por setenta e duas \n\nhoras a 37\u00b0C em atmosfera \u00famida de 5% de CO2 (Panasonic) na presen\u00e7a de \n\nant\u00edgenos particulados de L. (V.) braziliensis (Lb-Ag), preparados conforme descrito \n\na seguir no item 4.5.3. C\u00e9lulas n\u00e3o estimuladas (background \u2013 BG) e estimuladas \n\ncom fitohemaglutinina (PHA, Sigma-Aldrich) (5 ?g/mL) foram cultivadas nas mesmas \n\ncondi\u00e7\u00f5es experimentais, servindo como controle negativo e positivo de estimula\u00e7\u00e3o, \n\nrespectivamente. Seis horas antes do final do tempo de incuba\u00e7\u00e3o, foi adicionado \u00e0s \n\nculturas o AcMo anti-CD107a (BD Biosciences) e, ap\u00f3s uma hora, foi adicionada \n\nmonensina (BD Golgi-StopTM, BD Biosciences) (6 ?g/mL). Ap\u00f3s o per\u00edodo total de 72 \n\nhoras de incuba\u00e7\u00e3o, as c\u00e9lulas foram ent\u00e3o lavadas por centrifuga\u00e7\u00e3o (2000 rpm/ 5 \n\nmin.) em meio RPMI suplementado, ressuspendidas em 50 ?L de PBS azida e \n\nsubmetidas \u00e0 marca\u00e7\u00e3o com os seguintes AcMo: anti-CD3, anti-CD4, anti-CD8, anti-\n\nCD56, anti-CD38 e anti-CD279 (BD Biosciences; Beckman Coulter; and BioLegend, \n\nSan Diego, CA, E.U.A.); e ainda com 7-aminoactinomicina D (7AAD; Sigma-Aldrich), \n\npara a exclus\u00e3o de c\u00e9lulas mortas. Ap\u00f3s incuba\u00e7\u00e3o por 20 minutos a 4\u00baC protegidas \n\nda luz, as c\u00e9lulas foram lavadas por centrifuga\u00e7\u00e3o (2000 rpm/ 5min.), \n\nressuspendidas em PBS azida e adquiridas imediatamente em cit\u00f4metro de fluxo. \n\nEm algumas amostras de pacientes AD (n=9) e nas amostras de indiv\u00edduos sadios \n\n(n=7) foi inclu\u00edda a marca\u00e7\u00e3o com o AcMo anti-TCR V?24-J?18 (Biolegend) para \n\navalia\u00e7\u00e3o do TCR invariante das c\u00e9lulas NKT invariantes (iNKT). \n\nA combina\u00e7\u00e3o de marcadores utilizados nas an\u00e1lises citofluorim\u00e9tricas para \n\navaliar as caracter\u00edsticas celulares est\u00e1 descrita na Tabela 4. \n\n \n\n\n\n55 \n\nTabela 4: Combina\u00e7\u00e3o de anticorpos monoclonais utilizados como marcadores para avaliar diferentes \ncaracter\u00edsticas celulares por citometria de fluxo nos ensaios experimentais in vitro. \n \n\nAn\u00e1lise Citofluorim\u00e9trica Caracter\u00edstica Celular \n\n7AADneg C\u00e9lulas vi\u00e1veis \n\nCD56negCD3+CD4+ Linf\u00f3citos T CD4+ \n\nCD56negCD3+CD8+ Linf\u00f3citos T CD8+ \n\nCD3negCD56+ C\u00e9lulas NK \n\nCD3+CD56+ C\u00e9lulas NKT CD3+CD56+ \n\nCD3+ TCR-V?24-J?18+ C\u00e9lulas NKT invariantes \n\nCD107a+ C\u00e9lulas em degranula\u00e7\u00e3o \n\nCD38+ C\u00e9lulas ativadas \n\nCD279+ C\u00e9lulas em exaust\u00e3o \n\n  \n\nneg: negativo \n\n \n\n4.5.1. Citometria de Fluxo \n\nPara todas as aquisi\u00e7\u00f5es desta etapa do trabalho foi utilizado o cit\u00f4metro de \n\nfluxo MoFlo Astrios (Beckman Coulter), da Plataforma Multiusu\u00e1rios de Citometria de \n\nFluxo do IOC, N\u00facleo de Purifica\u00e7\u00e3o Celular (Cell Sorting), FIOCRUZ. As amostras \n\nforam adquiridas em um total de 50 mil eventos de acordo com seus par\u00e2metros \n\nmorfol\u00f3gicos de tamanho e granularidade e as an\u00e1lises citofluorim\u00e9tricas foram \n\nrealizadas utilizando o programa computacional espec\u00edfico Kaluza 1.5a (Beckman \n\nCoulter). \n\nForam utilizados AcMo isot\u00edpicos anti-IgG conjugados aos mesmos \n\nfluorocromos usados nos ensaios in vitro como controles negativos de marca\u00e7\u00e3o e \n\npara o ajuste da voltagem ideal. Amostras com marca\u00e7\u00e3o simples para cada \n\nfluorocromo foram utilizadas para a compensa\u00e7\u00e3o de cores e foi tamb\u00e9m empregada \n\na estrat\u00e9gia de FMO. Realizados ent\u00e3o todos os controles e ajustes, as amostras \n\nforam adquiridas em cit\u00f4metro de fluxo.  \n\n \n\n \n\n \n\n\n\n56 \n\n4.5.2. Cin\u00e9tica de padroniza\u00e7\u00e3o do tempo de cultivo in vitro \n\nCom intuito de determinar qual o melhor tempo de cultivo das CMSP para a \n\ndetec\u00e7\u00e3o do pico m\u00e1ximo de degranula\u00e7\u00e3o (CD107a) em resposta Lb-Ag, foi \n\nrealizado experimento cin\u00e9tico de at\u00e9 120 horas. CMSP de tr\u00eas pacientes de LC \n\nclinicamente curados (CC) foram ajustadas para a concentra\u00e7\u00e3o de 3,0 x 105 \n\nc\u00e9lulas/100 \u00b5L em meio RPMI suplementado acrescido de 10% de SFB e cultivadas \n\nna presen\u00e7a de Lb-Ag em placa de 96 po\u00e7os de fundo \u201cU\u201d (Corning Inc.), em um \n\nvolume final de 200 \u00b5L por po\u00e7o, a 37\u00baC, sob atmosfera \u00famida de 5% CO2 por 6, 12, \n\n24, 48, 72, 96 e 120 horas. AcMo anti-CD107a e BD GolgiStop\u2122 (BD Biosciences) \n\nforam adicionados 6 e 5 horas, respectivamente, antes do tempo final de cada \n\nincuba\u00e7\u00e3o. CMSP n\u00e3o estimuladas (BG) e CMSP estimuladas com PHA (Sigma-\n\nAldrich) (5 ?g/mL) foram cultivadas nas mesmas condi\u00e7\u00f5es, servindo como controle \n\nnegativo e positivo de estimula\u00e7\u00e3o, respectivamente. Ap\u00f3s os per\u00edodos de \n\nincuba\u00e7\u00e3o, as c\u00e9lulas foram ent\u00e3o lavadas por centrifuga\u00e7\u00e3o (2000 rpm/ 5 min.) em \n\nmeio RPMI suplementado, ressuspendidas em 50 ?L de PBS azida e submetidas \u00e0 \n\nmarca\u00e7\u00e3o com AcMo anti-CD3 e 7AAD. Ap\u00f3s incuba\u00e7\u00e3o por 20 minutos a 4\u00baC \n\nprotegidas da luz, as c\u00e9lulas foram lavadas por centrifuga\u00e7\u00e3o (2000 rpm/ 5min.), \n\nressuspendidas em PBS azida e adquiridas imediatamente no cit\u00f4metro de fluxo \n\nMoFlo Astrios (Beckman Coulter), da Plataforma Multiusu\u00e1rios de Citometria de \n\nFluxo do IOC, N\u00facleo de Purifica\u00e7\u00e3o Celular (Cell Sorting), FIOCRUZ. As c\u00e9lulas \n\nforam marcadas tamb\u00e9m imediatamente ap\u00f3s o descongelamento, sem serem \n\nsubmetidas \u00e0 cultura, correspondendo ao tempo zero da cin\u00e9tica (Figura 5). \n\nAtrav\u00e9s desse experimento de cin\u00e9tica, pudemos determinar o tempo de 72 \n\nhoras de incuba\u00e7\u00e3o como tempo \u00f3timo para detec\u00e7\u00e3o do pico de CD107a, tanto para \n\nas CMSP cultivadas com Lb-Ag, como para os controles negativos (BG) e positivos \n\n(PHA) de estimula\u00e7\u00e3o (Figura 5). A express\u00e3o dos ant\u00edgenos estudados n\u00e3o variou \n\ndevido ao processo de criopreserva\u00e7\u00e3o. \n\n \n\n \n\n\n\n57 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 5. Experimento de cin\u00e9tica para a detec\u00e7\u00e3o do pico de express\u00e3o de CD107a. As CMSP \nprovenientes de tr\u00eas pacientes de LC clinicamente curados foram submetidas \u00e0 marca\u00e7\u00e3o com 7AAD \ne com os AcMo anti-CD107a e anti-CD3 imediatamente ap\u00f3s descongelamento (0H) e ap\u00f3s 6, 24, 48, \n72, 96 e 120 horas. Gr\u00e1fico representando os resultados da cin\u00e9tica referentes \u00e0s CMSP sem \nestimula\u00e7\u00e3o (BG) (pontos), estimuladas com Lb-Ag (quadrados) e com PHA (tri\u00e2ngulos). Cada \ns\u00edmbolo representa a m\u00e9dia de 3 indiv\u00edduos \u00b1 erro padr\u00e3o. CMSP: c\u00e9lulas mononucleares de sangue \nperif\u00e9rico; 7AAD: 7-aminoactinomicina D; AcMo: anticorpos monoclonais; H: horas; BG: background; \nLb-Ag: ant\u00edgeno particulado de Leishmania (Viannia) braziliensis; PHA: fitohemaglutinina. \n \n\n4.5.3. Preparo do ant\u00edgeno particulado de L. (V.) braziliensis (Lb-Ag) \n\nFormas promastigotas da cepa de refer\u00eancia de L. (V.) braziliensis \n\nMCAN/BR/98/R619 foram utilizadas para a obten\u00e7\u00e3o de ant\u00edgenos totais \n\nparticulados (Lb-Ag), os quais foram utilizados nos ensaios in vitro. Os parasitos \n\nforam expandidos em garrafas de poliestireno de 25 cm2 contendo meio de cultura \n\nSchneider (pH 7,2) suplementado com 1,5 mM de L-glutamina, penicilina (200 UI), \n\nestreptomicina (200 \u00b5g/mL) e 20% de SFB (todos Sigma-Aldrich), al\u00e9m de 2% de \n\nurina humana (doador do sexo masculino). Ap\u00f3s o 5\u00ba dia de cultivo, quando os \n\nparasitos se encontravam em fase estacion\u00e1ria, foram submetidos a duas lavagens \n\npor centrifuga\u00e7\u00e3o (3000 rpm/ 15 minutos/ 20\u00ba C/ com acelera\u00e7\u00e3o e freio) em PBS. A \n\nseguir foi realizada a contagem e ajuste dos parasitos para 108 promastigotas/ml. A \n\nsuspens\u00e3o de Leishmania em PBS foi ent\u00e3o submetida a 10 ciclos de congelamento \n\nem nitrog\u00eanio l\u00edquido e descongelamento em banho-maria a 70\u00baC, a fim de lisar os \n\nparasitos e obter o ant\u00edgeno particulado. Ap\u00f3s a obten\u00e7\u00e3o da lise completa, atrav\u00e9s \n\nda aus\u00eancia de parasitos \u00edntegros, confirmada por microscopia \u00f3ptica, o ant\u00edgeno foi \n\naliquotado e conservado a 20\u00ba C negativos at\u00e9 o momento de sua utiliza\u00e7\u00e3o. \n\n \n\n \n\n \n\n\n\n58 \n\n4.6. Parte 3 \n\nA terceira parte do trabalho \u00e9 referente aos resultados que ainda n\u00e3o foram \n\ninclu\u00eddos para publica\u00e7\u00e3o. \n\n \n\n4.6.1. Experimentos in vitro \n\n4.6.1.1. Express\u00e3o de CLA \n\nFoi tamb\u00e9m avaliada nos experimentos in vitro a express\u00e3o da mol\u00e9cula CLA \n\n(do ingl\u00eas cutaneous lymphocyte-associated antigen), receptor membro da fam\u00edlia \n\ndas selectinas que \u00e9 importante marcador de endere\u00e7amento para pele. No painel \n\ncitofluorim\u00e9trico dos experimentos in vitro, al\u00e9m dos AcMo descrito no item 4.5., \n\ntamb\u00e9m foi adicionado o AcMo anti-CLA. A casu\u00edstica desta etapa contou com 15 \n\npacientes com leishmaniose cut\u00e2nea ativa (AD, do ingl\u00eas active disease), 14 \n\npacientes durante a terapia antimonial (DT, do ingl\u00eas during therapy) e 9 pacientes \n\ncom cura cl\u00ednica (CC, do ingl\u00eas clinical cure), al\u00e9m de 7 indiv\u00edduos sadios (HI, do \n\ningl\u00eas healthy individuals). \n\n \n\n4.6.1.2. Grupo de Pacientes com Falha Terap\u00eautica (FT) \n\nNos experimentos in vitro, al\u00e9m da amostragem descrita no item 4.5, foi \n\navaliado mais um grupo de pacientes de LC, os quais apresentaram falha \n\nterap\u00eautica ap\u00f3s o t\u00e9rmino da terapia (FT; n=3); ou seja, n\u00e3o apresentaram \n\ncicatriza\u00e7\u00e3o completa das les\u00f5es ap\u00f3s o tratamento com Glucantime\u00ae, sendo \n\nnecess\u00e1rio um esquema terap\u00eautico alternativo ou a repeti\u00e7\u00e3o de um ciclo da \n\nmesma terapia antimonial para alcan\u00e7ar a cura cl\u00ednica. Esses pacientes foram \n\navaliados quando ainda apresentavam a doen\u00e7a ativa; entretanto, ap\u00f3s um estudo \n\nretrospectivo, foi constatado que os mesmos apresentaram falha terap\u00eautica. As \n\nprincipais caracter\u00edsticas cl\u00ednicas e epidemiol\u00f3gicas dos pacientes FT est\u00e3o descritas \n\nna tabela 2 e as CMSP destes pacientes foram submetidas \u00e0 metodologia descrita \n\nno item 4.5.  \n\n\n\n59 \n\n \n\n4.6.2. Quantifica\u00e7\u00e3o de IL-15 \n\nNo presente estudo foi tamb\u00e9m realizada a quantifica\u00e7\u00e3o de IL-15, atrav\u00e9s da \n\nmetodologia de ELISA (do ingl\u00eas Enzyme-Linked Immunosorbent Assay). A \n\nquantifica\u00e7\u00e3o de IL-15 foi realizada a partir de tr\u00eas esp\u00e9cimes biol\u00f3gicos: \n\na) sobrenadante de cultura de CMSP \u2013 os sobrenadantes dos experimentos in \n\nvitro (Parte 2), descritos no item 4.5., foram coletados e armazenados a 80\u00ba C \n\nnegativos at\u00e9 o momento de sua utiliza\u00e7\u00e3o. \n\n \n\nb) plasma sangu\u00edneo \u2013 Amostras de sangue perif\u00e9rico de pacientes de LC e \n\nde indiv\u00edduos sadios, obtidas conforme descrito no item 4.2., foram centrifugadas a \n\n1500 rpm por 10 minutos, com acelera\u00e7\u00e3o e freio, e o plasma foi coletado e mantido \n\na 80\u00ba C negativos at\u00e9 o momento de sua utiliza\u00e7\u00e3o. Os pacientes de LC foram \n\ndivididos em 3 grupos: pacientes com a doen\u00e7a ativa (AD, do ingl\u00eas active disease) \n\n(n=10), pacientes durante a terapia antimonial (DT, do ingl\u00eas during therapy) (n=9) e \n\npacientes com cura cl\u00ednica (CC, do ingl\u00eas clinical cure) (n=5). Os indiv\u00edduos sadios \n\n(HI) (n=5) foram inclu\u00eddos como grupo controle, \n\n \n\nc) sobrenadante de macerado de amostras de biopsia de les\u00e3o \u2013 Amostras de \n\nbiopsia de les\u00e3o de pacientes de LC (n=10) foram obtidas em estudo anterior do \n\nnosso grupo no Laborat\u00f3rio de Imunoparasitologia, conforme descrito no artigo III \n\nem anexo (anexo 4). Os sobrenadantes dos macerados destas amostras de biopsia \n\nforam coletados (conforme descrito no anexo 4) e mantidos a -80\u00baC at\u00e9 o momento \n\nde sua utiliza\u00e7\u00e3o. Foram avaliados tamb\u00e9m sobrenadantes de macerado de biopsia \n\nde les\u00e3o de pacientes com esporotricose, submetidas \u00e0 mesma metodologia descrita \n\nno artigo em anexo (anexo 4), e inclu\u00eddos neste estudo como grupo de doen\u00e7a n\u00e3o-\n\nrelacionada \u00e0 LC (NR) (n=7). \n\n \n\nTodos os esp\u00e9cimes biol\u00f3gicos foram ent\u00e3o descongelados \u00e0 temperatura \n\nambiente e submetidos \u00e0 quantifica\u00e7\u00e3o de IL-15 pelo kit ELISA MAX\u2122 Deluxe Sets \n\n(Biolegend). De acordo com as instru\u00e7\u00f5es fornecidas pelo fabricante, placas de 96 \n\npo\u00e7os de fundo chato (produto inclu\u00eddo no kit) foram sensibilizadas com 100 \u00b5L do \n\n\n\n60 \n\nanticorpo de captura (produto inclu\u00eddo no kit) por 16 horas entre 2\u00b0C e 8\u00b0C. Ap\u00f3s \n\neste per\u00edodo, as placas foram lavadas 4 vezes em 300 \u00b5L de tamp\u00e3o de lavagem \n\nespec\u00edfico (produto inclu\u00eddo no kit), foram adicionados 200 \u00b5L de Diluente A (produto \n\ninclu\u00eddo no kit) em cada po\u00e7o, para o bloqueio de liga\u00e7\u00f5es inespec\u00edficas, e as placas \n\nforam incubadas a temperatura ambiente por uma hora em agitador orbital (Arsec). \n\nAs placas foram lavadas 4 vezes em 300 \u00b5L de tamp\u00e3o de lavagem espec\u00edfico, \n\nforam adicionados os controles para a curva padr\u00e3o (produtos inclu\u00eddos no kit) e as \n\namostras nos devidos po\u00e7os e seguida incuba\u00e7\u00e3o por duas horas a temperatura \n\nambiente em agitador orbital (Arsec). A curva padr\u00e3o e todas as amostras foram \n\nadicionadas em duplicatas. As placas foram ent\u00e3o lavadas 4 vezes em 300 \u00b5L de \n\ntamp\u00e3o de lavagem espec\u00edfico, foram adicionados 100 \u00b5L de anticorpo de detec\u00e7\u00e3o \n\n(produto inclu\u00eddo no kit) em cada po\u00e7o e seguida incuba\u00e7\u00e3o por uma hora a \n\ntemperatura ambiente em agitador orbital (Arsec). As placas foram novamente \n\nlavadas 4 vezes em 300 \u00b5L de tamp\u00e3o de lavagem espec\u00edfico, adicionados 100 \u00b5L \n\nde avidina-HRP (produto inclu\u00eddo no kit) em cada po\u00e7o e seguida incuba\u00e7\u00e3o por 30 \n\nminutos a temperatura ambiente em agitador orbital (Arsec). As placas foram \n\nlavadas mais 5 vezes em 300 \u00b5L de tamp\u00e3o de lavagem espec\u00edfico, foram \n\nadicionados 100 \u00b5L de solu\u00e7\u00e3o de substrato (produto inclu\u00eddo no kit) em cada po\u00e7o e \n\nincubadas por 15 minutos protegidas da luz. Foram ent\u00e3o adicionados 100 \u00b5L de \n\nsolu\u00e7\u00e3o de parada (Stop Solution for TMB Substrate, Biolegend) em cada po\u00e7o e as \n\nplacas foram imediatamente lidas em Leitor de Microplacas em Absorb\u00e2ncia (ELx \n\n800, BioTek Instruments, Winooski, VT, E.U.A.) de 450 nan\u00f4metros. Ap\u00f3s a leitura, a \n\nm\u00e9dia das duplicatas foi calculada e os resultados foram analisados com base na \n\nconfec\u00e7\u00e3o da curva padr\u00e3o. \n\n \n\n4.7. An\u00e1lise Estat\u00edstica \n\nO teste pareado Wilcoxon matched-pairs signed rank foi aplicado para as \n\ncompara\u00e7\u00f5es entre duas amostras relacionadas e o teste Mann\u2013Whitney U para a \n\ncompara\u00e7\u00e3o entre dois grupos. O intervalo de confian\u00e7a foi de 95%, sendo ent\u00e3o \n\nconsiderados estatisticamente significativos os resultados onde P ? 0,05. Para todas \n\nas an\u00e1lises estat\u00edsticas foi utilizado o programa computacional espec\u00edfico GraphPad \n\nPrism 6 (GraphPad Software Inc.). \n\n\n\n61 \n\n5. RESULTADOS \n\nOs resultados obtidos nesta tese est\u00e3o divididos em tr\u00eas partes: \n\n \n\n5.1. Parte 1 \u2013 Artigo I (Publicado; anexo 2) \n\nOs resultados da primeira parte do estudo resultaram na publica\u00e7\u00e3o do  \n\nartigo I, no qual avaliamos, em ensaios ex vivo, a frequ\u00eancia e os perfis de \n\nexpress\u00e3o de CD107a de c\u00e9lulas potencialmente citot\u00f3xicas do sangue perif\u00e9rico, \n\ncomo linf\u00f3citos T CD8+ e T CD4+, c\u00e9lulas NK e NKT, obtidas de pacientes de \n\nleishmaniose cut\u00e2nea em diferentes est\u00e1gios cl\u00ednicos de evolu\u00e7\u00e3o para a cura. \n\nAs an\u00e1lises foram realizadas com base no protocolo citofluorim\u00e9trico ilustrado \n\nna figura 6.  \n\n \n\n5.1.1. Frequencia de linf\u00f3citos T CD8+ e T CD4+, c\u00e9lulas NK e NKT. \n\nPara determinar os perfis celulares dos linf\u00f3citos T CD8+ e T CD4+, c\u00e9lulas \n\nNK e NKT durante a resposta imunol\u00f3gica na LC, n\u00f3s comparamos os percentuais \n\ndestas popula\u00e7\u00f5es celulares no sangue perif\u00e9rico de pacientes antes do tratamento \n\n(BT), durante o tratamento (DT) e ap\u00f3s a cura cl\u00ednica (CC), assim como de \n\nindiv\u00edduos sadios (HI). Foi poss\u00edvel observar que os pacientes CC apresentaram \n\nelevadas frequ\u00eancias de linf\u00f3citos T CD8+ (mediana \u00b1 intervalo interquartil: 30,7 \u00b1 \n\n9,6%) tanto em compara\u00e7\u00e3o aos pacientes BT (24,2 \u00b1 10,3%; P ? 0,05) e DT (25,6 \u00b1 \n\n4,8%; P ? 0,05), quanto aos HI (24,9 \u00b1 8,6%; P ? 0,05) (Figura 7a). Os pacientes BT \n\napresentaram baixas frequ\u00eancias de linf\u00f3citos T CD4+ (41,6 \u00b1 19,9%) em \n\ncompara\u00e7\u00e3o aos HI (50,9 \u00b1 8,8%; P ? 0,01). A frequ\u00eancia de linf\u00f3citos T CD4+ \n\nretornou aos percentuais de normalidade, detectados nos HI, com o tratamento (DT: \n\n44,7 \u00b1 17,4%) e a cura cl\u00ednica (CC: 43,5 \u00b1 33,3%) (Figura 7b). Todos os grupos de \n\npacientes de LC exibiram elevadas frequ\u00eancias de c\u00e9lulas NK (BT: 9,9 \u00b1 8,8%; DT: \n\n8,0 \u00b1 12,0%; CC: 8,2 \u00b1 7,8%) em compara\u00e7\u00e3o aos HI (3,4 \u00b1 4,1%) (P ? 0,01,  \n\nP ? 0,05 e P ? 0,01, respectivamente) (Figura 7c). N\u00e3o foram observadas diferen\u00e7as \n\nnos percentuais de c\u00e9lulas NKT entre os grupos estudados (dados n\u00e3o mostrados). \n\n \n\n \n \n \n\n\n\n62 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nFigura 6. Protocolo citofluorim\u00e9trico representativo para determinar as frequ\u00eancias das \nsubpopula\u00e7\u00f5es de linf\u00f3citos T CD4+ e T CD8+, c\u00e9lulas natural killer (NK) e natural killer T (NKT) (e \nsuas subpopula\u00e7\u00f5es) e suas express\u00f5es de CD107a. As c\u00e9lulas mononucleares do sangue perif\u00e9rico \nforam marcadas com anti-CD3, anti-CD4, anti-CD8, anti-CD56 e anti-CD107a. A regi\u00e3o dos linf\u00f3citos \n(\u201cLymphocytes\u201d) foi determinada com base no dot-plot morfol\u00f3gico de foward scatter (FSC-A) vs. side \nscatter (SSC-A) (a). Em seguida, as c\u00e9lulas delimitadas na regi\u00e3o de \u201cLymphocytes\u201d (a) foram \nanalisadas atrav\u00e9s de dot-plots FSC-H vs. FSC-A (b) e FSC-A vs. FSC-W (c) para exclus\u00e3o de \nagregados celulares e debris. As popula\u00e7\u00f5es de linf\u00f3citos T CD8+ e T CD4+ foram definidas nos dot-\nplots CD8 vs. CD3 (e) e CD4 vs. CD3 (f), respectivamente, a partir da regi\u00e3o de c\u00e9lulas CD56 \nnegativas (d). As popula\u00e7\u00f5es de c\u00e9lulas NK e NKT foram definidas atrav\u00e9s do dot-plot de CD56 vs. \nCD3 (g). As subpopula\u00e7\u00f5es de c\u00e9lulas NKT foram determinadas com base em sua express\u00e3o de CD8 \ne/ou CD4 (h). A express\u00e3o de CD107a foi analisada em dot-plots de FSC-A vs. CD107a, com base \nnas regi\u00f5es de defini\u00e7\u00e3o de cada popula\u00e7\u00e3o celular \u2013 representada aqui com base nas c\u00e9lulas c\u00e9lulas \nNK (i). \n\n(b) (a) (c) \n\n(d) (e) (f) \n\n(g) (h) (i) \n\n\n\n63 \n\n \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 7. Gr\u00e1ficos de dispers\u00e3o representando as frequ\u00eancias de linf\u00f3citos T CD8+ (a), linf\u00f3citos T \nCD4+ (b) e c\u00e9lulas NK (c). HI: indiv\u00edduos sadios, do ingl\u00eas healthy individuals (n = 11); BT: pacientes \nantes do tratamento, do ingl\u00eas before treatment (n = 8); DT: pacientes durante o tratamento, do ingl\u00eas \nduring treatment (n = 8); CC: pacientes clinicamente curados, do ingl\u00eas clinically cured (n = 8). Os \ndados s\u00e3o representados pela mediana \u00b1 intervalo interquartil. Cada ponto representa um indiv\u00edduo. \nAs compara\u00e7\u00f5es estat\u00edsticas foram realizadas com o teste U de Mann-Whitney, onde *P?0,05,  \n**P ?0, 01. \n \n\n5.1.2. Express\u00e3o de CD107a pelos linf\u00f3citos T CD8+ e T CD4+, c\u00e9lulas NK e \n\nNKT. \n\nA an\u00e1lise da express\u00e3o de CD107a pelos linf\u00f3citos T e c\u00e9lulas NK e NKT foi \n\nrealizada para avaliar seus percentuais de degranula\u00e7\u00e3o nas amostras de sangue \n\nperif\u00e9ricos dos pacientes de LC. N\u00f3s observamos que os pacientes CC \n\napresentaram os menores percentuais de express\u00e3o de CD107a por todas as \n\npopula\u00e7\u00f5es celulares estudadas. A frequ\u00eancia de linf\u00f3citos T CD8+ CD107a+ foi \n\nmenor nos pacientes CC (1,1 \u00b1 0,8%) quando comparado com os pacientes BT (2,1 \n\n\u00b1 3,5%; P ? 0,05)  e DT (1,8 \u00b1 3,7%; P ? 0,05), assim como com os HI (2,8 \u00b1 2,0;  \n\nP ? 0,01) (Figura 8a). Pacientes CC tamb\u00e9m apresentaram baixos percentuais de \n\nlinf\u00f3citos T CD4+ CD107a+ (0,7 \u00b1 0,9%), que foi estatisticamente significante em \n\ncompara\u00e7\u00e3o aos pacientes DT (2,1 \u00b1 1,5%; P ? 0,05) (Figura 8b). As c\u00e9lulas NK \n\napresentaram baixos percentuais de express\u00e3o de CD107a em todos os grupos de \n\npacientes de LC (BT: 3,5 \u00b1 8,6%, P ? 0,05; DT: 5,8 \u00b1 8,4%, P ? 0,05; CC: 3,8 \u00b1 \n\n4,8%; P ? 0,01) em compara\u00e7\u00e3o aos HI (12,8 \u00b1 15,7%) (Figura 8c). Entre os grupos \n\n\n\n64 \n\nde pacientes de LC, os menores percentuais de c\u00e9lulas NK CD107a+ foram \n\ndetectados nos pacientes CC, que foram significativamente menores do que os \n\nobservados nos pacientes DT (P ? 0,05) (Figura 8c). Os pacientes CC tamb\u00e9m \n\napresentaram baixos percentuais de express\u00e3o de CD107a pelas c\u00e9lulas NKT (2,4 \u00b1 \n\n3,1%), que foram significativamente menores em compara\u00e7\u00e3o aos pacientes DT (6,4 \n\n\u00b1 10,0%, P ? 0,01) (Figura 8d). \n\nCom intuito de avaliar qual popula\u00e7\u00e3o celular seria mais relevante na fun\u00e7\u00e3o \n\ncitot\u00f3xica nas diferentes fases cl\u00ednicas da LC, n\u00f3s realizamos outra estrat\u00e9gia de \n\nan\u00e1lise citofluorim\u00e9trica. Por esta an\u00e1lise, foi poss\u00edvel determinar a distribui\u00e7\u00e3o de \n\ncada popula\u00e7\u00e3o celular de interesse com base na express\u00e3o total de CD107a. Desta \n\nforma, observamos que os linf\u00f3citos T CD4+ s\u00e3o a principal popula\u00e7\u00e3o celular \n\nenvolvida com a express\u00e3o de CD107a em todos os grupos estudados, seguidos \n\npelos linf\u00f3citos T CD8+ e c\u00e9lulas NK, e, em menor propor\u00e7\u00e3o, pelas c\u00e9lulas NKT \n\n(Figura 9). \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 8. Gr\u00e1ficos de dispers\u00e3o representando a express\u00e3o de CD107a pelos linf\u00f3citos T CD8+ (a), \nlinf\u00f3citos T CD4+ (b), c\u00e9lulas NK (c) e c\u00e9lulas NKT (d). HI: indiv\u00edduos sadios, do ingl\u00eas healthy \nindividuals (n = 11); BT: pacientes antes do tratamento, do ingl\u00eas before treatment (n = 8); DT: \npacientes durante o tratamento, do ingl\u00eas during treatment (n = 8); CC: pacientes clinicamente \ncurados, do ingl\u00eas clinically cured (n = 8). Os dados s\u00e3o representados pela mediana \u00b1 intervalo \ninterquartil. Cada ponto representa um indiv\u00edduo. As compara\u00e7\u00f5es estat\u00edsticas foram realizadas com \no teste U de Mann-Whitney, onde *P?0,05, **P ?0, 01. \n\n\n\n65 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 9. Distribui\u00e7\u00e3o de linf\u00f3citos T CD8+ e T CD4+, c\u00e9lulas NK e NKT a partir do gate de c\u00e9lulas \nCD107a+. Os gr\u00e1ficos de setores ilustram a m\u00e9dia dos dados obtidos nos HI (indiv\u00edduos sadios, do \ningl\u00eas healthy individuals; n = 11) (a), BT (pacientes antes do tratamento, do ingl\u00eas before treatment;  \nn = 8) (b), DT (pacientes durante o tratamento, do ingl\u00eas during treatment; n = 8) (c) e CC (pacientes \nclinicamente curados, do ingl\u00eas clinically cured; n = 8) (d).  \n \n\n \n\n5.1.3. Densidade de express\u00e3o de CD8. \n\nN\u00f3s avaliamos duas subpopula\u00e7\u00f5es de linf\u00f3citos T CD8+ com base na \n\ndensidade de express\u00e3o da mol\u00e9cula CD8 (T CD8dim e T CD8bright). Foram \n\ndeterminadas suas frequ\u00eancias e express\u00e3o de CD107a no sangue perif\u00e9rico de \n\npacientes de LC, na tentativa de verificar se o perfil de express\u00e3o de CD8 poderia \n\nestar relacionado \u00e0 fase cl\u00ednica da doen\u00e7a. Observamos que a maioria dos linf\u00f3citos \n\nT CD8+ no sangue perif\u00e9rico dos pacientes de LC, em qualquer fase cl\u00ednica, \n\napresenta o fen\u00f3tipo CD8bright. No entanto, quando analisamos as frequ\u00eancias dos \n\nlinf\u00f3citos T CD8+ CD107a+, observamos que cerca de 70% dessas c\u00e9lulas \n\napresentaram o fen\u00f3tipo CD8dim em todos os grupos de pacientes de LC. Os HI \n\napresentaram resultados similares aos observados nos pacientes de LC quanto aos \n\nfen\u00f3tipos de linf\u00f3citos T CD8+ e sua express\u00e3o de CD107a. As diferen\u00e7as entre os \n\nfen\u00f3tipos de linf\u00f3citos T CD8+ foram extremamente significantes em todos os grupos \n\nestudados (P ? 0,001) (dados n\u00e3o mostrados). \n\n\n\n66 \n\n5.1.4. Densidade de express\u00e3o de CD56. \n\nCom base na densidade de express\u00e3o do receptor CD56, as c\u00e9lulas NK \n\npodem ser divididas em duas subpopula\u00e7\u00f5es distintas: c\u00e9lulas NK CD56bright e NK \n\nCD56dim. N\u00f3s avaliamos a express\u00e3o de CD56 em c\u00e9lulas NK obtidas de pacientes \n\nde LC, assim como de HI, com intuito de verificar se os perfis de express\u00e3o de CD56 \n\ns\u00e3o modulados na evolu\u00e7\u00e3o para a cura doen\u00e7a. N\u00f3s observamos que mais de 95% \n\ndas c\u00e9lulas NK, tanto dos pacientes de LC quanto dos HI, apresentaram fen\u00f3tipo \n\nCD56dim. Para avalia\u00e7\u00e3o da degranula\u00e7\u00e3o destas subpopula\u00e7\u00f5es, foram \n\nselecionadas as c\u00e9lulas NK CD107a+, e, a partir destas, avaliados os percentuais de \n\ncada subpopula\u00e7\u00e3o com base na densidade de express\u00e3o do CD56. Foi observado \n\nque mais de 95% das c\u00e9lulas NK CD107a+ tamb\u00e9m apresentaram o fen\u00f3tipo \n\nCD56dim. As diferen\u00e7as entre os fen\u00f3tipos de c\u00e9lulas NK foram extremamente \n\nsignificantes em todos os grupos estudados (P ? 0,001) (dados n\u00e3o mostrados). \n\n \n\n5.1.5. Subpopula\u00e7\u00f5es de c\u00e9lulas NKT \n\nAs c\u00e9lulas NKT humanas podem ser divididas de acordo com sua express\u00e3o \n\nde CD4 e/ou CD8 e s\u00e3o normalmente subdivididas em tr\u00eas subpopula\u00e7\u00f5es \n\nprincipais: CD8+, CD4+ ou CD8negCD4neg (duplo-negativas; DN) (232) (Bendelac et \n\nal, 2007). Ainda, alguns autores apontam para a exist\u00eancia de uma quarta \n\nsubpopula\u00e7\u00e3o, com fen\u00f3tipo CD8+CD4+ (duplo-positivas; DP) (281). Deste modo, a \n\npartir da defini\u00e7\u00e3o da popula\u00e7\u00e3o de c\u00e9lulas NKT nos grupos estudados, foi poss\u00edvel \n\navaliar a distribui\u00e7\u00e3o de suas subpopula\u00e7\u00f5es com base nas diferen\u00e7as de express\u00e3o \n\nde CD4 e CD8 nos pacientes de LC, assim como nos HI. N\u00f3s observamos que cerca \n\nde metade das c\u00e9lulas NKT de todos os grupos estudados apresentam o fen\u00f3tipo \n\nCD8+CD4neg (Figura 10a). Ainda, tanto os pacientes de LC quanto os HI \n\napresentaram propor\u00e7\u00f5es intermedi\u00e1rias das subpopula\u00e7\u00f5es NKT CD8negCD4+ e \n\nNKT DN e frequ\u00eancias mais baixas de c\u00e9lulas NKT DP (Figura 10a). Embora a \n\nsubpopula\u00e7\u00e3o NKT DP tenha sido detectada em pequenos percentuais, houve \n\ndiferen\u00e7as na frequ\u00eancia desta subpopula\u00e7\u00e3o entre os grupos estudados. Pacientes \n\nBT apresentaram percentuais de c\u00e9lulas NKT DP (m\u00e9dia \u00b1 erro padr\u00e3o: 1,2 \u00b1 0,5%) \n\nsignificativamente menores que os pacientes DT (5,1 \u00b1 1,7%; P ? 0,05) e CC (3,9 \u00b1 \n\n1,1%; P ? 0,05), assim como em rela\u00e7\u00e3o aos HI (6,6 \u00b1 1,9%; P ? 0,05) (Figura 10c). \n\nObservamos tamb\u00e9m diferen\u00e7as na frequ\u00eancia de c\u00e9lulas NKT DN, as quais foram \n\ndetectadas em percentuais maiores pacientes CC (21,3 \u00b1 4,0%), em compara\u00e7\u00e3o \n\n\n\n67 \n\naos HI (12,8 \u00b1 5,4%, P ? 0,05) (Figura 10d). As subpopula\u00e7\u00f5es NKT CD8+ e NKT \n\nCD4+ foram observadas em percentuais semelhantes em todos os grupos \n\nestudados.  \n\nForam avaliados tamb\u00e9m os fen\u00f3tipos das subpopula\u00e7\u00f5es de c\u00e9lulas NKT \n\nCD107a+ e observamos que estes variaram nos grupos estudados. Os pacientes BT \n\ne DT e os HI apresentaram maiores frequ\u00eancias de c\u00e9lulas NKT CD8+ CD107a+; \n\nenquanto nos pacientes CC esta frequ\u00eancia foi mais baixa, sendo detectadas neste \n\ngrupo maiores propor\u00e7\u00f5es de c\u00e9lulas NKT CD4+ CD107a+ e NKT DN CD107a+ \n\n(Figura 10b). Na compara\u00e7\u00e3o das frequ\u00eancias das subpopula\u00e7\u00f5es de c\u00e9lulas NKT \n\nem degranula\u00e7\u00e3o entre os grupos estudados, n\u00f3s observamos que os pacientes CC \n\napresentaram menores percentuais de c\u00e9lulas NKT CD8+ CD107a+ em rela\u00e7\u00e3o aos \n\npacientes DT (Figura 10e). Os pacientes DT apresentaram maior frequ\u00eancia da \n\nsubpopula\u00e7\u00e3o DN em degranula\u00e7\u00e3o em rela\u00e7\u00e3o aos HI (Figura 10f). Ainda, os \n\npacientes CC apresentaram menores percentuais de c\u00e9lulas NKT DP CD107a+ em \n\ncompara\u00e7\u00e3o aos HI (Figura 10g). \n\n \n\n \n\n \n\n \n\n\n\n68 \n\n \n\n \n\nFigura 10. An\u00e1lise da frequ\u00eancia e express\u00e3o de CD107a de subpopula\u00e7\u00f5es de c\u00e9lulas NKT. Os \ngr\u00e1ficos de setores mostram a m\u00e9dia dos dados observados em HI, BT, DT e CC: frequ\u00eancia (a) e \nexpress\u00e3o de CD107a (b). Os gr\u00e1ficos de barras representam m\u00e9dia \u00b1 SEM da compara\u00e7\u00e3o entre \ngrupos: frequ\u00eancia da subpopula\u00e7\u00e3o de c\u00e9lulas NKT DP (c); frequ\u00eancia da subpopula\u00e7\u00e3o NKT DN (d); \nfrequ\u00eancia da subpopula\u00e7\u00e3o NKT CD8+ CD107a+ (e); frequ\u00eancia da subpopula\u00e7\u00e3o NKT DN CD107a+ \n(f); frequ\u00eancia da subpopula\u00e7\u00e3o NKT DP CD107a+ (g). HI (indiv\u00edduos sadios, do ingl\u00eas healthy \nindividuals; n = 11); BT (pacientes antes do tratamento, do ingl\u00eas before treatment;  \nn = 8); DT (pacientes durante o tratamento, do ingl\u00eas during treatment; n = 8); CC (pacientes \nclinicamente curados, do ingl\u00eas clinically cured; n = 8).  As compara\u00e7\u00f5es estat\u00edsticas foram realizadas \ncom o teste U de Mann-Whitney, onde *P?0,05. \n\n\n\n69 \n\n \n\n5.2. Parte 2 \u2013 Artigo II (Submetido; anexo 3) \n\nOs resultados da segunda parte do estudo resultaram na reda\u00e7\u00e3o do artigo II, \n\nsubmetido \u00e0 Plos One. Neste artigo avaliamos, em ensaios in vitro, a resposta \n\ncitot\u00f3xica espec\u00edfica aos ant\u00edgenos de Leishmania (V.) braziliensis, assim como os \n\nperfis de ativa\u00e7\u00e3o e exaust\u00e3o de linf\u00f3citos T CD8+ e T CD4+, c\u00e9lulas NK e NKT, \n\nobtidas de sangue perif\u00e9rico de pacientes de leishmaniose cut\u00e2nea em diferentes \n\nest\u00e1gios cl\u00ednicos de evolu\u00e7\u00e3o para a cura. As an\u00e1lises foram realizadas com base no \n\nprotocolo citofluorim\u00e9trico ilustrado na figura11.  \n\n \n\n5.2.1. Caracter\u00edsticas dos pacientes. \n\nAs principais caracter\u00edsticas cl\u00ednico-epidemiol\u00f3gicas dos pacientes de LC \n\nest\u00e3o descritas na tabela 5. A m\u00e9dia de idade dos 24 pacientes de LC inclu\u00eddos \n\nnesta etapa foi de 37 \u00b1 14,26 anos e 79% (19) eram do sexo masculino. O n\u00famero \n\nde les\u00f5es variou de um a cinco e a dura\u00e7\u00e3o da doen\u00e7a de 15 a 330 dias. Os \n\ntamanhos das les\u00f5es foram vari\u00e1veis, com di\u00e2metros variando de 14 a 130 mm. A \n\nIDRM foi positiva em todos os pacientes testados. \n\n \n\n5.2.2. Os ant\u00edgenos de L. (V.) braziliensis induzem expans\u00e3o das c\u00e9lulas T \n\nCD8+, NK e CD3+ CD56+ NKT e contra\u00e7\u00e3o de linf\u00f3citos T CD4+ em \n\npacientes de LC. \n\nCom intuito de determinar a influ\u00eancia do Lb-Ag na frequ\u00eancia das c\u00e9lulas T \n\nCD8+, T CD4+, NK e CD3+CD56+ NKT dos pacientes de LC, n\u00f3s avaliamos os \n\npercentuais dessas popula\u00e7\u00f5es celulares sem est\u00edmulo antig\u00eanico (BG \u2013 \n\nbackground) e sob estimula\u00e7\u00e3o com Lb-Ag. N\u00f3s observamos nos pacientes AD \n\nmaiores percentuais de c\u00e9lulas T CD8+, NK e CD3+CD56+ NKT ap\u00f3s estimula\u00e7\u00e3o \n\ncom Lb-Ag (m\u00e9dia \u00b1 erro padr\u00e3o: 28,56 \u00b1 1,74%, 7,47 \u00b1 1,13% e 3,86 \u00b1 0,72%, \n\nrespectivamente) comparado \u00e0s c\u00e9lulas n\u00e3o estimuladas [27,43 \u00b1 1,76% (P?0,01); \n\n6,51 \u00b1 1,09% (P?0,5); e 3,19 \u00b1 0,66% (P?0,5)] (Figura 12A-C). Em contraste, nos \n\npacientes AD e DT, a estimula\u00e7\u00e3o antig\u00eanica induziu uma contra\u00e7\u00e3o nos linf\u00f3citos T \n\nCD4+ (68,24 \u00b1 3,55% e 65,11 \u00b1 2,08%, respectivamente), quando comparados com \n\nos percentuais observados nas culturas n\u00e3o estimuladas [70,50 \u00b1 3,38% (P?0,01); e \n\n66,07 \u00b1 2,16% (P?0,05), respectivamente] (Figuras 12D e 12E). Os HI n\u00e3o \n\n\n\n70 \n\napresentaram altera\u00e7\u00f5es nas frequ\u00eancias de nenhuma popula\u00e7\u00e3o celular estudada \n\ndevido \u00e0 estimula\u00e7\u00e3o antig\u00eanica (dados n\u00e3o apresentados). \n\n \n\nTabela 5. Principais caracter\u00edsticas cl\u00ednico-epidemiol\u00f3gicas dos pacientes inclu\u00eddos na segunda etapa \ndo estudo.  \n \n\nPaciente \nIdade \n\n(anos) \nSexo \n\nN\u00famero \n\nde les\u00f5es \n\nDura\u00e7\u00e3o \n\nda \n\ndoen\u00e7a \n\n(dias) \n\nTamanho \n\nda les\u00e3o \n\n(maior \n\ndi\u00e2metro \n\n\u2013 mm) \n\nIDRM \n\n(mm) \n\n1 22 M 1 40 34 24 \n\n2 56 F 1 60 36 36 \n\n3 24 M 1 90 45 n.d. \n\n4 28 M 1 30 20 11 \n\n5 44 M 1 120 28 n.d. \n\n6 29 M 1 120 50 n.d. \n\n7 70 M 1 15 - 25 \n\n8 46 M 4 180 75 27 \n\n9 52 M 1 90 24 47 \n\n10 51 F 1 60 40 n.d. \n\n11 32 F 1 120 130 n.d. \n\n12 30 M 5 45 - 20 \n\n13 52 M 1 120 22 n.d. \n\n14 31 M 1 330 47 n.d. \n\n15 59 M 1 120 60 11 \n\n16 23 F 1 120 35 n.d. \n\n17 31 M 1 150 58 19 \n\n18 19 M 1 60 22 18 \n\n19 26 M 4 60 - n.d. \n\n20 47 M 1 30 45 14 \n\n21 19 M 1 30 30 22 \n\n22 30 M 4 120 - n.d. \n\n23 25 M 1 - 14 n.d. \n\n24 42 F 1 90 35 10 \n\n \n\nmm: mil\u00edmetros; IDRM: Intradermorrea\u00e7\u00e3o de Montenegro; M: sexo masculino; F: sexo feminino; n.d.: \nn\u00e3o determinado. \n\n\n\n71 \n\nFigura 11. Protocolo citofluorim\u00e9trico representativo. As c\u00e9lulas mononucleares do sangue perif\u00e9rico \nforam marcadas com 7AAD, anti-CD3, anti-CD4, anti-CD8, anti-CD56, anti-CD107a, anti-CD38 e  \nanti-CD279, bem como com anti-V?24J?18-TCR em alguns casos. A regi\u00e3o dos linf\u00f3citos \n(\u201cLymphocytes\u201d) foi determinada com base no dot-plot morfol\u00f3gico de foward scatter (FSC-A) vs. side \nscatter (SSC-A) (A). Em seguida, as c\u00e9lulas delimitadas na regi\u00e3o de \"Linf\u00f3citos\" foram analisadas \natrav\u00e9s do dot-plot FSC-H vs. FSC-A, para exclus\u00e3o de agregados celulares e debris (regi\u00e3o \u201cNo \ndoublets\u201d) (B). As c\u00e9lulas vi\u00e1veis foram ent\u00e3o selecionadas com base na n\u00e3o-marca\u00e7\u00e3o de 7AAD \n(regi\u00e3o \u201cViable cells\u201d) (C). As popula\u00e7\u00f5es de linf\u00f3citos T CD8+ e CD4+ foram definidas nos dot-plots \nCD8 vs. CD3 (E) e CD4 vs. CD3 (F), respectivamente, a partir da regi\u00e3o de c\u00e9lulas vi\u00e1veis CD56neg, \ndefinidas pelo dot-plot FSC-A vs. CD56 (D). As popula\u00e7\u00f5es de c\u00e9lulas NK e CD3+CD56+ NKT foram \ndefinidas atrav\u00e9s do dot-plot CD56 vs. CD3 (G), a partir da regi\u00e3o de \"C\u00e9lulas vi\u00e1veis\". As express\u00f5es \nde CD107a, CD38 e CD279 foram analisadas em dot-plots FSC-A vs. cada uma destas mol\u00e9culas de \ninteresse, a partir da regi\u00e3o definida para cada popula\u00e7\u00e3o celular estudada \u2013 representada aqui para \nlinf\u00f3citos T CD4+ (H-J), respectivamente. Uma outra estrat\u00e9gia de gates foi adotada para avaliar as \npropor\u00e7\u00f5es de cada popula\u00e7\u00e3o celular estudada com base na express\u00e3o total de CD107a, CD38 e \nCD279: a express\u00e3o total de cada mol\u00e9cula de interesse foi determinada a partir da regi\u00e3o de \u201cc\u00e9lulas \n\n\n\n72 \n\nvi\u00e1veis\u201d (\u201cViable Cells\u201d) \u2013 representado aqui a avalia\u00e7\u00e3o da express\u00e3o de CD279 (K); e ent\u00e3o esta \nregi\u00e3o (CD279+) foi utilizada para avaliar a propor\u00e7\u00e3o de cada popula\u00e7\u00e3o celular previamente definida \n\u2013 representado aqui pelos linf\u00f3citos T CD4+ com base na regi\u00e3o de \u201cCD279+\u201d (L). Para algumas \namostras, tamb\u00e9m foi realizada a an\u00e1lise de c\u00e9lulas NKT invariantes (iNKT) atrav\u00e9s do dot-plot de \nCD3 vs. TCR invariante (V?24J?18-TCR) (L), a partir da regi\u00e3o de c\u00e9lulas vi\u00e1veis.  \n \n\nFigura 12. Compara\u00e7\u00e3o entre as c\u00e9lulas estimuladas com ant\u00edgeno de L. (V.) braziliensis (Lb-Ag) e \nn\u00e3o estimuladas (background \u2013 BG): linf\u00f3citos T CD8+ (A), c\u00e9lulas NK (B) e c\u00e9lulas NKT CD3+CD56+ \n(C) de pacientes antes do tratamento (AD, do ingl\u00eas active disease; n=17); e de linf\u00f3citos T CD4+ de \npacientes antes do tratamento (AD, do ingl\u00eas active disease; n=17) (D) e durante o tratamento (DT, \ndo ingl\u00eas during treatment; n = 16) (E). As linhas s\u00f3lidas conectam os resultados referentes ao \nmesmo indiv\u00edduo. As an\u00e1lises estat\u00edsticas foram realizadas pelo teste pareado n\u00e3o-param\u00e9trico de \nWilcoxon. Os resultados foram considerados significativos quando P?0,05. * (P?0,05) ** (P?0,01). \n \n\n5.2.3. A maioria das c\u00e9lulas NKT CD3+CD56+ n\u00e3o expresa TCR invariante. \n\nAs c\u00e9lulas NKT coexpressam receptores de c\u00e9lulas T (como CD3) juntamente \n\ncom receptores associados \u00e0 linhagem de c\u00e9lulas NK (como CD56, CD16 e / ou \n\nCD161). As c\u00e9lulas NKT reconhecem ant\u00edgenos lip\u00eddicos apresentados via CD1d e \n\ns\u00e3o divididas em duas subpopula\u00e7\u00f5es principais de acordo com sua capacidade de \n\nreconhecimento antig\u00eanico: invariantes (ou tipo I), que expressam um TCR \n\ninvariante; e c\u00e9lulas NKT variantes ou do tipo II, que expressam TCR diverso. Deste \n\nmodo, n\u00f3s objetivamos verificar a propor\u00e7\u00e3o de c\u00e9lulas NKT CD3+CD56+ que \n\nexpressam o TCR invariante V?24-J?18. Foi poss\u00edvel observar que apenas um baixo \n\npercentual de c\u00e9lulas NKT CD3+CD56+ expressaram o TCR V?24-J?18 (Figura \n\n12M). Este dado foi observado tanto nos pacientes AD (BG: 0,81 \u00b1 0,15%; Lb-Ag: \n\n\n\n73 \n\n0,69 \u00b1 0,22%) quanto nos HI (BG: 0,77 \u00b1 0,12%; Lb-Ag: 0,59 \u00b1 0,11%) e foi \n\nindependente da estimula\u00e7\u00e3o (dados n\u00e3o mostrados). \n\n \n\n5.2.4. Os ant\u00edgenos de L. (V.) braziliensis induzem aumento de c\u00e9lulas T CD4+, \n\nNK e NKT CD3+CD56+ ativadas e em degranula\u00e7\u00e3o em todos os grupos \n\nde pacientes de LC. \n\nCom o objetivo de verificar altera\u00e7\u00f5es nos perfis de ativa\u00e7\u00e3o e degranula\u00e7\u00e3o \n\nde c\u00e9lulas envolvidas em uma resposta espec\u00edfica anti-Leishmania, n\u00f3s analisamos \n\nas express\u00f5es CD38 e CD107a pelas c\u00e9lulas T CD8+, T CD4+, NK e NKT \n\nCD3+CD56+ em amostras de pacientes de LC, assim como de HI, na presen\u00e7a ou \n\naus\u00eancia de est\u00edmulo com Lb-Ag. N\u00f3s observamos nas culturas estimuladas com  \n\nLb-Ag frequ\u00eancias mais elevadas de c\u00e9lulas T CD4+ CD107a+, NK CD107a+ e NKT \n\nCD3+CD56+ CD107a+ de pacientes AD (0,52 \u00b1 0,07%, 3,24 \u00b1 0,52% e 2,96 \u00b1 0,76%, \n\nrespectivamente), DT (0.9 \u00b1 0.19%, 5.12 \u00b1 1.03% and 4.02 \u00b1 0.9%, respectivamente) \n\ne CC (0,68 \u00b1 0,08%, 5,75 \u00b1 1,08% e 2,86 \u00b1 0,66%, respectivamente), em \n\ncompara\u00e7\u00e3o com as culturas n\u00e3o estimuladas de pacientes AD (0,38 \u00b1 0,04%, \n\nP?0,05; 1,87 \u00b1 0,28%, P?0,05; e 2,1 \u00b1 0,66%, P?0,05; respectivamente), DT (0,72 \u00b1 \n\n0,19%, P?0,01; 3,92 \u00b1 1,06%, P?0,05; e 2,33 \u00b1 0,57%, P?0,001; respectivamente) e \n\nCC (0,45 \u00b1 0,04%, P?0,01; 2,87 \u00b1 0,7%, P?0,01; e 1,61 \u00b1 0,35%, P?0,01; \n\nrespectivamente) (Figura 13). \u00c9 importante destacar que os HI n\u00e3o apresentaram \n\naltera\u00e7\u00f5es na express\u00e3o de CD107a em resposta a Lb-Ag (Figura 13).  \n\nDe maneira semelhante, todos os grupos de pacientes de LC (AD, DT e CC) \n\napresentaram maiores percentuais de c\u00e9lulas T CD4+, NK e NKT CD3+CD56+ \n\nativadas em resposta ao Lb-Ag (AD: 15,21 \u00b1 2,29%, 55,52 \u00b1 5,73% e 19,69 \u00b1 2,49%; \n\nDT: 20,68 \u00b1 2,13%, 70,17 \u00b1 4,92% e 23,95 \u00b1 4,53%; CC: 16,67 \u00b1 2,29%, 72,05 \u00b1 \n\n3,63% e 26,7 \u00b1 5,98%, respectivamente) em compara\u00e7\u00e3o com as c\u00e9lulas n\u00e3o \n\nestimuladas [AD: 13,46 \u00b1 2,22% (P?0,05), 49,03 \u00b1 5,78% (P?0,05) e 15,33 \u00b1 2,46% \n\n(P?0,001); DT: 18,23 \u00b1 2,2% (P?0,001), 65,37 \u00b1 4,53% (P?0,05) e 18,82 \u00b1 3,69% \n\n(P?0,001); CC: 13,32 \u00b1 2,11% (P?0,001), 58,07 \u00b1 6,88% (P?0,001) e 23,01 \u00b1 5,42% \n\n(P?0,05); respectivamente] (Figura 14A). Os HI n\u00e3o apresentaram altera\u00e7\u00f5es na \n\nexpress\u00e3o de CD38 devido \u00e0 estimula\u00e7\u00e3o antig\u00eanica por nenhuma popula\u00e7\u00e3o celular \n\nestudada (Figura 14A).  \n\n\n\n74 \n\nEm rela\u00e7\u00e3o aos linf\u00f3citos T CD8+, n\u00e3o foram observadas diferen\u00e7as na \n\nfrequ\u00eancia de express\u00e3o de CD107a entre as c\u00e9lulas n\u00e3o estimuladas e estimuladas \n\ncom Lb-Ag dos pacientes de LC, assim como dos HI (dados n\u00e3o mostrados). Em \n\nrela\u00e7\u00e3o aos seus percentuais de ativa\u00e7\u00e3o, foi poss\u00edvel observar que o Lb-Ag induziu \n\naumento da frequ\u00eancia de linf\u00f3citos T CD8+ CD38+ dos pacientes DT (11,65 \u00b1 \n\n1,81%) em compara\u00e7\u00e3o \u00e0s culturas n\u00e3o estimuladas (9,25 \u00b1 1,68%, P? 0,05) (Figura \n\n14B). Os pacientes AD e CC, assim como os HI, n\u00e3o apresentaram altera\u00e7\u00f5es nos \n\npercentuais de linf\u00f3citos T CD8+ CD38+ em resposta \u00e0 estimula\u00e7\u00e3o antig\u00eanica \n\n(dados n\u00e3o mostrados). \n\n \n\nFigura 13. Compara\u00e7\u00e3o da express\u00e3o de CD107a pelas c\u00e9lulas T CD4+, NK e NKT CD3+CD56+ \nestimuladas (Lb-Ag) e n\u00e3o estimuladas (BG \u2013 background) dos pacientes com a doen\u00e7a ativa (AD, do \ningl\u00eas active disease; n=16), durante o tratamento (DT, do ingl\u00eas during treatment; n=16) e curados \n(CC, do ingl\u00eas clinically cured; n=10). As linhas s\u00f3lidas conectam os resultados referentes ao mesmo \nindiv\u00edduo. As an\u00e1lises estat\u00edsticas foram realizadas pelo teste pareado n\u00e3o-param\u00e9trico de Wilcoxon. \nOs resultados foram considerados significativos quando P?0,05. *(P?0,05) **(P?0,01)*** (P?0,001). \n\n\n\n75 \n\n \n\n \n\nFigura 14. Compara\u00e7\u00e3o entre as culturas estimuladas (Lb-Ag) e n\u00e3o estimuladas (BG \u2013 background) \nem rela\u00e7\u00e3o \u00e0 express\u00e3o de CD38 pelos: linf\u00f3citos T CD4+, c\u00e9lulas NK e NKT CD3+CD56+ dos \npacientes com a doen\u00e7a ativa (AD, do ingl\u00eas active disease; n=17), durante o tratamento (DT, do \ningl\u00eas during treatment; n=16) e curados (CC, do ingl\u00eas clinically cured; n=10) (A); e pelos linf\u00f3citos T \nCD8+ dos pacientes durante o tratamento (DT, do ingl\u00eas during treatment; n=16) (B). As linhas s\u00f3lidas \nconectam os resultados referentes ao mesmo indiv\u00edduo. As an\u00e1lises estat\u00edsticas foram realizadas \npelo teste pareado n\u00e3o-param\u00e9trico de Wilcoxon. Os resultados foram considerados significativos \nquando P?0,05. *(P?0,05) **(P?0,01) \n\n\n\n76 \n\n \n\n5.2.5. Os ant\u00edgenos de L. (V.) braziliensis induzem a exaust\u00e3o de c\u00e9lulas NK \n\nnos pacientes de LC. \n\nA express\u00e3o de CD279 foi analisada para verificar se o Lb-Ag induz exaust\u00e3o \n\ncelular durante as diferentes fases cl\u00ednicas da LC. A an\u00e1lise da exaust\u00e3o celular foi \n\nrealizada comparando os percentuais de c\u00e9lulas CD8+ T, CD4+ T, NK e NKT \n\nCD3+CD56+ que expressam CD279 sem estimula\u00e7\u00e3o antig\u00eanica com \u00e0quelas \n\nestimuladas com o Lb-Ag. N\u00f3s observamos maior frequ\u00eancia de c\u00e9lulas NK CD279+ \n\nap\u00f3s estimula\u00e7\u00e3o antig\u00eanica em todos os grupos de pacientes de LC (AD: 6,17 \u00b1 \n\n1,7%, DT: 6,06 \u00b1 1,26%, CC: 7,33 \u00b1 1,55%) em compara\u00e7\u00e3o aos percentuais \n\ndetectados nas culturas n\u00e3o estimuladas (AD: 4,22 \u00b1 1,27%, P?0,01; DT: 4,34 \u00b1 \n\n1,1%, P?0,05; CC: 3,42 \u00b1 1,05%, P?0,01) (Figura 15A). Nas culturas estimuladas \n\ncom Lb-Ag, tamb\u00e9m foi observada maior frequ\u00eancia de linf\u00f3citos T CD8+ CD279+ \n\nnos pacientes DT (5,04 \u00b1 1,38%) e de c\u00e9lulas NKT CD3+CD56+ CD279+ nos \n\npacientes CC (10,85 \u00b1 3,83%) quando comparadas \u00e0s c\u00e9lulas sem estimula\u00e7\u00e3o \n\nantig\u00eanica (4,18 \u00b1 1,15% e 7,29 \u00b1 2,75%, respectivamente) (P?0,05) (Figura 15B). \n\nOs HI n\u00e3o apresentaram altera\u00e7\u00f5es nos percentuais de express\u00e3o de CD279 por \n\nnenhuma popula\u00e7\u00e3o celular estudada em resposta ao est\u00edmulo com Lb-Ag (dados \n\nn\u00e3o mostrados). \n\n \n\n5.2.6. Os linf\u00f3citos T CD4+ representam a maior propor\u00e7\u00e3o de c\u00e9lulas que \n\nexpressam os biomarcadores CD107a, CD38 e CD279. \n\nUtilizando uma outra estrat\u00e9gia de an\u00e1lise citofluorim\u00e9trica, n\u00f3s avaliamos \n\nqual popula\u00e7\u00e3o celular seria mais relevante na fun\u00e7\u00e3o citot\u00f3xica e qual representaria \n\na maior parte das c\u00e9lulas que expressam CD38 e CD279 nas diferentes fases \n\ncl\u00ednicas da LC. Atrav\u00e9s desta abordagem, n\u00f3s determinamos a express\u00e3o total de \n\nCD107a, CD38 e CD279 com base na regi\u00e3o de linf\u00f3citos vi\u00e1veis (Figura 11) e \n\ndepois verificamos qual o percentual que cada popula\u00e7\u00e3o celular estudada \n\nrepresenta. Desta forma, foi poss\u00edvel observar em todos os grupos estudados (tanto \n\nnos pacientes LC quanto nos HI) e independentemente da estimula\u00e7\u00e3o antig\u00eanica \n\nque os linf\u00f3citos T CD4+ constitu\u00edram a maioria das c\u00e9lulas que expressam CD107a, \n\nCD38 e CD279. Com rela\u00e7\u00e3o \u00e0 express\u00e3o total de CD107a, CD38 e CD279, os \n\nperfis de express\u00e3o foi mantido em todos os grupos estudados e \n\nindependentemente do est\u00edmulo com Lb-Ag: os linf\u00f3citos T CD4+ representaram a \n\n\n\n77 \n\nmaioria, c\u00e9lulas T CD8+ e NK constitu\u00edram percentuais intermedi\u00e1rios e semelhantes \n\ne as c\u00e9lulas NKT CD3+CD56+ representaram a menor propor\u00e7\u00e3o. \n\nA Figura 16 ilustra os resultados da express\u00e3o total de CD107a ap\u00f3s \n\nestimula\u00e7\u00e3o com Lb-Ag  obtidos dos HI (linf\u00f3citos T CD4+: 42,37 \u00b1 3,55%, linf\u00f3citos T \n\nCD8+: 15,40 \u00b1 2,81%, c\u00e9lulas NK: 13,7 \u00b1 2,12% e c\u00e9lulas NKT CD3+CD56+: 5,13 \u00b1  \n\n1,35%) (Figura 16A) e dos pacientes AD (linf\u00f3citos T CD4+: 36,14 \u00b1 5,18%, linf\u00f3citos \n\nT CD8+: 17,51 \u00b1 4,0%, c\u00e9lulas NK: 17,78 \u00b1 3,60% e c\u00e9lulas NKT CD3+CD56+: 7,44 \u00b1 \n\n1,72%) (Figura 16B); bem como a express\u00e3o total de CD38 observada nos HI \n\n(linf\u00f3citos T CD4+: 55,1 \u00b1 1,91%, linf\u00f3citos T CD8+: 15,25 \u00b1 1,50%, c\u00e9lulas NK: 22,88 \n\n\u00b1 5,85% e c\u00e9lulas NKT CD3+CD56+: 3,94 \u00b1 1,57%) (Figura 16C) e pacientes AD \n\n(linf\u00f3citos T CD4+: 51,65 \u00b1 3,24%, linf\u00f3citos T CD8+: 12,89 \u00b1 1,23%, c\u00e9lulas NK: \n\n18,95 \u00b1 2,76% e c\u00e9lulas NKT CD3+CD56+: 6,17 \u00b1 2,47%) (Figura 16D); e a \n\nexpress\u00e3o total de CD279 observada nos HI (linf\u00f3citos T CD4+: 44,79 \u00b1 2,91%, \n\nlinf\u00f3citos T CD8+: 21,88 \u00b1 1,80%, c\u00e9lulas NK: 25,56 \u00b1 7,10% e c\u00e9lulas NKT \n\nCD3+CD56+: 4,21 \u00b1 0,69%) (Figura 16E) e pacientes AD (linf\u00f3citos T CD4+: 48,41 \u00b1 \n\n3,47%, linf\u00f3citos T CD8+: 23,88 \u00b1 2,04%, c\u00e9lulas NK: 19,14 \u00b1 3,66% e c\u00e9lulas NKT \n\nCD3+CD56+: 6,35 \u00b1 2,18%) (Figura 16F). \n\n\n\n78 \n\n \n\nFigura 15. Compara\u00e7\u00e3o da express\u00e3o de CD279 entre as c\u00e9lulas estimuladas (Lb-Ag) e n\u00e3o \nestimuladas (BG \u2013 background): (A) c\u00e9lulas NK de pacientes com a doen\u00e7a ativa (AD, do ingl\u00eas \nactive disease; n=17), durante o tratamento (DT, do ingl\u00eas during treatment; n=16) e curados (CC, do \ningl\u00eas clinically cured; n=10); (B) linf\u00f3citos T CD8+ de pacientes durante o tratamento (DT, do ingl\u00eas \nduring treatment; n=16) e c\u00e9lulas NKT CD3+CD56+ de pacientes curados (CC, do ingl\u00eas clinically \ncured; n=10). As linhas s\u00f3lidas conectam os resultados referentes ao mesmo indiv\u00edduo. As an\u00e1lises \nestat\u00edsticas foram realizadas pelo teste pareado n\u00e3o-param\u00e9trico de Wilcoxon. Os resultados foram \nconsiderados significativos quando P?0,05. *(P?0,05) **(P?0,01) \n \n \n\n\n\n79 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  \n\n \n\nFigura 16. Express\u00e3o total de CD107a, CD38 e CD279. Gr\u00e1ficos de barras representando a m\u00e9dia \ndos percentuais (\u00b1 erro padr\u00e3o) de linf\u00f3citos T CD4+ e T CD8+, c\u00e9lulas NK e NKT CD3+CD56+ com \nbase na an\u00e1lise da express\u00e3o total de CD107a (A-B), CD38 (C-D) e CD279 (E-F). Os resultados \nforam obtidos de indiv\u00edduos sadios (HI, do ingl\u00eas helthy individuals; n=7) e de pacientes com a \ndoen\u00e7a ativa (AD, do ingl\u00eas active disease; n=17). As compara\u00e7\u00f5es estat\u00edsticas foram realizadas com \no teste U de Mann-Whitney, onde *P ? 0.05, **P &lt;0.01, ***P &lt;0.001. \n\n\n\n80 \n\n \n\n5.3. Parte 3 \n\nA terceira parte do trabalho \u00e9 referente aos resultados que ainda n\u00e3o foram \n\nsubmetidos para publica\u00e7\u00e3o. \n\n \n\n5.3.1. Express\u00e3o de CLA \n\nNos ensaios experimentais in vitro, as CMSP foram submetidas \u00e0 marca\u00e7\u00e3o \n\ncom o AcMo anti-CLA, al\u00e9m da marca\u00e7\u00e3o com 7AAD e com os AcMo anti-CD3, anti-\n\nCD4, anti-CD8, anti-CD56, anti-CD107a, anti-CD38 e anti-CD279, conforme descrito \n\nno item 4.5. Atrav\u00e9s deste painel citofluorim\u00e9trico, foi ent\u00e3o poss\u00edvel avaliar a \n\nfrequ\u00eancia das quatro popula\u00e7\u00f5es celulares potencialmente citot\u00f3xicas de interesse \n\n\u2013 linf\u00f3citos T CD4+ e T CD8+, c\u00e9lulas NK e NKT \u2013 e seus percentuais de express\u00e3o \n\nde CD107a, CD38, CD279 e CLA. Nesta etapa, ser\u00e3o descritos apenas os \n\nresultados referentes \u00e0 express\u00e3o de CLA nos ensaios in vitro.   \n\nN\u00e3o foi poss\u00edvel observar diferen\u00e7as nos percentuais de express\u00e3o de CLA \n\npor nenhuma popula\u00e7\u00e3o celular estudada na compara\u00e7\u00e3o entre as culturas n\u00e3o \n\nestimuladas (background \u2013 BG) e estimuladas com o ant\u00edgeno de L. (V.) braziliensis \n\n(Lb-Ag) oriundas dos pacientes com a doen\u00e7a ativa (AD), sob a terapia antimonial \n\n(DT) e clinicamente curados (CC), assim como de indiv\u00edduos sadios (HI). Os \n\nlinf\u00f3citos T CD4+ apresentaram percentuais de express\u00e3o de CLA similares no BG e \n\nLb-Ag nos pacientes AD (m\u00e9dia \u00b1 erro padr\u00e3o; 16.27 \u00b1 1.55% e 15,13 \u00b1 1,25%, \n\nrespectivamente), DT (21.58 \u00b1 1,44% e 20,37 \u00b1 1,55%, respectivamente) e CC \n\n(23,58 \u00b1 2.47% e 23,80 \u00b1 1,99%, respectivamente), assim como nos HI (10,55 \u00b1 \n\n4,94% e 12.85 \u00b1 4.69%, respectivamente) (Figura 17). Da mesma forma, os linf\u00f3citos \n\nT CD8+ tamb\u00e9m apresentaram percentuais de express\u00e3o de CLA similares no BG e \n\nLb-Ag nos pacientes AD (7,22 \u00b1 0,96% e 7,64 \u00b1 0,89%, respectivamente), DT (9,45 \u00b1 \n\n1,30% e 9,23 \u00b1 1,14%, respectivamente) e CC (10,53 \u00b1 1,53% e 11,95 \u00b1 1,41%, \n\nrespectivamente) e nos HI (4,64 \u00b1 2,26% e 6,31 \u00b1 2,33%, respectivamente) (Figura \n\n18), assim como as c\u00e9lulas NK (AD: 17,21 \u00b1 2,75% e 17,71 \u00b1 2,64%, \n\nrespectivamente; DT: 17,11 \u00b1 3,48% e 18,16 \u00b1 3,59%, respectivamente; CC: 15,99 \u00b1 \n\n3,01% e 19,08 \u00b1 3,70%, respectivamente; HI: 12,56 \u00b1 6,11% e 17,93 \u00b1 6,99%, \n\nrespectivamente) (Figura 19) e NKT (AD: 20,18 \u00b1 4,28% e 21,27 \u00b1 3,39%, \n\nrespectivamente; DT: 18,54 \u00b1 4,02% e 20,73 \u00b1 5,03%, respectivamente; CC: 25,99 \u00b1 \n\n\n\n81 \n\n7,23% e 27,04 \u00b1 7,22%, respectivamente; HI: 9,64 \u00b1 4,55% e 13,20 \u00b1 5,33%, \n\nrespectivamente) (Figura 20). \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 17. Percentual de linf\u00f3citos T CD4+ CLA+ nas culturas n\u00e3o estimuladas (BG: background) e \nestimuladas com ant\u00edgenos de L. braziliensis (Lb-Ag) de pacientes com leishmaniose cut\u00e2nea ativa \n(AD: active disease; n=15), sob a terapia antimonial (DT: during therapy; n=14) e clinicamente \ncurados (CC: clinical cure; n=9) e de indiv\u00edduos sadios (HI: healthy individuals; n=7). As linhas \ncont\u00ednuas ligam os resultados referentes ao mesmo indiv\u00edduo. Valor de P>0,05, obtido pelo teste \npareado n\u00e3o-param\u00e9trico de Wilcoxon. \n\n\n\n82 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 18. Percentual de linf\u00f3citos T CD8+ CLA+ nas culturas n\u00e3o estimuladas (BG: background) e \nestimuladas com ant\u00edgenos de L. braziliensis (Lb-Ag) de pacientes com leishmaniose cut\u00e2nea ativa \n(AD: active disease; n=15), sob a terapia antimonial (DT: during therapy; n=14) e clinicamente \ncurados (CC: clinical cure; n=9) e de indiv\u00edduos sadios (HI: healthy individuals; n=7). As linhas \ncont\u00ednuas ligam os resultados referentes ao mesmo indiv\u00edduo. Valor de P>0,05, obtido pelo teste \npareado n\u00e3o-param\u00e9trico de Wilcoxon. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 19. Percentual de c\u00e9lulas NK CLA+ nas culturas n\u00e3o estimuladas (BG: background) e \nestimuladas com ant\u00edgenos de L. braziliensis (Lb-Ag) de pacientes com leishmaniose cut\u00e2nea ativa \n(AD: active disease; n=15), sob a terapia antimonial (DT: during therapy; n=14) e clinicamente \ncurados (CC: clinical cure; n=9) e de indiv\u00edduos sadios (HI: healthy individuals; n=7). As linhas \ncont\u00ednuas ligam os resultados referentes ao mesmo indiv\u00edduo. Valor de P>0,05, obtido pelo teste \npareado n\u00e3o-param\u00e9trico de Wilcoxon. \n\n\n\n83 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 20. Percentual de c\u00e9lulas NKT CLA+ nas culturas n\u00e3o estimuladas (BG: background) e \nestimuladas com ant\u00edgenos de L. braziliensis (Lb-Ag) de pacientes com leishmaniose cut\u00e2nea ativa \n(AD: active disease; n=15), sob a terapia antimonial (DT: during therapy; n=14) e clinicamente \ncurados (CC: clinical cure; n=9) e de indiv\u00edduos sadios (HI: healthy individuals; n=7). As linhas \ncont\u00ednuas ligam os resultados referentes ao mesmo indiv\u00edduo. Valor de P>0,05, obtido pelo teste \npareado n\u00e3o-param\u00e9trico de Wilcoxon. \n\n \n\nAtrav\u00e9s de outra estrat\u00e9gia de an\u00e1lise citofluorim\u00e9trica, foi avaliada a \n\nexpress\u00e3o total de CLA a partir do gate de c\u00e9lulas vi\u00e1veis (Figura 11). A partir da \n\nexpress\u00e3o total de CLA, ent\u00e3o, foram verificados os percentuais expressos por cada \n\npopula\u00e7\u00e3o celular de interesse (c\u00e9lulas T CD8+, T CD4+, NK e NKT). Desta forma, foi \n\nposs\u00edvel determinar a propor\u00e7\u00e3o que cada popula\u00e7\u00e3o celular representa no 100% de \n\nexpress\u00e3o de CLA. Foi verificado que os linf\u00f3citos T CD4+ representam a maior parte \n\ndas c\u00e9lulas que expressam CLA em todos os grupos estudados e independente da \n\nestimula\u00e7\u00e3o antig\u00eanica, enquanto as c\u00e9lulas NK e NKT representam as menores \n\npropor\u00e7\u00f5es. As figuras 21-24 apresentam os resultados de express\u00e3o de CLA a \n\npartir do gate de express\u00e3o total, ou seja, 100% de express\u00e3o, de CLA em \n\npropor\u00e7\u00e3o (gr\u00e1ficos de pizza) e em m\u00e9dia \u00b1 erro padr\u00e3o (gr\u00e1fico de barras) pelos \n\nlinf\u00f3citos T CD4+ e T CD8+, c\u00e9lulas NK e NKT, estimulados com o Lb-Ag e n\u00e3o \n\nestimulados (BG \u2013 background) nos grupos estudados. Nos pacientes AD, os \n\nlinf\u00f3citos T CD4+, tanto nas culturas estimuladas com Lb-Ag como nas n\u00e3o \n\nestimuladas, representam a maior parte das c\u00e9lulas que expressam CLA (P?0,001) \n\n\n\n84 \n\n(69,12 \u00b1 3,42% e 72,48 \u00b1 3,48%, respectivamente), seguidos em menores \n\npercentuais pelos linf\u00f3citos T CD8+ (16,59 \u00b1 1,29% e 14.91 \u00b1 1,31%, \n\nrespectivamente), c\u00e9lulas NK (10,96 \u00b1 2,34% e 9,33 \u00b1 2,27%, respectivamente) e \n\nNKT (4,68 \u00b1 0,77% e 3,43 \u00b1 0,70%, respectivamente) (Figura 21). Os pacientes DT \n\npossuem, tanto nas culturas estimuladas com Lb-Ag quanto nas n\u00e3o estimuladas, os \n\nlinf\u00f3citos T CD4+ como as c\u00e9lulas majorit\u00e1rias na express\u00e3o de CLA (P?0,001) \n\n(69,20 \u00b1 3,29% e 71,29 \u00b1 3,46%, respectivamente), os linf\u00f3citos T CD8+ \n\nrepresentando uma popula\u00e7\u00e3o intermedi\u00e1ria (17,89 \u00b1 1,22% e 16,79 \u00b1 1,23%, \n\nrespectivamente) e as c\u00e9lulas NK (7,58 \u00b1 2,80% e 7,11 \u00b1 3,08%, respectivamente) e \n\nNKT (4,64 \u00b1 0,68% e 3,91 \u00b1 0,68%, respectivamente) com os menores percentuais \n\n(Figura 22). Da mesma forma, tanto sob est\u00edmulo antig\u00eanico quanto sem \n\nestimula\u00e7\u00e3o, a maior parte de c\u00e9lulas que expressam CLA nos pacientes CC \n\ncorresponde aos os linf\u00f3citos T CD4+ (P?0,001) (68,88 \u00b1 4,36% e 71,12 \u00b1 4,73%, \n\nrespectivamente), enquanto as menores correspondem \u00e0s c\u00e9lulas NK (7,21 \u00b1 3,96% \n\ne 6,81 \u00b1 4,06%, respectivamente) e NKT (4,42 \u00b1 1,28% e 3,05 \u00b1 0,90%, \n\nrespectivamente); e os linf\u00f3citos T CD8+ representam percentuais intermedi\u00e1rios \n\n(17,67 \u00b1 2,08% e 15,81 \u00b1 1,98%, respectivamente) (Figura 23). Nos HI foi poss\u00edvel \n\nobservar a mesma distribui\u00e7\u00e3o observada nos grupos de pacientes nas culturas \n\nestimuladas com o Lb-Ag: os linf\u00f3citos T CD4+ representando a maior parte das \n\nc\u00e9lulas que expressam CLA (P?0,01) (56,35 \u00b1 4,73%), seguidos em menores \n\npercentuais pelos linf\u00f3citos T CD8+ (23,70 \u00b1 1,82%), c\u00e9lulas NK (14,52 \u00b1 3,55) e \n\nNKT (4,14 \u00b1 1,81%). Nas c\u00e9lulas n\u00e3o estimuladas dos HI, entretanto, os percentuais \n\nde linf\u00f3citos T CD4+ e T CD8+ que expressam CLA s\u00e3o similares (42,09 \u00b1 7,44% e \n\n32,69 \u00b1 3,45%, respectivamente), as c\u00e9lulas NKT representam os menores \n\npercentuais de c\u00e9lulas que expressam CLA (4,99 \u00b1 1,22%) e as c\u00e9lulas NK \n\nrepresentam uma popula\u00e7\u00e3o intermedi\u00e1ria (16,78 \u00b1 3,09%) (Figura 24). \n\n\n\n85 \n\n \n\nFigura 21. Distribui\u00e7\u00e3o das popula\u00e7\u00f5es celulares a partir da express\u00e3o total de CLA em pacientes \ncom leishmaniose cut\u00e2nea ativa (AD, active disease) (n=15). Resultados representativos das (A) \nculturas estimuladas com ant\u00edgeno de Leishmania braziliensis (Lb-Ag) e (B) sem est\u00edmulo. Gr\u00e1fico de \nbarras representando m\u00e9dia \u00b1 erro padr\u00e3o, onde *P?0,05 e ***P?0,001. Valor de p obtido pelo teste \nestat\u00edstico n\u00e3o-param\u00e9trico Mann-Whitney. Nos gr\u00e1ficos de setores est\u00e3o representadas as \npropor\u00e7\u00f5es de cada popula\u00e7\u00e3o celular baseadas nas m\u00e9dias percentuais de express\u00e3o de CLA.  \n\n(A) Lb-Ag \n\n(B) background \n\nPacientes AD \n\n\n\n86 \n\n \n\n \n\n \n\nFigura 22. Distribui\u00e7\u00e3o das popula\u00e7\u00f5es celulares a partir da express\u00e3o total de CLA em pacientes \nsob a terapia antimonial (DT, during therapy) (n=14). Resultados representativos das (A) culturas \nestimuladas com ant\u00edgeno de Leishmania braziliensis (Lb-Ag) e (B) sem est\u00edmulo. Gr\u00e1fico de barras \nrepresentando m\u00e9dia \u00b1 erro padr\u00e3o, onde ***P?0,001. Valor de p obtido pelo teste estat\u00edstico n\u00e3o-\nparam\u00e9trico Mann-Whitney. Nos gr\u00e1ficos de setores est\u00e3o representadas as propor\u00e7\u00f5es de cada \npopula\u00e7\u00e3o celular baseadas nas m\u00e9dias percentuais de express\u00e3o de CLA.  \n\n(A) Lb-Ag \n\n(B) background \n\nPacientes DT \n\n\n\n87 \n\n \n\n \n\nFigura 23. Distribui\u00e7\u00e3o das popula\u00e7\u00f5es celulares a partir da express\u00e3o total de CLA em pacientes \ncom cura cl\u00ednica (CC, clinical cure) (n=9). Resultados representativos das (A) culturas estimuladas \ncom ant\u00edgeno de Leishmania braziliensis (Lb-Ag) e (B) sem est\u00edmulo. Gr\u00e1fico de barras \nrepresentando m\u00e9dia \u00b1 erro padr\u00e3o, onde **P?0,01 e ***P?0,001. Valor de p obtido pelo teste \nestat\u00edstico n\u00e3o-param\u00e9trico Mann-Whitney. Nos gr\u00e1ficos de setores est\u00e3o representadas as \npropor\u00e7\u00f5es de cada popula\u00e7\u00e3o celular baseadas nas m\u00e9dias percentuais de express\u00e3o de CLA.  \n\n(A) Lb-Ag \n\n(B) background \n\nPacientes CC \n\n\n\n88 \n\n \n\n \n\nFigura 24. Distribui\u00e7\u00e3o das popula\u00e7\u00f5es celulares a partir da express\u00e3o total de CLA em indiv\u00edduos \nsadios (HI, healthy individuals) (n=7). Resultados representativos das (A) culturas estimuladas com \nant\u00edgeno de Leishmania braziliensis (Lb-Ag) e (B) sem est\u00edmulo. Gr\u00e1fico de barras representando \nm\u00e9dia \u00b1 erro padr\u00e3o, onde *P?0,05, **P?0,01 e ***P?0,001. Valor de p obtido pelo teste estat\u00edstico \nn\u00e3o-param\u00e9trico Mann-Whitney. Nos gr\u00e1ficos de setores est\u00e3o representadas as propor\u00e7\u00f5es de cada \npopula\u00e7\u00e3o celular baseadas nas m\u00e9dias percentuais de express\u00e3o de CLA.  \n\n(A) Lb-Ag \n\n(B) background \n\nHI \n\n\n\n89 \n\n \n\n5.3.2. Grupo de Pacientes com Falha Terap\u00eautica (FT) \n\nNos ensaios experimentais in vitro, al\u00e9m da amostragem descrita no item 4.5, \n\nque incluiu pacientes com a doen\u00e7a ativa (AD), sob a terapia (DT) e com cura cl\u00ednica \n\n(CC), foi avaliado tamb\u00e9m mais um grupo de pacientes de LC: pacientes que \n\napresentaram falha terap\u00eautica ap\u00f3s o t\u00e9rmino da terapia (FT; n=3). A amostra de \n\nsangue perif\u00e9rico destes pacientes foi coletada quando eles apresentavam a doen\u00e7a \n\nativa; entretanto, ap\u00f3s um estudo retrospectivo, foi constatado que os mesmos \n\napresentaram falha terap\u00eautica.  \n\nFoi realizada a compara\u00e7\u00e3o entre a resposta espec\u00edfica aos Lb-Ag dos \n\npacientes com a doen\u00e7a ativa que evolu\u00edram para a cura cl\u00ednica ap\u00f3s a terapia \n\n(pacientes AD) com a resposta dos pacientes com a doen\u00e7a ativa que apresentaram \n\nfalha terap\u00eautica (pacientes FT). Tal resposta espec\u00edfica foi obtida calculando-se a \n\nraz\u00e3o entre os percentuais obtidos com a estimula\u00e7\u00e3o antig\u00eanica e os percentuais \n\nobtidos sem estimula\u00e7\u00e3o (Lb-Ag / BG). Desta forma, foi poss\u00edvel observar que os \n\nvalores absolutos das raz\u00f5es entre os percentuais de c\u00e9lulas CD107a+ estimuladas \n\ncom o Lb-Ag e de c\u00e9lulas n\u00e3o estimuladas foram maiores nos pacientes AD (1,61 \u00b1 \n\n0,14%) em compara\u00e7\u00e3o aos pacientes FT (0,14 \u00b1 0,08%) (P?0,001) (Figura 25). \n\nDevido ao tamanho da amostragem do grupo de pacientes FT, n\u00e3o foi poss\u00edvel fazer \n\nas an\u00e1lises estat\u00edsticas pareadas pelo teste de Wilcoxon.  \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 25. Avalia\u00e7\u00e3o da express\u00e3o de CD107a espec\u00edfica ao Lb-Ag. A raz\u00e3o entre os percentuais de \nc\u00e9lulas CD107a+ detectados nas culturas estimuladas com ant\u00edgenos de Leishmania braziliensis (Lb-\nAg) e os percentuais detectados nas culturas n\u00e3o estimuladas foi calculada e os resultados obtidos \nnos pacientes com a doen\u00e7a ativa (AD) (n=17) foram comparados com os resultados dos pacientes \ncom falha terap\u00eautica (FT) (n=3). ***P<0,001, teste n\u00e3o-param\u00e9trico Mann-Whitney. Cada ponto \nrepresenta a raz\u00e3o entre os percentuais de c\u00e9lulas CD107a+ detectados nas culturas com est\u00edmulo \nantig\u00eanico e os percentuais detectados nas culturas n\u00e3o estimuladas de um mesmo indiv\u00edduo. A barra \nrepresenta a m\u00e9dia \u00b1 erro padr\u00e3o. \n\n\n\n90 \n\n \n\n5.3.3. Quantifica\u00e7\u00e3o de IL-15 \n\nA quantifica\u00e7\u00e3o de IL-15 foi realizada por ELISA em amostras de \n\nsobrenadante de cultura de CMSP, plasma sangu\u00edneo e sobrenadante de macerado \n\nde biopsia de les\u00e3o de pacientes de LC.  \n\nN\u00e3o foram observadas diferen\u00e7as entre as concentra\u00e7\u00f5es de IL-15 detectadas \n\nno sobrenadante das culturas de CMSP estimuladas com o Lb-Ag e o sobrenadante \n\ndas culturas n\u00e3o estimuladas dos pacientes AD (4,20 \u00b1 0,13 pg/mL e 4,27 \u00b1 0,13 \n\npg/mL, respectivamente), DT (4,35 \u00b1 0,13 pg/mL e 4,28 \u00b1 0,14 pg/mL, \n\nrespectivamente) e CC (4,19 \u00b1 0,29 pg/mL e 3,97 \u00b1 0,21 pg/mL, respectivamente) \n\nassim como dos HI (4,71 \u00b1 0,24 pg/mL e 4,77 \u00b1 0,30 pg/mL, respectivamente) \n\n(Figura 26). Tamb\u00e9m n\u00e3o foi detectada diferen\u00e7a de concentra\u00e7\u00e3o de IL-15 na \n\ncompara\u00e7\u00e3o entre os grupos estudados (Figura 27).  \n\nNa quantifica\u00e7\u00e3o de IL-15 plasm\u00e1tica tamb\u00e9m n\u00e3o observamos diferen\u00e7as \n\nentre os grupos estudados. As concentra\u00e7\u00f5es de IL-15 no plasma de pacientes AD \n\n(10,13 \u00b1 0,63 pg/mL), DT (10,69 \u00b1 1,19 pg/mL) e CC (9,71 \u00b1 1,91 pg/mL) foram \n\nsimilares, assim como nos HI (9,62 \u00b1 1,87 pg/mL) (Figura 28). \n\nA quantifica\u00e7\u00e3o de IL-15 em sobrenadantes obtidos da macera\u00e7\u00e3o de \n\namostras de biopsias de les\u00f5es de pacientes de LC e de esporotricose revelou \n\ndiferen\u00e7as entre estes dois grupos. A concentra\u00e7\u00e3o de IL-15 foi maior nos \n\nsobrenadantes dos pacientes de LC (8,52 \u00b1 0,55 pg/mL) em compara\u00e7\u00e3o aos \n\npacientes com esporotricose (NR; doen\u00e7a n\u00e3o-relacionada) (6,14 \u00b1 0,23 pg/mL) \n\n(P?0,001), como demonstrado na Figura 29. \n\n \n\n\n\n91 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 26. Compara\u00e7\u00e3o da concentra\u00e7\u00e3o de IL-15 no sobrenadante das culturas de CMSP \nestimuladas com ant\u00edgenos de L. braziliensis (Lb-Ag) e das culturas n\u00e3o estimuladas (BG: \nbackground) de pacientes com leishmaniose cut\u00e2nea ativa (AD: active disease; n=17), sob a terapia \nantimonial (DT: during therapy; n=16) e clinicamente curados (CC: clinical cure; n=10) e de indiv\u00edduos \nsadios (HI: healthy individuals; n=7). As linhas cont\u00ednuas ligam os resultados referentes ao mesmo \nindiv\u00edduo. Valor de P>0,05, obtido pelo teste pareado de Wilcoxon. CMSP: c\u00e9lulas mononucleares de \nsangue perif\u00e9rico. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 27. Concentra\u00e7\u00e3o de IL-15 no sobrenadante das culturas de CMSP. Gr\u00e1fico de dispers\u00e3o e \nbarras representando os resultados da concentra\u00e7\u00e3o de IL-15 no sobrenadante das culturas de \nCMSP n\u00e3o estimuladas (BG: background) e estimuladas com ant\u00edgenos de L. braziliensis (Lb-Ag) na \ncompara\u00e7\u00e3o entre os grupos estudados: indiv\u00edduos sadios (HI: healthy individuals; n=7) e pacientes \ncom leishmaniose cut\u00e2nea ativa (AD: active disease; n=17), sob a terapia antimonial (DT: during \ntherapy; n=16) e clinicamente curados (CC: clinical cure; n=10). Cada ponto representa um indiv\u00edduo \ne as barras representam a m\u00e9dia \u00b1 erro padr\u00e3o. Valor de P>0,05, obtido pelo teste n\u00e3o-param\u00e9trico \nMann-Whitney. \n \n\n \n\n\n\n92 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 28. Concentra\u00e7\u00e3o de IL-15 plasm\u00e1tica. Gr\u00e1fico de dispers\u00e3o e barras representando os \nresultados da concentra\u00e7\u00e3o de IL-15 no plasma sangu\u00edneo de indiv\u00edduos sadios (HI: healthy \nindividuals; n=5) e pacientes com leishmaniose cut\u00e2nea ativa (AD: active disease; n=10), sob a \nterapia antimonial (DT: during therapy; n=9) e clinicamente curados (CC: clinical cure; n=5). Cada \nponto representa um indiv\u00edduo e as barras representam a m\u00e9dia \u00b1 erro padr\u00e3o. Valor de P>0,05, \nobtido pelo teste n\u00e3o-param\u00e9trico Mann-Whitney. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 29. Concentra\u00e7\u00e3o de IL-15 no sobrenadante de macerado de amostras de biopsia de les\u00e3o. \nGr\u00e1fico de dispers\u00e3o representando os resultados da concentra\u00e7\u00e3o de IL-15 de sobrenadantes \nobtidos a partir de macera\u00e7\u00e3o de amostras de biopsia de les\u00f5es de pacientes de leishmaniose \ncut\u00e2nea (LC) (n=10) e de pacientes de esporotricose, doen\u00e7a n\u00e3o relacionada \u00e0 LC (NR) (n=7). Cada \nponto representa um indiv\u00edduo e as barras representam a m\u00e9dia \u00b1 erro padr\u00e3o. ***P?0,001, obtido \npelo teste n\u00e3o-param\u00e9trico Mann-Whitney. \n\n\n\n93 \n\n6. DISCUSS\u00c3O \n\nAs leishmanioses s\u00e3o consideradas pela Organiza\u00e7\u00e3o Mundial de Sa\u00fade uma \n\ndas doen\u00e7as tropicais de maior import\u00e2ncia para a sa\u00fade p\u00fablica no mundo. A LTA \u00e9 \n\nend\u00eamica no Brasil, onde se registram anualmente cerca de 20.000 novos casos, a \n\nmaioria causada pela esp\u00e9cie Leishmania (V.) braziliensis (8). A LTA exibe um \n\namplo espectro de apresenta\u00e7\u00f5es cl\u00ednicas de gravidade variada, causando desde \n\nles\u00f5es localizadas a graves deforma\u00e7\u00f5es, sendo a leishmaniose cut\u00e2nea (LC) a \n\nforma cl\u00ednica mais comum (37). A doen\u00e7a \u00e9 end\u00eamica no Estado do Rio de Janeiro, \n\nonde o agente etiol\u00f3gico \u00e9 a Leishmania (V.) braziliensis. A infec\u00e7\u00e3o por L. (V.) \n\nbraziliensis geralmente resulta na predomin\u00e2ncia de uma resposta imune Th1, que \n\npode levar \u00e0 resolu\u00e7\u00e3o das les\u00f5es ou a uma resposta inflamat\u00f3ria exagerada \n\nrespons\u00e1vel pelo dano tecidual (130). Sendo assim, um maior conhecimento dos \n\nfen\u00f4menos que ocorrem na resposta imune contra a Leishmania torna-se de \n\nfundamental import\u00e2ncia para estabelecer par\u00e2metros imunol\u00f3gicos associados com \n\na patog\u00eanese, assim como com a prote\u00e7\u00e3o, que certamente nortear\u00e3o o \n\ndesenvolvimento de protocolos vacinais e imunoterapias.  \n\nA imunidade protetora contra a infec\u00e7\u00e3o parasit\u00e1ria \u00e9 criticamente dependente \n\ndo desenvolvimento de uma resposta multifuncional de c\u00e9lulas T que lisam \n\ndiretamente as c\u00e9lulas infectadas ou induzem ativa\u00e7\u00e3o de fag\u00f3citos para destruir os \n\nparasitos intracelulares (282). Os linf\u00f3citos T CD4+ s\u00e3o cruciais para direcionar \n\napropriadamente a resposta imune durante a defesa do hospedeiro e est\u00e1 \n\nestabelecido na literatura que as c\u00e9lulas CD4+ Th1 s\u00e3o essenciais no controle da \n\ninfec\u00e7\u00e3o por Leishmania (107). Em adi\u00e7\u00e3o \u00e0s fun\u00e7\u00f5es auxiliares tradicionalmente \n\natribu\u00eddas \u00e0s subpopula\u00e7\u00f5es de linf\u00f3citos T CD4+, foi evidenciado que os linf\u00f3citos T \n\nCD4+ podem tamb\u00e9m desempenhar fun\u00e7\u00f5es citot\u00f3xicas (138). Linf\u00f3citos T CD4+ \n\ncom potencial citol\u00edtico v\u00eam sendo observados h\u00e1 d\u00e9cadas (283), mas foram \n\nconsiderados por muito tempo como artefatos de cultura. Entretanto, novos estudos \n\nsurgiram mostrando que estes linf\u00f3citos T CD4+ circulantes s\u00e3o terminalmente \n\ndiferenciados, s\u00e3o gerados tanto em infec\u00e7\u00f5es agudas quanto cr\u00f4nicas e podem \n\ncontribuir para respostas protetoras (284). Os linf\u00f3citos T CD4+ citot\u00f3xicos t\u00eam sido \n\nimplicados no controle de uma variedade de infec\u00e7\u00f5es virais persistentes, tais como \n\nHIV-1, CMV, EBV, influenza, hantav\u00edrus e dengue (152). No entanto, seu papel na \n\nLC \u00e9 pouco conhecido. Neste contexto, al\u00e9m das c\u00e9lulas citot\u00f3xicas cl\u00e1ssicas, como \n\nlinf\u00f3citos T CD8+ e c\u00e9lulas NK, torna-se extremamente necess\u00e1rio levar em \n\n\n\n94 \n\nconsidera\u00e7\u00e3o o impacto da fun\u00e7\u00e3o citot\u00f3xica desempenhada pelos linf\u00f3citos T CD4+ \n\nna imunopatogenia multifacetada das doen\u00e7as relacionadas ao sistema imunol\u00f3gico \n\n(152). \n\nNo processo de citotoxicidade exercido por estas c\u00e9lulas, a via de secre\u00e7\u00e3o \n\nde gr\u00e2nulos l\u00edticos \u00e9 a mais comum e compartilhada pelas diferentes linhagens de \n\nc\u00e9lulas citot\u00f3xicas, como c\u00e9lulas T e NK (285). Esta fun\u00e7\u00e3o efetora \u00e9 exercida pela \n\nsecre\u00e7\u00e3o coordenada de gr\u00e2nulos citot\u00f3xicos contendo perforina e proteases \n\nefetoras (granulisina e prote\u00ednas da fam\u00edlia das granzimas) que s\u00e3o liberados na \n\nsinapse formada entre os linf\u00f3citos citot\u00f3xicos e as c\u00e9lulas-alvo e iniciam uma \n\ncascata de morte celular de maneira apopt\u00f3tica e n\u00e3o apopt\u00f3tica (286). Durante o \n\nprocesso de degranula\u00e7\u00e3o celular s\u00e3o expostas na membrana das c\u00e9lulas \n\ncitot\u00f3xicas as prote\u00ednas de membrana associadas a lisossomos, como CD107a, que \n\ns\u00e3o pr\u00e9-requisito para a lise das c\u00e9lulas-alvo mediada por gr\u00e2nulos (167). Estudos \n\nrecentes indicam que os linf\u00f3citos T CD4+ que apresentam mol\u00e9culas citot\u00f3xicas \n\nexpressam o fator de transcri\u00e7\u00e3o T-bet (285,287). Entretanto, apesar de \n\ncompartilharem esta caracter\u00edstica com os linf\u00f3citos Th1, uma condi\u00e7\u00e3o polarizada \n\npor citocinas com este perfil n\u00e3o \u00e9 ideal para a gera\u00e7\u00e3o da subpopula\u00e7\u00e3o citot\u00f3xica, \n\nsendo melhores induzidos na presen\u00e7a de IL-2, IL-12 e IL-15 (151,175).  \n\nDe maneira interessante, foi observado no nosso estudo linf\u00f3citos T CD4+ \n\nexpressando CD107a em todos os indiv\u00edduos avaliados. Nos ensaios ex vivo, \n\nobservamos que os pacientes curados apresentaram percentuais mais baixos de \n\nexpress\u00e3o de CD107a+, n\u00e3o s\u00f3 pelos linf\u00f3citos T CD4+, como tamb\u00e9m pelos \n\nlinf\u00f3citos T CD8+ e c\u00e9lulas NK e NKT. A menor atividade de degranula\u00e7\u00e3o observada \n\nnos pacientes curados pode ser devido a um retorno do sistema imunol\u00f3gico a um \n\nestado de repouso (resting) fisiol\u00f3gico ap\u00f3s a resolu\u00e7\u00e3o da infec\u00e7\u00e3o e \u00e0 \n\ndiferencia\u00e7\u00e3o de c\u00e9lulas efetoras em c\u00e9lulas de mem\u00f3ria (288). De fato, estudos \n\nap\u00f3s a cura cl\u00ednica da LC demonstraram uma redu\u00e7\u00e3o na ativa\u00e7\u00e3o de c\u00e9lulas \n\nefetoras e na quantidade de mediadores inflamat\u00f3rios, apontando para um \n\nimportante papel dos mecanismos regulat\u00f3rios na manuten\u00e7\u00e3o da cura cl\u00ednica \n\n(104,189,289\u2013291). Apesar dos menores percentuais de express\u00e3o de CD107a \n\npelos linf\u00f3citos T CD4+ nos pacientes curados, a frequ\u00eancia total destes linf\u00f3citos foi \n\ndetectada em percentuais normais, similares aos observados nos indiv\u00edduos sadios. \n\nNos pacientes com a doen\u00e7a ativa, entretanto, observamos que a frequ\u00eancia de \n\nlinf\u00f3citos T CD4+ foi mais baixa, o que se reestabeleceu com a terapia.  \n\n\n\n95 \n\nN\u00f3s avaliamos a resposta citot\u00f3xica espec\u00edfica aos ant\u00edgenos de L. (V.) \n\nbraziliensis atrav\u00e9s de ensaios de cultivo celular in vitro, nos quais pudemos \n\nobservar que tanto os pacientes com LC ativa quanto os pacientes sob a terapia \n\nantimonial e ap\u00f3s a cura cl\u00ednica apresentaram expans\u00e3o ant\u00edgeno-espec\u00edfica de \n\nlinf\u00f3citos T CD4+ em degranula\u00e7\u00e3o. Em \u00e1rea end\u00eamica de L. (L.) major j\u00e1 foi \n\nobservado que pacientes de LC curados apresentaram expans\u00e3o de linf\u00f3citos T \n\nCD4+ granzima B+ em resposta aos ant\u00edgenos de L. (L.) major, enquanto os \n\npercentuais de linf\u00f3citos T CD8+ granzima B+ n\u00e3o foram alterados pela presen\u00e7a do \n\nant\u00edgeno (292). Tal relato corrobora nossa evid\u00eancia de que a Leishmania induz um \n\naumento de linf\u00f3citos T CD4+ citot\u00f3xicos circulantes, que parecem estar sendo \n\nativados especificamente para exercerem suas fun\u00e7\u00f5es citot\u00f3xicas na doen\u00e7a. A \n\navalia\u00e7\u00e3o da ativa\u00e7\u00e3o celular foi realizada nos ensaios in vitro com base na \n\nexpress\u00e3o do receptor CD38 e, assim, pudemos observar tamb\u00e9m expans\u00e3o de \n\nlinf\u00f3citos T CD4+ ativados em resposta ao Lb-Ag por todos os grupos de pacientes.  \n\nO Lb-Ag induziu a contra\u00e7\u00e3o da frequ\u00eancia de linf\u00f3citos T CD4+ totais nos \n\npacientes com a doen\u00e7a ativa e naqueles sob a terapia. Como nos ensaios ex vivo \n\nn\u00f3s detectamos uma menor frequ\u00eancia de linf\u00f3citos T CD4+ nos pacientes com a \n\ndoen\u00e7a ativa, isto nos leva a sugerir que o parasito \u00e9 o respons\u00e1vel pela baixa \n\nfrequ\u00eancia destas c\u00e9lulas. A invers\u00e3o dos percentuais de linf\u00f3citos T CD4+ e T CD8+ \n\nap\u00f3s o tratamento descrita por Da-Cruz et al.(187,189) n\u00e3o foi observada em \n\nnenhum dos ensaios realizados neste estudo. Nos ensaios ex vivo, observamos \n\nmaiores percentuais de linf\u00f3citos T CD8+ nos pacientes ap\u00f3s o tratamento em \n\ncompara\u00e7\u00e3o aos outros grupos, entretanto n\u00e3o foi observada invers\u00e3o quando \n\ncomparados aos percentuais de linf\u00f3citos T CD4+. Nos ensaios in vitro, mesmo o  \n\nLb-Ag induzindo contra\u00e7\u00e3o dos linf\u00f3citos T CD4+ nos pacientes com a LC ativa, e \n\nopostamente, uma expans\u00e3o dos linf\u00f3citos T CD8+, tamb\u00e9m n\u00e3o foi poss\u00edvel \n\ndetectar maiores percentuais de linf\u00f3citos T CD8+ totais em compara\u00e7\u00e3o aos \n\nlinf\u00f3citos T CD4+. Os linf\u00f3citos T CD4+ foram as c\u00e9lulas predominantes no sangue \n\nperif\u00e9rico de todos os indiv\u00edduos avaliados no estudo, independente da doen\u00e7a ou \n\nda estimula\u00e7\u00e3o antig\u00eanica.   \n\nApesar da contra\u00e7\u00e3o da frequ\u00eancia de linf\u00f3citos T CD4+ induzida pelo Lb-Ag \n\nobservada nos pacientes com a doen\u00e7a ativa, a funcionalidade dessas c\u00e9lulas n\u00e3o \n\nest\u00e1 alterada, uma vez que seus percentuais de ativa\u00e7\u00e3o e degranula\u00e7\u00e3o \n\naumentaram em resposta ao Lb-Ag nesses pacientes. Al\u00e9m disso, precisamente \n\n\n\n96 \n\ncom intuito de verificar se a L. (V.) braziliensis induz preju\u00edzo da funcionalidade \n\ncelular, n\u00f3s avaliamos nos ensaios in vitro a express\u00e3o de CD279, um receptor \n\ninibit\u00f3rio envolvido na exaust\u00e3o de c\u00e9lulas T. Desta forma, foi poss\u00edvel observar que \n\no Lb-Ag n\u00e3o influenciou a express\u00e3o de CD279 pelos linf\u00f3citos T CD4+ dos \n\npacientes de LC, evidenciando um bom estado funcional destes linf\u00f3citos durante a \n\ndoen\u00e7a. Um estudo em modelo murino de infec\u00e7\u00e3o por L. (L.) major encontrou \n\nassocia\u00e7\u00e3o positiva entre a cronicidade da doen\u00e7a e o comprometimento de \n\nprolifera\u00e7\u00e3o ant\u00edgeno-espec\u00edfica e de produ\u00e7\u00e3o de IFN-?, com aumento \n\nconcomitante de express\u00e3o de CD279 por linf\u00f3citos T CD4+ (293). Entretanto, no \n\npresente estudo, n\u00f3s n\u00e3o observamos percentuais elevados de linf\u00f3citos T CD4+ \n\nCD279+ circulantes nos pacientes de LC em compara\u00e7\u00e3o aos indiv\u00edduos sadios e \n\nn\u00e3o encontramos associa\u00e7\u00e3o da express\u00e3o de CD279 com o tempo de evolu\u00e7\u00e3o da \n\ndoen\u00e7a.  \n\nNa LC humana, os linf\u00f3citos T CD8+ s\u00e3o ativados e proliferam em resposta \u00e0 \n\napresenta\u00e7\u00e3o antig\u00eanica da Leishmania, enquadrando-se como uma popula\u00e7\u00e3o de \n\nc\u00e9lulas T espec\u00edficas capazes de montar uma resposta imune contra o parasito \n\n(187). N\u00e3o \u00e9 totalmente compreendido como os linf\u00f3citos T CD8+ s\u00e3o ativados na \n\nleishmaniose, mas \u00e9 conhecido que eles respondem durante a infec\u00e7\u00e3o (177). Em \n\nconcord\u00e2ncia com os dados de que os linf\u00f3citos T CD8+ s\u00e3o capazes de reconhecer \n\na Leishmania e montar desenvolver uma resposta espec\u00edfica, nos ensaios in vitro, \n\nn\u00f3s detectamos uma expans\u00e3o de linf\u00f3citos T CD8+ em resposta ao Lb-Ag nos \n\npacientes com LC ativa. Da mesma maneira, as c\u00e9lulas NK e NKT destes pacientes \n\ntamb\u00e9m apresentaram expans\u00e3o ant\u00edgeno-espec\u00edfica.  \n\nNos ensaios ex vivo, n\u00f3s detectamos que a frequ\u00eancia de linf\u00f3citos T CD8+ foi \n\nmais elevada nos pacientes curados. Entretanto, em rela\u00e7\u00e3o aos seus percentuais \n\nde degranula\u00e7\u00e3o, observamos que foram os mais baixos nestes pacientes. Outros \n\nautores j\u00e1 relataram uma menor atividade de linf\u00f3citos T CD8+ ap\u00f3s a terapia, como \n\ndemonstrado pela diminui\u00e7\u00e3o dos n\u00edveis de IFN-? em pacientes de LC e LM curados \n\n(291). Neste contexto, nosso grupo demonstrou baixas frequ\u00eancias de linf\u00f3citos T \n\nCD8+ efetores circulantes em pacientes de LC causada por L. (V.) braziliensis ap\u00f3s \n\na cura (294) (anexo 5). Adicionalmente, estes pacientes curados apresentaram \n\nelevadas frequ\u00eancias de linf\u00f3citos T CD8+ de mem\u00f3ria em compara\u00e7\u00e3o com os \n\npacientes com LC ativa e durante o tratamento (Ferraz R, manuscrito em \n\nprepara\u00e7\u00e3o, comunica\u00e7\u00e3o pessoal). Assim, a baixa frequ\u00eancia de linf\u00f3citos T CD8+ \n\n\n\n97 \n\nCD107a+ circulantes observada nos pacientes curados parece ser consequ\u00eancia da \n\ndiferencia\u00e7\u00e3o dos linf\u00f3citos T CD8+ em c\u00e9lulas de mem\u00f3ria. \n\nOs linf\u00f3citos T CD8+ contribuem para a resist\u00eancia contra a infec\u00e7\u00e3o prim\u00e1ria \n\ne secund\u00e1ria e t\u00eam sido considerados alvos para o desenvolvimento de vacinas, \n\nprincipalmente devido \u00e0 sua r\u00e1pida produ\u00e7\u00e3o de IFN-? associada com a prote\u00e7\u00e3o em \n\nmodelos de infec\u00e7\u00e3o por L. (L.) major (180,182\u2013185). Foi sugerido que, em adi\u00e7\u00e3o \u00e0 \n\nprodu\u00e7\u00e3o de IFN-?, a produ\u00e7\u00e3o de perforina por linf\u00f3citos T CD8+ tamb\u00e9m \u00e9 crucial \n\npara a imunidade induzida por vacina contra L. (L.) amazonensis (186). Alguns \n\nestudos apontaram para um papel protetor e ben\u00e9fico dos linf\u00f3citos T CD8+ na \n\ninfec\u00e7\u00e3o por L. (V.) braziliensis (40,187\u2013190,294). Um menor percentual de linf\u00f3citos \n\nT CD8+ apopt\u00f3ticos foi observado em les\u00f5es de pacientes que curaram \n\nespontaneamente em compara\u00e7\u00e3o com pacientes na fase ativa da doen\u00e7a, \n\napontando para um papel importante destes linf\u00f3citos no microambiente da les\u00e3o \n\n(295).  \n\nEntretanto, estudos v\u00eam relacionando a fun\u00e7\u00e3o citot\u00f3xica dos linf\u00f3citos T \n\nCD8+ ao dano tecidual e exacerba\u00e7\u00e3o da doen\u00e7a, principalmente na LC humana \n\ncausada por L. (V.) braziliensis (141,143,144,296). Marcadores de citotoxicidade \n\ndependente de gr\u00e2nulos foram detectados em linf\u00f3citos T CD8+ isolados de les\u00f5es \n\nde pacientes de LC e os pacientes que apresentaram grandes \u00falceras cut\u00e2neas \n\npossu\u00edam maiores percentuais de linf\u00f3citos T CD8+ granzima A+ em compara\u00e7\u00e3o aos \n\npacientes com les\u00f5es nodulares (141). Nas les\u00f5es cut\u00e2neas de pacientes tamb\u00e9m \n\nfoi verificada alta express\u00e3o de genes associados com a via citol\u00edtica, nas quais os \n\nlinf\u00f3citos T CD8+ presentes exibiram um fen\u00f3tipo citot\u00f3xico (142,143). Ainda, \n\npacientes com a forma mucosa apresentaram maiores n\u00edveis de mRNA para \n\nmarcadores citol\u00edticos em compara\u00e7\u00e3o aos pacientes com a forma cut\u00e2nea (192). \n\nEstudos no modelo murino de infec\u00e7\u00e3o por L. (V.) braziliensis revelaram que a \n\nprogress\u00e3o da doen\u00e7a e a met\u00e1stase s\u00e3o independentes da carga parasit\u00e1ria, mas \n\ndiretamente associadas com a presen\u00e7a de linf\u00f3citos T CD8+. Nos animais que \n\napresentaram patologia severa foi relatada presen\u00e7a de linf\u00f3citos T CD8+ em \n\ndegranula\u00e7\u00e3o e lise de c\u00e9lulas infectadas com L. (V.) braziliensis (142). Em conjunto, \n\nestes resultados apontam para a citotoxicidade como caracter\u00edstica marcante da \n\nleishmaniose causada por L. (V.) braziliensis e sugerem que a atividade citot\u00f3xica \n\ndos linf\u00f3citos T CD8+ promova a progress\u00e3o da doen\u00e7a. No entanto, de acordo com \n\nos nossos resultados, a citotoxicidade mediada por linf\u00f3citos T CD8+ n\u00e3o est\u00e1 \n\nrelacionada com a patologia. Nos ensaios ex vivo, os percentuais de linf\u00f3citos T \n\n\n\n98 \n\nCD8+ CD107a+ detectados nos pacientes com LC ativa foram semelhantes aos \n\nobservados nos indiv\u00edduos sadios. Avaliando a resposta antig\u00eanica espec\u00edfica dos \n\nensaios in vitro, observamos que os linf\u00f3citos T CD8+ n\u00e3o apresentaram altera\u00e7\u00e3o \n\nem seus percentuais de degranula\u00e7\u00e3o em nenhum grupo de pacientes de LC, \n\nevidenciando que a infec\u00e7\u00e3o por L. (V.) braziliensis n\u00e3o induz aumento de atividade \n\ncitot\u00f3xica por estas c\u00e9lulas. \n\nUma quest\u00e3o interessante de discuss\u00e3o relaciona-se com as diferentes \n\nestrat\u00e9gias de avalia\u00e7\u00e3o fenot\u00edpica das celulas citot\u00f3xicas pela citometria de fluxo. \n\nEm alguns casos, mesmo a citotoxicidade sendo avaliada, n\u00e3o foi analisado se esta \n\nfun\u00e7\u00e3o poderia estar sendo exercida pelos linf\u00f3citos T CD4+ ou outras c\u00e9lulas \n\ncitot\u00f3xicas, como as c\u00e9lulas NK e NKT. Ainda, alguns estudos definiram a popula\u00e7\u00e3o \n\nde linf\u00f3citos T CD8+ avaliando os biomarcadores CD3 e CD8, e outros definiram esta \n\npopula\u00e7\u00e3o celular avaliando apenas a express\u00e3o de CD8, sem exclus\u00e3o de c\u00e9lulas \n\nNKT e/ou NK. No presente estudo, durante a an\u00e1lise citofluorim\u00e9trica, foi delimitada \n\na express\u00e3o positiva de CD3 para definir a popula\u00e7\u00e3o de linf\u00f3citos T e as c\u00e9lulas \n\nCD56+ foram exclu\u00eddas de tal an\u00e1lise, a fim de eliminar qualquer poss\u00edvel presen\u00e7a \n\nde c\u00e9lulas NK e NKT que poderiam estar sendo englobadas e, desta forma, \n\nanalisadas equivocadamente. \n\nDe acordo com o exposto, nosso grupo tamb\u00e9m evidenciou que os linf\u00f3citos T \n\nCD8+ n\u00e3o parecem ser respons\u00e1veis pela destrui\u00e7\u00e3o tecidual observada nas les\u00f5es \n\nde LC causada por L. (V.) braziliensis. Ferraz et al. (2017) (297) (anexo 4) \n\nobservaram que as popula\u00e7\u00f5es celulares mais comprometidas com a atividade \n\ncitot\u00f3xica no microambiente da les\u00e3o leishmani\u00f3tica s\u00e3o as c\u00e9lulas NKT, T CD4+ e T \n\nCD4negCD8neg (T duplo-negativas; DN), dado seus elevados percentuais de \n\nexpress\u00e3o de CD107a. Quando foi analisado o pool de c\u00e9lulas CD107a+, foi \n\nobservado que as maiores propor\u00e7\u00f5es foram de c\u00e9lulas T DN e NKT. \n\nSurpreendentemente, as c\u00e9lulas T CD8+ e NK representaram apenas 3% e 4%, \n\nrespectivamente, do total de c\u00e9lulas CD107a+. Foi encontrada ainda uma correla\u00e7\u00e3o \n\npositiva entre a frequ\u00eancia de c\u00e9lulas CD107a+ e a produ\u00e7\u00e3o de granzima B no local \n\nda les\u00e3o (297) (anexo 4).  \n\nNeste contexto, apesar de nossos resultados n\u00e3o revelarem atividade \n\ncitot\u00f3xica Leishmania-espec\u00edfica por linf\u00f3citos T CD8+, n\u00f3s evidenciamos que os \n\nlinf\u00f3citos T CD4+, c\u00e9lulas NK e NKT aumentam seus percentuais de express\u00e3o de \n\nCD107a em resposta ao Lb-Ag, fato este observado em todos os grupos de \n\npacientes de LC. Al\u00e9m disso, tamb\u00e9m detectamos expans\u00e3o de c\u00e9lulas T CD4+, NK \n\n\n\n99 \n\ne NKT ativadas ant\u00edgeno-espec\u00edficas em todos os grupos de pacientes. Desta forma, \n\nparece que a citotoxicidade, caracter\u00edstica da infec\u00e7\u00e3o por L. (V.) braziliensis, \u00e9 \n\nmesmo delet\u00e9ria na evolu\u00e7\u00e3o da doen\u00e7a. Entretanto, \u00e9 necess\u00e1rio ter cuidado na \n\navalia\u00e7\u00e3o das popula\u00e7\u00f5es celulares respons\u00e1veis por essa fun\u00e7\u00e3o efetora citot\u00f3xica, \n\numa vez que tais resultados podem refletir na descoberta de novos alvos vacinais e \n\nterap\u00eauticos. \n\nA mol\u00e9cula CD8 n\u00e3o \u00e9 expressa de uma forma homog\u00eanea na superf\u00edcie das \n\nc\u00e9lulas T do sangue perif\u00e9rico humano, sendo os linf\u00f3citos T CD8+ ent\u00e3o, pass\u00edveis \n\nde serem divididos em duas subpopula\u00e7\u00f5es com base na quantidade deste receptor. \n\nAtrav\u00e9s dos ensaios ex vivo n\u00f3s observamos que os linf\u00f3citos T CD8bright s\u00e3o a \n\nsubpopula\u00e7\u00e3o predominante na circula\u00e7\u00e3o; enquanto os linf\u00f3citos T CD8dim, apesar \n\nda baixa frequ\u00eancia, s\u00e3o a popula\u00e7\u00e3o respons\u00e1vel pela atividade citot\u00f3xica. Estes \n\nachados est\u00e3o de acordo com dados descritos na literatura, que relatam que os \n\nlinf\u00f3citos T CD8bright s\u00e3o mais encontrados na circula\u00e7\u00e3o e possuem fun\u00e7\u00f5es \n\nregulat\u00f3rias, enquanto a subpopula\u00e7\u00e3o T CD8dim compreende as c\u00e9lulas efetoras-\n\nativadas e com fun\u00e7\u00e3o citot\u00f3xica associada (298). Foi demonstrado que os linf\u00f3citos \n\nT CD8dim circulantes podem exercer rapidamente as suas fun\u00e7\u00f5es efetoras ap\u00f3s o \n\nreconhecimento do ant\u00edgeno (298). Assim, a presen\u00e7a destas c\u00e9lulas pode refletir \n\num estado cont\u00ednuo de baixa estimula\u00e7\u00e3o antig\u00eanica. Entretanto, nossos resultados \n\nn\u00e3o mostram diferen\u00e7as nas frequ\u00eancias de linf\u00f3citos T CD8dim ou CD8bright entre os \n\npacientes de LC e os indiv\u00edduos sadios.  \n\nPouco se conhece sobre o papel das c\u00e9lulas NK na LC causada por L. (V.) \n\nbraziliensis. Estudos em modelos experimentais com outras esp\u00e9cies de Leishmania \n\nt\u00eam discutido que estas podem n\u00e3o ser essenciais para a resolu\u00e7\u00e3o da patologia \n\n(195); e alguns autores propuseram que na infec\u00e7\u00e3o por L. (V.) braziliensis a \n\ncitotoxicidade mediada por c\u00e9lulas NK contribui para o dano tecidual (140). Nos \n\nensaios ex vivo, foi poss\u00edvel observar que a frequ\u00eancia de c\u00e9lulas NK foi maior nos \n\npacientes com LC ativa em compara\u00e7\u00e3o aos percentuais observados nos indiv\u00edduos \n\nsadios, corroborando dados observados anteriormente (299). Al\u00e9m disso, a \n\nfrequ\u00eancia de c\u00e9lulas NK permanece elevada durante o tratamento e ap\u00f3s a cura \n\ncl\u00ednica. Ao avaliarmos a resposta ant\u00edgeno-espec\u00edfica, observamos que todos os \n\ngrupos de pacientes de LC apresentaram expans\u00e3o de c\u00e9lulas NK, sugerindo que o \n\nparasito induz altos percentuais de c\u00e9lulas NK, mesmo nos pacientes com a cura \n\ncl\u00ednica recente. Nos ensaios ex vivo, os percentuais de c\u00e9lulas NK em degranula\u00e7\u00e3o \n\nde todos os grupos de pacientes foram menores do que os observados nos \n\n\n\n100 \n\nindiv\u00edduos sadios. Entretanto, ao avaliarmos a degranula\u00e7\u00e3o ant\u00edgeno-espec\u00edfica, \n\nobservamos que estas c\u00e9lulas foram capazes de responder ao Lb-Ag, aumentando \n\nseus percentuais de degranula\u00e7\u00e3o, al\u00e9m dos seus percentuais de ativa\u00e7\u00e3o e \n\nprolifera\u00e7\u00e3o.  \n\nOs baixos percentuais de c\u00e9lulas NK CD107a+ dos pacientes de LC \n\ndetectados nos ensaios ex vivo pode ser resultante de uma supress\u00e3o da atividade \n\ndas c\u00e9lulas NK pelo parasito, um fen\u00f4meno j\u00e1 observado na infec\u00e7\u00e3o por L. (L.) \n\nmajor. Foi demonstrado que a L. (L.) major foi capaz de reduzir a capacidade das \n\nc\u00e9lulas NK de lisarem as c\u00e9lulas-alvo e inibir a citotoxicidade e produ\u00e7\u00e3o de IFN-? \n\npor c\u00e9lulas NK humanas. Ainda, o contato direto das c\u00e9lulas NK com promastigotas \n\nresultou na morte de ambas as c\u00e9lulas (223,300). Alguns fatores podem contribuir \n\npara esta baixa atividade, como a a\u00e7\u00e3o de citocinas como TGF-? e IL-10 (199,203). \n\nNesse sentido, nossos ensaios in vitro mostraram claramente uma expans\u00e3o das \n\nc\u00e9lulas NK CD279+ em todos os grupos de pacientes de LC, evidenciando um \n\nestado de exaust\u00e3o celular induzido pelo Lb-Ag. Uma condi\u00e7\u00e3o de pobre \n\nfuncionalidade de c\u00e9lulas NK, caracter\u00edstica de um estado de exaust\u00e3o, foi relatada \n\nna LCD causada por L. (L.) mexicana e esta foi associada \u00e0 gravidade da doen\u00e7a \n\n(299). Na LCD causada por L. (L.) mexicana tamb\u00e9m foi demonstrada exaust\u00e3o de \n\nlinf\u00f3citos T CD8+ e encontrada correla\u00e7\u00e3o positiva entre a severidade da patologia e \n\na express\u00e3o de CD279 por linf\u00f3citos T CD8+ circulantes de pacientes com a doen\u00e7a \n\n(301). Em nosso estudo, observamos expans\u00e3o ant\u00edgeno-espec\u00edfica de linf\u00f3citos T \n\nCD8+ CD279+ apenas nos pacientes sob a terapia antimonial. Estes pacientes sob a \n\nterapia tamb\u00e9m apresentaram expans\u00e3o de linf\u00f3citos T CD8+ ativados, sugerindo \n\numa poss\u00edvel a\u00e7\u00e3o da terapia antimonial em conjunto com o ant\u00edgeno. Neste \n\ncontexto, parece que o ant\u00edgeno de L. (V.) braziliensis induz exaust\u00e3o das c\u00e9lulas \n\nNK, que pode estar impedindo a ativa\u00e7\u00e3o e atividade \u00f3timas destas c\u00e9lulas. \n\nEntretanto, ainda assim, apesar desta aparente supress\u00e3o da funcionalidade, essas \n\nc\u00e9lulas s\u00e3o capazes de reconhecer e responder ao ant\u00edgeno de L. (V.) braziliensis, \n\ncomo demonstrado pelo aumento de seus percentuais totais, de ativa\u00e7\u00e3o e \n\ndegranula\u00e7\u00e3o. \n\nAs c\u00e9lulas NK humanas s\u00e3o geralmente divididas em duas subpopula\u00e7\u00f5es \n\nbaseado na densidade de express\u00e3o da mol\u00e9cula CD56: CD56bright, que s\u00e3o a \n\nsubpopula\u00e7\u00e3o predominante nos tecidos linfoides secund\u00e1rios, e CD56dim, \n\npredominantes no sangue perif\u00e9rico (196). As c\u00e9lulas NK CD56bright s\u00e3o a principal \n\n\n\n101 \n\nfonte de produ\u00e7\u00e3o de citocinas, enquanto as c\u00e9lulas NK CD56dim s\u00e3o associadas \u00e0 \n\nfun\u00e7\u00e3o citot\u00f3xica e indu\u00e7\u00e3o de morte de c\u00e9lulas-alvo (196,302). Corroborando com \n\nestas descri\u00e7\u00f5es, n\u00f3s observamos nos ensaios ex vivo que mais de 95% das c\u00e9lulas \n\nNK circulantes apresentam fen\u00f3tipo CD56dim em todos os indiv\u00edduos estudados. \n\nQuando avaliamos a degranula\u00e7\u00e3o celular, pudemos observar que a maioria das \n\nc\u00e9lulas NK CD107a+ apresentou o fen\u00f3tipo CD56dim, refor\u00e7ando o comprometimento \n\ndesta subpopula\u00e7\u00e3o com a fun\u00e7\u00e3o citot\u00f3xica. Essa dicotomia das subpopula\u00e7\u00f5es de \n\nc\u00e9lulas NK n\u00e3o foi alterada pela doen\u00e7a, o que demonstra uma estabilidade destas \n\nsubpopula\u00e7\u00f5es.  \n\nPor fim, o papel das c\u00e9lulas NKT na resist\u00eancia ou susceptibilidade da \n\ninfec\u00e7\u00e3o por Leishmania tamb\u00e9m n\u00e3o est\u00e1 definido, uma vez que dados \n\ncontroversos persistem na literatura (261). As c\u00e9lulas NKT s\u00e3o mais bem estudadas \n\nna LV, onde foi demonstrado que sua ativa\u00e7\u00e3o ocorre por uma via direta, na qual \n\nant\u00edgenos do glicoc\u00e1lix da Leishmania, apresentados via CD1d, se ligam ao TCR \n\ninvariante da NKT, que atuam ent\u00e3o produzindo citocinas e lisando c\u00e9lulas-alvo \n\natrav\u00e9s da atividade citot\u00f3xica (254,255,303). Entretanto, os estudos na LC s\u00e3o \n\nescassos. Recentemente foi demonstrado que a ativa\u00e7\u00e3o de c\u00e9lulas NKT na LC \n\npode tamb\u00e9m ocorrer atrav\u00e9s de uma via indireta. O LPG de L. (L.) mexicana foi \n\ncapaz de ativar c\u00e9lulas dendr\u00edticas, resultando na indu\u00e7\u00e3o da produ\u00e7\u00e3o de IFN-? por \n\nc\u00e9lulas NKT (208). As c\u00e9lulas NKT s\u00e3o conhecidas produtoras de citocinas tanto do \n\ntipo I como do tipo II, e podem assim auxiliar no direcionamento da resposta imune \n\nna LC devido \u00e0 sua intera\u00e7\u00e3o com c\u00e9lulas dendr\u00edticas (304,305). Nossos resultados \n\nevidenciaram a participa\u00e7\u00e3o citot\u00f3xica das c\u00e9lulas NKT atrav\u00e9s da via de libera\u00e7\u00e3o \n\nde gr\u00e2nulos l\u00edticos na LC. Nos ensaios ex vivo n\u00f3s observamos que os percentuais \n\nde c\u00e9lulas NKT expressando CD107a variou amplamente entre os indiv\u00edduos \n\nestudados, mas ainda assim foi poss\u00edvel observar que os pacientes curados \n\napresentaram menores percentuais de c\u00e9lulas NKT CD107a+ em compara\u00e7\u00e3o aos \n\nindiv\u00edduos durante a terapia. Nos ensaios in vitro, revelamos que o Lb-Ag induziu \n\nativa\u00e7\u00e3o das c\u00e9lulas NKT, resultando em uma expans\u00e3o de c\u00e9lulas NKT totais e \n\nativadas em todos os grupos de pacientes de LC. A atividade citot\u00f3xica das c\u00e9lulas \n\nNKT tamb\u00e9m estava aumentada, visto que todos os grupos de pacientes \n\napresentaram maiores percentuais de c\u00e9lulas NKT CD107a+ especificamente em \n\nresposta ao Lb-Ag. Nosso grupo evidenciou em outro estudo a participa\u00e7\u00e3o \n\ncitot\u00f3xica das c\u00e9lulas NKT em les\u00f5es cut\u00e2neas de pacientes de LC, mostrando que \n\nesta \u00e9 a popula\u00e7\u00e3o celular mais comprometida com a citotoxicidade no \n\n\n\n102 \n\nmicroambiente da les\u00e3o (297) (anexo 4). Em tal estudo, revelamos que as c\u00e9lulas \n\nNKT s\u00e3o a quarta popula\u00e7\u00e3o de c\u00e9lulas T mais encontrada nas les\u00f5es de LC e \n\ncorrespondem \u00e0 segunda popula\u00e7\u00e3o em propor\u00e7\u00e3o de todas as c\u00e9lulas que \n\nexpressam CD107a (297) (anexo 4).  \n\nAs c\u00e9lulas NKT humanas podem ser divididas de acordo com sua express\u00e3o \n\nde CD4 ou CD8 e s\u00e3o normalmente subdivididas em tr\u00eas subpopula\u00e7\u00f5es principais: \n\nCD8+, CD4+ ou CD8negCD4neg (duplo-negativas; DN) (232). Al\u00e9m destas, alguns \n\nautores relataram uma subpopula\u00e7\u00e3o com fen\u00f3tipo CD8+CD4+ (duplo-positivas; DP) \n\n(252,281,306), a qual tamb\u00e9m observamos em nosso estudo. Atrav\u00e9s dos ensaios \n\nex vivo, n\u00f3s detectamos altas frequ\u00eancias de c\u00e9lulas NKT CD8+ e baixas frequ\u00eancias \n\nda subpopula\u00e7\u00e3o DP, tanto nos pacientes de LC como nos indiv\u00edduos sadios. Outros \n\nautores tamb\u00e9m observaram altas frequ\u00eancias da subpopula\u00e7\u00e3o CD8+ em indiv\u00edduos \n\nsadios e em pacientes com outras patologias (247,307). Nossos resultados \n\nmostraram tamb\u00e9m que as c\u00e9lulas NKT CD8+ s\u00e3o a principal subpopula\u00e7\u00e3o \n\nenvolvida na citotoxicidade e isso corrobora dados previamente descritos (252). Um \n\nestudo em LV, com foco nas c\u00e9lulas NKT, mostrou que os pacientes com doen\u00e7a \n\nativa apresentaram menor frequ\u00eancia de c\u00e9lulas NKT CD4+ e NKT CD8+ em \n\ncompara\u00e7\u00e3o aos indiv\u00edduos sadios. Ap\u00f3s o t\u00e9rmino da terapia, os pacientes de LV \n\nmantiveram baixa frequ\u00eancia de c\u00e9lulas NKT CD4+, enquanto as c\u00e9lulas NKT CD8+ \n\nretornaram aos percentuais normais, associando ent\u00e3o esta subpopula\u00e7\u00e3o com um \n\npapel protetor na LV (308). No presente estudo, n\u00f3s observamos uma menor \n\nfrequ\u00eancia da subpopula\u00e7\u00e3o DP nos pacientes com LC ativa, que foi reestabelecida \n\na percentuais similares aos detectados nos indiv\u00edduos sadios com a terapia e ap\u00f3s a \n\ncura cl\u00ednica, sugerindo um papel protetor dessa subpopula\u00e7\u00e3o na LC. \n\nA principal divis\u00e3o das c\u00e9lulas NKT humanas est\u00e1 relacionada \u00e0 sua \n\nespecificidade de reconhecimento antig\u00eanico, pois podem apresentar um TCR semi-\n\ninvariante (tipo I) ou diverso (tipo II) (251). Estudos relatam que cerca de 70% das \n\nc\u00e9lulas NKT apresentam um perfil invariante (232); no entanto, tal frequ\u00eancia varia \n\nmuito nos seres humanos e alguns autores v\u00eam encontrando elevados percentuais \n\nde c\u00e9lulas NKT tipo II (309,310). Por esta raz\u00e3o, n\u00f3s decidimos analisar qual a \n\npropor\u00e7\u00e3o de c\u00e9lulas NKT invariantes estava presente em nossa amostragem nos \n\nestudos in vitro. Inesperadamente, verificamos que apenas uma baixa frequ\u00eancia de \n\nc\u00e9lulas NKT expressou o TCR invariante V?24-J?18, tanto nos pacientes de LC ativa \n\nquanto nos indiv\u00edduos sadios. As c\u00e9lulas NKT tipo II s\u00e3o reativas \u00e0 glicolip\u00eddeos e \n\n\n\n103 \n\nfosfol\u00edpideos pr\u00f3prios, mas tamb\u00e9m aos microrganismos, podendo promover \n\nresposta imune inata e adaptativa protetoras ou que contribuem para a inj\u00faria \n\ntecidual (240,310). Alguns ligantes para NKT tipo II derivados de microrganismos j\u00e1 \n\nforam identificados, como fosfatidilglicerol e difosfatidilglicerol de Mycobacterium \n\ntuberculosis (311).  \n\nAo avaliar se o Lb-Ag poderia modular a funcionalidade das c\u00e9lulas NKT, n\u00f3s \n\nobservamos que nos pacientes com doen\u00e7a ativa e durante a terapia n\u00e3o houve \n\naltera\u00e7\u00e3o dos percentuais de c\u00e9lulas NKT CD279+. Entretanto, observamos \n\nexpans\u00e3o de c\u00e9lulas NKT CD279+ em resposta ao Lb-Ag nos pacientes curados. Um \n\nmecanismo de inibi\u00e7\u00e3o da atividade de c\u00e9lulas NKT por CD279 foi descrito em \n\npacientes com tuberculose. Foi observado que o bloqueio de CD279 impediu a \n\napoptose de c\u00e9lulas NKT produtoras de IFN-? e aumentou seus percentuais de \n\ndegranula\u00e7\u00e3o (273). Estudos adicionais s\u00e3o necess\u00e1rios para entender porque \n\nsomente os pacientes curados de LC apresentaram aumento de exaust\u00e3o das \n\nc\u00e9lulas NKT na presen\u00e7a do Lb-Ag e, al\u00e9m disso, verificar se o bloqueio da via \n\nCD279 resulta em aumento da atividade celular na LC. Na LCD foi poss\u00edvel restaurar \n\nos mecanismos efetores dos linf\u00f3citos T CD8+ em exaust\u00e3o atrav\u00e9s do bloqueio de \n\nCD279 (301). Neste contexto, nosso grupo mostrou pela primeira vez a distribui\u00e7\u00e3o \n\ne a contribui\u00e7\u00e3o das c\u00e9lulas NKT na citotoxicidade na LC, tanto na resposta \n\nlocalizada, como na sist\u00eamica, evidenciando sua capacidade de reconhecimento \n\nantig\u00eanico e funcionalidade de resposta especifica.  \n\nDevido \u00e0 import\u00e2ncia do tr\u00e1fego de linf\u00f3citos na din\u00e2mica da infec\u00e7\u00e3o e sua \n\nrela\u00e7\u00e3o com a forma\u00e7\u00e3o do infiltrado inflamat\u00f3rio e do processo de cicatriza\u00e7\u00e3o, n\u00f3s \n\navaliamos a express\u00e3o de CLA nos ensaios in vitro. A modula\u00e7\u00e3o da express\u00e3o de \n\nCLA pelo Lb-Ag pode influenciar a fun\u00e7\u00e3o e os padr\u00f5es de migra\u00e7\u00e3o das c\u00e9lulas \n\nefetoras. No entanto, n\u00f3s n\u00e3o observamos altera\u00e7\u00e3o nos percentuais de express\u00e3o \n\nde CLA devido ao est\u00edmulo com Lb-Ag em nenhuma popula\u00e7\u00e3o celular estudada e \n\nem nenhum grupo de pacientes ou nos indiv\u00edduos sadios. Entretanto, j\u00e1 foi \n\ndemonstrado que ant\u00edgenos de L. (V.) braziliensis modulam positivamente a \n\nexpress\u00e3o de CLA nos linf\u00f3citos T durante a LC ativa (279). A diverg\u00eancia com \n\nnossos resultados pode ser devido a diferen\u00e7as metodol\u00f3gicas, uma vez que n\u00f3s \n\navaliamos apenas a express\u00e3o de CLA ant\u00edgeno-espec\u00edfica, comparando os \n\nresultados das c\u00e9lulas estimuladas com Lb-Ag com as c\u00e9lulas n\u00e3o estimuladas, sob \n\nas mesmas condi\u00e7\u00f5es de cultivo. Mendes-Aguiar et al. (2009) compararam a \n\n\n\n104 \n\nexpress\u00e3o de CLA ap\u00f3s estimula\u00e7\u00e3o antig\u00eanica in vitro com os resultados obtidos \n\nem ensaios ex vivo. N\u00f3s acreditamos que n\u00e3o detectamos modula\u00e7\u00e3o da express\u00e3o \n\nde CLA in vitro devido ao fato de que fatores quimiot\u00e1ticos sol\u00faveis derivados do \n\ntecido s\u00e3o necess\u00e1rios para o tr\u00e1fego de c\u00e9lulas T para os tecidos inflamados (275). \n\n\u00c9 importante ressaltar que, nos ensaios in vitro, os indiv\u00edduos sadios n\u00e3o \n\napresentaram altera\u00e7\u00e3o dos percentuais de nenhuma mol\u00e9cula avaliada (CD107a, \n\nCD38, CD279 e CLA) em nenhuma popula\u00e7\u00e3o celular estudada, evidenciando que \n\nas c\u00e9lulas destes indiv\u00edduos, por n\u00e3o terem sido primadas in vivo, n\u00e3o foram \n\ncapazes de reconhecer e responder aos ant\u00edgenos de L. (V.) braziliensis. Tal dado \n\nconfirma o car\u00e1ter espec\u00edfico da resposta imune estudada, corroborando o postulado \n\nde que a maioria das c\u00e9lulas T de pacientes de LC e LM \u00e9 pr\u00e9-ativada no sangue \n\nperif\u00e9rico (312). \n\nN\u00e3o s\u00e3o bem conhecidos quais os fatores que direcionam as c\u00e9lulas a se \n\ntornarem citot\u00f3xicas. Tem sido discutido que a IL-15 est\u00e1 associada ao aumento da \n\ncitotoxicidade em c\u00e9lulas NK (313) e indu\u00e7\u00e3o de gera\u00e7\u00e3o de linf\u00f3citos T CD4+ \n\ncitot\u00f3xicos (314). A IL-15 tamb\u00e9m tem sido relacionada \u00e0 indu\u00e7\u00e3o de prolifera\u00e7\u00e3o e \n\nmanuten\u00e7\u00e3o de linf\u00f3citos T CD8+ (315), T CD4+ (316), c\u00e9lulas NK (317,318) e NKT \n\n(319), al\u00e9m da manuten\u00e7\u00e3o de c\u00e9lulas T de mem\u00f3ria (320\u2013322). Na LC, foi \n\ndemonstrado que a neutraliza\u00e7\u00e3o de IL-15 modula negativamente a secre\u00e7\u00e3o de \n\nIFN-? induzida por ant\u00edgenos sol\u00faveis de L. (V.) braziliensis por CMSP, o que aponta \n\npara uma rela\u00e7\u00e3o desta citocina com a resposta inflamat\u00f3ria na doen\u00e7a (312). \n\nEntretanto, n\u00f3s n\u00e3o observamos, nos ensaios in vitro, correla\u00e7\u00e3o entre a \n\nconcentra\u00e7\u00e3o de IL-15 do sobrenadante das culturas estimuladas com o Lb-Ag e a \n\nprolifera\u00e7\u00e3o, ativa\u00e7\u00e3o, degranula\u00e7\u00e3o, exaust\u00e3o ou endere\u00e7amento para a les\u00e3o de \n\nc\u00e9lulas T CD4+, T CD8+, NK e NKT. Em rela\u00e7\u00e3o \u00e0 concentra\u00e7\u00e3o de IL-15 nos \n\nsobrenadantes das CMSP, n\u00e3o foram observadas diferen\u00e7as entre os pacientes de \n\nLC ativa, durante o tratamento e com cura cl\u00ednica, e nem mesmo com os indiv\u00edduos \n\nsadios. Tamb\u00e9m n\u00e3o foram observadas diferen\u00e7as entre as concentra\u00e7\u00f5es de IL-15 \n\nno plasma sangu\u00edneo de pacientes com a LC ativa, durante o tratamento antimonial \n\ne com cura cl\u00ednica recente e indiv\u00edduos sadios. Foi realizada a quantifica\u00e7\u00e3o de IL-15 \n\nem sobrenadantes obtidos da macera\u00e7\u00e3o de amostras de biopsias de les\u00f5es de \n\npacientes de LC com intuito de verificar a concentra\u00e7\u00e3o desta citocina na resposta \n\nimune localizada. Para crit\u00e9rio de compara\u00e7\u00e3o, utilizamos amostras de biopsia de \n\nles\u00e3o de pacientes com esporotricose, uma doen\u00e7a f\u00fangica subcut\u00e2nea, tamb\u00e9m \n\n\n\n105 \n\nend\u00eamica no estado do Rio de Janeiro e clinicamente semelhante \u00e0 LC, o que torna \n\nnecess\u00e1rio o diagn\u00f3stico diferencial entre as duas patologias (323). Observamos \n\nque a concentra\u00e7\u00e3o de IL-15 foi maior nos sobrenadantes dos pacientes de LC em \n\ncompara\u00e7\u00e3o aos pacientes com esporotricose. Poucos s\u00e3o os estudos em \n\nesporotricose focando a resposta imune do hospedeiro, todavia alguns autores \n\nsugerem que o ac\u00famulo de linf\u00f3citos T CD4+ observado nas les\u00f5es de pacientes \n\ncom esta patologia deva ser devido a uma resposta imune sist\u00eamica, e n\u00e3o \n\nrelacionada especificamente ao agente etiol\u00f3gico (324). A maior concentra\u00e7\u00e3o de IL-\n\n15 na les\u00e3o dos pacientes de LC pode estar associada a uma resposta inflamat\u00f3ria \n\nmais robusta nesta patologia, com participa\u00e7\u00e3o de diferentes tipos celulares \n\nespecificamente em resposta \u00e0 Leishmania. Entretanto, mais estudos s\u00e3o \n\nnecess\u00e1rios para avaliar a associa\u00e7\u00e3o de IL-15 com a resposta inflamat\u00f3ria na LC. \n\nCom base no exposto, a evolu\u00e7\u00e3o para a cura cl\u00ednica da LC depende na \n\nmaior parte do tipo e magnitude da resposta imune desencadeada pelo hospedeiro, \n\nal\u00e9m das caracter\u00edsticas das esp\u00e9cies do parasito (107). Na busca para desvendar \n\nqual o perfil de resposta \u00e9 necess\u00e1rio para controlar a doen\u00e7a, deve-se que levar em \n\nconsidera\u00e7\u00e3o quais as singularidades entre os pacientes que evoluem para a cura \n\ndaqueles que se tornam refrat\u00e1rios ao tratamento. Uma hip\u00f3tese para a ocorr\u00eancia \n\nde falha terap\u00eautica \u00e9 que haja um defeito na resposta imune celular do hospedeiro \n\nassociado \u00e0 persist\u00eancia parasit\u00e1ria (8,290,325,326). O fato de que a administra\u00e7\u00e3o \n\nde um inibidor de TNF-? em associa\u00e7\u00e3o com a terapia antimonial melhora a \n\ncicatriza\u00e7\u00e3o dos pacientes de LM suporta em parte esta hip\u00f3tese (327). A falha \n\nterap\u00eautica \u00e9 definida pelo Minist\u00e9rio da Sa\u00fade como o caso que recebeu dois \n\nesquemas terap\u00eauticos regulares com antimoniato de N-metilglucamina \n\n(Glucantime\u00ae) sem apresentar cura cl\u00ednica da doen\u00e7a (8). Nesses casos, o mesmo \n\nesquema terap\u00eautico deve ser repetido, e nos casos de n\u00e3o resposta ap\u00f3s duas \n\naplica\u00e7\u00f5es do mesmo esquema, uma droga de segunda escolha deve ser utilizada \n\n(8). No presente estudo, a falha terap\u00eautica foi considerada quando o paciente n\u00e3o \n\napresentou cura cl\u00ednica ap\u00f3s o primeiro esquema de tratamento, conforme a \n\ndefini\u00e7\u00e3o adotada na rotina cl\u00ednica de atendimento do Laborat\u00f3rio de Vigil\u00e2ncia em \n\nLeishmaniose do INI/FIOCRUZ. Observamos uma taxa de falha terap\u00eautica muito \n\nbaixa (9,37%). Esta baixa propor\u00e7\u00e3o de falha na popula\u00e7\u00e3o estudada corrobora a \n\nefici\u00eancia obtida com o tratamento antimonial no Estado do Rio de Janeiro (92\u2013\n\n94,96,328). Entretanto, difere de outros estudos em outras regi\u00f5es do pa\u00eds, onde s\u00e3o \n\n\n\n106 \n\nregistradas taxas de 46 a 75% de falha ao tratamento com antimonial pentavalente \n\n(325,329\u2013331).  \n\nPouco \u00e9 conhecido acerca das peculiaridades imunol\u00f3gicas dos pacientes \n\nque n\u00e3o s\u00e3o capazes de evoluir para a cura. N\u00f3s avaliamos a diferen\u00e7a entre a \n\nresposta citot\u00f3xica espec\u00edfica ao Lb-Ag dos pacientes com a doen\u00e7a ativa que \n\nevolu\u00edram para a cura cl\u00ednica ap\u00f3s a terapia, com a resposta dos pacientes com a \n\ndoen\u00e7a ativa que apresentaram falha terap\u00eautica. Um resultado interessante foi que \n\nos pacientes que apresentaram falha terap\u00eautica exibiram menores percentuais de \n\nc\u00e9lulas em degranula\u00e7\u00e3o especificamente reativas ao ant\u00edgeno em compara\u00e7\u00e3o aos \n\npacientes que apresentaram cura ap\u00f3s a terapia. Isto nos leva a hipotetizar que os \n\npacientes que n\u00e3o evoluem para a cura cl\u00ednica podem apresentar uma \n\nirresponsividade celular aos ant\u00edgenos de Leishmania durante a fase ativa, \n\nresultando em uma incapacidade de montar uma resposta imune efetiva. Um estudo \n\nrecente em \u00e1rea end\u00eamica de L. (V.) guyanensis sugere um mecanismo de \n\nirresponsividade imunol\u00f3gica associada \u00e0 falha terap\u00eautica, uma vez que foi \n\ndetectada baixa produ\u00e7\u00e3o de IFN-? em resposta ao ant\u00edgeno (332). Neste sentido, \n\num estudo com foco na LV verificou que a produ\u00e7\u00e3o de TGF-?, uma citocina \n\nimunorregulat\u00f3ria, foi associada \u00e0 falha terap\u00eautica (333). Alguns autores sugerem \n\nque a refratariedade ao tratamento na LC, que resulta em infec\u00e7\u00e3o recorrente, pode \n\nestar relacionada com a exaust\u00e3o do sistema imunol\u00f3gico e a persist\u00eancia \n\nparasit\u00e1ria (334). Entretanto, n\u00f3s n\u00e3o observamos diferen\u00e7as nos percentuais de \n\nCD279 entre os pacientes com LC ativa que n\u00e3o foram capazes de evoluir para a \n\ncura cl\u00ednica em compara\u00e7\u00e3o com aqueles que curaram. Devido \u00e0 baixa taxa de falha \n\nterap\u00eautica em nosso estudo, n\u00e3o foi poss\u00edvel realizarmos muitas infer\u00eancias \n\nestat\u00edsticas, o que prejudicou o entendimento dos nossos resultados. \u00c9 necess\u00e1rio \n\nincluir mais pacientes com falha terap\u00eautica em nosso estudo para podermos tirar \n\nconclus\u00f5es acerca dos resultados obtidos. Contudo, para atingirmos progressos no \n\ndesenvolvimento de estrat\u00e9gias mais eficazes de controle da doen\u00e7a, seja na \n\nformula\u00e7\u00e3o de vacinas ou melhorias nos f\u00e1rmacos, \u00e9 necess\u00e1rio um maior \n\nentendimento da resposta imunol\u00f3gica associada \u00e0 cura e \u00e0 prote\u00e7\u00e3o, assim como \n\ndos mecanismos envolvidos na a\u00e7\u00e3o patol\u00f3gica. \n\n\n\n107 \n\n7. CONCLUS\u00d5ES \n\nNosso estudo fornece novos insights e fortes evid\u00eancias sobre o envolvimento \n\nde linf\u00f3citos T CD8+ e linf\u00f3citos T CD4+, c\u00e9lulas NK e c\u00e9lulas NKT na resposta \n\ncitot\u00f3xica na LC. Nos ensaios ex vivo, observamos percentuais similares ou at\u00e9 \n\nmenores de c\u00e9lulas em degranula\u00e7\u00e3o nos pacientes com LC ativa em compara\u00e7\u00e3o \n\naos indiv\u00edduos sadios, n\u00e3o possibilitando uma associa\u00e7\u00e3o entre a fun\u00e7\u00e3o citot\u00f3xica e \n\no dano tecidual. Nestes ensaios, os pacientes curados apresentaram baixos \n\npercentuais de express\u00e3o de CD107a por todas as popula\u00e7\u00f5es celulares estudadas. \n\nEsta baixa atividade citot\u00f3xica parece estar relacionada a uma recupera\u00e7\u00e3o do \n\nsistema imunol\u00f3gico ap\u00f3s a infec\u00e7\u00e3o para um estado de repouso e diferencia\u00e7\u00e3o \n\ndas popula\u00e7\u00f5es celulares em c\u00e9lulas de mem\u00f3ria. Nos ensaios in vitro, n\u00f3s \n\nmostramos que a resposta citot\u00f3xica espec\u00edfica aos ant\u00edgenos sol\u00faveis de L. (V.) \n\nbraziliensis \u00e9 exercida por diferentes popula\u00e7\u00f5es celulares, com destaque para o \n\npapel dos linf\u00f3citos T CD4+ por representarem a popula\u00e7\u00e3o celular mais expressiva \n\nem rela\u00e7\u00e3o \u00e0s propor\u00e7\u00f5es das c\u00e9lulas em ativa\u00e7\u00e3o, em degranula\u00e7\u00e3o, em exaust\u00e3o \n\ne endere\u00e7amento para a les\u00e3o. A resposta espec\u00edfica ao ant\u00edgeno de L. (V.) \n\nbraziliensis pelos pacientes de LC resultou na expans\u00e3o de c\u00e9lulas T CD4+, NK e \n\nNKT totais, ativadas e em degranula\u00e7\u00e3o, al\u00e9m de c\u00e9lulas NK em exaust\u00e3o. Tal \n\naumento de ativa\u00e7\u00e3o e de atividade citot\u00f3xica pode estar relacionado com o dano \n\ntecidual resultante da forte resposta inflamat\u00f3ria caracter\u00edstica da doen\u00e7a. Contudo, \n\nos linf\u00f3citos T CD8+ n\u00e3o apresentaram atividade citot\u00f3xica espec\u00edfica aos ant\u00edgenos \n\nparticulados de L. (V.) braziliensis, indicando que estas c\u00e9lulas participam na \n\nimunopatogenia LC, respondem com prolifera\u00e7\u00e3o ant\u00edgeno-espec\u00edfica, mas n\u00e3o s\u00e3o \n\nrespons\u00e1veis pela a\u00e7\u00e3o citot\u00f3xica delet\u00e9ria caracter\u00edstica da LC. \n\n\n\n108 \n\n8. REFER\u00caNCIAS BIBLIOGR\u00c1FICAS \n\n1.  Pigott DM, Bhatt S, Golding N, Duda KA, Battle KE, Brady OJ, et al. Global distribution maps of \nthe leishmaniases. eLife [Internet]. 2014 Jun 27 [cited 2017 Mar 8];3. Available from: \nhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103681/ \n\n2.  PAHO WHO [Internet]. [cited 2017 Jan 16]. Available from: \nhttp://www.paho.org/hq/index.php?option=com_topics&amp;view=article&amp;id=29&amp;Itemid=40754&amp;lang\n=pt \n\n3.  WHO | Leishmaniasis [Internet]. WHO. [cited 2017 Jan 16]. Available from: \nhttp://www.who.int/gho/neglected_diseases/leishmaniasis/en/ \n\n4.  Desjeux P. Leishmaniasis. Nat Rev Microbiol. 2004 Sep;2(9):692.  \n\n5.  Kevric I, Cappel MA, Keeling JH. New World and Old World Leishmania Infections: A Practical \nReview. Dermatol Clin. 2015 Jul;33(3):579\u201393.  \n\n6.  WHO | Epidemiological situation [Internet]. WHO. [cited 2017 Jan 16]. Available from: \nhttp://www.who.int/leishmaniasis/burden/en/ \n\n7.  WHO [Internet]. 2016 [cited 2017 Mar 10]. Available from: \nhttp://apps.who.int/neglected_diseases/ntddata/leishmaniasis/leishmaniasis.html \n\n8.  SVS S de V em S Minist\u00e9rio da Sa\u00fade. Manual de Vigil\u00e2ncia da Leishmaniose Tegumentar \nAmericana [Internet]. 2013. Available from: \nhttp://portal.saude.gov.br/portal/arquivos/pdf/manual2_lta_2ed.pdf \n\n9.  PAHO OPa-A de S. PAHO [Internet]. 2016 [cited 2017 Jan 16]. Available from: \nhttp://www.panaftosa.org/leish/inf2014_es/InfoLT2014BRA_PT.pdf \n\n10.  Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R. Leishmaniasis: a \nreview. F1000Research. 2017;6:750.  \n\n11.  SINAN [Internet]. 2016 [cited 2017 Mar 9]. Available from: \nhttp://portalsinan.saude.gov.br/leishmaniose-tegumentar-americana \n\n12.  DATASUS [Internet]. [cited 2017 Mar 9]. Available from: \nhttp://www2.datasus.gov.br/DATASUS/index.php?area=0203&amp;id=29892200&amp;VObj=http://tabne\nt.datasus.gov.br/cgi/deftohtm.exe?sinannet/cnv/lta \n\n13.  SVS/MS M da S. Leishmaniose Tegumentar - Gr\u00e1ficos e Mapas [Internet]. 2016 [cited 2017 \nOct 3]. Available from: http://portalarquivos.saude.gov.br/images/pdf/2017/marco/03/LT-\nGraficos-e-Mapas.pdf \n\n14.  Akhoundi M, Kuhls K, Cannet A, Vot\u00fdpka J, Marty P, Delaunay P, et al. A Historical Overview \nof the Classification, Evolution, and Dispersion of Leishmania Parasites and Sandflies. PLoS \nNegl Trop Dis. 2016 Mar;10(3):e0004349.  \n\n15.  Lainson R, Shaw J. Evolution, classification and geographical distribution. In: The \nLeishmaniases in Biology and Medicine. Londres - Academic Press: Peters, W.; Killick-\nKendrick, R.; 1987. p. 1\u2013120.  \n\n16.  Jones TC, Johnson WD Jr, Barretto AC, Lago E, Badaro R, Cerf B, et al. Epidemiology of \nAmerican cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis. \n1987 Jul;156(1):73\u201383.  \n\n17.  Grimaldi G Jr, McMahan-Pratt D. Leishmaniasis and its etiologic agents in the New World: an \noverview. Prog Clin Parasitol. 1991;2:73\u2013118.  \n\n18.  Rabello E. Caso de Leishmaniose. Bol Soc Bras Dermatol. 1913;2.  \n\n\n\n109 \n\n19.  de Oliveira-Neto MP, Mattos MS, Perez MA, Da-Cruz AM, Fernandes O, Moreira J, et al. \nAmerican tegumentary leishmaniasis (ATL) in Rio de Janeiro State, Brazil: main clinical and \nepidemiologic characteristics. Int J Dermatol. 2000 Jul;39(7):506\u201314.  \n\n20.  Cupolillo E, Brahim LR, Toaldo CB, de Oliveira-Neto MP, de Brito MEF, Falqueto A, et al. \nGenetic polymorphism and molecular epidemiology of Leishmania (Viannia) braziliensis from \ndifferent hosts and geographic areas in Brazil. J Clin Microbiol. 2003 Jul;41(7):3126\u201332.  \n\n21.  Vieira-Gon\u00e7alves R, Pirmez C, Jorge ME, Souza WJS, Oliveira MP, Rutowitsch MS, et al. \nClinical features of cutaneous and disseminated cutaneous leishmaniasis caused by \nLeishmania (Viannia) braziliensis in Paraty, Rio de Janeiro. Int J Dermatol. 2008 \nSep;47(9):926\u201332.  \n\n22.  Rangel EF, Lainson R. Proven and putative vectors of American cutaneous leishmaniasis in \nBrazil: aspects of their biology and vectorial competence. Mem Inst Oswaldo Cruz. 2009 \nNov;104(7):937\u201354.  \n\n23.  dos Santos GPL, Sanavria A, Marzochi MC de A, dos Santos EGOB, Silva VL, Pacheco R da \nS, et al. [Prevalence of canine infection from endemic areas of American cutaneous \nleishmaniasis in Paracambi District, Rio de Janeiro State, between 1992 and 1993]. Rev Soc \nBras Med Trop. 2005 Apr;38(2):161\u20136.  \n\n24.  Akhoundi M, Downing T, Vot\u00fdpka J, Kuhls K, Luke\u0161 J, Cannet A, et al. Leishmania infections: \nMolecular targets and diagnosis. Mol Aspects Med. 2017 Jan 31;  \n\n25.  Souza NA, Brazil RP, Araki AS. The current status of the Lutzomyia longipalpis (Diptera: \nPsychodidae: Phlebotominae) species complex. Mem Inst Oswaldo Cruz. 2017 \nMar;112(3):161\u201374.  \n\n26.  Grimaldi GJ, Tesh RB. Leishmaniases of the New World: current concepts and implications for \nfuture research. Clin Microbiol Rev. 1993 Jul;6(3):230\u201350.  \n\n27.  Killick-Kendrick R. The biology and control of phlebotomine sand flies. Clin Dermatol. 1999 \nJun;17(3):279\u201389.  \n\n28.  Miranda JC, Reis E, Schriefer A, Gon\u00e7alves M, Reis MG, Carvalho L, et al. Frequency of \nInfection of Lutzomyia Phlebotomines with Leishmania braziliensis in a Brazilian Endemic Area \nas Assessed by Pinpoint Capture and Polymerase Chain Reaction. Mem Inst Oswaldo Cruz. \n2002 Mar;97(2):185\u20138.  \n\n29.  Reb\u00ealo JMM, Assun\u00e7\u00e3o J\u00fanior AN, Silva O, Moraes JLP. Occurrence of sand flies (Diptera, \nPsychodidae) in leishmaniasis foci in an ecotourism area around the Len\u00e7\u00f3is Maranhenses \nNational Park, Brazil. Cad Sa\u00fade P\u00fablica. 2010 Jan;26(1):195\u20138.  \n\n30.  Aguilar CM, Rangel EF, Garcia L, Fernandez E, Momen H, Grimaldi Filho G, et al. Zoonotic \ncutaneous leishmaniasis due to Leishmania (Viannia) braziliensis associated with domestic \nanimals in Venezuela and Brazil. Mem Inst Oswaldo Cruz. 1989 Mar;84(1):19\u201328.  \n\n31.  Da-Cruz AM, Pirmez C. Leishmaniose Tegumentar Americana. In: Din\u00e2mica das Doen\u00e7as \nInfecciosas e Parasit\u00e1rias. 1st ed. Rio de Janeiro - Gunabara Koogan: Coura, JR; 2005.  \n\n32.  Ba\u00f1uls A-L, Hide M, Prugnolle F. Leishmania and the leishmaniases: a parasite genetic update \nand advances in taxonomy, epidemiology and pathogenicity in humans. Adv Parasitol. \n2007;64:1\u2013109.  \n\n33.  Sharma U, Singh S. Insect vectors of Leishmania: distribution, physiology and their control. J \nVector Borne Dis. 2008 Dec;45(4):255\u201372.  \n\n34.  Cardo LJ. Leishmania: risk to the blood supply. Transfusion (Paris). 2006 Sep;46(9):1641\u20135.  \n\n\n\n110 \n\n35.  Panagopoulos P, Mitsopoulos V, Papadopoulos A, Theodorou S, Christodoulaki C, \nAloupogiannis K, et al. Visceral leishmaniasis during pregnancy: A rare case report from \nGreece. PLoS Negl Trop Dis. 2017 Feb;11(2):e0005134.  \n\n36.  Kaye P, Scott P. Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol. \n2011 Aug;9(8):604\u201315.  \n\n37.  Azeredo-Coutinho RB, Mendonca SC. Formas Cl\u00ednicas das LeishmaniosesTegumentares nas \nAm\u00e9ricas. In: Leishmanioses do Continente Americano. Rio de Janeiro: Editora Fiocruz: \nConcei\u00e7\u00e3o-Silva, F.; Alvez, C.R.; 2014.  \n\n38.  WHO. Control of leishmaniases. Report of a meeting of the WHO Expert Committee. [Internet]. \n2010. Available from: http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf \n\n39.  Follador I, Ara\u00fajo C, Bacellar O, Ara\u00fajo CB, Carvalho LP, Almeida RP, et al. Epidemiologic and \nimmunologic findings for the subclinical form of Leishmania braziliensis infection. Clin Infect Dis \nOff Publ Infect Dis Soc Am. 2002 Jun 1;34(11):E54-58.  \n\n40.  Bittar RC, Nogueira RS, Vieira-Gon\u00e7alves R, Pinho-Ribeiro V, Mattos MS, Oliveira-Neto MP, et \nal. T-cell responses associated with resistance to Leishmania infection in individuals from \nendemic areas for Leishmania (Viannia) braziliensis. Mem Inst Oswaldo Cruz. 2007 \nAug;102(5):625\u201330.  \n\n41.  Reithinger R, Dujardin J-C, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous \nleishmaniasis. Lancet Infect Dis. 2007 Sep;7(9):581\u201396.  \n\n42.  Goto H, Lauletta Lindoso JA. Cutaneous and mucocutaneous leishmaniasis. Infect Dis Clin \nNorth Am. 2012 Jun;26(2):293\u2013307.  \n\n43.  Costa JM, Vale KC, Fran\u00e7a F, Saldanha AC, da Silva JO, Lago EL, et al. [Spontaneous healing \nof leishmaniasis caused by Leishmania viannia braziliensis in cutaneous lesions]. Rev Soc \nBras Med Trop. 1990 Dec;23(4):205\u20138.  \n\n44.  Fagundes A, Schubach A, Paula CC de, Bogio A, Antonio L de F, Schiavoni PB, et al. \nEvaluation of polymerase chain reaction in the routine diagnosis for tegumentary leishmaniasis \nin a referral centre. Mem Inst Oswaldo Cruz. 2010 Feb;105(1):109\u201312.  \n\n45.  Schubach A, Haddad F, Oliveira-Neto MP, Degrave W, Pirmez C, Grimaldi G Jr, et al. \nDetection of Leishmania DNA by polymerase chain reaction in scars of treated human patients. \nJ Infect Dis. 1998 Sep;178(3):911\u20134.  \n\n46.  Schubach A, Marzochi MC, Cuzzi-Maya T, Oliveira AV, Araujo ML, Oliveira AL, et al. \nCutaneous scars in American tegumentary leishmaniasis patients: a site of Leishmania \n(Viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical \ncure. Am J Trop Med Hyg. 1998 Jun;58(6):824\u20137.  \n\n47.  Scorza BM, Carvalho EM, Wilson ME. Cutaneous Manifestations of Human and Murine \nLeishmaniasis. Int J Mol Sci. 2017 Jun 18;18(6).  \n\n48.  Oliveira-Neto MP, Mattos M, Souza CS, Fernandes O, Pirmez C. Leishmaniasis recidiva cutis \nin New World cutaneous leishmaniasis. Int J Dermatol. 1998 Nov;37(11):846\u20139.  \n\n49.  Bittencourt AL, Costa JM, Carvalho EM, Barral A. Leishmaniasis recidiva cutis in American \ncutaneous leishmaniasis. Int J Dermatol. 1993 Nov;32(11):802\u20135.  \n\n50.  Calvopina M, Uezato H, Gomez EA, Korenaga M, Nonaka S, Hashiguchi Y. Leishmaniasis \nrecidiva cutis due to Leishmania (Viannia) panamensis in subtropical Ecuador: isoenzymatic \ncharacterization. Int J Dermatol. 2006 Feb;45(2):116\u201320.  \n\n51.  Landau M, Srebrnik A, Brenner S. Leishmaniasis recidivans mimicking lupus vulgaris. Int J \nDermatol. 1996 Aug;35(8):572\u20133.  \n\n\n\n111 \n\n52.  Mavilia L, Rossi R, Massi D, Difonzo EM, Campolmi P, Cappugi P. Leishmaniasis recidiva \ncutis: an unusual two steps recurrence. Int J Dermatol. 2002 Aug;41(8):506\u20137.  \n\n53.  Stefanidou MP, Antoniou M, Koutsopoulos AV, Neofytou YT, Krasagakis K, Kr\u00fcger-Krasagakis \nS, et al. A rare case of leishmaniasis recidiva cutis evolving for 31 years caused by Leishmania \ntropica. Int J Dermatol. 2008 Jun;47(6):588\u20139.  \n\n54.  Ghersetich I, Menchini G, Teofoli P, Lotti T. Immune response to Leishmania infection in \nhuman skin. Clin Dermatol. 1999 Jun;17(3):333\u20138.  \n\n55.  Carvalho EM, Barral A, Costa JM, Bittencourt A, Marsden P. Clinical and immunopathological \naspects of disseminated cutaneous leishmaniasis. Acta Trop. 1994 Apr;56(4):315\u201325.  \n\n56.  Machado PR, Rosa MEA, Costa D, Mignac M, Silva JS, Schriefer A, et al. Reappraisal of the \nimmunopathogenesis of disseminated leishmaniasis: in situ and systemic immune response. \nTrans R Soc Trop Med Hyg. 2011 Aug;105(8):438\u201344.  \n\n57.  Couppi\u00e9 P, Clyti E, Sainte-Marie D, Dedet JP, Carme B, Pradinaud R. Disseminated cutaneous \nleishmaniasis due to Leishmania guyanensis: case of a patient with 425 lesions. Am J Trop \nMed Hyg. 2004 Nov;71(5):558\u201360.  \n\n58.  Turetz ML, Machado PR, Ko AI, Alves F, Bittencourt A, Almeida RP, et al. Disseminated \nleishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J \nInfect Dis. 2002 Dec 15;186(12):1829\u201334.  \n\n59.  Costa JM, Marsden PD, Llanos-Cuentas EA, Netto EM, Carvalho EM, Barral A, et al. \nDisseminated cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases. J \nTrop Med Hyg. 1986 Dec;89(6):319\u201323.  \n\n60.  Jirmanus L, Glesby MJ, Guimar\u00e3es LH, Lago E, Rosa ME, Machado PR, et al. Epidemiological \nand clinical changes in American tegumentary leishmaniasis in an area of Leishmania (Viannia) \nbraziliensis transmission over a 20-year period. Am J Trop Med Hyg. 2012 Mar;86(3):426\u201333.  \n\n61.  Bryceson AD. Diffuse cutaneous leishmaniasis in Ethiopia. I. The clinical and histological \nfeatures of the disease. Trans R Soc Trop Med Hyg. 1969;63(6):708\u201337.  \n\n62.  Convit J, Pinardi ME, Rond\u00f3n AJ. Diffuse cutaneous leishmaniasis: a disease due to an \nimmunological defect of the host. Trans R Soc Trop Med Hyg. 1972;66(4):603\u201310.  \n\n63.  Barral A, Costa JM, Bittencourt AL, Barral-Netto M, Carvalho EM. Polar and subpolar diffuse \ncutaneous leishmaniasis in Brazil: clinical and immunopathologic aspects. Int J Dermatol. 1995 \nJul;34(7):474\u20139.  \n\n64.  Costa AAUML, Saldanha ACR, Leite BMC, Ramos B, Junior IA, Noronha ALL, et al. Imaging \nexams of bone lesions in patients with diffuse cutaneous leishmaniasis (DCL). Acta Trop. 2005 \nOct;96(1):9\u201315.  \n\n65.  Marsden PD. Mucosal leishmaniasis (\u201cespundia\u201d Escomel, 1911). Trans R Soc Trop Med Hyg. \n1986;80(6):859\u201376.  \n\n66.  Amato VS, de Andrade HF, Duarte MIS. Mucosal leishmaniasis: in situ characterization of the \nhost inflammatory response, before and after treatment. Acta Trop. 2003 Jan;85(1):39\u201349.  \n\n67.  Carvalho EM, Johnson WD, Barreto E, Marsden PD, Costa JL, Reed S, et al. Cell mediated \nimmunity in American cutaneous and mucosal leishmaniasis. J Immunol Baltim Md 1950. 1985 \nDec;135(6):4144\u20138.  \n\n68.  Strazzulla A, Cocuzza S, Pinzone MR, Postorino MC, Cosentino S, Serra A, et al. Mucosal \nleishmaniasis: an underestimated presentation of a neglected disease. BioMed Res Int. \n2013;2013:805108.  \n\n\n\n112 \n\n69.  Saravia NG, Holgu\u00edn AF, McMahon-Pratt D, D\u2019Alessandro A. Mucocutaneous leishmaniasis in \nColombia: Leishmania braziliensis subspecies diversity. Am J Trop Med Hyg. 1985 \nJul;34(4):714\u201320.  \n\n70.  Santrich C, Segura I, Arias AL, Saravia NG. Mucosal disease caused by Leishmania \nbraziliensis guyanensis. Am J Trop Med Hyg. 1990 Jan;42(1):51\u20135.  \n\n71.  Barral A, Pedral-Sampaio D, Grimaldi J\u00fanior G, Momen H, McMahon-Pratt D, Ribeiro de Jesus \nA, et al. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a \nwide spectrum of clinical disease. Am J Trop Med Hyg. 1991 May;44(5):536\u201346.  \n\n72.  Guerra JA de O, Prestes SR, Silveira H, Coelho LI de ARC, Gama P, Moura A, et al. Mucosal \nLeishmaniasis Caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) \nguyanensis in the Brazilian Amazon. PLoS Negl Trop Dis. 2011 Mar 8;5(3):e980.  \n\n73.  El Hajj L, Thellier M, Carri\u00e8re J, Bricaire F, Danis M, Caumes E. Localized cutaneous \nleishmaniasis imported into Paris: a review of 39 cases. Int J Dermatol. 2004 Feb;43(2):120\u20135.  \n\n74.  Scarisbrick JJ, Chiodini PL, Watson J, Moody A, Armstrong M, Lockwood D, et al. Clinical \nfeatures and diagnosis of 42 travellers with cutaneous leishmaniasis. Travel Med Infect Dis. \n2006 Jan;4(1):14\u201321.  \n\n75.  Lederman ER, Weld LH, Elyazar IRF, von Sonnenburg F, Loutan L, Schwartz E, et al. \nDermatologic conditions of the ill returned traveler: an analysis from the GeoSentinel \nSurveillance Network. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2008 Nov;12(6):593\u2013602.  \n\n76.  David CV, Craft N. Cutaneous and mucocutaneous leishmaniasis. Dermatol Ther. 2009 \nDec;22(6):491\u2013502.  \n\n77.  Schubach A, Cuzzi-Maya T, Oliveira AV, Sartori A, de Oliveira-Neto MP, Mattos MS, et al. \nLeishmanial antigens in the diagnosis of active lesions and ancient scars of American \ntegumentary leishmaniasis patients. Mem Inst Oswaldo Cruz. 2001 Oct;96(7):987\u201396.  \n\n78.  de Mello CX, de Oliveira Schubach A, de Oliveira RVC, Concei\u00e7\u00e3o-Silva F, Pimentel MIF, Lyra \nMR, et al. Comparison of the sensitivity of imprint and scraping techniques in the diagnosis of \nAmerican tegumentary leishmaniasis in a referral centre in Rio de Janeiro, Brazil. Parasitol \nRes. 2011 Sep;109(3):927\u201333.  \n\n79.  Goto H, Lindoso JAL. Current diagnosis and treatment of cutaneous and mucocutaneous \nleishmaniasis. Expert Rev Anti Infect Ther. 2010 Apr;8(4):419\u201333.  \n\n80.  Shaw JJ, Lainson R. Leishmaniasis in Brazil: X. Some observations of intradermal reactions to \ndifferent trypanosomatid antigens of patients suffering from cutaneous and mucocutaneous \nleishmaniasis. Trans R Soc Trop Med Hyg. 1975;69(3):323\u201335.  \n\n81.  Reed SG. Diagnosis of leishmaniasis. Clin Dermatol. 1996 Oct;14(5):471\u20138.  \n\n82.  Sassi A, Louzir H, Ben Salah A, Mokni M, Ben Osman A, Dellagi K. Leishmanin skin test \nlymphoproliferative responses and cytokine production after symptomatic or asymptomatic \nLeishmania major infection in Tunisia. Clin Exp Immunol. 1999 Apr;116(1):127\u201332.  \n\n83.  Guimar\u00e3es MC, Celeste BJ, Franco EL, Cuc\u00e9 LC, Belda W Jr. Evaluation of serological \ndiagnostic indices for mucocutaneous leishmaniasis: immunofluorescence tests and enzyme-\nlinked immunoassays for IgG, IgM and IgA antibodies. Bull World Health Organ. \n1989;67(6):643\u20138.  \n\n84.  Guimar\u00e3es MC, Celeste BJ, Franco EL. Diagnostic performance indices for immunofluorescent \ntests and enzyme immunoassays of leishmaniasis sera from northern and north-eastern Brazil. \nBull World Health Organ. 1990;68(1):39\u201343.  \n\n85.  Romero GAS, de la Gl\u00f3ria Orge Orge M, de Farias Guerra MV, Paes MG, de Oliveira Mac\u00eado \nV, de Carvalho EM. Antibody response in patients with cutaneous leishmaniasis infected by \n\n\n\n113 \n\nLeishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil. Acta Trop. \n2005 Jan;93(1):49\u201356.  \n\n86.  Barroso-Freitas APT, Passos SRL, Mouta-Confort E, Madeira MF, Schubach AO, Santos GPL, \net al. Accuracy of an ELISA and indirect immunofluorescence for the laboratory diagnosis of \nAmerican tegumentary leishmaniasis. Trans R Soc Trop Med Hyg. 2009 Apr;103(4):383\u20139.  \n\n87.  Sati MH. Antimony treatment of Sudan kala-azar. Ann Trop Med Parasitol. 1942;36.  \n\n88.  Kirk R, Sati MH. Further Notes on Some Cases of Sudan Kala-Azar Treated with Certain \nAromatic Diamidines. Ann Trop Med Parasitol. 1943 Apr 30;37(1):34\u20137.  \n\n89.  Berman JD. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and \nfuture strategies. Rev Infect Dis. 1988 Jun;10(3):560\u201386.  \n\n90.  Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium \nstibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg. 1992 \nMar;46(3):296\u2013306.  \n\n91.  Oliveira Neto MP, Schubach A, Araujo ML, Pirmez C. High and low doses of antimony (Sbv) in \nAmerican cutaneous leishmaniasis. A five years follow-up study of 15 patients. Mem Inst \nOswaldo Cruz. 1996 Apr;91(2):207\u20139.  \n\n92.  Oliveira-Neto MP, Schubach A, Mattos M, Gon\u00e7alves-Costa SC, Pirmez C. Treatment of \nAmerican cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high \ndosage (20 mg/kg/day) antimony regimens. Pathol Biol (Paris). 1997 Jun;45(6):496\u20139.  \n\n93.  Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C. A low-dose \nantimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up \nstudies (up to 10 years). Am J Trop Med Hyg. 1997 Dec;57(6):651\u20135.  \n\n94.  Schubach A de O, Marzochi KBF, Moreira JS, Schubach TMP, Ara\u00fajo ML, Vale ACF do, et al. \nRetrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine \nantimoniate. Rev Soc Bras Med Trop. 2005 Jun;38(3):213\u20137.  \n\n95.  Schubach AO, Concei\u00e7\u00e3o-Silva F. Estado da Arte no Tratamento da Leishmaniose \nTegumentar Americana no Brasil. In: Leishmanioses do Continente Americano. Rio de Janeiro: \nEditora Fiocruz; 2014.  \n\n96.  Saheki MN, Lyra MR, Bedoya-Pacheco SJ, Ant\u00f4nio L de F, Pimentel MIF, Salgueiro M de M, et \nal. Low versus high dose of antimony for American cutaneous leishmaniasis: A randomized \ncontrolled blind non-inferiority trial in Rio de Janeiro, Brazil. PloS One. 2017;12(5):e0178592.  \n\n97.  Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzochi MC, et al. \nSystematic review of the adverse effects of cutaneous leishmaniasis treatment in the New \nWorld. Acta Trop. 2011 May;118(2):87\u201396.  \n\n98.  Wolf Nassif P, DE Mello TFP, Navasconi TR, Mota CA, Demarchi IG, Aristides SMA, et al. \nSafety and efficacy of current alternatives in the topical treatment of cutaneous leishmaniasis: a \nsystematic review. Parasitology. 2017 Apr 3;1\u201310.  \n\n99.  Machado PR, Ampuero J, Guimar\u00e3es LH, Villasboas L, Rocha AT, Schriefer A, et al. \nMiltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in \nBrazil: a randomized and controlled trial. PLoS Negl Trop Dis. 2010;4(12):e912.  \n\n100.  Sundar S, Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. Expert Opin \nPharmacother. 2013 Jan;14(1):53\u201363.  \n\n101.  Grogl M, Thomason TN, Franke ED. Drug resistance in leishmaniasis: its implication in \nsystemic chemotherapy of cutaneous and mucocutaneous disease. Am J Trop Med Hyg. 1992 \nJul;47(1):117\u201326.  \n\n\n\n114 \n\n102.  Romero GA, Guerra MV, Paes MG, Mac\u00eado VO. Comparison of cutaneous leishmaniasis due \nto Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to \nmeglumine antimoniate. Am J Trop Med Hyg. 2001 Nov;65(5):456\u201365.  \n\n103.  de Azeredo-Coutinho RBG, Mendon\u00e7a SCF. An intermittent schedule is better than continuous \nregimen of antimonial therapy for cutaneous leishmaniasis in the municipality of Rio de Janeiro, \nBrazil. Rev Soc Bras Med Trop. 2002 Oct;35(5):477\u201381.  \n\n104.  Morgado FN, Schubach A, Vasconcellos E, Azeredo-Coutinho RB, Valete-Rosalino CM, \nQuintella LP, et al. Signs of an in situ inflammatory reaction in scars of human American \ntegumentary leishmaniasis. Parasite Immunol. 2010 Apr;32(4):285\u201395.  \n\n105.  Mendon\u00e7a MG, de Brito MEF, Rodrigues EHG, Bandeira V, Jardim ML, Abath FGC. \nPersistence of leishmania parasites in scars after clinical cure of American cutaneous \nleishmaniasis: is there a sterile cure? J Infect Dis. 2004 Mar 15;189(6):1018\u201323.  \n\n106.  De Luca PM, Macedo ABB. Cutaneous Leishmaniasis Vaccination: A Matter of Quality. Front \nImmunol. 2016;7:151.  \n\n107.  Scott P, Novais FO. Cutaneous leishmaniasis: immune responses in protection and \npathogenesis. Nat Rev Immunol. 2016 Sep;16(9):581\u201392.  \n\n108.  Carrada G, Ca\u00f1eda C, Salaiza N, Delgado J, Ruiz A, Sanchez B, et al. Monocyte cytokine and \ncostimulatory molecule expression in patients infected with Leishmania mexicana. Parasite \nImmunol. 2007 Mar;29(3):117\u201326.  \n\n109.  Schnorr D, Muniz AC, Passos S, Guimaraes LH, Lago EL, Bacellar O, et al. IFN-? Production \nto Leishmania Antigen Supplements the Leishmania Skin Test in Identifying Exposure to L. \nbraziliensis Infection. PLoS Negl Trop Dis. 2012 Dec;6(12):e1947.  \n\n110.  Abdeladhim M, Kamhawi S, Valenzuela JG. What\u2019s behind a sand fly bite? The profound effect \nof sand fly saliva on host hemostasis, inflammation and immunity. Infect Genet Evol J Mol \nEpidemiol Evol Genet Infect Dis. 2014 Dec;28:691\u2013703.  \n\n111.  de Oliveira Cardoso F, de Souza C da SF, Mendes VG, Abreu-Silva AL, Gon\u00e7alves da Costa \nSC, Calabrese K da S. Immunopathological studies of Leishmania amazonensis infection in \nresistant and in susceptible mice. J Infect Dis. 2010 Jun 15;201(12):1933\u201340.  \n\n112.  Ashour DS. Toll-like receptor signaling in parasitic infections. Expert Rev Clin Immunol. 2015 \nJun;11(6):771\u201380.  \n\n113.  Carlsen ED, Liang Y, Shelite TR, Walker DH, Melby PC, Soong L. Permissive and protective \nroles for neutrophils in leishmaniasis. Clin Exp Immunol. 2015 Nov;182(2):109\u201318.  \n\n114.  Guimar\u00e3es-Costa AB, Nascimento MTC, Froment GS, Soares RPP, Morgado FN, Concei\u00e7\u00e3o-\nSilva F, et al. Leishmania amazonensis promastigotes induce and are killed by neutrophil \nextracellular traps. Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6748\u201353.  \n\n115.  Rochael NC, Guimar\u00e3es-Costa AB, Nascimento MTC, DeSouza-Vieira TS, Oliveira MP, Garcia \ne Souza LF, et al. Classical ROS-dependent and early/rapid ROS-independent release of \nNeutrophil Extracellular Traps triggered by Leishmania parasites. Sci Rep. 2015 Dec \n17;5:18302.  \n\n116.  Savill J. Apoptosis in resolution of inflammation. Kidney Blood Press Res. 2000;23(3\u20135):173\u20134.  \n\n117.  van Zandbergen G, Klinger M, Mueller A, Dannenberg S, Gebert A, Solbach W, et al. Cutting \nedge: neutrophil granulocyte serves as a vector for Leishmania entry into macrophages. J \nImmunol Baltim Md 1950. 2004 Dec 1;173(11):6521\u20135.  \n\n118.  Afonso L, Borges VM, Cruz H, Ribeiro-Gomes FL, DosReis GA, Dutra AN, et al. Interactions \nwith apoptotic but not with necrotic neutrophils increase parasite burden in human \nmacrophages infected with Leishmania amazonensis. J Leukoc Biol. 2008 Aug;84(2):389\u201396.  \n\n\n\n115 \n\n119.  Ribeiro-Gomes FL, Peters NC, Debrabant A, Sacks DL. Efficient capture of infected neutrophils \nby dendritic cells in the skin inhibits the early anti-leishmania response. PLoS Pathog. 2012 \nFeb;8(2):e1002536.  \n\n120.  Ribeiro-Gomes FL, Romano A, Lee S, Roff\u00ea E, Peters NC, Debrabant A, et al. Apoptotic cell \nclearance of Leishmania major-infected neutrophils by dendritic cells inhibits CD8+ T-cell \npriming in vitro by Mer tyrosine kinase-dependent signaling. Cell Death Dis. 2015 Dec \n10;6:e2018.  \n\n121.  Ng LG, Hsu A, Mandell MA, Roediger B, Hoeller C, Mrass P, et al. Migratory dermal dendritic \ncells act as rapid sensors of protozoan parasites. PLoS Pathog. 2008 Nov;4(11):e1000222.  \n\n122.  Goncalves R, Zhang X, Cohen H, Debrabant A, Mosser DM. Platelet activation attracts a \nsubpopulation of effector monocytes to sites of Leishmania major infection. J Exp Med. 2011 \nJun 6;208(6):1253\u201365.  \n\n123.  Bogdan C, R\u00f6llinghoff M. How do protozoan parasites survive inside macrophages? Parasitol \nToday Pers Ed. 1999 Jan;15(1):22\u20138.  \n\n124.  Novais FO, Nguyen BT, Beiting DP, Carvalho LP, Glennie ND, Passos S, et al. Human \nclassical monocytes control the intracellular stage of Leishmania braziliensis by reactive \noxygen species. J Infect Dis. 2014 Apr 15;209(8):1288\u201396.  \n\n125.  Bogdan C. Nitric oxide and the immune response. Nat Immunol. 2001 Oct;2(10):907\u201316.  \n\n126.  Iniesta V, G\u00f3mez-Nieto LC, Corraliza I. The inhibition of arginase by N(omega)-hydroxy-l-\narginine controls the growth of Leishmania inside macrophages. J Exp Med. 2001 Mar \n19;193(6):777\u201384.  \n\n127.  No\u00ebl W, Raes G, Hassanzadeh Ghassabeh G, De Baetselier P, Beschin A. Alternatively \nactivated macrophages during parasite infections. Trends Parasitol. 2004 Mar;20(3):126\u201333.  \n\n128.  Kreider T, Anthony RM, Urban JF Jr, Gause WC. Alternatively activated macrophages in \nhelminth infections. Curr Opin Immunol. 2007 Aug;19(4):448\u201353.  \n\n129.  Ruiz JH, Becker I. CD8 cytotoxic T cells in cutaneous leishmaniasis. Parasite Immunol. 2007 \nDec;29(12):671\u20138.  \n\n130.  da Silva Santos C, Brodskyn CI. The Role of CD4 and CD8?T Cells in Human Cutaneous \nLeishmaniasis. Front Public Health. 2014;2:165.  \n\n131.  Scott P, Natovitz P, Coffman RL, Pearce E, Sher A. Immunoregulation of cutaneous \nleishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T \nhelper subsets and respond to distinct parasite antigens. J Exp Med. 1988 Nov 1;168(5):1675\u2013\n84.  \n\n132.  Oliveira WN, Ribeiro LE, Schrieffer A, Machado P, Carvalho EM, Bacellar O. The role of \ninflammatory and anti-inflammatory cytokines in the pathogenesis of human tegumentary \nleishmaniasis. Cytokine. 2014 Apr;66(2):127\u201332.  \n\n133.  Antonelli LRV, Dutra WO, Almeida RP, Bacellar O, Carvalho EM, Gollob KJ. Activated \ninflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. Immunol \nLett. 2005 Nov 15;101(2):226\u201330.  \n\n134.  Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell \nlineage with regulatory T cell ties. Immunity. 2006 Jun;24(6):677\u201388.  \n\n135.  Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008 Sep 1;112(5):1557\u201369.  \n\n136.  Ma CS, Deenick EK, Batten M, Tangye SG. The origins, function, and regulation of T follicular \nhelper cells. J Exp Med. 2012 Jul 2;209(7):1241\u201353.  \n\n\n\n116 \n\n137.  Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4+ T cells in immunity to viruses. \nNat Rev Immunol. 2012 Jan 20;12(2):136\u201348.  \n\n138.  Brown DM. Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy. Cell \nImmunol. 2010;262(2):89\u201395.  \n\n139.  Brodskyn CI, Barral A, Boaventura V, Carvalho E, Barral-Netto M. Parasite-driven in vitro \nhuman lymphocyte cytotoxicity against autologous infected macrophages from mucosal \nleishmaniasis. J Immunol Baltim Md 1950. 1997 Nov 1;159(9):4467\u201373.  \n\n140.  Machado P, Kanitakis J, Almeida R, Chalon A, Ara\u00fajo C, Carvalho EM. Evidence of in situ \ncytotoxicity in American cutaneous leishmaniasis. Eur J Dermatol EJD. 2002 Oct;12(5):449\u201351.  \n\n141.  Faria DR, Souza PEA, Dur\u00e3es FV, Carvalho EM, Gollob KJ, Machado PR, et al. Recruitment of \nCD8(+) T cells expressing granzyme A is associated with lesion progression in human \ncutaneous leishmaniasis. Parasite Immunol. 2009 Aug;31(8):432\u20139.  \n\n142.  Novais FO, Carvalho LP, Graff JW, Beiting DP, Ruthel G, Roos DS, et al. Cytotoxic T cells \nmediate pathology and metastasis in cutaneous leishmaniasis. PLoS Pathog. \n2013;9(7):e1003504.  \n\n143.  Santos C da S, Boaventura V, Ribeiro Cardoso C, Tavares N, Lordelo MJ, Noronha A, et al. \nCD8(+) granzyme B(+)-mediated tissue injury vs. CD4(+)IFN?(+)-mediated parasite killing in \nhuman cutaneous leishmaniasis. J Invest Dermatol. 2013 Jun;133(6):1533\u201340.  \n\n144.  Cardoso TM, Machado \u00c1, Costa DL, Carvalho LP, Queiroz A, Machado P, et al. Protective and \npathological functions of CD8+ T cells in Leishmania braziliensis infection. Infect Immun. 2015 \nMar;83(3):898\u2013906.  \n\n145.  Wagner H, Starzinski-Powitz A, Jung H, R\u00f6llinghoff M. Induction of I region-restricted hapten-\nspecific cytotoxic T lymphocytes. J Immunol Baltim Md 1950. 1977 Oct;119(4):1365\u20138.  \n\n146.  Feighery C, Stastny P. HLA-D region-associated determinants serve as targets for human cell-\nmediated lysis. J Exp Med. 1979 Feb 1;149(2):485\u201394.  \n\n147.  Fleischer B. Acquisition of specific cytotoxic activity by human T4+ T lymphocytes in culture. \nNature. 1984 Mar 22;308(5957):365\u20137.  \n\n148.  Tite JP, Janeway CA Jr. Cloned helper T cells can kill B lymphoma cells in the presence of \nspecific antigen: Ia restriction and cognate vs. noncognate interactions in cytolysis. Eur J \nImmunol. 1984 Oct;14(10):878\u201386.  \n\n149.  Lukacher AE, Morrison LA, Braciale VL, Malissen B, Braciale TJ. Expression of specific \ncytolytic activity by H-2I region-restricted, influenza virus-specific T lymphocyte clones. J Exp \nMed. 1985 Jul 1;162(1):171\u201387.  \n\n150.  Maimone MM, Morrison LA, Braciale VL, Braciale TJ. Features of target cell lysis by class I and \nclass II MHC-restricted cytolytic T lymphocytes. J Immunol Baltim Md 1950. 1986 Dec \n1;137(11):3639\u201343.  \n\n151.  Marshall NB, Swain SL. Cytotoxic CD4 T cells in antiviral immunity. J Biomed Biotechnol. \n2011;2011:954602.  \n\n152.  Juno JA, van Bockel D, Kent SJ, Kelleher AD, Zaunders JJ, Munier CML. Cytotoxic CD4 T \nCells\u2014Friend or Foe during Viral Infection? Front Immunol [Internet]. 2017 [cited 2017 Feb \n13];8. Available from: http://journal.frontiersin.org/article/10.3389/fimmu.2017.00019/abstract \n\n153.  Keesen TSL, Gomes JAS, Fares RCG, de Ara\u00fajo FF, Ferreira KS, Chaves AT, et al. \nCharacterization of CD4(+) Cytotoxic Lymphocytes and Apoptosis Markers Induced by \nTrypanossoma cruzi Infection. Scand J Immunol. 2012 Sep;76(3):311\u20139.  \n\n\n\n117 \n\n154.  Menezes CAS, Sullivan AK, Falta MT, Mack DG, Freed BM, Rocha MOC, et al. Highly \nconserved CDR3 region in circulating CD4(+)V?5(+) T cells may be associated with cytotoxic \nactivity in Chagas disease. Clin Exp Immunol. 2012 Aug;169(2):109\u201318.  \n\n155.  Kyaw T, Peter K, Li Y, Tipping P, Toh B-H, Bobik A. Cytotoxic lymphocytes and \natherosclerosis: significance, mechanisms and therapeutic challenges. Br J Pharmacol. 2017 \nMay 4;  \n\n156.  Meng F, Zhen S, Song B. HBV-specific CD4+ cytotoxic T cells in hepatocellular carcinoma are \nless cytolytic toward tumor cells and suppress CD8+ T cell-mediated antitumor immunity. \nAPMIS Acta Pathol Microbiol Immunol Scand. 2017 May 11;  \n\n157.  Thewissen M, Somers V, Hellings N, Fraussen J, Damoiseaux J, Stinissen P. CD4+CD28null T \ncells in autoimmune disease: pathogenic features and decreased susceptibility to \nimmunoregulation. J Immunol Baltim Md 1950. 2007 Nov 15;179(10):6514\u201323.  \n\n158.  Takeuchi A, Saito T. CD4 CTL, a Cytotoxic Subset of CD4(+) T Cells, Their Differentiation and \nFunction. Front Immunol. 2017;8:194.  \n\n159.  Williams NS, Engelhard VH. Identification of a population of CD4+ CTL that utilizes a perforin- \nrather than a Fas ligand-dependent cytotoxic mechanism. J Immunol Baltim Md 1950. 1996 \nJan 1;156(1):153\u20139.  \n\n160.  Echchakir H, Bagot M, Doroth\u00e9e G, Martinvalet D, Le Gouvello S, Boumsell L, et al. Cutaneous \nT cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile \nand use a fas-independent pathway for specific tumor cell lysis. J Invest Dermatol. 2000 \nJul;115(1):74\u201380.  \n\n161.  Dotiwala F, Mulik S, Polidoro RB, Ansara JA, Burleigh BA, Walch M, et al. Killer lymphocytes \nuse granulysin, perforin and granzymes to kill intracellular parasites. Nat Med. 2016 \nFeb;22(2):210\u20136.  \n\n162.  Faroudi M, Utzny C, Salio M, Cerundolo V, Guiraud M, M\u00fcller S, et al. Lytic versus stimulatory \nsynapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation \nthreshold. Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14145\u201350.  \n\n163.  Lopez JA, Brennan AJ, Whisstock JC, Voskoboinik I, Trapani JA. Protecting a serial killer: \npathways for perforin trafficking and self-defence ensure sequential target cell death. Trends \nImmunol. 2012 Aug;33(8):406\u201312.  \n\n164.  Page LJ, Darmon AJ, Uellner R, Griffiths GM. L is for lytic granules: lysosomes that kill. \nBiochim Biophys Acta. 1998 Feb 4;1401(2):146\u201356.  \n\n165.  Balaji KN, Schaschke N, Machleidt W, Catalfamo M, Henkart PA. Surface cathepsin B protects \ncytotoxic lymphocytes from self-destruction after degranulation. J Exp Med. 2002 Aug \n19;196(4):493\u2013503.  \n\n166.  Peters PJ, Borst J, Oorschot V, Fukuda M, Kr\u00e4henb\u00fchl O, Tschopp J, et al. Cytotoxic T \nlymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp \nMed. 1991 May 1;173(5):1099\u2013109.  \n\n167.  Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, et al. Sensitive and \nviable identification of antigen-specific CD8+ T cells by a flow cytometric assay for \ndegranulation. J Immunol Methods. 2003 Oct 1;281(1\u20132):65\u201378.  \n\n168.  Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural \nkiller cell activity. J Immunol Methods. 2004 Nov;294(1\u20132):15\u201322.  \n\n169.  S\u00e1ez-Border\u00edas A, Gum\u00e1 M, Angulo A, Bellosillo B, Pende D, L\u00f3pez-Botet M. Expression and \nfunction of NKG2D in CD4+ T cells specific for human cytomegalovirus. Eur J Immunol. 2006 \nDec;36(12):3198\u2013206.  \n\n\n\n118 \n\n170.  Graham CM, Christensen JR, Thomas DB. Differential induction of CD94 and NKG2 in CD4 \nhelper T cells. A consequence of influenza virus infection and interferon-gamma? Immunology. \n2007 Jun;121(2):238\u201347.  \n\n171.  Workman AM, Jacobs AK, Vogel AJ, Condon S, Brown DM. Inflammation enhances IL-2 driven \ndifferentiation of cytolytic CD4 T cells. PloS One. 2014;9(2):e89010.  \n\n172.  Gagnon SJ, Ennis FA, Rothman AL. Bystander target cell lysis and cytokine production by \ndengue virus-specific human CD4(+) cytotoxic T-lymphocyte clones. J Virol. 1999 \nMay;73(5):3623\u20139.  \n\n173.  Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, Waters A, et al. Characterization of \nCD4(+) CTLs ex vivo. J Immunol Baltim Md 1950. 2002 Jun 1;168(11):5954\u20138.  \n\n174.  Brien JD, Uhrlaub JL, Nikolich-Zugich J. West Nile virus-specific CD4 T cells exhibit direct \nantiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection. J Immunol \nBaltim Md 1950. 2008 Dec 15;181(12):8568\u201375.  \n\n175.  Brown DM, Kamperschroer C, Dilzer AM, Roberts DM, Swain SL. IL-2 and antigen dose \ndifferentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4+ T \ncells. Cell Immunol. 2009;257(1\u20132):69\u201379.  \n\n176.  Bertholet S, Goldszmid R, Morrot A, Debrabant A, Afrin F, Collazo-Custodio C, et al. \nLeishmania antigens are presented to CD8+ T cells by a transporter associated with antigen \nprocessing-independent pathway in vitro and in vivo. J Immunol Baltim Md 1950. 2006 Sep \n15;177(6):3525\u201333.  \n\n177.  Novais FO, Scott P. CD8(+) T cells in cutaneous leishmaniasis: the good, the bad, and the \nugly. Semin Immunopathol. 2015 Mar 24;  \n\n178.  Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for \nvaccine development. Nat Rev Immunol. 2002 Apr;2(4):251\u201362.  \n\n179.  Jordan KA, Hunter CA. Regulation of CD8+ T cell responses to infection with parasitic \nprotozoa. Exp Parasitol. 2010 Nov;126(3):318\u201325.  \n\n180.  da Concei\u00e7\u00e3o-Silva F, Perlaza BL, Louis JA, Romero P. Leishmania major infection in mice \nprimes for specific major histocompatibility complex class I-restricted CD8+ cytotoxic T cell \nresponses. Eur J Immunol. 1994 Nov;24(11):2813\u20137.  \n\n181.  M\u00fcller I, Kropf P, Louis JA, Milon G. Expansion of gamma interferon-producing CD8+ T cells \nfollowing secondary infection of mice immune to Leishmania major. Infect Immun. 1994 \nJun;62(6):2575\u201381.  \n\n182.  Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, et al. Vaccination \nwith DNA encoding the immunodominant LACK parasite antigen confers protective immunity to \nmice infected with Leishmania major. J Exp Med. 1997 Oct 6;186(7):1137\u201347.  \n\n183.  Rhee EG, Mendez S, Shah JA, Wu C, Kirman JR, Turon TN, et al. Vaccination with heat-killed \nleishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces \nlong-term memory CD4+ and CD8+ T cell responses and protection against leishmania major \ninfection. J Exp Med. 2002 Jun 17;195(12):1565\u201373.  \n\n184.  Uzonna JE, Joyce KL, Scott P. Low dose Leishmania major promotes a transient T helper cell \ntype 2 response that is down-regulated by interferon gamma-producing CD8+ T cells. J Exp \nMed. 2004 Jun 7;199(11):1559\u201366.  \n\n185.  Bertholet S, Debrabant A, Afrin F, Caler E, Mendez S, Tabbara KS, et al. Antigen requirements \nfor efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells. Infect Immun. \n2005 Oct;73(10):6620\u20138.  \n\n\n\n119 \n\n186.  Colmenares M, Kima PE, Samoff E, Soong L, McMahon-Pratt D. Perforin and gamma \ninterferon are critical CD8+ T-cell-mediated responses in vaccine-induced immunity against \nLeishmania amazonensis infection. Infect Immun. 2003 Jun;71(6):3172\u201382.  \n\n187.  Da-Cruz AM, Concei\u00e7\u00e3o-Silva F, Bertho AL, Coutinho SG. Leishmania-reactive CD4+ and \nCD8+ T cells associated with cure of human cutaneous leishmaniasis. Infect Immun. 1994 \nJun;62(6):2614\u20138.  \n\n188.  Coutinho SG, Da-Cruz AM, Bertho AL, Santiago MA, De-Luca P. Immunologic patterns \nassociated with cure in human American cutaneous leishmaniasis. Braz J Med Biol Res Rev \nBras Pesqui M\u00e9dicas E Biol\u00f3gicas Soc Bras Biof\u00edsica Al. 1998 Jan;31(1):139\u201342.  \n\n189.  Da-Cruz AM, Bittar R, Mattos M, Oliveira-Neto MP, Nogueira R, Pinho-Ribeiro V, et al. T-cell-\nmediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term \nevaluation after therapy. Clin Diagn Lab Immunol. 2002 Mar;9(2):251\u20136.  \n\n190.  Da-Cruz AM, Bertho AL, Oliveira-Neto MP, Coutinho SG. Flow cytometric analysis of cellular \ninfiltrate from American tegumentary leishmaniasis lesions. Br J Dermatol. 2005 \nSep;153(3):537\u201343.  \n\n191.  Barral-Netto M, Barral A, Brodskyn C, Carvalho EM, Reed SG. Cytotoxicity in human mucosal \nand cutaneous leishmaniasis. Parasite Immunol. 1995 Jan;17(1):21\u20138.  \n\n192.  Maretti-Mira AC, Bittner J, Oliveira-Neto MP, Liu M, Kang D, Li H, et al. Transcriptome patterns \nfrom primary cutaneous Leishmania braziliensis infections associate with eventual \ndevelopment of mucosal disease in humans. PLoS Negl Trop Dis. 2012;6(9):e1816.  \n\n193.  M\u00fcller K, van Zandbergen G, Hansen B, Laufs H, Jahnke N, Solbach W, et al. Chemokines, \nnatural killer cells and granulocytes in the early course of Leishmania major infection in mice. \nMed Microbiol Immunol (Berl). 2001 Nov;190(1\u20132):73\u20136.  \n\n194.  Baj\u00e9noff M, Breart B, Huang AYC, Qi H, Cazareth J, Braud VM, et al. Natural killer cell \nbehavior in lymph nodes revealed by static and real-time imaging. J Exp Med. 2006 Mar \n20;203(3):619\u201331.  \n\n195.  Bogdan C. Natural killer cells in experimental and human leishmaniasis. Front Cell Infect \nMicrobiol [Internet]. 2012 May 29 [cited 2015 Apr 23];2. Available from: \nhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417408/ \n\n196.  Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends \nImmunol. 2001 Nov;22(11):633\u201340.  \n\n197.  Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L. What is a natural killer cell? Nat \nImmunol. 2002 Jan;3(1):6\u20138.  \n\n198.  Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood. 1990 \nDec 15;76(12):2421\u201338.  \n\n199.  Laouar Y, Sutterwala FS, Gorelik L, Flavell RA. Transforming growth factor-beta controls T \nhelper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat \nImmunol. 2005 Jun;6(6):600\u20137.  \n\n200.  Loza MJ, Zamai L, Azzoni L, Rosati E, Perussia B. Expression of type 1 (interferon gamma) \nand type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell \ndifferentiation from progenitor cells. Blood. 2002 Feb 15;99(4):1273\u201381.  \n\n201.  Robertson MJ. Role of chemokines in the biology of natural killer cells. J Leukoc Biol. 2002 \nFeb;71(2):173\u201383.  \n\n202.  Dorner BG, Smith HRC, French AR, Kim S, Poursine-Laurent J, Beckman DL, et al. Coordinate \nexpression of cytokines and chemokines by NK cells during murine cytomegalovirus infection. J \nImmunol Baltim Md 1950. 2004 Mar 1;172(5):3119\u201331.  \n\n\n\n120 \n\n203.  Maroof A, Beattie L, Zubairi S, Svensson M, Stager S, Kaye PM. Posttranscriptional regulation \nof II10 gene expression allows natural killer cells to express immunoregulatory function. \nImmunity. 2008 Aug 15;29(2):295\u2013305.  \n\n204.  Blanca IR, Bere EW, Young HA, Ortaldo JR. Human B cell activation by autologous NK cells is \nregulated by CD40-CD40 ligand interaction: role of memory B cells and CD5+ B cells. J \nImmunol Baltim Md 1950. 2001 Dec 1;167(11):6132\u20139.  \n\n205.  Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk between \nactivated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol \nBaltim Md 1950. 2004 Sep 15;173(6):3716\u201324.  \n\n206.  Orange JS, Ballas ZK. Natural killer cells in human health and disease. Clin Immunol Orlando \nFla. 2006 Jan;118(1):1\u201310.  \n\n207.  Chan WK, Kung Sutherland M, Li Y, Zalevsky J, Schell S, Leung W. Antibody-dependent cell-\nmediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing \ninhibitory KIR ligands but not activating ligands. Clin Cancer Res Off J Am Assoc Cancer Res. \n2012 Nov 15;18(22):6296\u2013305.  \n\n208.  Zamora-Chimal J, Fern\u00e1ndez-Figueroa EA, Ruiz-Remigio A, Wilkins-Rodr\u00edguez AA, Delgado-\nDom\u00ednguez J, Salaiza-Suazo N, et al. NKT cell activation by Leishmania mexicana LPG: \nDescription of a novel pathway. Immunobiology. 2017 Feb;222(2):454\u201362.  \n\n209.  Ch\u00e1vez-Gal\u00e1n L, Arenas-Del Angel MC, Zenteno E, Ch\u00e1vez R, Lascurain R. Cell death \nmechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol. 2009 Feb;6(1):15\u201325.  \n\n210.  Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008 \nMay;9(5):495\u2013502.  \n\n211.  Yokoyama WM. Mistaken notions about natural killer cells. Nat Immunol. 2008 May;9(5):481\u20135.  \n\n212.  Yokoyama WM. Inhibitory receptors signal activation. Immunity. 2008 Oct 17;29(4):515\u20137.  \n\n213.  Lanier LL. On guard--activating NK cell receptors. Nat Immunol. 2001 Jan;2(1):23\u20137.  \n\n214.  Held W, Kijima M, Angelov G, Bessoles S. The function of natural killer cells: education, \nreminders and some good memories. Curr Opin Immunol. 2011 Apr;23(2):228\u201333.  \n\n215.  Maasho K, Sanchez F, Schurr E, Hailu A, Akuffo H. Indications of the protective role of natural \nkiller cells in human cutaneous leishmaniasis in an area of endemicity. Infect Immun. 1998 \nJun;66(6):2698\u2013704.  \n\n216.  Nyl\u00e9n S, Maasho K, S\u00f6derstrom K, Ilg T, Akuffo H. Live Leishmania promastigotes can directly \nactivate primary human natural killer cells to produce interferon-gamma. Clin Exp Immunol. \n2003 Mar;131(3):457\u201367.  \n\n217.  Resnick M, Roguel N, Bercovier H, Enk C, Frankenburg S, Kedar E. Lysis of murine \nmacrophages infected with intracellular pathogens by interleukin 2-activated killer (LAK) cells in \nvitro. Cell Immunol. 1988 Apr 15;113(1):214\u20139.  \n\n218.  Scharton TM, Scott P. Natural killer cells are a source of interferon gamma that drives \ndifferentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in \nmice. J Exp Med. 1993 Aug 1;178(2):567\u201377.  \n\n219.  Laskay T, Diefenbach A, R\u00f6llinghoff M, Solbach W. Early parasite containment is decisive for \nresistance to Leishmania major infection. Eur J Immunol. 1995 Aug;25(8):2220\u20137.  \n\n220.  Diefenbach A, Schindler H, Donhauser N, Lorenz E, Laskay T, MacMicking J, et al. Type 1 \ninterferon (IFNalpha/beta) and type 2 nitric oxide synthase regulate the innate immune \nresponse to a protozoan parasite. Immunity. 1998 Jan;8(1):77\u201387.  \n\n\n\n121 \n\n221.  Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, et al. An antimicrobial \nactivity of cytolytic T cells mediated by granulysin. Science. 1998 Oct 2;282(5386):121\u20135.  \n\n222.  Aranha FCS, Ribeiro U Jr, Basse P, Corbett CEP, Laurenti MD. Interleukin-2-activated natural \nkiller cells may have a direct role in the control of Leishmania (Leishmania) amazonensis \npromastigote and macrophage infection. Scand J Immunol. 2005 Oct;62(4):334\u201341.  \n\n223.  Lieke T, Nyl\u00e9n S, Eidsmo L, Schmetz C, Berg L, Akuffo H. The interplay between Leishmania \npromastigotes and human Natural Killer cells in vitro leads to direct lysis of Leishmania by NK \ncells and modulation of NK cell activity by Leishmania promastigotes. Parasitology. 2011 Sep \n9;1\u201312.  \n\n224.  Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat \nImmunol. 2008 May;9(5):503\u201310.  \n\n225.  Krebs P, Barnes MJ, Lampe K, Whitley K, Bahjat KS, Beutler B, et al. NK-cell-mediated killing \nof target cells triggers robust antigen-specific T-cell-mediated and humoral responses. Blood. \n2009 Jun 25;113(26):6593\u2013602.  \n\n226.  Prajeeth CK, Haeberlein S, Sebald H, Schleicher U, Bogdan C. Leishmania-infected \nmacrophages are targets of NK cell-derived cytokines but not of NK cell cytotoxicity. Infect \nImmun. 2011 Jul;79(7):2699\u2013708.  \n\n227.  Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what\u2019s in a \nname? Nat Rev Immunol. 2004 Mar;4(3):231\u20137.  \n\n228.  Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. CD1 recognition \nby mouse NK1+ T lymphocytes. Science. 1995 May 12;268(5212):863\u20135.  \n\n229.  Taniguchi M, Seino K-I, Nakayama T. The NKT cell system: bridging innate and acquired \nimmunity. Nat Immunol. 2003 Dec;4(12):1164\u20135.  \n\n230.  Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol. \n2004;22:817\u201390.  \n\n231.  Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu \nRev Immunol. 2005;23:877\u2013900.  \n\n232.  Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. \n2007;25:297\u2013336.  \n\n233.  Van Kaer L. NKT cells: T lymphocytes with innate effector functions. Curr Opin Immunol. 2007 \nJun;19(3):354\u201364.  \n\n234.  Porcelli S, Yockey CE, Brenner MB, Balk SP. Analysis of T cell antigen receptor (TCR) \nexpression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use \nof several V beta genes and an invariant TCR alpha chain. J Exp Med. 1993 Jul 1;178(1):1\u201316.  \n\n235.  Dellabona P, Padovan E, Casorati G, Brockhaus M, Lanzavecchia A. An invariant V alpha 24-J \nalpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T \ncells. J Exp Med. 1994 Sep 1;180(3):1171\u20136.  \n\n236.  Lantz O, Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of \nmajor histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. \nJ Exp Med. 1994 Sep 1;180(3):1097\u2013106.  \n\n237.  Arrenberg P, Halder R, Kumar V. Cross-regulation between distinct natural killer T cell subsets \ninfluences immune response to self and foreign antigens. J Cell Physiol. 2009 Feb;218(2):246\u2013\n50.  \n\n\n\n122 \n\n238.  Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-restricted and TCR-\nmediated activation of valpha14 NKT cells by glycosylceramides. Science. 1997 Nov \n28;278(5343):1626\u20139.  \n\n239.  Rhost S, Sedimbi S, Kadri N, Cardell SL. Immunomodulatory type II natural killer T \nlymphocytes in health and disease. Scand J Immunol. 2012 Sep;76(3):246\u201355.  \n\n240.  Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention of autoimmunity by \ntargeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp \nMed. 2004 Apr 5;199(7):947\u201357.  \n\n241.  Van Rhijn I, Young DC, Im JS, Levery SB, Illarionov PA, Besra GS, et al. CD1d-restricted T cell \nactivation by nonlipidic small molecules. Proc Natl Acad Sci U S A. 2004 Sep \n14;101(37):13578\u201383.  \n\n242.  Chang DH, Deng H, Matthews P, Krasovsky J, Ragupathi G, Spisek R, et al. Inflammation-\nassociated lysophospholipids as ligands for CD1d-restricted T cells in human cancer. Blood. \n2008 Aug 15;112(4):1308\u201316.  \n\n243.  Arrenberg P, Halder R, Dai Y, Maricic I, Kumar V. Oligoclonality and innate-like features in the \nTCR repertoire of type II NKT cells reactive to a beta-linked self-glycolipid. Proc Natl Acad Sci \nU S A. 2010 Jun 15;107(24):10984\u20139.  \n\n244.  Godfrey DI, Pellicci DG, Patel O, Kjer-Nielsen L, McCluskey J, Rossjohn J. Antigen recognition \nby CD1d-restricted NKT T cell receptors. Semin Immunol. 2010 Apr;22(2):61\u20137.  \n\n245.  Van Kaer L, Parekh VV, Wu L. Invariant natural killer T cells: bridging innate and adaptive \nimmunity. Cell Tissue Res. 2011 Jan;343(1):43\u201355.  \n\n246.  Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT \ncells. J Clin Invest. 2004 Nov;114(10):1379\u201388.  \n\n247.  Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-\nrestricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med. 2002 Mar \n4;195(5):625\u201336.  \n\n248.  Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V(alpha)24 \nnatural killer T cells. J Exp Med. 2002 Mar 4;195(5):637\u201341.  \n\n249.  Chen X, Wang X, Besra GS, Gumperz JE. Modulation of CD1d-restricted NKT cell responses \nby CD4. J Leukoc Biol. 2007 Dec;82(6):1455\u201365.  \n\n250.  Thedrez A, de Lalla C, Allain S, Zaccagnino L, Sidobre S, Garavaglia C, et al. CD4 \nengagement by CD1d potentiates activation of CD4+ invariant NKT cells. Blood. 2007 Jul \n1;110(1):251\u20138.  \n\n251.  Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol. 2010 \nMar;11(3):197\u2013206.  \n\n252.  O\u2019Reilly V, Zeng SG, Bricard G, Atzberger A, Hogan AE, Jackson J, et al. Distinct and \nOverlapping Effector Functions of Expanded Human CD4+, CD8?+ and CD4-CD8?- Invariant \nNatural Killer T Cells. PLoS ONE [Internet]. 2011 Dec 12 [cited 2013 Jan 11];6(12). Available \nfrom: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236218/ \n\n253.  Teige A, Bockermann R, Hasan M, Olofsson KE, Liu Y, Issazadeh-Navikas S. CD1d-\ndependent NKT cells play a protective role in acute and chronic arthritis models by ameliorating \nantigen-specific Th1 responses. J Immunol Baltim Md 1950. 2010 Jul 1;185(1):345\u201356.  \n\n254.  Amprey JL, Im JS, Turco SJ, Murray HW, Illarionov PA, Besra GS, et al. A subset of liver NK T \ncells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J \nExp Med. 2004 Oct 4;200(7):895\u2013904.  \n\n\n\n123 \n\n255.  Karmakar S, Paul J, De T. Leishmania donovani glycosphingolipid facilitates antigen \npresentation by inducing relocation of CD1d into lipid rafts in infected macrophages. Eur J \nImmunol. 2011 May;41(5):1376\u201387.  \n\n256.  Zajonc DM, Girardi E. Recognition of Microbial Glycolipids by Natural Killer T Cells. Front \nImmunol [Internet]. 2015 Aug 4 [cited 2017 Mar 14];6. Available from: \nhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4523824/ \n\n257.  Nagarajan NA, Kronenberg M. Invariant NKT cells amplify the innate immune response to \nlipopolysaccharide. J Immunol Baltim Md 1950. 2007 Mar 1;178(5):2706\u201313.  \n\n258.  Donovan MJ, Jayakumar A, McDowell MA. Inhibition of groups 1 and 2 CD1 molecules on \nhuman dendritic cells by Leishmania species. Parasite Immunol. 2007 Oct;29(10):515\u201324.  \n\n259.  Ishikawa H, Hisaeda H, Taniguchi M, Nakayama T, Sakai T, Maekawa Y, et al. CD4(+) \nv(alpha)14 NKT cells play a crucial role in an early stage of protective immunity against \ninfection with Leishmania major. Int Immunol. 2000 Sep;12(9):1267\u201374.  \n\n260.  Wiethe C, Debus A, Mohrs M, Steinkasserer A, Lutz M, Gessner A. Dendritic cell differentiation \nstate and their interaction with NKT cells determine Th1/Th2 differentiation in the murine model \nof Leishmania major infection. J Immunol Baltim Md 1950. 2008 Apr 1;180(7):4371\u201381.  \n\n261.  Zamora-Chimal J, Hern\u00e1ndez-Ruiz J, Becker I. NKT cells in leishmaniasis. Immunobiology. \n2016 Dec 5;  \n\n262.  Wherry EJ. T cell exhaustion. Nat Immunol. 2011 Jun;12(6):492\u20139.  \n\n263.  Trimble LA, Kam LW, Friedman RS, Xu Z, Lieberman J. CD3zeta and CD28 down-modulation \non CD8 T cells during viral infection. Blood. 2000 Aug 1;96(3):1021\u20139.  \n\n264.  Reignat S, Webster GJM, Brown D, Ogg GS, King A, Seneviratne SL, et al. Escaping high viral \nload exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J \nExp Med. 2002 May 6;195(9):1089\u2013101.  \n\n265.  Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected \nimmunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature. 1993 Apr \n22;362(6422):758\u201361.  \n\n266.  Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, et al. Viral \nimmune evasion due to persistence of activated T cells without effector function. J Exp Med. \n1998 Dec 21;188(12):2205\u201313.  \n\n267.  Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters \nCD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional \nimpairment. J Virol. 2003 Apr;77(8):4911\u201327.  \n\n268.  Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell. 2009 Jul \n10;138(1):30\u201350.  \n\n269.  Chang W-S, Kim J-Y, Kim Y-J, Kim Y-S, Lee J-M, Azuma M, et al. Cutting edge: Programmed \ndeath-1/programmed death ligand 1 interaction regulates the induction and maintenance of \ninvariant NKT cell anergy. J Immunol Baltim Md 1950. 2008 Nov 15;181(10):6707\u201310.  \n\n270.  Moll M, Kuylenstierna C, Gonzalez VD, Andersson SK, Bosnjak L, S\u00f6nnerborg A, et al. Severe \nfunctional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained \nduring chronic HIV-1 infection. Eur J Immunol. 2009 Mar;39(3):902\u201311.  \n\n271.  Durgan K, Ali M, Warner P, Latchman YE. Targeting NKT cells and PD-L1 pathway results in \naugmented anti-tumor responses in a melanoma model. Cancer Immunol Immunother CII. \n2011 Apr;60(4):547\u201358.  \n\n\n\n124 \n\n272.  Kee S-J, Kwon Y-S, Park Y-W, Cho Y-N, Lee S-J, Kim T-J, et al. Dysfunction of natural killer T \ncells in patients with active Mycobacterium tuberculosis infection. Infect Immun. 2012 \nJun;80(6):2100\u20138.  \n\n273.  Singh A, Dey AB, Mohan A, Mitra DK. Programmed death-1 receptor suppresses ?-IFN \nproducing NKT cells in human tuberculosis. Tuberc Edinb Scotl. 2014 May;94(3):197\u2013206.  \n\n274.  Della Chiesa M, Pesce S, Muccio L, Carlomagno S, Sivori S, Moretta A, et al. Features of \nMemory-Like and PD-1(+) Human NK Cell Subsets. Front Immunol. 2016;7:351.  \n\n275.  Sch\u00f6n MP, Zollner TM, Boehncke W-H. The Molecular Basis of Lymphocyte Recruitment to the \nSkin: Clues for Pathogenesis and Selective Therapies of Inflammatory Disorders. J Invest \nDermatol. 2003 Nov 1;121(5):951\u201362.  \n\n276.  Santamaria-Bab\u00ed LF. CLA(+) T cells in cutaneous diseases. Eur J Dermatol EJD. 2004 \nFeb;14(1):13\u20138.  \n\n277.  Sigmundsd\u00f3ttir H, Gudj\u00f3nsson JE, J\u00f3nsd\u00f3ttir I, L\u00fadv\u00edksson BR, Valdimarsson H. The \nfrequency of CLA+ CD8+ T cells in the blood of psoriasis patients correlates closely with the \nseverity of their disease. Clin Exp Immunol. 2001 Nov;126(2):365\u20139.  \n\n278.  Ant\u00fanez C, Torres MJ, Mayorga C, Cornejo-Garc\u00eda JA, Santamar\u00eda-Babi LF, Blanca M. \nDifferent cytokine production and activation marker profiles in circulating cutaneous-\nlymphocyte-associated antigen T cells from patients with acute or chronic atopic dermatitis. \nClin Exp Allergy J Br Soc Allergy Clin Immunol. 2004 Apr;34(4):559\u201366.  \n\n279.  Mendes-Aguiar C de O, Gomes-Silva A, Nunes E, Pereira-Carvalho R, Nogueira RS, Oliveira-\nNeto M de P, et al. The skin homing receptor cutaneous leucocyte-associated antigen (CLA) is \nup-regulated by Leishmania antigens in T lymphocytes during active cutaneous leishmaniasis. \nClin Exp Immunol. 2009 Sep;157(3):377\u201384.  \n\n280.  Cunha CF. Avalia\u00e7\u00e3o da Citotoxicidade na Evolu\u00e7\u00e3o para a Cura Cl\u00ednica da Leishmaniose \nTegumentar Americana [Disserta\u00e7\u00e3o de Mestrado]. [Rio de Janeiro]: Instituto Oswaldo Cruz; \nFunda\u00e7\u00e3o Oswaldo Cruz; 2013.  \n\n281.  Overgaard NH, Jung J-W, Steptoe RJ, Wells JW. CD4+/CD8+ double-positive T cells: more \nthan just a developmental stage? J Leukoc Biol. 2015 Jan;97(1):31\u20138.  \n\n282.  Macedo ABB, S\u00e1nchez-Arcila JC, Schubach AO, Mendon\u00e7a SCF, Marins-Dos-Santos A, de \nFatima Madeira M, et al. Multifunctional CD4+ T cells in patients with American cutaneous \nleishmaniasis. Clin Exp Immunol. 2012 Mar;167(3):505\u201313.  \n\n283.  Billings P, Burakoff S, Dorf ME, Benacerraf B. Cytotoxic T lymphocytes specific for I region \ndeterminants do not require interactions with H-2K or D gene products. J Exp Med. 1977 May \n1;145(5):1387\u201392.  \n\n284.  Appay V. The physiological role of cytotoxic CD4(+) T-cells: the holy grail? Clin Exp Immunol. \n2004 Oct;138(1):10\u20133.  \n\n285.  Bengsch B, Ohtani T, Herati RS, Bovenschen N, Chang K-M, Wherry EJ. Deep immune \nprofiling by mass cytometry links human T and NK cell differentiation and cytotoxic molecule \nexpression patterns. J Immunol Methods [Internet]. [cited 2017 Apr 6]; Available from: \nhttp://www.sciencedirect.com/science/article/pii/S0022175917301321 \n\n286.  Voskoboinik I, Whisstock JC, Trapani JA. Perforin and granzymes: function, dysfunction and \nhuman pathology. Nat Rev Immunol. 2015 Jun;15(6):388\u2013400.  \n\n287.  Cruz-Guilloty F, Pipkin ME, Djuretic IM, Levanon D, Lotem J, Lichtenheld MG, et al. Runx3 and \nT-box proteins cooperate to establish the transcriptional program of effector CTLs. J Exp Med. \n2009 Jan 16;206(1):51\u20139.  \n\n\n\n125 \n\n288.  Glennie ND, Scott P. Memory T cells in cutaneous leishmaniasis. Cell Immunol. 2016 \nNov;309:50\u20134.  \n\n289.  Toledo VP, Mayrink W, Gollob KJ, Oliveira MA, Costa CA, Genaro O, et al. \nImmunochemotherapy in American cutaneous leishmaniasis: immunological aspects before \nand after treatment. Mem Inst Oswaldo Cruz. 2001 Jan;96(1):89\u201398.  \n\n290.  Reis LC, Brito MEF, Souza MA, Medeiros ACR, Silva CJ, Luna CF, et al. Cellular immune \nresponse profile in patients with American tegumentary leishmaniasis prior and post \nchemotherapy treatment. J Clin Lab Anal. 2009;23(1):63\u20139.  \n\n291.  Carvalho AM, Magalh\u00e3es A, Carvalho LP, Bacellar O, Scott P, Carvalho EM. Immunologic \nresponse and memory T cells in subjects cured of tegumentary leishmaniasis. BMC Infect Dis. \n2013;13:529.  \n\n292.  Naouar I, Boussoffara T, Ben Ahmed M, Belhaj Hmida N, Gharbi A, Gritli S, et al. Involvement \nof different CD4(+) T cell subsets producing granzyme B in the immune response to \nLeishmania major antigens. Mediators Inflamm. 2014;2014:636039.  \n\n293.  Mou Z, Muleme HM, Liu D, Jia P, Okwor IB, Kuriakose SM, et al. Parasite-derived arginase \ninfluences secondary anti-Leishmania immunity by regulating programmed cell death-1-\nmediated CD4+ T cell exhaustion. J Immunol Baltim Md 1950. 2013 Apr 1;190(7):3380\u20139.  \n\n294.  Ferraz R, Cunha CF, Gomes-Silva A, Schubach AO, Pimentel MIF, Lyra MR, et al. Apoptosis \nand frequency of total and effector CD8+ T lymphocytes from cutaneous leishmaniasis patients \nduring antimonial therapy. BMC Infect Dis. 2015;15(1):74.  \n\n295.  Bertho AL, Santiago MA, Da-Cruz AM, Coutinho SG. Detection of early apoptosis and cell \ndeath in T CD4+ and CD8+ cells from lesions of patients with localized cutaneous \nleishmaniasis. Braz J Med Biol Res Rev Bras Pesqui M\u00e9dicas E Biol\u00f3gicas Soc Bras Biof\u00edsica \nAl. 2000 Mar;33(3):317\u201325.  \n\n296.  de Oliveira Mendes-Aguiar C, Vieira-Gon\u00e7alves R, Guimar\u00e3es LH, de Oliveira-Neto MP, \nCarvalho EM, Da-Cruz AM. Effector memory CD4+ T cells differentially express activation \nassociated molecules depending on the duration of American cutaneous leishmaniasis lesions. \nClin Exp Immunol. 2016 Aug 1;185(2):202\u20139.  \n\n297.  Ferraz R, Cunha CF, Pimentel MIF, Lyra MR, Pereira-Da-Silva T, Schubach AO, et al. \nCD3(+)CD4(neg)CD8(neg) (double negative) T lymphocytes and NKT cells as the main \ncytotoxic-related-CD107a(+) cells in lesions of cutaneous leishmaniasis caused by Leishmania \n(Viannia) braziliensis. Parasit Vectors. 2017 May 3;10(1):219.  \n\n298.  Trautmann A, R\u00fcckert B, Schmid-Grendelmeier P, Niederer E, Br\u00f6cker E-B, Blaser K, et al. \nHuman CD8 T cells of the peripheral blood contain a low CD8 expressing cytotoxic/effector \nsubpopulation. Immunology. 2003 Mar;108(3):305\u201312.  \n\n299.  Ca\u00f1eda-Guzm\u00e1n IC, Salaiza-Suazo N, Fern\u00e1ndez-Figueroa EA, Carrada-Figueroa G, Aguirre-\nGarc\u00eda M, Becker I. NK cell activity differs between patients with localized and diffuse \ncutaneous leishmaniasis infected with Leishmania mexicana: a comparative study of TLRs and \ncytokines. PloS One. 2014;9(11):e112410.  \n\n300.  Lieke T, Nyl\u00e9n S, Eidsmo L, McMaster WR, Mohammadi AM, Khamesipour A, et al. \nLeishmania surface protein gp63 binds directly to human natural killer cells and inhibits \nproliferation. Clin Exp Immunol. 2008 Aug;153(2):221\u201330.  \n\n301.  Hern\u00e1ndez-Ruiz J, Salaiza-Suazo N, Carrada G, Escoto S, Ruiz-Remigio A, Rosenstein Y, et \nal. CD8 cells of patients with diffuse cutaneous leishmaniasis display functional exhaustion: the \nlatter is reversed, in vitro, by TLR2 agonists. PLoS Negl Trop Dis. 2010;4(11):e871.  \n\n302.  Inngjerdingen M, Kveberg L, Naper C, Vaage JT. Natural killer cell subsets in man and rodents. \nTissue Antigens. 2011 Aug;78(2):81\u20138.  \n\n\n\n126 \n\n303.  Campos-Mart\u00edn Y, Colmenares M, Gozalbo-L\u00f3pez B, L\u00f3pez-N\u00fa\u00f1ez M, Savage PB, Mart\u00ednez-\nNaves E. Immature human dendritic cells infected with Leishmania infantum are resistant to \nNK-mediated cytolysis but are efficiently recognized by NKT cells. J Immunol Baltim Md 1950. \n2006 May 15;176(10):6172\u20139.  \n\n304.  Joyee AG, Uzonna J, Yang X. Invariant NKT cells preferentially modulate the function of CD8 \nalpha+ dendritic cell subset in inducing type 1 immunity against infection. J Immunol Baltim Md \n1950. 2010 Feb 15;184(4):2095\u2013106.  \n\n305.  Griewank KG, Lorenz B, Fischer MR, Boon L, Lopez Kostka S, von Stebut E. Immune \nmodulating effects of NKT cells in a physiologically low dose Leishmania major infection model \nafter ?GalCer analog PBS57 stimulation. PLoS Negl Trop Dis. 2014 Jun;8(6):e2917.  \n\n306.  Montoya CJ, Pollard D, Martinson J, Kumari K, Wasserfall C, Mulder CB, et al. Characterization \nof human invariant natural killer T subsets in health and disease using a novel invariant natural \nkiller T cell-clonotypic monoclonal antibody, 6B11. Immunology. 2007 Sep;122(1):1\u201314.  \n\n307.  Carvalho KI, Melo KM, Bruno FR, Snyder-Cappione JE, Nixon DF, Costa-Carvalho BT, et al. \nSkewed distribution of circulating activated natural killer T (NKT) cells in patients with common \nvariable immunodeficiency disorders (CVID). PloS One. 2010;5(9).  \n\n308.  Kumari S, Jamal F, Shivam P, Thakur A, Kumar M, Bimal S, et al. Leishmania donovani skews \nthe CD56(+) Natural Killer T cell response during human visceral leishmaniasis. Cytokine. 2015 \nMay;73(1):53\u201360.  \n\n309.  Exley MA, Tahir SM, Cheng O, Shaulov A, Joyce R, Avigan D, et al. A major fraction of human \nbone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed \nlymphocyte responses. J Immunol Baltim Md 1950. 2001 Nov 15;167(10):5531\u20134.  \n\n310.  Dhodapkar MV, Kumar V. Type II NKT Cells and Their Emerging Role in Health and Disease. J \nImmunol Baltim Md 1950. 2017 Feb 1;198(3):1015\u201321.  \n\n311.  Tatituri RVV, Watts GFM, Bhowruth V, Barton N, Rothchild A, Hsu F-F, et al. Recognition of \nmicrobial and mammalian phospholipid antigens by NKT cells with diverse TCRs. Proc Natl \nAcad Sci U S A. 2013 Jan 29;110(5):1827\u201332.  \n\n312.  Carvalho LP, PASSOS S, BACELLAR O, LESSA M, ALMEIDA RP, MAGALH\u00c3ES A, et al. \nDifferential immune regulation of activated T cells between cutaneous and mucosal \nleishmaniasis as a model for pathogenesis. Parasite Immunol. 2007 May;29(5):251\u20138.  \n\n313.  Zhang C, Zhang J, Niu J, Zhang J, Tian Z. Interleukin-15 improves cytotoxicity of natural killer \ncells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 \nand ERK1/2 phosphorylation. Cytokine. 2008 Apr;42(1):128\u201336.  \n\n314.  Alonso-Arias R, Moro-Garc\u00eda MA, Vidal-Casti\u00f1eira JR, Solano-Jaurrieta JJ, Su\u00e1rez-Garc\u00eda FM, \nCoto E, et al. IL-15 preferentially enhances functional properties and antigen-specific \nresponses of CD4+CD28(null) compared to CD4+CD28+ T cells. Aging Cell. 2011 \nOct;10(5):844\u201352.  \n\n315.  Becker TC, Wherry EJ, Boone D, Murali-Krishna K, Antia R, Ma A, et al. Interleukin 15 is \nrequired for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med. 2002 Jun \n17;195(12):1541\u20138.  \n\n316.  Dooms H, Desmedt M, Vancaeneghem S, Rottiers P, Goossens V, Fiers W, et al. Quiescence-\ninducing and antiapoptotic activities of IL-15 enhance secondary CD4+ T cell responsiveness \nto antigen. J Immunol Baltim Md 1950. 1998 Sep 1;161(5):2141\u201350.  \n\n317.  Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, et al. Interleukin (IL) 15 is \na novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J \nExp Med. 1994 Oct 1;180(4):1395\u2013403.  \n\n\n\n127 \n\n318.  Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. \n2001 Jan 1;97(1):14\u201332.  \n\n319.  Ohteki T, Ho S, Suzuki H, Mak TW, Ohashi PS. Role for IL-15/IL-15 receptor beta-chain in \nnatural killer 1.1+ T cell receptor-alpha beta+ cell development. J Immunol Baltim Md 1950. \n1997 Dec 15;159(12):5931\u20135.  \n\n320.  Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, et al. Reversible defects \nin natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med. \n2000 Mar 6;191(5):771\u201380.  \n\n321.  Hasan MS, Kallas EG, Thomas EK, Looney J, Campbell M, Evans TG. Effects of interleukin-15 \non in vitro human T cell proliferation and activation. J Interferon Cytokine Res Off J Int Soc \nInterferon Cytokine Res. 2000 Feb;20(2):119\u201323.  \n\n322.  van Leeuwen EMM, Sprent J, Surh CD. Generation and maintenance of memory CD4(+) T \nCells. Curr Opin Immunol. 2009 Apr;21(2):167\u201372.  \n\n323.  Antonio L de F, Pimentel MIF, Lyra MR, Madeira M de F, Miranda L de FC, Paes RA, et al. \nSporothrix schenckii Sensu Lato identification in fragments of skin lesion cultured in NNN \nmedium for differential diagnosis of cutaneous leishmaniasis. Diagn Microbiol Infect Dis. 2017 \nFeb;87(2):118\u201320.  \n\n324.  Morgado FN, Schubach AO, Barros MBL, Concei\u00e7\u00e3o-Silva F. The in situ inflammatory profile of \nlymphocutaneous and fixed forms of human sporotrichosis. Med Mycol. 2011 Aug;49(6):612\u2013\n20.  \n\n325.  Machado P, Ara\u00fajo C, Da Silva AT, Almeida RP, D\u2019Oliveira Jr A, Bittencourt A, et al. Failure of \nearly treatment of cutaneous leishmaniasis in preventing the development of an ulcer. Clin \nInfect Dis Off Publ Infect Dis Soc Am. 2002 Jun 15;34(12):E69-73.  \n\n326.  Stefanidou MP, Antoniou M, Koutsopoulos AV, Neofytou YT, Krasagakis K, Kr\u00fcger-Krasagakis \nS, et al. A rare case of leishmaniasis recidiva cutis evolving for 31 years caused by Leishmania \ntropica. Int J Dermatol. 2008 Jun;47(6):588\u20139.  \n\n327.  Lessa HA, Machado P, Lima F, Cruz AA, Bacellar O, Guerreiro J, et al. Successful treatment of \nrefractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg. 2001 \nAug;65(2):87\u20139.  \n\n328.  Antonio L de F, Fagundes A, Oliveira RVC, Pinto PG, Bedoya-Pacheco SJ, Vasconcellos \u00c9 de \nCF e, et al. MONTENEGRO SKIN TEST AND AGE OF SKIN LESION AS PREDICTORS OF \nTREATMENT FAILURE IN CUTANEOUS LEISHMANIASIS. Rev Inst Med Trop S\u00e3o Paulo. \n2014 Sep;56(5):375\u201380.  \n\n329.  Deps PD, Viana MC, Falqueto A, Dietze R. [Comparative assessment of the efficacy and \ntoxicity of N-methyl-glucamine and BP88 sodium stibogluconate in the treatment of localized \ncutaneous leishmaniasis]. Rev Soc Bras Med Trop. 2000 Dec;33(6):535\u201343.  \n\n330.  Rodrigues AM, Hueb M, Santos TARR dos, Fontes CJF. [Factors associated with treatment \nfailure of cutaneous leishmaniasis with meglumine antimoniate]. Rev Soc Bras Med Trop. 2006 \nApr;39(2):139\u201345.  \n\n331.  Teixeira AC, Paes MG, Guerra J de O, Prata A, Silva-Vergara ML. Failure of both azithromycin \nand antimony to treat cutaneous leishmaniasis in Manaus, AM, Brazil. Rev Inst Med Trop Sao \nPaulo. 2008 Jun;50(3):157\u201360.  \n\n332.  Lima JR. ESTUDO PROSPECTIVO DE PACIENTES COM LEISHMANIOSE TEGUMENTAR \nAMERICANA EM MANAUS (AM): FATORES IMUNOL\u00d3GICOS ENVOLVIDOS NO CURSO \nTERAP\u00caUTICO COM ANTIMONIAL PENTAVALENTE [Disserta\u00e7\u00e3o de Mestrado]. [Rio de \nJaneiro]: FIOCRUZ; 2017.  \n\n\n\n128 \n\n333.  Elmekki MA, Elhassan MM, Ozbak HA, Mukhtar MM. Elevated TGF-beta levels in drug-\nresistant visceral leishmaniasis. Ann Saudi Med. 2016 Feb;36(1):73\u20137.  \n\n334.  Pereira L de OR, Moreira RB, de Oliveira MP, Reis S de O, de Oliveira Neto MP, Pirmez C. Is \nLeishmania (Viannia) braziliensis parasite load associated with disease pathogenesis? Int J \nInfect Dis IJID Off Publ Int Soc Infect Dis. 2017 Apr;57:132\u20137.  \n\n \n\n \n\n\n\n129 \n\n9. ANEXOS \n\n9.1. ANEXO 1  \n\nTermo de Consentimento Livre e Esclarecido \n\n \n \n\nTERMO DE CONSENTIMENTO LIVRE E ESCLARECIDO  \n Volunt\u00e1rio  \n\n \nINSTITUI\u00c7\u00c3O: Instituto Oswaldo Cruz - FIOCRUZ, Lab. Imunoparasitologia, Pav. Le\u00f4nidas Deane, \n\nsala 408-A, Av Brasil 4365, Manguinhos. Rio de Janeiro, RJ. \n \nT\u00cdTULO DO PROJETO: Perfil Funcional de C\u00e9lulas CD8+ na Imunopatogenia da Leishmaniose \nTegumentar Americana \n \nPesquisador Respons\u00e1vel: \u00c1lvaro Luiz Bertho dos Santos, Doutor, Biom\u00e9dico, Pesquisador Titular.  \nEm caso de d\u00favida entre em contato pelo tel. 3865.8126 cel. 21 91590719 \nExecutores do Projeto: Raquel Ferraz  \n\n             Clarissa Cunha                    \nNome do Volunt\u00e1rio: _____________________________________________ \n\n \nEu declaro que aceito participar como volunt\u00e1rio da investiga\u00e7\u00e3o cient\u00edfica que est\u00e1 sendo \n\nrealizada pelo Instituto Oswaldo Cruz - FIOCRUZ com o objetivo de se estudar os mecanismos que \nlevam o organismo humano a se curar da leishmaniose. Fui informado de que este estudo n\u00e3o me \nbeneficiar\u00e1 diretamente, mas poder\u00e1 auxiliar os estudos para a obten\u00e7\u00e3o de melhores esquemas de \ntratamento e de uma vacina contra a doen\u00e7a. \n\nMinha colabora\u00e7\u00e3o ser\u00e1 submeter-me aos seguintes procedimentos a serem realizados por \nprofissionais de sa\u00fade especializados: \n\n1. Exame cl\u00ednico; \n2. Teste de Montenegro. Este consiste na aplica\u00e7\u00e3o de 0,1 ml de uma solu\u00e7\u00e3o contendo \n\nparasitos mortos pelo fenol a 0,4%. A leitura \u00e9 feita em 48 h. \n3. Coleta de 4 tubos de sangue (aproximadamente 40 mL) atrav\u00e9s de pun\u00e7\u00e3o na veia do \n\nbra\u00e7o.  \n4. Bi\u00f3psia da les\u00e3o antes do in\u00edcio da terapia.    \nEsclarecimento sobre os procedimentos e inconvenientes: \nO teste de Montenegro \u00e9 utilizado rotineiramente para o diagn\u00f3stico da Leishmaniose e sua \n\npositividade indica a exposi\u00e7\u00e3o ao parasito. No entanto, o teste n\u00e3o deve ser aplicado nos indiv\u00edduos \nal\u00e9rgicos a mertiolate. A rea\u00e7\u00e3o positiva se acompanha de vermelhid\u00e3o e endurecimento restritos \u00e0 \n\u00e1rea de aplica\u00e7\u00e3o do teste. Rea\u00e7\u00f5es mais intensas como inflama\u00e7\u00e3o, ulcera\u00e7\u00e3o na pele ou mesmo \nfebre s\u00e3o bastante raras.. Os poss\u00edveis desconfortos, se ocorrerem, s\u00e3o relacionados a problemas \nocorridos durante a pun\u00e7\u00e3o venosa local, como extravasamento de sangue que leva a dor e \nhematoma, mas que regridem em cerca de 3 a 5 dias. A bi\u00f3psia da les\u00e3o ser\u00e1 realizada com punch \nde 6 mm, ap\u00f3s anestesia local com Lidoca\u00edna. O volume de sangue e o tamanho da bi\u00f3psia obtidos \nn\u00e3o causam danos ou riscos ao organismo, n\u00e3o havendo assim necessidade de indeniza\u00e7\u00f5es para \nqualquer um dos problemas citados. Os investigadores dever\u00e3o, a qualquer momento, esclarecer \nminhas d\u00favidas sobre a doen\u00e7a, a utiliza\u00e7\u00e3o do material biol\u00f3gico retirado do meu organismo e os \nresultados obtidos com o estudo. Estes resultados poder\u00e3o ser divulgados na forma de comunica\u00e7\u00e3o \ncient\u00edfica, mas n\u00e3o ser\u00e1 permitida a minha identifica\u00e7\u00e3o. Autorizo, ainda, eventual armazenamento da \namostra biol\u00f3gica para utiliza\u00e7\u00e3o futura. Fui informado, tamb\u00e9m, que posso me retirar e meu \nconsentimento em qualquer fase da pesquisa sem penalidade alguma e sem preju\u00edzo ao meu \ncuidado. \n\nDeclaro estar ciente do teor deste Termo de Consentimento Livre e Esclarecido, decidindo-\nme a participar da investiga\u00e7\u00e3o proposta. Este documento ficar\u00e1 arquivado no Laborat\u00f3rio de \nImunoparasitologia do Instituto Oswaldo Cruz, FIOCRUZ, ficando Eu de posse de uma c\u00f3pia. \n\n \nVolunt\u00e1rio: __________________________________________________ \n\nAssinatura \n \nInvestigador: _____________________________________________________ \n\nAssinatura \n\n\n\n130 \n\n9.2. ANEXO 2 \n\nArtigo publicado: Cytotoxic cell involvement in human cutaneous \n\nleishmaniasis: assessments in active disease, under therapy and after \n\nclinical cure. (2016) \n\n\n\nCytotoxic cell involvement in human cutaneous leishmaniasis:\n\nassessments in active disease, under therapy and after clinical cure\n\nC. F. CUNHA,\n1\nR. FERRAZ,\n\n1,2\nM. I. F. PIMENTEL,\n\n3\nM. R. LYRA,\n\n3\nA. O. SCHUBACH,\n\n3\nA. M. DA-CRUZ\n\n4\n&amp; A. L. BERTHO\n\n1,2\n\n1\nLaboratory of Immunoparasitology, Oswaldo Cruz Institute (IOC), FIOCRUZ, Rio de Janeiro, RJ, Brazil,\n\n2\nFlow Cytometry Sorting Core,\n\nOswaldo Cruz Institute (IOC), FIOCRUZ, Rio de Janeiro, RJ, Brazil,\n3\nLaboratory of Surveillance for Leishmaniasis, Evandro Chagas\n\nNational Institute of Infectology (INI), FIOCRUZ, Rio de Janeiro, RJ, Brazil,\n4\nLaboratory of Interdisciplinary Medical Research, Oswaldo\n\nCruz Institute (IOC), FIOCRUZ, Rio de Janeiro, RJ, Brazil\n\nSUMMARY\n\nCutaneous leishmaniasis (CL) is an important public health\n\nissue worldwide. The control of Leishmania infection\n\ndepends on cellular immune mechanisms, and the inflamma-\n\ntory response may contribute to pathogenesis. A beneficial\n\nrole of CD8\n+\nT lymphocytes has been proposed; neverthe-\n\nless, other studies suggest a cytotoxic role of CD8\n+\nT lym-\n\nphocytes involved in tissue damage, showing controversial\n\nrole of these cells. The goal of the current study was to\n\nunderstand the immunopathology of CL and determine the\n\nprofile of cytotoxic cells \u2013 such as CD4\n+\nT, natural killer\n\nand natural killer T cells \u2013 that might be involved in trigger-\n\ning immunological mechanisms, and may lead to cure or dis-\n\nease progression. The frequencies of cytotoxic cell\n\npopulations in peripheral blood, obtained from patients with\n\nactive disease, during treatment and after clinical healing,\n\nwere assessed by flow cytometry. Cytotoxicity could not be\n\nrelated to a deleterious role in Leishmania braziliensis\n\ninfection, as patients with active CL showed similar percent-\n\nages of degranulation to healthy individuals (HI). Cured\n\npatients exhibited a lower percentage of degranulating cells,\n\nwhich may be due to a downregulation of the immune\n\nresponse. The understanding of the immunopathological\n\nmechanisms involved in CL and the commitment of cyto-\n\ntoxic cells enables improvements in therapeutic strategies.\n\nKeywords CD107a, cytotoxic T cells, flow cytometry, human\n\ncutaneous leishmaniasis, NK cells, NKT cells\n\nINTRODUCTION\n\nCutaneous leishmaniasis (CL) is a neglected parasitic\n\ndisease that affects humans and generates about 1?3 million\n\nnew cases worldwide annually (1). Its aetiological agent is\n\nLeishmania spp., which is transmitted by sand flies (1). In\n\nBrazil, CL is known to occur all over the country, especially\n\nin Rio de Janeiro state, where it is endemic and caused\n\nmainly by L. braziliensis. The disease presents itself with a\n\nbroad spectrum of clinical, immunological and histopatho-\n\nlogical manifestations (2), and the host immune response\n\nplays an essential role in pathogenesis, being the susceptibil-\n\nity or resistance dependent on cellular behaviour (3).\n\nThe immune response against Leishmania has been\n\nextensively studied in murine models and it has been\n\nalready demonstrated that CD4\n+\nT lymphocytes can drive\n\nthe immune response to a pro-inflammatory Th1 profile,\n\nwhich was associated with a good prognosis and progres-\n\nsion to healing; or to an anti-inflammatory Th2 profile,\n\nwhich was related to a cellular anergy and disease progres-\n\nsion (4). However, in humans this polarization is not\n\nclearly ascertained, remaining obscure mechanisms that\n\nmay contribute to an efficient immune response in patients\n\nwith CL. CD8\n+\nT lymphocytes act as cytotoxic cells and\n\ncytokine producers; nonetheless, their role in this proto-\n\nzoan infection is still controversial. CD8\n+\nT lymphocytes\n\nare associated with a cytotoxic function, nevertheless, if\n\nthey are protective, pathologic, or irrelevant to the process\n\ndepend on several factors, whose descriptions have\n\nrecently begun to emerge (5). Our group and others have\n\nshown the key role of CD8\n+\nT lymphocytes in cure and\n\nprotection in human CL (6\u201312). Regardless of that, other\n\nstudies suggest an antagonistic role, relating CD8\n+\nT-lym-\n\nphocyte performance to tissue damage and CL progression\n\n(13\u201315). It is important to notice that these studies have\n\nbeen focused on CD8\n+\nT lymphocytes, which are consid-\n\nered a classical-cytotoxic cell population and are associ-\n\nCorrespondence: Alvaro Luiz Bertho, Laboratory of Immunopara-\n\nsitology, Oswaldo Cruz Institute, IOC/FIOCRUZ, Av. Brazil,\n\n4365, Manguinhos, Pavilh\u00e3o Le\u00f4nidas Deane, sala 408-A, CEP:\n\n21040-900 Rio de Janeiro, RJ, Brazil (e-mail: alvaro.bertho@\n\nioc.fiocruz.br).\n\nReceived: 15 September 2015\n\nAccepted for publication: 23 February 2016\n\n\u00a9 2016 John Wiley &amp; Sons Ltd244\n\nParasite Immunology, 2016, 38, 244\u2013254 DOI: 10.1111/pim.12312\n\n\n\nated with the development of an antigenic-specific immune\n\nresponse. Nevertheless, other cell populations as natural\n\nkiller (NK) and natural killer T cells (NKT) are also typi-\n\ncally cytotoxic and could exert an important role in CL\n\noutcome.\n\nThe role of NK cells in CL immunity has been dis-\n\ncussed. Some studies suggest a protective role of cytotoxic\n\nNK cells on the lysis of Leishmania-infected macrophages\n\nand the elimination of extracellular promastigotes (16\u201318).\n\nHowever, there is some evidence that the NK cell-cytotoxic\n\nfunction could contribute to the exacerbation of CL lesions\n\n(13). Regarding NKT cells in CL murine models, few\n\nreports have demonstrated the role of these cells on block-\n\ning parasite expansion and also driving the immune\n\nresponse according to the cytokine milieu produced (19,\n\n20). In spite of that, the cytotoxic role of NKT cells in the\n\nimmune response in human CL has not yet been described.\n\nApart from the well-defined helper function of CD4\n+\nlym-\n\nphocytes, a novel role as cytotoxic cells for this T cell sub-\n\npopulation has emerged, along with their immunological\n\nrelevance in viral infections, tumours and in some infec-\n\ntious diseases (21). Anyhow, the involvement of cytotoxic\n\nCD4\n+\nT lymphocytes in CL has been barely demonstrated\n\n(22). Such potentially cytotoxic cell populations (CD8\n+\n\nand CD4\n+\nT lymphocytes, NK and NKT cells) share the\n\nmain cytotoxic pathway of exocytosis of preformed lytic\n\ngranules. On this perforin\u2013granzyme-mediated pathway,\n\npreformed lytic granules surrounded by lipid bilayers con-\n\ntaining LAMPs, including CD107a (LAMP-1), are fused\n\nto the plasma membrane (23). Cell surface mobilization of\n\nLAMPs indicates that degranulation has taken place and it\n\nis associated with perforin release by cells (24).\n\nThe immunopathological and protective mechanisms in\n\nLeishmania infections are challenging, as well as the deter-\n\nmination of the nature of effector cells involved in resistance\n\nand the parasite antigens targeted by this immune response.\n\nThese features impair the development of vaccines and new\n\ntherapeutic approaches (22). Thus, a more detailed under-\n\nstanding on the immunological mechanisms involved in CL\n\ncure will certainly result in an improvement in treatment\n\nschemes. For this purpose, the aim of this study was to\n\ninvestigate the cytotoxic behaviour of peripheral CD8\n+\nand\n\nCD4\n+\nT lymphocytes, NK and NKT cells from patients\n\nwith CL in different clinical stages \u2013 active disease, under\n\nantimonial treatment and recently clinically cured (CC).\n\nMATERIALS AND METHODS\n\nEthical consideration\n\nThis study is part of a project approved by Committee on\n\nEthics in Research of the Evandro Chagas National\n\nInstitute of Infectology (CEP-INI/FIOCRUZ 029/2012),\n\nRio de Janeiro, Brazil. This Committee adheres to the\n\nprinciples established in the Declaration of Helsinki on\n\nhuman subject research. All participants were volunteers,\n\nand an informed consent was obtained from them prior to\n\ncollection of the blood samples.\n\nStudy population\n\nIn this study, 14 patients with CL from the state of Rio de\n\nJaneiro, Brazil, were included and subdivided into three\n\ncohorts: (i) patients before antimonial treatment (BT),\n\nevaluated after diagnosis confirmation; (ii) patients during\n\ntreatment (DT), evaluated on the 20th day after the begin-\n\nning of antimonial therapy; and (iii) patients after the end\n\nof treatment, showing recent clinical cure (CC), corre-\n\nsponding to the 80th day after the beginning of treatment.\n\nSome patients were repeated in groups, so the number of\n\nblood samples processed was eight per group, which\n\namounts to 24 blood samples in the whole study. Healthy\n\nindividuals without previous history of CL (HI, n = 11)\n\nwere recruited from nonendemic areas for L. braziliensis\n\ninfection to be included as a reference group.\n\nCutaneous leishmaniasis was diagnosed and treated\n\naccording to the Surveillance Manual of American Cuta-\n\nneous Leishmaniasis, Brazilian Ministry of Health (25), in\n\nthe Laboratory of Surveillance in Leishmaniasis of Evandro\n\nChagas National Institute of Infectology (INI), Oswaldo\n\nCruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil. Diag-\n\nnosis of leishmaniasis was based on clinical, laboratorial and\n\nepidemiological criteria. Ulcerated cutaneous lesions were\n\nassociated with a positive Montenegro skin test and positive\n\nparasitological examinations to confirm the diagnosis.\n\nBesides, the differential diagnosis to other diseases through\n\nmycological and bacteriological tests was performed. The\n\nexclusion criteria were as follows: patients younger than 18\n\nand older than 60 years, presence of comorbidity or preg-\n\nnancy, previous treatment with anti-Leishmania drugs and\n\nrecent visit to an endemic area. Furthermore, none of the\n\npatients showed progression to mucosal or disseminated\n\nclinical forms. All patients were submitted to antimoniate-\n\nN-methyl-glucamine treatment according to the guidelines\n\nof the Brazilian Ministry of Health (25) and after treatment,\n\nall patients presented clinical cure, which was characterized\n\nby full epithelialization of ulcerated lesions, regression of\n\ncrusts, desquamation and infiltration. Basic clinical informa-\n\ntion on the studied groups is summarized in Table 1.\n\nIsolation of peripheral blood mononuclear cells\n\nHeparinized peripheral venous blood was collected from\n\npatients with CL and HI. Peripheral blood mononuclear\n\n\u00a9 2016 John Wiley &amp; Sons Ltd, Parasite Immunology, 38, 244\u2013254 245\n\nVolume 38, Number 4, April 2016 Cytotoxic cells in human cutaneous leishmaniasis\n\n\n\ncells (PBMCs) were obtained by Ficoll-Histopaque\n\n(Sigma, Saint Louis, MO, USA) density gradient centrifu-\n\ngation at 400 g, 20\u00b0C, 30 min, without brake and washed\n\nthree times in RPMI-1640 medium supplemented with\n\n10 mM HEPES, 1?5 mM L-glutamine, 0?04 mM 2-mercap-\n\ntoethanol and antibiotics (200 IU/mL penicillin and\n\n200 mg/mL streptomycin) (all from Sigma). The viability\n\nof PBMC was higher than 80% after trypan blue (Sigma)\n\nexclusion.\n\nFor cryopreservation protocol, approximately 1 9 10\n7\n\nPBMCs were suspended in 1 mL of freezing solution [90%\n\ninactivated foetal calf serum (FCS; Gibco\n?\n, Invitrogen,\n\nLife Technologies, Rockville, MD, USA) plus 10%\n\ndimethyl sulfoxide (DMSO \u2013 Sigma)] in cryotubes (Nunc\n\nA/S, Kamstrupvej, Roskilde, DNK). Afterwards, the cry-\n\notubes were placed at Mr. Frosty\nTM\n\nFreezing Container\n\n(Thermo Fisher Scientific, Waltham, MA, USA), stored\n\ninitially at ?80\u00b0C for 24 h and then transferred to racks\n\nand stored in liquid nitrogen.\n\nOn the experiment day, cells were thawed by placing\n\ncryotubes in a 37\u00b0C warm water bath for three minutes\n\nand then diluted in RPMI 1640 medium supplemented\n\nwith 20% FCS, quantified and adjusted to 1?5 9\n\n10\n6\ncells/mL to be submitted to flow cytometry staining\n\nprotocol.\n\nCD107a-degranulation marker and immunophenotyping\n\nThe frequencies of CD4\n+\n\nT, CD8\n+\n\nT, NK and NKT\n\nexpressing CD107a were determined by a five-colour flow\n\ncytometry staining protocol, as follows. Anti-CD107a\n\n(BD Biosciences, San Jose, CA, USA) was added to\n\n200 lL of RPMI 1640 medium supplemented with 20%\n\nFCS containing the thawed PBMC suspension\n\n(3?0 9 10\n5\ncells/well). The solution was incubated for one\n\nhour at 37\u00b0C in 5% CO2. After that, six lg/mL of BD\n\nGolgiStop containing monensin (BD Biosciences) was\n\nadded and then again incubated for additional five\n\nhours, based on a protocol described elsewhere (26).\n\nMonensin prevents the acidification of endocytic vesicles\n\nby avoiding degradation of re-internalized CD107a pro-\n\nteins from the cell surface. As positive control, PBMCs\n\nwith anti-CD107a were stimulated with phorbol-12-myris-\n\ntate-13-acetate (PMA, 10 ng/mL) plus ionomycin\n\n(500 ng/mL) (both from Sigma). After six hours of incu-\n\nbation, cells were washed and stained with anti-CD3,\n\nanti-CD4, anti-CD8 and anti-CD56 monoclonal antibod-\n\nies (BD Biosciences; and Beckman Coulter, Brea, CA,\n\nUSA). They were incubated for 30 min at 4\u00b0C, in the\n\ndark. Then, cells were washed, fixed in 1% paraformalde-\n\nhyde (Sigma) and acquired in flow cytometer within\n\n24 h.\n\nFlow cytometry\n\nAt least 50 000 events were acquired per sample using\n\nMoFlo Astrios (Beckman Coulter) and BD FACSAria II\n\n(BD Biosciences) flow cytometers. Single stained controls\n\nwere used to set compensation parameters, and fluores-\n\ncence-minus-one (FMO) and isotype-matched Ab controls\n\nwere used to set analysis gates.\n\nAfter acquisition, frequencies of CD8\n+\nT lymphocytes,\n\nCD4\n+\n\nT lymphocytes, NK cells and NKT cells express-\n\ning CD107a were analysed through a 7-parameter flow\n\ncytometric protocol created with Kaluza Software v1?2\n\n(Beckman Coulter). As gate strategy, a region based on\n\nforward- (FSC) and side-scatter (SSC) profiles was estab-\n\nlished. Next, cells were gated on singlets regions in two\n\ndot-plots created to exclude cell aggregates from analy-\n\nses: FSC-H vs. FSC-A and FSC-A vs. FSC-W. After\n\nthat, cell populations of interest were set as follows:\n\nCD8\n+\nT lymphocytes: CD3\n\n+\nCD8\n\n+\nCD56\n\nneg\n; CD4\n\n+\nT lym-\n\nphocytes: CD3\n+\nCD4\n\n+\nCD56\n\nneg\n; NK cells: CD3\n\nneg\nCD56\n\n+\n;\n\nand NKT cells: CD3\n+\nCD56\n\n+\n. Furthermore, the NK cell\n\nTable 1 Clinical and laboratorial characteristics of groups included in the study\n\nClinical and laboratorial characteristics\n\nCutaneous leishmaniasis patients\n\nBT DT CC HI\n\nNumber of volunteers (n) 8 8 8 11\n\nSex (M/F) 7/1 3/5 2/6 2/9\n\nAge\na\n(years) 46?6 ? 16?7 35?6 ? 15?4 41?7 ? 17?1 31?9 ? 11?8\n\nNumber of lesions\na\n\n2?1 ? 2?1 1?3 ? 0?7 1?7 ? 2?1 NA\n\nMontenegro skin test (mm)\na\n\n11?0 ? 0?8 10?5 ? 1?3 10?6 ? 1?0 NA\n\nDuration of disease (months)\na\n\n3?6 ? 2?1 3?3 ? 1?5 3?2 ? 1?5 NA\n\nNA, not applicable; BT, before treatment; DT, during treatment; CC, clinically cured; HI, healthy individuals.\na\nMean ? standard deviation.\n\n246 \u00a9 2016 John Wiley &amp; Sons Ltd, Parasite Immunology, 38, 244\u2013254\n\nC. F. Cunha et al. Parasite Immunology\n\n\n\nsubsets and CD8\n+\nT lymphocytes were determined based\n\non the density of CD56 and CD8 expressions, respec-\n\ntively, and also NKT subsets were assessed by their CD4\n\nand/or CD8 expressions. The cells in degranulation pro-\n\ncess were defined based on surface CD107a expression\n\n(Figure 1).\n\n(a) (b) (c)\n\n(d) (e) (f)\n\n(g) (h) (i)\n\nFigure 1 Flow cytometry-representative protocol to determine the frequencies of CD3\n+\nT-lymphocyte subsets, natural killer (NK) cells,\n\nnatural killer T cells (NKT) subsets and expression of CD107a. Peripheral blood mononuclear cells were stained with anti-CD3, anti-CD4,\n\nanti-CD8, anti-CD56 and anti-CD107a. \u2018Lymphocytes\u2019 region were created on forward (FSC) vs. side-scatter (SSC) dot-plot (a). Then, the\n\ncells gated on \u2018Lymphocytes\u2019 region were analysed through dot-plots FSC-H vs. FSC-A (b) and FSC-A vs. FSC-W (c) to exclude cell\n\naggregates and debris. CD8\n+\nand CD4\n\n+\nT-lymphocyte populations were defined using CD8 vs. CD3 (e) and CD4 vs. CD3 (f) dot-plots\n\ngated on CD56\nneg\n\ncells defined on a FSC vs. CD56 dot-plot (d), respectively. NK and NKT cell populations were defined through CD56\n\nvs. CD3 dot-plot (g). CD8\n+\nand CD4\n\n+\nNKT subsets were defined based on CD8 vs. CD4 dot-plot gated on NKT cells (h). CD107a\n\nexpression was analysed on a FSC vs. CD107a dot-plots, gated on each defined cell population \u2013 represented here for NK cells (i).\n\n\u00a9 2016 John Wiley &amp; Sons Ltd, Parasite Immunology, 38, 244\u2013254 247\n\nVolume 38, Number 4, April 2016 Cytotoxic cells in human cutaneous leishmaniasis\n\n\n\nStatistical analysis\n\nFor comparison between each two groups, Mann\u2013Whitney\n\nU-test was used for unpaired observations. A probability\n\nlevel of P &lt;0?05 was considered statistically significant.\n\nStatistical analysis was performed with GRAPHPAD PRISM\n\nversion 5.01 for Windows (GraphPad Prism 5 Software,\n\nSan Diego, CA, USA).\n\nRESULTS\n\nFrequencies of CD8\n+\nT, CD4\n\n+\nT and NK cells are\n\naltered by Leishmania infection\n\nTo demonstrate the CD8\n+\nT, CD4\n\n+\nT, NK and NKT cel-\n\nlular profiles during an immunological response, we com-\n\npared the percentage of these cells from peripheral blood\n\nof patients BT, DT and CC, along with samples from HI.\n\nOur data showed that CC patients demonstrated high fre-\n\nquency of CD8\n+\n\nT lymphocytes (median ? interquartile\n\nrange: 30?7 ? 9?6), which was significant when compared\n\nto HI (24?9 ?8?6, P &lt;0?05), as well as to BT (24?2 ? 10?3,\n\nP &lt;0?05) and DT (25?6 ? 4?8, P &lt;0?05) patients\n\n(Figure 2a). BT patients exhibited lower frequencies of\n\nCD4\n+\n\nT lymphocytes (41?6 ? 19?9) in comparison with\n\nHI (50?9 ? 8?8, P &lt;0?01). The frequency of CD4\n+\nT lym-\n\nphocytes increases with treatment (DT: 44?7 ? 17?4) and\n\nCC (43?5 ? 33?3) (Figure 2b). All groups of patients with\n\nCL presented significant higher frequencies of NK cells\n\n(BT: 9?9 ? 8?8; DT: 8?0 ? 12?0; CC: 8?2 ? 7?8) than HI\n\n(3?4 ? 4?1) (P &lt;0?01, P &lt;0?05 and P &lt;0?01, respectively)\n\n(Figure 2c). Regarding NKT cells, there were no differ-\n\nences in frequencies among the studied groups (data not\n\nshown).\n\nCells from cured CL patients showed the lowest\n\nfrequencies of CD107a-cytotoxic marker expression\n\nCD107a expression analysis of T, NK and NKT cells was\n\nperformed to check their degranulation in samples from\n\nCL patients and HI. Degranulation analysis was con-\n\nducted by comparing the percentage of CD107a expres-\n\nsion in all groups of patients with CL and healthy\n\nsubjects, which is shown in Figure 3. We observed that\n\nCC patients presented lower frequencies of CD107a\n+\nCD8\n\n+\n\nT lymphocytes (median ? interquartile range: 1?1 ? 0?8),\n\ncompared with HI (2?8 ? 2?0, P &lt;0?01), BT (2?1 ? 3?5,\n\nP &lt;0?05) and DT patients (1?8 ? 3?7, P &lt;0?05) (Fig-\n\nure 3a). Clinically cured patients showed lower frequencies\n\nof CD107a\n+\nCD4\n\n+\nT lymphocytes (0?7 ? 0?9) in relation\n\nto DT patients (2?1 ? 1?5, P &lt;0?05) (Figure 3b). Natural\n\nkiller cells displayed low expression of CD107a in all CL\n\ngroups (BT: 3?5 ? 8?6, P &lt;0?05; DT: 5?8 ? 8?4, P &lt;0?05;\n\nCC: 3?8 ? 4?8, P &lt;0?01), in comparison with HI\n\n(12?8 ? 15?7) (Figure 3c). Among the CL groups, CC\n\npatients showed low frequencies of CD107a\n+\nNK cells and\n\nit was significant when correlated to DT patients\n\n(P &lt;0?05) (Figure 3c). Clinically cured patients also\n\nexhibited low percentages of CD107a expression by NKT\n\ncells (2?4 ? 3?1), which was significantly lower than DT\n\npatients (6?4 ? 10?0, P &lt;0?01) (Figure 3d).\n\nTo determine which cell population would be more rele-\n\nvant to cytotoxicity in clinical phases of CL, we performed\n\nanother flow cytometry approach, aiming to assess the dis-\n\ntribution of each cell population gated on all CD107a-\n\nexpressing cells. In every group, we could observe that\n\nCD4\n+\nT lymphocytes represent the largest cell population\n\nexpressing CD107a, followed by CD8\n+\nT lymphocytes and\n\nNK cells, and NKT cells in a smaller proportion (Fig-\n\nure 4).\n\nThe CD8\ndim\n\nT-lymphocyte subset displays a cytotoxic\n\nphenotype\n\nAdditionally to the global definition of CD8\n+\nT lympho-\n\ncytes, we also determined the frequencies of CD8\nbright\n\nand\n\nCD8\ndim\n\nT cells in the blood of patients with CL in an\n\nattempt to define whether the profile of CD8 expression\n\ncould be related to the clinical phase of the disease. We\n\nobserved that the majority of CD8\n+\n\nT lymphocytes in\n\nperipheral blood from all CL patients and HI were\n\nCD8\nbright\n\n. However, when we analysed the frequencies of\n\nCD107a\n+\nCD8\n\n+\nT lymphocytes, about 70% of these cells\n\nshowed the CD8\ndim\n\nphenotype in all subjects, both in CL\n\npatients and HI. Such differences on CD8 expression were\n\nextremely significant (P&lt;0?001) (data not shown).\n\nThe majority of circulating NK cells are CD56\ndim\n\nand\n\nshows a cytotoxic profile\n\nWe analysed CD56 expression in NK cells obtained from\n\nCL patients and HI to ascertain a profile of the expression\n\nof CD56, correlating with the clinical phase of disease.\n\nCorroborating other reports, we observed that more than\n\n95% of NK and CD107a\n+\nNK cells from both HI and CL\n\npatients presented a CD56\ndim\n\nphenotype (data not\n\nshown).\n\nPatients with active disease have lower frequencies of\n\nCD4\n+\nCD8\n\n+\nNKT cells\n\nWe also analysed the subsets of NKT cells based on their\n\nexpressions of CD4 and CD8 molecules. Our results\n\nclearly showed that about half of the sum of circulating\n\n248 \u00a9 2016 John Wiley &amp; Sons Ltd, Parasite Immunology, 38, 244\u2013254\n\nC. F. Cunha et al. Parasite Immunology\n\n\n\nNKT cells from the entirety of groups studied was from\n\nthe CD8\n+\nNKT subset. Moreover, all groups showed inter-\n\nmediate proportions of CD4\n+\nand CD4\n\nneg\nCD8\n\nneg\n(double\n\nnegative \u2013 DN) NKT subsets and lower frequencies of\n\nCD4\n+\nCD8\n\n+\n(double positive \u2013 DP) NKT subset (Fig-\n\nure 5a). Even though DP NKT subset was detected in\n\nsmall amounts in each group, there were differences\n\namong them. Before treatment patients presented signifi-\n\ncant lower DP NKT cells percentage (mean ? SEM:\n\n1?2 ? 0?5%), compared with HI (6?6 ? 1?9%; P &lt;0?05), as\n\nwell as to other patient groups (DT: 5?1 ? 1?7, P &lt;0?05;\n\nCC: 3?9 ? 1?1, P &lt;0?05) (Figure 5c). We also observed\n\ndifferences in DN NKT frequencies, which were signifi-\n\ncantly higher in CC patients (21?3 ? 4?0%), in comparison\n\n(a)\n\n(c)\n\n(b)\n\nFigure 2 Scatter plots of cell population\n\nfrequencies. (a) Total CD8\n+\nT lymphocytes;\n\n(b) CD4\n+\nT lymphocytes; and (c) natural\n\nkiller cells. HI, healthy individuals (n = 11);\n\nBT, before treatment patients (n = 8); DT,\n\nduring treatment patients (n = 8); CC,\n\nclinically cured patients (n = 8). The data\n\nare represented by median ? interquartile\n\nrange. Each dot represents one subject.\n\nStatistical comparisons were performed with\n\nthe Mann\u2013Whitney U-test. *P &lt;0?05,\n\n**P &lt;0?01\n\n(a) (b)\n\n(c) (d)\n\nFigure 3 Scatter plots of CD107a expression\n\nby (a) CD8\n+\nT lymphocytes; (b) CD4\n\n+\nT\n\nlymphocytes; (c) natural killer cells; and (d)\n\nnatural killer T cells. HI, healthy individuals\n\n(n = 11); BT, before treatment patients\n\n(n = 8); DT, during treatment patients\n\n(n = 8); CC, clinically cured patients (n = 8).\n\nThe data are represented by\n\nmedian ? interquartile range. Each dot\n\nrepresents one subject. Statistical\n\ncomparisons were performed with the\n\nMann\u2013Whitney U-test. *P &lt;0.05,\n\n**P &lt;0?01\n\n\u00a9 2016 John Wiley &amp; Sons Ltd, Parasite Immunology, 38, 244\u2013254 249\n\nVolume 38, Number 4, April 2016 Cytotoxic cells in human cutaneous leishmaniasis\n\n\n\nto HI (12?8 ? 5?4%; P &lt;0?05) (Figure 5d). CD8\n+\n\nand\n\nCD4\n+\n\nsingle-positive NKT subsets have similar percent-\n\nages through the studied groups.\n\nWe also evaluated the frequencies of CD107a\n+\n\nNKT\n\nsubsets and it varied widely among all subjects. Regardless\n\nof the high frequencies of the CD107a\n+\nCD8\n\n+\nNKT subset\n\npresented by HI and patients before and during treatment,\n\nCC patients showed the highest frequency of the\n\nCD107a\n+\nCD4\n\n+\nNKT and CD107a\n\n+\nDN NKT subsets\n\n(Figure 5b). Concerning variations of CD107a-expressing\n\nNKT subsets, it is possible to highlight the lower fre-\n\nquency of CD107a\n+\nCD8\n\n+\nNKT subset in CC patients,\n\nrelated to DT patients (Figure 5e); also, there was a higher\n\nfrequency of CD107a\n+\n\nDN NKT in DT patients (Fig-\n\nure 5f) and a lower frequency of CD107a\n+\nDP NKT in\n\nCC patients, both correlated to HI (Figure 5g).\n\nDISCUSSION\n\nThe immunopathogenesis of human CL is still not com-\n\npletely understood and there are some controversial\n\naspects, which need to be elucidated. Disease outcome\n\ndepends on both the parasite specie and the immune\n\nresponse developed by patient (27). In this context, it is\n\nknown that patients infected by L. braziliensis exhibit a\n\nTh1 immune response, leading to resolution of the lesions,\n\nor to an exaggerated inflammatory response that produces\n\ntissue damage (28). Thus, these dichotomy patterns of the\n\nimmune response may guide to cure or disease progres-\n\nsion, with an imperative participation of specific activated\n\nT lymphocytes (29). Even so, the role of these cells\n\nremains paradoxical, once they can either protect from\n\ndisease or contribute to aggravation (5). The understand-\n\ning of the immunopathological mechanisms and the\n\ninvolvement of each cell population in immune response is\n\nessential for the development of therapeutic and vaccine\n\nstrategies.\n\nIn human CL, CD8\n+\nT lymphocytes activate and prolif-\n\nerate in response to Leishmania-antigenic presentation,\n\nframing a population of specific T cells able to assemble\n\nan immune response against the parasite (6). Hence, the\n\ncritical question is what role CD8\n+\n\nT lymphocytes play\n\nafter their activation. Our group and others have reported\n\nthe increase in CD8\n+\n\nT-lymphocyte frequencies in cured\n\npatients, suggesting the beneficial participation of these\n\ncells on immune response against Leishmania. These cells\n\nwould also exert direct cytotoxic effects over infected\n\nmacrophages, possibly along with regulatory effects (6\u20138,\n\n30, 31). In the present study, we observed high frequencies\n\nof CD8\n+\nT lymphocytes in cured patients, in comparison\n\nwith patients with active disease, patients under treatment\n\nand HI, and this corroborates the statements above.\n\nDespite the high frequency of CD8\n+\n\nT lymphocytes\n\nnoticed in cured patients, the cytotoxic activity was lower\n\nin this group.\n\nSome studies attribute a deleterious cytotoxic role to\n\nCD8\n+\n\nT lymphocytes in human CL, especially in\n\nL. braziliensis infection. CD8\n+\n\nT cells isolated from the\n\nskin of patients with CL exhibit markers of granule-depen-\n\ndent cytotoxicity and the frequency of granzyme A\n+\nCD8\n\n+\n\nT cells was higher in patients with larger skin ulcers than\n\nin those with nodular lesions (14). A wide transcriptional\n\ngenome analysis comparing cutaneous lesions from\n\nL. braziliensis patients with normal skin also points to\n\ncytotoxicity as the hallmark of the disease (32). In addi-\n\ntion, transcriptional profiling correlating lesions from\n\nL. braziliensis-infected patients with CL and mucosal leish-\n\nmaniasis (ML) showed greater mRNA levels for cytolytic\n\nmarkers in mucosal milieu (33). Furthermore, it was\n\ndemonstrated that cytotoxic CD8\n+\n\nT lymphocytes\n\nobtained from lesions express CD107a (15, 32). Taken\n\ntogether, these observations suggest that the cytolytic\n\nactivity of CD8\n+\nT lymphocytes promotes disease progres-\n\nsion. Nevertheless, according to our results, CD8\n+\nT lym-\n\nphocyte-mediated cytotoxicity may not be related to tissue\n\ndamage, as the percentage of CD107a\n+\nCD8\n\n+\nT lympho-\n\ncytes of patients with active leishmaniasis were similar to\n\nHI, at least in peripheral blood pool. An interesting issue\n\nof discussion relates to the phenotypic evaluation\n\n(a) (b)\n\n(c) (d)\n\nFigure 4 Distribution of CD8\n+\nT lymphocytes, CD4\n\n+\nT\n\nlymphocytes, natural killer cells and natural killer T cells gated on\n\nCD107a\n+\ncells. The pie graphs show the mean of data observed\n\nin: (a) HI (healthy individuals \u2013 n = 11); (b) BT (before treatment\n\npatients \u2013 n = 8); (c) DT (during treatment patients \u2013 n = 8); and\n\n(d) CC (clinically cured patients \u2013 n = 8).\n\n250 \u00a9 2016 John Wiley &amp; Sons Ltd, Parasite Immunology, 38, 244\u2013254\n\nC. F. Cunha et al. Parasite Immunology\n\n\n\nstrategies, as some studies defined the population of CD8\n+\n\nT lymphocytes using CD3 and CD8 biomarkers, without\n\nNKT exclusion. In this study, we excluded the CD56\n+\ncells\n\nfrom CD8\n+\nT-lymphocyte gate, to avoid a mistaken analy-\n\nsis due to the presence of NKT cells on it. According to\n\nthis, our group also observed that CD8\n+\nT lymphocytes\n\ndo not seem to be responsible for the tissue destruction\n\nobserved in CL lesions caused by L. braziliensis. This\n\nstudy showed that in a leishmanial-lesion microenviron-\n\nment, the highest expression of CD107a was detected in\n\nNKT cells, when compared to other cytotoxic cell popula-\n\ntions. CD8\n+\nT lymphocytes were the less committed cyto-\n\ntoxic population, showing the lowest CD107a expression.\n\nIn the same study, we also observed a positive correlation\n\nbetween the frequency of cytotoxic-CD107a\n+\ncells and the\n\nproduction of granzyme B on the lesion site (Ferraz et al.,\n\npersonal communication).\n\nRegarding the low frequencies of cytotoxic cell popula-\n\ntions observed in CC patients, other authors have\n\ndescribed a lower activity of CD8\n+\n\nT lymphocytes after\n\ntherapy, as detected by the decrease in anti-Leishmania\n\nIFN-c levels in cured CL and ML patients (34). In this\n\ncontext, Ferraz et al. (12) demonstrated low frequencies of\n\ncirculating effector CD8\n+\n\nT lymphocytes in CC CL\n\npatients. Additionally, these CL cured patients exhibited\n\nhigher frequencies of memory CD8\n+\nT lymphocytes com-\n\npared with patients with active disease or during treat-\n\nment, as observed by Ferraz et al. (personal\n\ncommunication). Hence, the low frequency of\n\nCD107a\n+\nCD8\n\n+\nT lymphocytes detected in cured patients\n\n(a)\n\n(b)\n\n(c) (d)\n\n(e) (f) (g)\n\nFigure 5 Analysis of frequency and CD107a expression of natural killer T cells subsets. The pie graphs show the mean of data observed in\n\nHI, BT, DT and CC: (a) frequency; (b) CD107a expression. The bar graphs represent mean ? SEM of the comparison between groups: (c)\n\nfrequency of DP NKT subset; (d) frequency of DN NKT subset; (e) frequency of CD107a\n+\nCD8\n\n+\nNKT subset; (f) frequency of CD107a\n\n+\n\nDN NKT subset; and (g) frequency of CD107a\n+\nDP NKT subset. HI, healthy individuals (n = 11); BT, before treatment patients (n = 8);\n\nDT, during treatment patients (n = 8); CC, clinically cured patients (n = 8). Statistical comparisons were performed with the Mann\u2013\n\nWhitney U-test. *P &lt;0?05.\n\n\u00a9 2016 John Wiley &amp; Sons Ltd, Parasite Immunology, 38, 244\u2013254 251\n\nVolume 38, Number 4, April 2016 Cytotoxic cells in human cutaneous leishmaniasis\n\n\n\nseems to be a consequence of differentiation into memory\n\nCD8\n+\nT cells.\n\nCD8 marker is not expressed on the surface of human\n\nperipheral blood T cells in a homogeneous way. CD8\n+\nT\n\nlymphocytes can be gathered based on the level of CD8\n\nexpression in CD8\nbright\n\nand CD8\ndim\n\ncells. CD8\ndim\n\nT subset\n\nrepresents activated-effector CD8\n+\nT cells, while CD8\n\nbright\n\nT subset is the mostly found CD8\n+\nT lymphocytes in cir-\n\nculation, and has been reported to have a regulatory func-\n\ntion (35). In accordance with these published data, our\n\nfindings showed a predominance of circulating CD8\nbright\n\nT lymphocytes and that CD8\ndim\n\nT cells were the most\n\ncytotoxicity-committed subset. As previously reported,\n\nother authors described abundant perforin and granzyme\n\nB in CD8\ndim\n\nT lymphocytes, which may indicate their role\n\nas cytotoxic/effector T cells (35). It has been discussed that\n\ncirculating CD8\ndim\n\nT lymphocytes may rapidly perform\n\ntheir effector functions after antigen recognition. Thus, the\n\npresence of these cells could reflect a continuous state of\n\nlow-level-antigenic stimulation. However, our results do\n\nnot show differences in frequencies of CD8\ndim\n\nor CD8\nbright\n\nT cells between patients with CL and HI.\n\nThe paucity of knowledge regarding cytotoxicity phe-\n\nnomena in CL immunopathogenesis led us to investigate\n\nwhich cell populations were able to perform this function,\n\nbesides CD8\n+\n\nT lymphocytes. Reports refer to NK and\n\nNKT cells, as well as to CD4\n+\nT lymphocytes, being able\n\nto play the cytotoxic function through granule exocytosis\n\npathway and probably being involved in pathological and\n\nprotective mechanisms in CL (27). CD4\n+\nT lymphocytes\n\nare known to play a key role in CL by driving the immune\n\nresponse according to the milieu of cytokines they produce,\n\nalong with the cytotoxic function of CD4\n+\nT cells that have\n\nbeen already described (21). The role of cytotoxic CD4\n+\nT\n\nlymphocytes in CL is still unclear, and a recent study\n\ndemonstrated a cytotoxic activity by these lymphocytes in\n\npatients infected with L. major (22). In our results, the fre-\n\nquencies of CD4\n+\n\nT lymphocytes are impaired in active\n\ndisease, being predisposed to reestablishment with therapy\n\nand recovery to normal levels after cure, which suggests\n\nthat these cells would take part in the CL healing process.\n\nWe observed substantial frequencies of CD107a\n+\nCD4\n\n+\nT\n\nlymphocytes in all studied subjects. Cured patients exhibit\n\nlower percentages of CD107a\n+\n\nexpression by these cells,\n\ndespite the high frequency of total CD4\n+\nT lymphocytes\n\nthat were observed in this group.\n\nNatural killer cells are activated at the beginning of CL\n\ninfection, but whether their cytotoxic role is beneficial or\n\ndeleterious is not well known (36). Some reports suggest\n\nthat NK cell-mediated cytotoxicity acts in host defence,\n\nwhich has been demonstrated in studies about interaction\n\nbetween human NK cells and L. major promastigotes (18).\n\nLikewise, susceptibility of L. major to granulysin (16) and\n\nkilling of promastigotes by human-activated NK cells (17,\n\n18) have been evidenced. However, other authors propose\n\nthat NK cell-mediated cytotoxicity contributes to tissue\n\ndamage (13). We observed that the frequency of NK cells\n\nin patients with active disease was much higher than in HI,\n\ncorroborating previous data (37). Moreover, the frequency\n\nof NK cells remains high during treatment, as well as after\n\nclinical cure. Interestingly, we observed low frequencies of\n\nCD107a\n+\nNK cells in all patients with CL, which are in\n\nfact lower than in HI. Still, the percentage of CD107a\n\nexpression by NK cells was low in cured patients. This\n\nfinding confirms previous studies that showed the suppres-\n\nsion of NK cell activity during leishmaniasis. Some factors\n\nmay contribute to this low activity, such as the action of\n\ncytokines, mainly TGF-b and IL-10 (38, 39). Additionally,\n\nthe parasite could contribute to the inhibition of prolifera-\n\ntion, cytotoxicity and IFN-c production by human NK\n\ncells during infection (18). Despite the apparent suppres-\n\nsion of NK cell activity in CL, our results showed that NK\n\ncells are a population firmly committed to cytotoxicity.\n\nHuman NK cells are generally divided into two subsets\n\nbased on the relative surface density of CD56 antigen:\n\nCD56\nbright\n\nNK cells, predominant in secondary lymphoid\n\ntissues, and CD56\ndim\n\nNK cells, predominant in peripheral\n\nblood (40). It is commonly accepted that CD56\nbright\n\nNK\n\ncells are the main source of cytokine production, while\n\nCD56\ndim\n\nare mostly responsible for cytotoxic activity and\n\nkilling of targeted cells (40, 41). Our results are in agree-\n\nment with that, since over 95% of the circulating NK cells\n\nshowed the CD56\ndim\n\nphenotype in all studied individuals.\n\nWhen we assessed cell degranulation, we could observe that\n\nmost of the CD107a\n+\nNK cells presented the CD56\n\ndim\nphe-\n\nnotype, strengthening the commitment of this subset with\n\ncytotoxic function. Such NK subset dichotomy was not\n\nrelated to the presence of disease, demonstrating the con-\n\nstancy of these subsets.\n\nStudies on the distribution and function of NKT cells\n\nin CL are scarce and mostly focused on the role of NKT\n\ncells as producer of cytokines, leading to an inflammatory\n\nresponse type I or II through their interaction with den-\n\ndritic cells (20, 42). In our study, there were no differences\n\nin NKT cells frequency among the groups of patients and\n\nHI. Nonetheless, the frequency of CD107a\n+\n\nNKT cells\n\nvaried widely between the studied subjects and CC\n\npatients presented the lowest percentages of CD107a\n+\n\nNKT cells. Human NKT cells differ from one another\n\nbased on their expression of CD8 and CD4 molecules and\n\nare commonly subdivided into CD8\n+\n, CD4\n\n+\nor DN NKT\n\n(43). Apart from these, some authors reported a subset\n\nwith DP phenotype (44\u201346), which was also observed in\n\nour study. We detected high frequencies of CD8\n+\n\nNKT\n\n252 \u00a9 2016 John Wiley &amp; Sons Ltd, Parasite Immunology, 38, 244\u2013254\n\nC. F. Cunha et al. Parasite Immunology\n\n\n\ncells and low frequencies of DP NKT cells in both\n\npatients with CL and HI. Despite the quite variable distri-\n\nbution of NKT cell subsets, other authors also observed\n\nhigh frequencies of CD8\n+\n\nNKT subsets in HI and in\n\npatients with other diseases (47, 48). We found that the\n\nCD8\n+\nNKT cells are the main subset involved in cytotoxi-\n\ncity and this also corroborates data previously described\n\n(45), except for cured patients. A recent study about NKT\n\ncells in visceral leishmaniasis (VL) showed that patients\n\nwith active disease had lower frequencies of CD4\n+\nNKT\n\nand CD8\n+\nNKT subsets, compared with HI. After the end\n\nof therapy, patients with VL kept low frequency of CD4\n+\n\nNKT subset, while the CD8\n+\nNKT subset levels returned\n\nto normal, thereby associating CD8\n+\nNKT subset with a\n\nprotective role in VL (49). We observed a lower frequency\n\nof DP NKT cells in patients with active disease, which\n\nwas re-established to healthy subject\u2019s levels with therapy\n\nand after healing, suggesting a protective role of this sub-\n\nset in CL.\n\nFinally, our study provides new insights and strong evi-\n\ndence regarding the involvement of CD8\n+\nT and CD4\n\n+\nT\n\nlymphocytes, NK cells and NKT cells in the cytotoxic\n\nresponse to CL. Cytotoxicity could not be linked to a\n\ndeleterious role in L. braziliensis infection, as patients with\n\nactive CL showed similar or lower levels of degranulation,\n\nin comparison with HI. Still, cured patients showed low\n\npercentages of CD107a expression by the studied cell pop-\n\nulations. Such low cytotoxic activity could be related to a\n\nrecovery of the immune system to a resting state and/or to\n\ndifferentiation of some cell populations, probably into\n\nmemory cells. We would like to emphasize the involvement\n\nof different NKT subsets in CL healing process and the\n\npresence of cytotoxic CD4\n+\n\nT lymphocytes. These cell\n\npopulations deserve further consideration during Leishma-\n\nnia infection, to figure out whether they are actually\n\ninvolved in the promotion or protection of CL.\n\nAUTHORS\u2019 CONTRIBUTIONS\n\nCunha, CF performed most of the experiments; designed\n\nthe research study; analysed the data; and wrote the manu-\n\nscript. Ferraz, R helped perform some experiments and\n\nperformed flow cytometry acquisitions. Da-Cruz, AM con-\n\ntributed with scientific discussion and reviewed manu-\n\nscript. Pimentel, MIF; Lyra, MR; and Schubach, AO\n\nfollowed the patients, helped in parasite isolation, collected\n\nthe patient\u2019s blood smears and were in charge of evalua-\n\ntion of clinical aspects of the study. Bertho AL designed\n\nthe research study; helped perform Flow Cytometry analy-\n\nsis; wrote and reviewed the manuscript; obtained the\n\ngrant; and coordinated the research.\n\nACKNOWLEDGEMENTS\n\nThe authors would like to thank Alessandro Marins dos\n\nSantos of the Flow Cytometry Sorting Core, Oswaldo\n\nCruz Institute, FIOCRUZ (MoFlo ASTRIOS) and Iris\n\nPeixoto Alvim of Platform of Flow Cytometry, PDTIS-\n\nFIOCRUZ (FACSARIA II) for flow cytometry acquisi-\n\ntions. This research was supported in part by an internal\n\nfunding from IOC-FIOCRUZ and PROEP-CNPq-IOC\n\n(402557/2011-5); FAPERJ APQ1 E-26/110332/2014.\n\nCFC and RF had a fellowship from CNPq and CAPES,\n\nrespectively.\n\nDISCLOSURE\n\nNone.\n\nREFERENCES\n\n1 WHO|Leishmaniasis [Internet]. WHO. [cited\n\n2015 Mar 25]. Available from: http://\n\nwww.who.int/mediacentre/factsheets/fs375/en/.\n\n2 De Oliveira-Neto MP, Mattos MS, Perez\n\nMA, et al. American tegumentary leishmani-\n\nasis (ATL) in Rio de Janeiro State, Brazil:\n\nmain clinical and epidemiologic characteris-\n\ntics. Int J Dermatol 2000; 39: 506\u2013514.\n\n3 Brelaz-de-Castro MCA, de Almeida AF, de\n\nOliveira AP, de Assis-Souza M, da Rocha\n\nLF &amp; Pereira VRA. Cellular immune\n\nresponse evaluation of cutaneous leishmania-\n\nsis patient cells stimulated with Leishmania\n\n(Viannia) braziliensis antigenic fractions\n\nbefore and after clinical cure. Cell Immunol\n\n2012; 279: 180\u2013186.\n\n4 Kaye P &amp; Scott P. Leishmaniasis: complexity\n\nat the host-pathogen interface. Nat Rev\n\nMicrobiol 2011; 9: 604\u2013615.\n\n5 Novais FO &amp; Scott P. CD8(+) T cells in\n\ncutaneous leishmaniasis: the good, the bad,\n\nand the ugly. Semin Immunopathol 2015; 37:\n\n251\u2013259.\n\n6 Da-Cruz AM, Conceic?~ao-Silva F, Bertho AL\n\n&amp; Coutinho SG. Leishmania-reactive CD4\n+\n\nand CD8\n+\n\nT cells associated with cure of\n\nhuman cutaneous leishmaniasis. Infect\n\nImmun 1994; 62: 2614\u20132618.\n\n7 Da-Cruz AM, Bittar R, Mattos M, et al. T-\n\ncell-mediated immune responses in patients\n\nwith cutaneous or mucosal leishmaniasis:\n\nlong-term evaluation after therapy. Clin\n\nDiagn Lab Immunol 2002; 9: 251\u2013256.\n\n8 Da-Cruz AM, Bertho AL, Oliveira-Neto\n\nMP &amp; Coutinho SG. Flow cytometric analy-\n\nsis of cellular infiltrate from American tegu-\n\nmentary leishmaniasis lesions. Br J Dermatol\n\n2005; 153: 537\u2013543.\n\n9 Coutinho SG, Da-Cruz AM, Bertho AL,\n\nSantiago MA &amp; De-Luca P. Immunologic\n\npatterns associated with cure in human\n\nAmerican cutaneous leishmaniasis. Braz J\n\nMed Biol Res 1998; 31: 139\u2013142.\n\n10 Bittar RC, Nogueira RS, Vieira-Gonc?alves\n\nR, et al. T-cell responses associated with\n\nresistance to Leishmania infection in individ-\n\nuals from endemic areas for Leishmania\n\n(Viannia) braziliensis. Mem Inst Oswaldo\n\nCruz 2007; 102: 625\u2013630.\n\n11 Bertho AL, Santiago MA, Da-Cruz AM &amp;\n\nCoutinho SG. Detection of early apoptosis\n\nand cell death in T CD4\n+\n\nand CD8\n+\n\ncells\n\nfrom lesions of patients with localized cuta-\n\nneous leishmaniasis. Braz J Med Biol Res\n\n2000; 33: 317\u2013325.\n\n12 Ferraz R, Cunha CF, Gomes-Silva A, et al.\n\nApoptosis and frequency of total and effec-\n\n\u00a9 2016 John Wiley &amp; Sons Ltd, Parasite Immunology, 38, 244\u2013254 253\n\nVolume 38, Number 4, April 2016 Cytotoxic cells in human cutaneous leishmaniasis\n\n\n\ntor CD8\n+\n\nT lymphocytes from cutaneous\n\nleishmaniasis patients during antimonial\n\ntherapy. BMC Infect Dis 2015; 15: 74.\n\n13 Machado P, Kanitakis J, Almeida R, Chalon\n\nA, Ara?ujo C &amp; Carvalho EM. Evidence of\n\nin situ cytotoxicity in American cutaneous\n\nleishmaniasis. Eur J Dermatol 2002; 12: 449\u2013\n\n451.\n\n14 Faria DR, Souza PEA, Dur~aes FV, et al.\n\nRecruitment of CD8(+) T cells expressing\n\ngranzyme A is associated with lesion pro-\n\ngression in human cutaneous leishmaniasis.\n\nParasite Immunol 2009; 31: 432\u2013439.\n\n15 Santos Cda S, Boaventura V, Ribeiro Car-\n\ndoso C, et al. CD8(+) granzyme\n\nB(+)-mediated tissue injury vs. CD4(+)IFNc\n\n(+)-mediated parasite killing in human cuta-\n\nneous leishmaniasis. J Invest Dermatol 2013;\n\n133: 1533\u20131540.\n\n16 Stenger S, Hanson DA, Teitelbaum R, et al.\n\nAn antimicrobial activity of cytolytic T cells\n\nmediated by granulysin. Science 1998; 282:\n\n121\u2013125.\n\n17 Aranha FCS, Ribeiro U Jr, Basse P, Corbett\n\nCEP &amp; Laurenti MD. Interleukin-2-activated\n\nnatural killer cells may have a direct role in\n\nthe control of Leishmania (Leishmania)\n\namazonensis promastigote and macrophage\n\ninfection. Scand J Immunol 2005; 62: 334\u2013\n\n341.\n\n18 Lieke T, Nyl?en S, Eidsmo L, Schmetz C,\n\nBerg L &amp; Akuffo H. The interplay between\n\nLeishmania promastigotes and human Natu-\n\nral Killer cells in vitro leads to direct lysis of\n\nLeishmania by NK cells and modulation of\n\nNK cell activity by Leishmania promastig-\n\notes. Parasitology 2011; 9: 1\u201312.\n\n19 Ishikawa H, Hisaeda H, Taniguchi M, et al.\n\nCD4(+) v(alpha)14 NKT cells play a crucial\n\nrole in an early stage of protective immunity\n\nagainst infection with Leishmania major. Int\n\nImmunol 2000; 12: 1267\u20131274.\n\n20 Joyee AG, Uzonna J &amp; Yang X. Invariant\n\nNKT cells preferentially modulate the func-\n\ntion of CD8 alpha+ dendritic cell subset in\n\ninducing type 1 immunity against infection.\n\nJ Immunol Baltim Md 1950 2010; 184: 2095\u2013\n\n2106.\n\n21 Brown DM. Cytolytic CD4 cells: direct\n\nmediators in infectious disease and malig-\n\nnancy. Cell Immunol 2010; 262: 89\u201395.\n\n22 Naouar I, Boussoffara T, Ben Ahmed M,\n\net al. Involvement of different CD4(+) T cell\n\nsubsets producing granzyme B in the\n\nimmune response to Leishmania major\n\nantigens. Mediators Inflamm 2014; 2014:\n\n636039.\n\n23 Lopez JA, Brennan AJ, Whisstock JC, Vos-\n\nkoboinik I &amp; Trapani JA. Protecting a\n\nserial killer: pathways for perforin traffick-\n\ning and self-defence ensure sequential target\n\ncell death. Trends Immunol 2012; 33:\n\n406\u2013412.\n\n24 Aktas E, Kucuksezer UC, Bilgic S, Erten G\n\n&amp; Deniz G. Relationship between CD107a\n\nexpression and cytotoxic activity. Cell Immu-\n\nnol 2009; 254: 149\u2013154.\n\n25 SVS, Minist?erio da Sa?ude. Manual de Vig-\n\nila?ncia da Leishmaniose Tegumentar Ameri-\n\ncana [Internet]. 2010 [cited 2012 Nov 13].\n\nAvailable from: http://portal.saude.gov.br/por-\n\ntal/arquivos/pdf/manual2_lta_2ed.pdf.\n\n26 Betts MR, Brenchley JM, Price DA, et al.\n\nSensitive and viable identification of antigen-\n\nspecific CD8\n+\n\nT cells by a flow cytometric\n\nassay for degranulation. J Immunol Methods\n\n2003; 281: 65\u201378.\n\n27 Cardoso TM, Machado ?A, Costa DL, et al.\n\nProtective and pathological functions of\n\nCD8\n+\nT cells in Leishmania braziliensis infec-\n\ntion. Infect Immun 2015; 83: 898\u2013906.\n\n28 Da Silva Santos C &amp; Brodskyn CI. The role\n\nof CD4 and CD8 T cells in human cuta-\n\nneous leishmaniasis. Front Public Health\n\n2014; 2: 165.\n\n29 Macedo ABB, S?anchez-Arcila JC, Schubach\n\nAO, et al. Multifunctional CD4\n+\n\nT cells in\n\npatients with American cutaneous leishma-\n\nniasis. Clin Exp Immunol 2012; 167: 505\u2013\n\n513.\n\n30 Coutinho SG, Oliveira MP, Da-Cruz AM,\n\net al. T-cell responsiveness of American\n\ncutaneous leishmaniasis patients to purified\n\nLeishmania pifanoi amastigote antigens and\n\nLeishmania braziliensis promastigote anti-\n\ngens: immunologic patterns associated with\n\ncure. Exp Parasitol 1996; 84: 144\u2013155.\n\n31 Toledo VP, Mayrink W, Gollob KJ, et al.\n\nImmunochemotherapy in American cuta-\n\nneous leishmaniasis: immunological aspects\n\nbefore and after treatment. Mem Inst\n\nOswaldo Cruz 2001; 96: 89\u201398.\n\n32 Novais FO, Carvalho LP, Graff JW, et al.\n\nCytotoxic T cells mediate pathology and\n\nmetastasis in cutaneous leishmaniasis. PLoS\n\nPathog 2013; 9: e1003504.\n\n33 Maretti-Mira AC, Bittner J, Oliveira-Neto\n\nMP, et al. Transcriptome patterns from pri-\n\nmary cutaneous Leishmania braziliensis\n\ninfections associate with eventual develop-\n\nment of mucosal disease in humans. PLoS\n\nNegl Trop Dis 2012; 6: e1816.\n\n34 Carvalho AM, Magalh~aes A, Carvalho LP,\n\nBacellar O, Scott P &amp; Carvalho EM.\n\nImmunologic response and memory T cells\n\nin subjects cured of tegumentary leishmania-\n\nsis. BMC Infect Dis 2013; 13: 529.\n\n35 Trautmann A, R\u20acuckert B, Schmid-Grendel-\n\nmeier P, et al. Human CD8 T cells of the\n\nperipheral blood contain a low CD8 express-\n\ning cytotoxic/effector subpopulation.\n\nImmunology 2003; 108: 305\u2013312.\n\n36 Baj?enoff M, Breart B, Huang AYC, et al.\n\nNatural killer cell behavior in lymph nodes\n\nrevealed by static and real-time imaging. J\n\nExp Med 2006; 203: 619\u2013631.\n\n37 Ca~neda-Guzm?an IC, Salaiza-Suazo N,\n\nFern?andez-Figueroa EA, Carrada-Figueroa\n\nG, Aguirre-Garc??a M &amp; Becker I. NK cell\n\nactivity differs between patients with local-\n\nized and diffuse cutaneous leishmaniasis\n\ninfected with Leishmania mexicana: a com-\n\nparative study of TLRs and cytokines. PLoS\n\nOne 2014; 9: e112410.\n\n38 Laouar Y, Sutterwala FS, Gorelik L &amp; Flavell\n\nRA. Transforming growth factor-beta controls\n\nT helper type 1 cell development through regu-\n\nlation of natural killer cell interferon-gamma.\n\nNat Immunol 2005; 6: 600\u2013607.\n\n39 Maroof A, Beattie L, Zubairi S, Svensson\n\nM, Stager S &amp; Kaye PM. Posttranscriptional\n\nregulation of II10 gene expression allows\n\nnatural killer cells to express immunoregula-\n\ntory function. Immunity 2008; 29: 295\u2013305.\n\n40 Cooper MA, Fehniger TA &amp; Caligiuri MA.\n\nThe biology of human natural killer-cell sub-\n\nsets. Trends Immunol 2001; 22: 633\u2013640.\n\n41 Inngjerdingen M, Kveberg L, Naper C &amp;\n\nVaage JT. Natural killer cell subsets in man\n\nand rodents. Tissue Antigens 2011; 78: 81\u201388.\n\n42 Griewank KG, Lorenz B, Fischer MR, Boon\n\nL, Lopez Kostka S &amp; von Stebut E. Immune\n\nmodulating effects of NKT cells in a physio-\n\nlogically low dose Leishmania major infec-\n\ntion model after aGalCer analog PBS57\n\nstimulation. PLoS Negl Trop Dis 2014; 8:\n\ne2917.\n\n43 Bendelac A, Savage PB &amp; Teyton L. The\n\nbiology of NKT cells. Annu Rev Immunol\n\n2007; 25: 297\u2013336.\n\n44 Overgaard NH, Jung J-W, Steptoe RJ &amp;\n\nWells JW. CD4\n+\n/CD8\n\n+\ndouble-positive T\n\ncells: more than just a developmental stage?\n\nJ Leukoc Biol 2015; 97: 31\u201338.\n\n45 O\u2019Reilly V, Zeng SG, Bricard G, et al. Dis-\n\ntinct and overlapping effector functions of\n\nexpanded human CD4\n+\n, CD8a+ and CD4-\n\nCD8a- invariant natural killer T cells. PLoS\n\nOne 2011; 6: e28648.\n\n46 Montoya CJ, Pollard D, Martinson J, et al.\n\nCharacterization of human invariant natural\n\nkiller T subsets in health and disease using a\n\nnovel invariant natural killer T cell-clonoty-\n\npic monoclonal antibody, 6B11. Immunology\n\n2007; 122: 1\u201314.\n\n47 Gumperz JE, Miyake S, Yamamura T &amp;\n\nBrenner MB. Functionally distinct subsets of\n\nCD1d-restricted natural killer T cells\n\nrevealed by CD1d tetramer staining. J Exp\n\nMed 2002; 195: 625\u2013636.\n\n48 Carvalho KI, Melo KM, Bruno FR, et al.\n\nSkewed distribution of circulating activated\n\nnatural killer T (NKT) cells in patients with\n\ncommon variable immunodeficiency disor-\n\nders (CVID). PLoS One 2010; 5: e12652.\n\n49 Kumari S, Jamal F, Shivam P, et al. Leish-\n\nmania donovani skews the CD56(+) natural\n\nkiller T cell response during human visceral\n\nleishmaniasis. Cytokine 2015; 73: 53\u201360.\n\n254 \u00a9 2016 John Wiley &amp; Sons Ltd, Parasite Immunology, 38, 244\u2013254\n\nC. F. Cunha et al. Parasite Immunology\n\n\n\n142 \n\n9.3. ANEXO 3 \n\nArtigo submetido: Contributions of CD4\n+\n and CD8\n\n+\n T lymphocytes, NK \n\nand CD3\n+\nCD56\n\n+ \nNKT cells in Leishmania-specific in vitro immune \n\nresponse: cytotoxicity, activation and exhaustion processes in human \n\ncutaneous leishmaniasis. (2017) \n\n\n\nPowered by Editorial Manager\u00ae and ProduXion Manager\u00ae from Aries Systems Corporation\n\n\n\n1 \n\n \n\nTitle: Contributions of CD4+ and CD8+ T lymphocytes, NK and CD3+CD56+NKT cells in 1 \n\nLeishmania-specific in vitro immune response: cytotoxicity, activation and exhaustion 2 \n\nprocesses in human cutaneous leishmaniasis.3 \n\n4 \n\nShort Title:  Contributions of cytotoxic cell populations in human leishmaniasis 5 \n\n6 \n\nClarissa F. CUNHA1, Raquel FERRAZ 1, 2, 3, Thaize Q. CHOMETON2 Maria In\u00eas F. 7 \n\nPIMENTEL4, Marcelo R. LYRA4, Armando O. SCHUBACH4, Alda Maria DA-CRUZ5,8 \n\nAlvaro Luiz BERTHO 1, 2, * 9 \n\n10 \n\n1. Laboratory of Immunoparasitology, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, 11 \n\nRJ, Brazil. 12 \n\n2. Flow Cytometry Core Facility, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, RJ, 13 \n\nBrazil. 14 \n\n3. Beckman Coulter Life Sciences, S\u00e3o Paulo, Brazil (current affilliations)15 \n\n4. Laboratory of Surveillance for Leishmaniasis, Evandro Chagas National Institute of 16 \n\nInfectology, FIOCRUZ, Rio de Janeiro, RJ, Brazil. 17 \n\n5. Laboratory of Interdisciplinary Medical Research, Oswaldo Cruz Institute, FIOCRUZ, 18 \n\nRio de Janeiro, RJ, Brazil. 19 \n\n20 \n\n* Corresponding author: Dr. Alvaro Luiz Bertho, Laborat\u00f3rio de Imunoparasitologia, 21 \n\nInstituto Oswaldo Cruz, FIOCRUZ. Av. Brasil, 4365, Manguinhos, Pavilh\u00e3o Le\u00f4nidas 22 \n\nDeane, sala 408-A, CEP: 21040-900, Rio de Janeiro, RJ, Brasil. Email: 23 \n\nalvaro.bertho@hotmail.com24 \n\n25 \n\n26 \n\n\n\n2 \n\n \n\nAbstract 27 \n\nThe pathogenesis of human leishmaniasis is dictated largely by the immune 28 \n\nresponse developed. The understanding of the immunological mechanisms that 29 \n\ngenerate the tissue damage or resolution and protection is the key for the development 30 \n\nof effective vaccine protocols and therapeutic schemes. It is clear that the specific 31 \n\nresponse mediated by T cells is responsible for the resolution of the disease, however, 32 \n\nthe role that T cells play in immunopathogenesis has been discussed and their cytotoxic 33 \n\nfunction has been associated with tissue damage in Leishmania braziliensis infection. 34 \n\nThe present report explores the specific-cytotoxic response of CD8+ T, CD4+ T, NK and 35 \n\nCD3+CD56+ NKT cells in L. braziliensis infection, as well as their activation and 36 \n\nexhaustion profiles. Peripheral blood cells from patients with active cutaneous 37 \n\nleishmaniasis, patients under therapy and after clinical cure were assessed by flow 38 \n\ncytometry. We detected high frequencies of CD8+, NK and CD3+CD56+ NKT cells in Ag-39 \n\nstimulated cell cultures from patients with active disease, while low frequencies of CD4+40 \n\nT lymphocytes were observed from these patients due to antigenic stimulation. All groups 41 \n\nof patients showed expansion of activated and cytotoxic CD4+ T, NK and CD3+CD56+42 \n\nNKT cells in response to L. braziliensis antigens, and also presented high frequencies of 43 \n\nNK cells in an exhaustion state. In contrast, no changes due to the antigenic stimulation 44 \n\nwere detected in percentages of cytotoxic CD8+ T lymphocytes in the studied groups. 45 \n\nThe increased antigen-specific activation and cytotoxic activity is in line with the strong 46 \n\ninflammatory response described in the disease, a likely cause of tissue damage. These 47 \n\nfindings reinforce the involvement of different cytotoxic cell populations in the 48 \n\nimmunopathogenesis of cutaneous leishmaniasis, highlighting a large contribution of 49 \n\nCD4+ T lymphocytes and a non-cytotoxic-deleterious role of CD8+ T lymphocytes in 50 \n\ncontrast to other cell populations.51 \n\nKey terms: T lymphocytes, NK, NKT, Flow cytometry, cytotoxicity, CD107a, exhaustion, 52 \n\nLeishmania braziliensis53 \n\n\n\n3 \n\n \n\nIntroduction 54 \n\nLeishmaniasis are a complex of world-wide diseases with a range of clinical and 55 \n\nepidemiological features caused by Leishmania spp. protozoan parasites [1]. The 56 \n\ntransmission is mediated by the sandfly and may follow an anthroponotic or zoonotic 57 \n\ncycle that also varies by region [2]. The range of clinical manifestations depends on the 58 \n\nspecies and strain of Leishmania, degree of virulence and the magnitude of the immune 59 \n\nresponse of the host [3]. Cutaneous leishmaniasis (CL) is the most common form and 60 \n\nmanifests as localized skin lesions that may resolve but can become chronic, leading to 61 \n\nsevere tissue destruction and disfigurement [3]. Endemic in Brazil, CL has an incidence 62 \n\nrate of 20.000 cases per year, and has been recorded in all states [4,5].63 \n\nCurrent therapeutic approaches used worldwide are unable to achieve sterile 64 \n\ncure and there is no vaccine available [6,7]. A detailed understanding of the mechanisms 65 \n\ninvolved in the immune response, which lead to healing and to protection, is still a 66 \n\nchallenge and is the key for a better comprehension of the pathogenesis and to develop 67 \n\nsatisfactory therapeutic schemes to be applied.68 \n\nSince the definition of CD4+ T helper 1 (Th1) and T helper 2 (Th2) cells, studies 69 \n\nabout CL immunopathogenesis in mice have answered some immunological questions 70 \n\nconcerning the development and maintenance of T-cell subsets in the immune response 71 \n\nagainst the parasite [8,9]. Advances in our knowledge about which cells can contribute 72 \n\nin the protection against Leishmania infection and the exacerbation of the disease led to 73 \n\nnew approaches for vaccine development and immunotherapy [10]. However, it is still 74 \n\nunclear which mechanisms are actually involved in these processes because the 75 \n\ndynamics of the disease are quite complex in humans. Much is discussed about the 76 \n\nevents associated with the infection and it has been suggested that CD4+ T lymphocytes 77 \n\nmediate protective immunity, whereas CD8+ T lymphocytes would have a pathological-78 \n\ncytotoxic role [11,12]. Nevertheless, in L. braziliensis-caused-human CL, some 79 \n\nevidences suggest that high percentages of producing IFN-? CD4+ T lymphocytes are 80 \n\n\n\n4 \n\n \n\nassociated with larger lesions and an exacerbated Th1 response is observed in mucosal 81 \n\nleishmaniasis (ML) [13,14]. Furthermore, a protective role for CD8+ T lymphocytes has 82 \n\nbeen reported [15\u201321], which imprints a controversial character to this discussion. 83 \n\nRecently, our group reported a significant participation of CD4+ T lymphocytes in CL 84 \n\nimmune response acting as cytotoxic cells, along with other ones, such as classical-85 \n\ncytotoxic CD8+ T and NK cells, as well as NKT cells. In such study, cytotoxicity could not 86 \n\nbe related to a deleterious status of immune response, since it was observed that 87 \n\npatients with active disease showed similar or lower frequencies of degranulating cells 88 \n\nin comparison to healthy individuals [22].89 \n\nCytotoxic-CD4+ T lymphocytes have been highlighted in studies on their 90 \n\ncontributions in immune response against viral infections [23], however little is known 91 \n\nabout their role in protozoan diseases, particularly in leishmaniasis [24,25]. Furthermore, 92 \n\nreports about the cytotoxic action of NK cells are scarce in such diseases, regarding NKT 93 \n\ncells there are even fewer [26,27]. Besides cytotoxic activity, it is important to evaluate 94 \n\nthe activation features of these cell populations to understand their functional status. It 95 \n\nis well established that chronic parasite persistence has a profound impact on the 96 \n\neffector capacity of antigen-specific T cells, inducing their gradual loss of function [28].97 \n\nCD279, also known as programmed death-1 (PD-1), which is a major inhibitory receptor 98 \n\ninvolved in T-cell exhaustion, which is a status defined by poor effector function, 99 \n\nsustained expression of inhibitory receptors and a transcriptional state distinct from that 100 \n\nof functional-effector or memory T cells, thus preventing optimal control of the infection101 \n\n[28].102 \n\nIn this context, we developed in this present manuscript a longitudinal study with 103 \n\nCL patients to evaluate the specific response of CD4+ and CD8+ T lymphocytes, NK and 104 \n\nNKT cells to L. braziliensis-antigens, concerning their cytotoxic profiles and functional 105 \n\nstatus (activation and exhaustion), to determine their contribution to the promotion or 106 \n\nresolution of CL.107 \n\n\n\n5 \n\n \n\nMaterials and Methods108 \n\nEthical consideration109 \n\nThis study is part of a project approved by the Ethics in Research Committee of 110 \n\nthe Evandro Chagas National Institute of Infectology (CEP-INI/FIOCRUZ 029/2012), Rio 111 \n\nde Janeiro, Brazil. This Committee adheres to the principles established in the 112 \n\nDeclaration of Helsinki on human subject research. All participants were volunteers and 113 \n\nan informed consent was obtained from them prior to collection of the blood samples.114 \n\n115 \n\nStudy population116 \n\nTwenty-four CL patients from the state of Rio de Janeiro, Brazil, where 117 \n\nL. braziliensis is endemic, were sub-divided into three cohorts: 1) patients with an active 118 \n\nform of the disease, evaluated after diagnosis confirmation (AD, n=17, 36.71 \u00b1 3.74 years 119 \n\nold, 82.35% males); 2) patients during antimonial treatment, evaluated between the 15th120 \n\nand 20th day after beginning antimonial therapy (DT, n=16, 40.0 \u00b1 3.65 years old, 81.25% 121 \n\nmales); 3) patients after the end of treatment, showing recent clinical cure, corresponding 122 \n\nto the 80th day after the beginning of treatment (CC, n=10, 42.20 \u00b1 4.38 years old, 70.0% 123 \n\nmales). Healthy individuals (HI, n=7, 30.29 \u00b1 4.78 years old, 14.20% males) had no 124 \n\nclinical or epidemiological evidence of Leishmania infection and were recruited from L. 125 \n\nbraziliensis-non-endemic areas. Some patients were found repeated in groups, so the 126 \n\nnumber of blood samples processed was varied in each group, totalizing 43 blood 127 \n\nsamples from patients throughout the study. 128 \n\nCutaneous leishmaniasis was diagnosed and treated according to the 129 \n\nSurveillance Manual of American Cutaneous Leishmaniasis, Brazilian Ministry of Health, 130 \n\nin the Laboratory of Leishmaniasis Surveillance of Evandro Chagas National Institute of 131 \n\nInfectology (INI), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil. 132 \n\nDiagnosis of leishmaniasis was based on clinical, laboratorial and epidemiological 133 \n\n\n\n6 \n\n \n\ncriteria. Ulcerated cutaneous lesions were associated to a positive Montenegro skin test 134 \n\n(MST) and positive parasitological exams to confirm the diagnosis. Besides that, the 135 \n\ndifferential diagnosis to other diseases through mycological and bacteriological tests was 136 \n\nalso performed. The exclusion criteria were: patients younger than 18 and older than 70 137 \n\nyears old, presence of comorbidity or pregnancy, previous treatment with anti-138 \n\nLeishmania drugs and recent visit to an endemic area outside Rio de Janeiro state.139 \n\nFurthermore, none of the patients showed progression to mucosal or disseminated 140 \n\nclinical forms. All patients were submitted to antimoniate-N-methyl-glucamine treatment 141 \n\naccording to the guidelines of the Brazilian Ministry of Health. After treatment, all patients 142 \n\npresented clinical cure, which was characterized by full epithelialization of ulcerated 143 \n\nlesions, regression of crusts, desquamation and infiltration. 144 \n\n145 \n\nIsolation of peripheral blood mononuclear cells 146 \n\nHeparinized peripheral venous blood was collected from CL patients and healthy 147 \n\nindividuals. Afterwards, peripheral blood mononuclear cells (PBMC) were obtained 148 \n\nthrough Ficoll-Histopaque (Sigma-Aldrich, Saint Louis, MO, USA) density gradient 149 \n\ncentrifugation at 400xg, 20\u00baC, 30 minutes, without brake and washed three times in 150 \n\nRPMI-1640 medium supplemented with 10 mM HEPES, 1.5 mM L-glutamine, 0.04 mM 151 \n\n2-mercaptoethanol and antibiotics (200 IU/mL penicillin and 200 mg/mL streptomycin) 152 \n\n(all from Sigma-Aldrich). The viability of the PBMC was higher than 80% after trypan blue 153 \n\n(Sigma-Aldrich) exclusion.154 \n\nFor cryopreservation protocol, approximately 1x107 PBMCs were suspended in 155 \n\n1 mL of freezing solution [90% inactivated fetal calf serum (FCS; Gibco\u00ae, Invitrogen, Life 156 \n\nTechnologies, Rockville, MD, USA) plus 10% dimethyl sulfoxide (DMSO - Sigma-157 \n\nAldrich)]  in cryotubes (Nunc\u00ae, Kamstrupvej, Roskilde, DNK). Afterwards the cryotubes 158 \n\nwere placed in a Mr. Frosty\u2122 Freezing Container (Thermo Fisher Scientific, Waltham, 159 \n\nMA, USA), stored initially at ?80\u00b0C for 24 h, and then transferred to racks and stored in 160 \n\n\n\n7 \n\n \n\nliquid nitrogen. On the experiment day, cells were thawed by placing cryotubes in a 37\u00baC-161 \n\nwarm water bath for three minutes and then diluted in supplemented RPMI-1640 medium 162 \n\nadded with 20% FCS.163 \n\n164 \n\nL. braziliensis cell response in vitro assay165 \n\nThe recovered cells were adjusted (3x105/well) in supplemented RPMI medium 166 \n\nwith 10% FCS and displaced in 96-well round-bottomed plates (Nunc\u00ae) in a final volume 167 \n\nof 200 \u00b5L per well. PBMC were then incubated for 72 hours at 37\u00b0C in a humidified 168 \n\natmosphere of 5% CO2 air, in the presence of particulate antigens of L. braziliensis (Lb-169 \n\nAg) (obtained after disruption in repeated freeze/thaw cycles and a subsequent 5-170 \n\nminutes ultrasonication). Non-stimulated and 1 ?g/well-Phytohemagglutinin (PHA)-171 \n\nstimulated cells (Sigma-Aldrich) were used as negative and positive controls of 172 \n\nstimulation, respectively. Six hours before the end of incubation time, anti-CD107a (BD 173 \n\nBiosciences, San Jose, CA, USA) was added to the cell cultures and, after one hour, 6 174 \n\n?g/mL of BD GolgiStop containing monensin (BD Biosciences) was added, according to 175 \n\nthe protocol described elsewhere [29]. Monensin is important to prevent the acidification 176 \n\nof endocytic vesicles, avoiding degradation of reinternalized CD107a proteins from the 177 \n\ncell membrane.178 \n\nAfter 72-hour incubation, the PBMC were collected, washed and submitted to a 179 \n\nstaining protocol, using the following monoclonal-antibody panel: anti-CD3, anti-CD4, 180 \n\nanti-CD8, anti-CD56, anti-CD38, anti-CD279(BD Biosciences; Beckman Coulter, Brea, 181 \n\nCA, USA; and BioLegend, San Diego, CA); and 7AAD (Sigma-Aldrich) for dead-cell 182 \n\nexclusion. Then, cells were incubated for 20 minutes at 4\u00baC in the dark, washed and 183 \n\nacquired in flow cytometer. In some samples [AD (n=9) an d HI (n=7)], a staining protocol 184 \n\nincluding anti-TCR V?24-J?18 monoclonal antibody (BioLegend) was also performed to 185 \n\ndefine invariant NKT (iNKT) cell population.186 \n\n\n\n8 \n\n \n\nFlow cytometry187 \n\nAt least 50,000 events from each sample were acquired using MoFlo Astrios Cell 188 \n\nSorter flow cytometer (Beckman Coulter). Single stained controls were used to set 189 \n\ncompensation parameters and fluorescence-minus-one (FMO), and isotype-matched Ab 190 \n\ncontrols were used to set analysis gates. After acquisition, frequencies of CD8+ T191 \n\nlymphocytes, CD4+ T lymphocytes, NK cells and CD3+CD56+ NKT cells and their 192 \n\nexpressions of CD107a, CD38 and CD279 were determined using Kaluza Software 193 \n\nv1.5a (Beckman Coulter). As gate strategy, a region surrounding cells based on forward-194 \n\n(FSC-A) and side-scatter (SSC-A) parameters was established (Figure 1A). Next, to 195 \n\nexclude cell aggregates from analyses, cells were gated on singlets regions in FSC-H196 \n\nvs. FSC-A dot-plot (Figure 1B). 7AADneg cells (viable cells) were defined by a gate in 197 \n\nFSC-A vs. 7AAD dot-plot (Figure 1C). From this gate, CD56neg cells were defined based 198 \n\non a FSC-A vs. CD56 dot-plot (Figure 1D) and then CD8+ T lymphocytes (Figure 1E) and 199 \n\nCD4+ T lymphocytes (Figure 1F) were determined.  A CD3 vs. CD56 dot-plot, gated on 200 \n\n\u2018Viable cells\u2019, was used to set NK and CD3+CD56+ NKT cells (Figure 1G). From a gate 201 \n\non each cell population, the expressions of CD107a, CD38 and CD279 were determined 202 \n\nin respective histograms, represented here for CD4+ T-lymphocyte population (Figures 203 \n\n1H-J). In another approach of analysis, we also evaluated the percentages of each cell 204 \n\npopulation based on gates encompassing the total expression of CD107a, CD38 and 205 \n\nCD279. Based on \u201cViable cells\u201d gate, we defined the total expression of CD107a, CD38 206 \n\nand CD279 represented here only the CD279+ cells dot-plot (Figure 1K). Then, we 207 \n\nplaced the dot-plots in which we previously defined the studied cell populations (CD8+ T, 208 \n\nCD4+ T, NK and CD3+CD56+ NKT cells) in function of each of the gates of the total 209 \n\nexpression, represented here only as the CD4+ T lymphocytes dot-plot gated on 210 \n\n\u201cCD279+\u201d cells (Figure 1L). Besides, for some samples, another gate strategy was done 211 \n\nincluding the assessment of invariant NKT cells (iNKT) based on a CD3 vs. TCR V?24-212 \n\nJ?18 dot-plot (Figure 1M).213 \n\n\n\n9 \n\n \n\nFig 1: Flow cytometry-representative protocol. Peripheral blood mononuclear cells 214 \n\nwere stained with 7AAD, anti-CD3, anti-CD4, anti-CD8, anti-CD56, anti-CD107a, anti-215 \n\nCD38 and anti-CD279; as well as with anti-V?24J?18-TCR in some cases. 216 \n\n\u2018Lymphocytes\u2019 region were created on forward (FSC-A) vs. side-scatter (SSC-A) dot-plot 217 \n\n(A). Then, the cells gated on \u2018Lymphocytes\u2019 region were analyzed through dot-plots FSC-218 \n\nH vs. FSC-A (B) to exclude cell aggregates and debris \u2013 \u2018No doublets\u2019 gate. The viable 219 \n\ncells were then selected based on the non-labeling of 7AAD (C). CD8+ and CD4+ T220 \n\nlymphocyte populations were defined using CD8 vs. CD3 (E) and CD4 vs. CD3 (F) dot-221 \n\nplots, respectively, gated on CD56neg viable cells defined on a FSC vs. CD56 dot-plot 222 \n\n(D). NK and CD3+CD56+NKT cell populations were defined through CD56 vs. CD3 dot-223 \n\nplot gated on \u2018Viable cells\u2019 (G). Expressions of CD107a, CD38 and CD279 were analyzed 224 \n\non dot-plots by FSC-A, gated on each defined cell population \u2013 represented here for 225 \n\nCD4+ T lymphocytes (H-J), respectively. Another analysis strategy was adopted to 226 \n\nevaluate the proportion of CD107a, CD38 and CD279 expression by the different studied 227 \n\ncell populations: the total expression of each molecule was determined from the \u201cViable 228 \n\ncells\u201d \u2013 represented here for CD279 expression (K); and then these gates were used for 229 \n\ndetermined the expressions by each previously defined cell population \u2013 represented 230 \n\nhere the CD4+ T lymphocytes based on \u201cCD279+\u201d gate (L). For some samples, was also 231 \n\nperformed the analysis of invariant NKT (iNKT) cells through a CD3 vs. invariant TCR 232 \n\n(V?24J?18-TCR) dot-plot gated on \u2018Viable cells\u2019 (M).233 \n\n234 \n\nStatistical analysis 235 \n\nThe Wilcoxon matched-pairs signed rank test was used for comparison between 236 \n\ntwo related samples, and the Mann\u2013Whitney U-test was used for comparison between 237 \n\neach two groups, for unpaired observations. A probability level of P?0.05 was considered 238 \n\nstatistically significant. Statistical analysis was performed with GraphPad Prism version 239 \n\n6.0 for Windows (GraphPad Prism 6 Software, San Diego, CA, USA).240 \n\n\n\n10 \n\n \n\nResults241 \n\nPatients\u2019 characteristics242 \n\nThe mean age of 24 CL patients was 37 \u00b1 14.26 (\u00b1 SEM) years and 79% of them 243 \n\n(19) were of male sex. The number of lesions ranged from one to five and the illness 244 \n\nduration from 15 to 330 days. The lesion sizes were variable, with diameters ranging 245 \n\nfrom 14 to 130 mm. The MST was positive in all patients tested (Table 1). 246 \n\n247 \n\nTable 1: Characteristics of cutaneous leishmaniasis patients enrolled in this study.248 \n\n249 \n\nPatient \nnumber\n\nAge \n(years)\n\nGender Number \nof\n\nlessions\n\nDuration \nof illness \n\n(days)\n\nLesion \nsize\n\n( largest \ndiameter -\n\nmm) \n\nMSTd\n\n(mm)\n\n1 22 Ma 1 40 34 24\n2 56 Fb 1 60 36 36\n3 24 M 1 90 45 n.d.c\n\n4 28 M 1 30 20 11\n5 44 M 1 120 28 n.d.\n6 29 M 1 120 50 n.d.\n7 70 M 1 15 - 25\n8 46 M 4 180 75 27\n9 52 M 1 90 24 47\n\n10 51 F 1 60 40 n.d.\n11 32 F 1 120 130 n.d.\n12 30 M 5 45 - 20\n13 52 M 1 120 22 n.d.\n14 31 M 1 330 47 n.d.\n15 59 M 1 120 60 11\n16 23 F 1 120 35 n.d.\n17 31 M 1 150 58 19\n18 19 M 1 60 22 18\n19 26 M 4 60 - n.d.\n20 47 M 1 30 45 14\n21 19 M 1 30 30 22\n22 30 M 4 120 - n.d.\n23 25 M 1 - 14 n.d.\n24 42 F 1 90 35 10\n\n250 \n\naM - male 251 \n\nbF \u2013 female252 \n\ncn.d.- not determined253 \n\ndMST - Montenegro skin test254 \n\n255 \n\n\n\n11 \n\n \n\nL. braziliensis antigens induce expansion of CD8+ T, NK and CD3+CD56+ NKT cells, 256 \n\nand contraction of CD4+ T lymphocytes in CL patients257 \n\nIn order to determine the influence of the L. braziliensis antigens (Lb-Ag) on the 258 \n\nfrequencies of CD8+ T, CD4+ T, NK and CD3+CD56+ NKT cells, from all groups of 259 \n\npatients (AD, DT and CC) and HI, we evaluated by flow cytometry (Figure 1) the 260 \n\npercentages of these cell populations without (background \u2013 BG) or with in vitro-Lb-Ag 261 \n\nstimulation. We observed in cell cultures from AD patients higher percentages of CD8+262 \n\nT, NK and CD3+CD56+ NKT cells after Lb-Ag stimulation (mean \u00b1 SEM: 28.56 \u00b1 1.74; 263 \n\n7.47 \u00b1 1.13; and 3.86 \u00b1 0.72, respectively) compared to non-stimulated cells [27.43 \u00b1 264 \n\n1.76 (P?0.01); 6.51 \u00b1 1.09 (P?0.5); and 3.19 \u00b1 0.66 (P?0.5)] (Figures 2A-2C). In contrast, 265 \n\nthe antigenic stimulation induced a contraction in CD4+ T lymphocytes of AD (68.24 \u00b1 266 \n\n3.55) and DT (65.11 \u00b1 2.08) patients, when compared to mean percentages observed in267 \n\nnon-stimulated cells [70.50 \u00b1 3.38 (P?0.01); and 66.07 \u00b1 2.16 (P?0.05), respectively] 268 \n\n(Figures 2D and 2E). HI showed no significant changes in the frequencies of the cell 269 \n\npopulation when stimulated with Lb-Ag (data not shown).270 \n\n271 \n\nFig 2: L. braziliensis antigens induce expansion of CD8+ T, NK and CD3+CD56+ NKT 272 \n\ncells, and contraction of CD4+ T lymphocytes in CL patients. Comparison between 273 \n\nstimulated (Lb-Ag) and non-stimulated (BG \u2013 background): (A) CD8+ T (B) NK and (C)274 \n\nCD3+CD56+ NKT cells from AD (n=17); and (D) CD4+ T lymphocytes from AD (n=17) 275 \n\nand (E) DT (n=16). Solid lines connect the results for the same individual. Statistical 276 \n\nanalyses were performed by nonparametric Wilcoxon matched pairs test. Results were 277 \n\nconsidered significant with P?0.05. *(P?0.05) **(P?0.01).278 \n\n279 \n\nMost CD3+CD56+ NKT cells did not express invariant TCR  280 \n\nNKT cells co-expresses T-cell receptors (as CD3) together with markers 281 \n\nassociated with NK cell lineages (as CD56, CD16 and/or CD161). This lymphocyte 282 \n\n\n\n12 \n\n \n\nsubset recognizes lipid antigens presented by a class I MHC-like molecule CD1d and is 283 \n\nsubdivided into type I, which expresses an invariant-TCR, and type II NKT cells, 284 \n\npresenting diverse TCR. Thereby, we decided to verify the proportion of CD3+CD56+285 \n\nNKT cells that express the invariant V?24-J?18 TCR by flow cytometry analyses. We 286 \n\ndetected a small proportion of CD3+CD56+ NKT cells expressing V?24-J?18 TCR 287 \n\n(Figure 1M), data observed in all studied individuals, regardless of antigenic stimulation. 288 \n\nThe Lb-Ag did not induce change in iNKT cell frequency, since the percentages observed 289 \n\nwith and without antigenic stimulation were similar in both AD patients (Lb-Ag: 0.69 \u00b1 290 \n\n0.22; BG: 0.81 \u00b1 0.15) and HI (Lb-Ag: 0.59 \u00b1 0.11; BG: 0.77 \u00b1 0.12) (data not shown). 291 \n\n292 \n\nL. braziliensis antigens induce increase of activated and degranulating CD4+ T, NK 293 \n\nand CD3+CD56+ NKT cells in all CL patients groups294 \n\nAiming to determine changes in the activation and degranulation profiles of cells 295 \n\ninvolved in a Leishmania-specific response, we analyzed CD38 and CD107a 296 \n\nexpressions by CD8+ T, CD4+ T, NK and CD3+CD56+ NKT cells in samples from CL 297 \n\npatients and HI, in presence or lack of Lb-Ag stimuli. We observed high frequencies of 298 \n\nCD107a+CD4+ T, CD107a+ NK and CD107a+CD3+CD56+ NKT cells in Lb-Ag-stimulated-299 \n\ncell cultures from AD (0.52 \u00b1 0.07; 3.24 \u00b1 0.52 and 2.96 \u00b1 0.76, respectively), DT (0.9 \u00b1 300 \n\n0.19, 5.12 \u00b1 1.03 and 4.02 \u00b1 0.9, respectively) and CC (0.68 \u00b1 0.08; 5.75 \u00b1 1.08; and 301 \n\n2.86 \u00b1 0.66, respectively) patients, compared to non-stimulated cells from AD (0.38 \u00b1 302 \n\n0.04; P?0.05;  1.87 \u00b1 0.28, P?0.05; and 2.1 \u00b1 0.66, P?0.05; respectively), DT (0.72 \u00b1 303 \n\n0.19, P?0.01; 3.92 \u00b1 1.06, P?0.05; and 2.33 \u00b1 0.57, P?0.001; respectively) and CC (0.45 304 \n\n\u00b1 0.04, P?0.01; 2.87 \u00b1 0.7, P?0.01; and 1.61 \u00b1 0.35, P?0.01; respectively). It is important 305 \n\nto note that HI showed no changes in CD107a expression in response to Lb-Ag (Figure 306 \n\n3). Likewise, all groups of CL patients (AD, DT and CC) have increased their percentages 307 \n\nof activated CD4+ T, NK and CD3+CD56+ NKT cells in response to Lb-Ag (AD: 15.21 \u00b1 308 \n\n2.29; 55.52 \u00b1 5.73 and 19.69 \u00b1 2.49; DT: 20.68 \u00b1 2.13; 70.17 \u00b1 4.92; and 23.95 \u00b1 4.53; 309 \n\n\n\n13 \n\n \n\nCC: 16.67 \u00b1 2.29;  72.05 \u00b1 3.63; and 26.7 \u00b1 5.98, respectively), comparing to non-310 \n\nstimulated cells (AD: 13.46 \u00b1 2.22, P?0.05; 49.03 \u00b1 5.78, P?0.05; and 15.33 \u00b1 2.46, 311 \n\nP?0.001; DT: 18.23 \u00b1 2.2, P?0.001; 65.37 \u00b1 4.53, P?0.05; and 18.82 \u00b1 3.69, P?0.001; 312 \n\nCC: 13.32 \u00b1 2.11, P?0.001; 58.07 \u00b1 6.88, P?0.001; and 23.01 \u00b1 5.42, P?0.05; 313 \n\nrespectively). Interestingly, in the HI group the percentages of all cell populations 314 \n\nexpressing CD38 were not altered by the presence of Lb-Ag (Figure 4A). 315 \n\n316 \n\nFig 3: L. braziliensis antigens induce increase of degranulating CD4+ T, NK and 317 \n\nCD3+CD56+ NKT cells. Comparison of CD107a expression between stimulated (Lb-Ag) 318 \n\nand non-stimulated (BG \u2013 background) CD4+ T, NK and CD3+CD56+ NKT cells from AD 319 \n\n(n=16), DT (n=16) and CC (n=10). Solid lines connect the results for the same individual. 320 \n\nStatistical analyses were performed by nonparametric Wilcoxon matched pairs test. 321 \n\nResults were considered significant with P?0.05. *(P?0.05) **(P?0.01) ***(P?0.001).322 \n\n323 \n\nFig 4: L. braziliensis antigens induce increase of activated CD4+ T, NK and 324 \n\nCD3+CD56+ NKT cells. Comparison of CD38 expression between stimulated (Lb-Ag) 325 \n\nand non-stimulated (BG \u2013 background): (A) CD4+ T, NK and CD3+CD56+ NKT cells from 326 \n\nAD (n=17), DT (n=16) and CC (n=10); (B) CD8+ T lymphocytes from DT (n=17). Solid 327 \n\nlines connect the results for the same individual. Statistical analyses were performed by 328 \n\nnonparametric Wilcoxon matched pairs test. Results were considered significant with329 \n\nP?0.05. *(P?0.05) **(P?0.01).330 \n\n331 \n\nRegarding CD8+ T lymphocytes, no differences were observed in their 332 \n\nfrequencies of CD107a expression between non- and stimulated cell cultures, even to 333 \n\npatient\u2019s (AD, DT and CC) and to HI groups (data not shown). Concerning evaluation of 334 \n\nCD38+CD8+ T lymphocytes, it was possible to observe that Lb-Ag induced higher 335 \n\nfrequency of activated CD8+ T cells from DT patients, when compared  to non-stimulated 336 \n\ncells (11.65 \u00b1 1.81 and 9.25 \u00b1 1.68, respectively; P?0.05) (Figure 4B). AD and CC, as 337 \n\n\n\n14 \n\n \n\nwell as HI, did not present differences in percentage of CD38+CD8+ T lymphocytes in 338 \n\npresence of Lb-Ag (data not shown).339 \n\n340 \n\nL. braziliensis antigens induce NK exhaustion in CL patients341 \n\nCD279 expression was analyzed to check whether Lb-Ag-stimulation induces 342 \n\ncellular exhaustion during evolution to CL healing. Exhaustion analysis was conducted 343 \n\nby comparing the percentage of CD8+ T, CD4+ T, NK and CD3+CD56+ NKT cells 344 \n\nexpressing CD279 after Lb -Ag stimulation with those non-stimulated. We observed in 345 \n\nall CL patients\u2019 groups a higher frequency of CD279+NK cells under 346 \n\nLb-Ag stimulation (AD: 6.17 \u00b1 1.7; DT: 6.06 \u00b1 1.26; CC: 7.33 \u00b1 1.55) than those detected 347 \n\nin non-stimulated cultures (AD: 4.22 \u00b1 1.27, P?0.001; DT: 4.34 \u00b1 1.1, P?0.05; CC: 3.42 348 \n\n\u00b1 1.05, P?0.01) (Figure 5A). We also detected higher frequencies of CD279+CD8+ T349 \n\nlymphocytes and of CD279+CD3+CD56+ NKT cells in DT (5.04 \u00b1 1.38) and CC (10.85 \u00b1 350 \n\n3.83) patients, respectively, when compared to the same cells without antigenic 351 \n\nstimulation (4.18 \u00b1 1.15 and 7.29 \u00b1 2.75, respectively) (P?0.05) (Figure 5B). HI have not 352 \n\npresented any changes in the percentages of cell populations expressing CD279 when 353 \n\nstimulated with Lb-Ag (data not shown).354 \n\n355 \n\nFig 5: L. braziliensis antigens induce NK exhaustion in CL patients. Comparison of 356 \n\nCD279 expression between stimulated (Lb-Ag) and non-stimulated (BG \u2013 background): 357 \n\n(A) NK cells from AD (n=17), DT (n=16) and CC (n=10); (B) CD8+ T lymphocytes from 358 \n\nDT (n=17) and CD3+CD56+ NKT cells from CC (n=10). Solid lines connect the results for 359 \n\nthe same individual. Statistical analyses were performed by nonparametric Wilcoxon 360 \n\nmatched pairs test. Results were considered significant with P?0.05. *(P?0.05) 361 \n\n**(P?0.01).362 \n\n363 \n\n364 \n\n\n\n15 \n\n \n\nCD4+ T lymphocytes represent the highest proportion of cells expressing CD107a, 365 \n\nCD38 and CD279 biomarkers366 \n\nUsing another flow cytometry approach, we evaluated which cell population 367 \n\nwould be more relevant in cytotoxic function and represent the majority of cells368 \n\nexpressing CD38 and CD279 in the clinical stages of evolution for CL healing. In such 369 \n\napproach, we determined the total-expression of CD107a, CD38 and CD279 based on 370 \n\na gate encompassing all viable cells (Figure 1C) and then verified the percentages that 371 \n\neach cell population represented. We observed in all studied groups (both CL patients 372 \n\nand HI), regardless of antigenic stimulation, that CD4+ T lymphocytes constituted the 373 \n\nmajority of cells expressing CD107a, CD38 and CD279. Considering the total-expression374 \n\nof CD107a, CD38 and CD279, their expression profile was maintained in all studied 375 \n\ngroups and regardless of Lb-Ag stimulus: CD4+ T lymphocytes represented the majority, 376 \n\nCD8+ T and NK cells constituted intermediate and similar percentages, and 377 \n\nCD3+CD56+NKT cells represented the smallest frequency. Figure 6 shows the results 378 \n\nafter Lb-Ag stimulation of CD107a total-expression detected in HI (CD4+ T: 42.37 \u00b1 379 \n\n3.55%; CD8+ T: 15.40 \u00b1 2.81%; NK: 13.7 \u00b1 2.12%; CD3+CD56+NKT: 5.13 \u00b1 1.35%) 380 \n\n(Figure 6A) and AD patients (CD4+ T: 36.14 \u00b1 5.18%; CD8+ T: 17.51 \u00b1 4.0%; NK: 17.78 381 \n\n\u00b1 3.60%; CD3+CD56+NKT: 7.44 \u00b1 1.72%) (Figure 6B), as well as CD38 total-expression 382 \n\nobserved in HI (CD4+ T: 55.1 \u00b1 1.91%; CD8+ T: 15.25 \u00b1 1.50%; NK: 22.88 \u00b1 5.85%; 383 \n\nCD3+CD56+NKT: 3.94 \u00b1 1.57%) (Figure 6C) and AD patients (CD4+ T: 51.65 \u00b1 3.24%; 384 \n\nCD8+ T: 12.89 \u00b1 1.23%; NK: 18.95 \u00b1 2.76%; CD3+CD56+NKT: 6.17 \u00b1 2.47%) (Figure 6D) 385 \n\nand CD279 total-expression observed in HI (CD4+ T: 44.79 \u00b1 2.91%; CD8+ T: 21.88 \u00b1 386 \n\n1.80%; NK: 25.56 \u00b1 7.10%; CD3+CD56+NKT: 4.21 \u00b1 0.69%) (Figure 6E) and AD patients 387 \n\n(CD4+ T: 48.41 \u00b1 3.47%; CD8+ T: 23.88 \u00b1 2.04%; NK: 19.14 \u00b1 3.66%; CD3+CD56+NKT: 388 \n\n6.35 \u00b1 2.18%) (Figure 6F).389 \n\n390 \n\n\n\n16 \n\n \n\nFig 6. Total expression of CD107a, CD38 and CD279. Column bar graphs represent 391 \n\nthe percentages of CD4+ T, CD8+ T, NK and CD3+CD56+ NKT cells based on analyses 392 \n\nof the total-expression of CD107a (A and B), CD38 (C and D) and CD279 (E and F).393 \n\nResults obtained from healthy individuals (HI; n=7) and patients with active cutaneous 394 \n\nleishmaniasis (AD; n=17). The data are represented by median \u00b1 standard error.395 \n\nStatistical comparisons were performed with the Mann\u2013Whitney U-test. *P ? 0.05, **P &lt;396 \n\n0.01, ***P &lt;0.001. 397 \n\n398 \n\nDiscussion 399 \n\nThe immunopathogenesis of human CL is dictated largely by the type and 400 \n\nmagnitude of the host\u00b4s immune response, but also by differences between the infecting 401 \n\nLeishmania spp [11]. The cytokine profiles produced by T cells were associated with the 402 \n\nhealing process [15,18,30] or with the development of the disease [31\u201333], as well as 403 \n\nprotective mechanisms [34]. Studies in the literature have shown the important role 404 \n\nplayed by CD4+ T lymphocytes in protection against CL by producing cytokines able to 405 \n\nactivate the macrophages that kill the parasites [12]. Additionally, a protective role 406 \n\nperformed by CD8+ T lymphocytes has also been reported [15\u201321]. Nevertheless, a 407 \n\nstrong inflammatory response contributes to lesion development and the pathogenesis 408 \n\nof the disease, which has been associated with cytotoxic function, mainly by CD8+ T409 \n\nlymphocytes [12]. Recently, our group demonstrated cytotoxic activity by different cell 410 \n\npopulations, other than the classical-cytotoxic NK and CD8+ T cells. Cytotoxic-CD4+ T411 \n\nlymphocytes and NKT cells are also able to have a cytotoxic function in L. braziliensis 412 \n\ninfection, thus augmenting the discussion about the real role of these cell populations in 413 \n\nthe CL pathogenesis [22]. Advances in our knowledge about which cells participate in 414 \n\nprotection and mediate the exacerbation of the disease will certainly assist in new 415 \n\nprotocols for vaccine development and immunotherapy.416 \n\nProtective immunity against parasitic infection is critically dependent on the 417 \n\ndevelopment of a multifunctional T cell response that directly kills infected cells or 418 \n\n\n\n17 \n\n \n\ninduces phagocyte activation to destroy intracellular parasites [35]. CD4+ T lymphocytes 419 \n\nare crucial for directing appropriate immune responses during host defense and it is well 420 \n\nestablished that CD4+ Th1 cells are essential for controlling Leishmania [11]. In addition 421 \n\nto their key roles as helper cells, they may play a pathogenic role as cytotoxic cells, and 422 \n\nit is necessary to consider the impact of this fact on the multifaceted pathology of 423 \n\nimmune-related diseases [23,36]. Cytotoxic-CD4+ T lymphocytes have been implicated 424 \n\nin the control of a variety of persistent viral infections, such as HIV-1, CMV, EBV, 425 \n\ninfluenza, hantavirus and dengue infections [23]. However, the role of cytotoxic-CD4+ T426 \n\nlymphocytes in CL is poorly understood. Analyses of cytotoxic-CD4+ T lymphocytes 427 \n\ndemonstrated that they have lytic granules containing cytotoxic factors, such as 428 \n\ngranzymes and perforin [37]. Our group evaluated CD4+ T lymphocyte degranulation 429 \n\nthrough CD107a expression [22], a lysosomal protein that is transiently exposed at the 430 \n\ncell surface upon degranulation process [29]. We could observe through this ex vivo431 \n\nstudy the presence of degranulating-CD4+ T lymphocytes both in CL patients at different 432 \n\nclinical stages and in healthy individuals [22]. Still, cured patients exhibit lower 433 \n\npercentages of cells expressing CD107a+, which was associated with a possible 434 \n\ndifferentiation of these lymphocytes into memory cells [22]. In this present study, we 435 \n\naimed to evaluate the specific cytotoxicity in response to L. braziliensis antigens. We 436 \n\nincluded in our study patients with active CL (AD), during treatment (DT) and clinically 437 \n\ncured (CC) and observed that in vitro assays from patients of all groups studied 438 \n\npresented an increase of degranulating-CD4+ T lymphocytes specifically when 439 \n\nstimulated with L. braziliensis antigen (Lb-Ag). Healthy individuals (HI) were used as 440 \n\ncontrols and it was not possible to verify any increase of this cell population in response 441 \n\nto Lb-Ag. It has been shown that cured CL patients from endemic areas for L. major442 \n\nexhibit increased percentages of GranzymeB+CD4+ T lymphocytes in response to L. 443 \n\nmajor antigen, while the percentage of GranzymeB+CD8+ T lymphocytes was not altered 444 \n\nby the antigen [25]. This observation reinforces our findings that Leishmania induces an 445 \n\nincrease of cytotoxic CD4+ T lymphocytes, which seem to be activated and exert their 446 \n\n\n\n18 \n\n \n\ncytotoxicity-effecting functions in the disease. We evaluated cell activation through CD38 447 \n\nexpression, which allowed us to state that all groups of CL patients exhibit expansion of 448 \n\nactivated CD4+ T lymphocytes in response to Lb-Ag. When evaluating the frequency of 449 \n\ntotal CD4+ T lymphocytes, we observed that the Lb-Ag induced a decrease of the 450 \n\npercentages in patients with active disease and in those under therapy. Recent results451 \n\nfrom our group showed a lower frequency of CD4+ T lymphocytes in patients with active 452 \n\nCL [22]. However, despite a frequency contraction in CL patients due to Lb-Ag, the 453 \n\nfunctionality of these cells does not appear to be altered, since their activation and454 \n\ndegranulation percentages increase in these patients. In addition, precisely in order to 455 \n\nevaluate whether L. braziliensis induces impairment of cellular functionality, we 456 \n\nevaluated the CD279 expression. We observed that Lb-Ag did not influence the 457 \n\nexpression of CD279 by CD4+ T lymphocytes when evaluating CL patients, evidencing 458 \n\na functional status of these lymphocytes during the disease. A study in L. major mouse 459 \n\nmodel associated chronic disease with impaired antigen-specific cell proliferation and 460 \n\nIFN-? production, with a concomitant increase in CD279 expression by CD4+ T461 \n\nlymphocytes [38]. However, in the present study, we did not observe high percentages 462 \n\nof circulating CD279+CD4+ T cells in CL patients compared to HI and it was not possible 463 \n\nto associate such CD279 expression with disease evolution time (data not shown). 464 \n\nFollowing infection with Leishmania, CD8+ T lymphocytes respond to the MHC I-465 \n\npeptide complexes by proliferating, leading to a population of Leishmania-specific T cells. 466 \n\nIt is not fully understood how CD8+ T cells get activated in leishmaniasis, but it is clear 467 \n\nthat they do respond during Leishmania infection [39]. Indeed, we detected an expansion 468 \n\nof CD8+ T lymphocytes from patients with active disease in response to L. braziliensis.469 \n\nIn the same way, NK and CD3+CD56+ NKT cells from these patients also had antigen-470 \n\nspecific expansion. CD8+ T lymphocytes contribute to resistance against primary and 471 \n\nsecondary infection and have been targeted for vaccine development, mainly because 472 \n\ntheir rapid IFN-? production was associated with protection in L. major infection models 473 \n\n[40\u201345]. However, recent studies in human CL caused by L. braziliensis show that CD8+474 \n\n\n\n19 \n\n \n\nT cells may increase pathology due to their cytotoxic role [46\u201349]. Nevertheless, in some 475 \n\ncases, the cytotoxic role of CD4+ T lymphocytes was not evaluated and/or no analysis 476 \n\nwas performed to exclude NK and/or NKT cells in their methodologies. It is known that 477 \n\nNK and NKT cells can express CD4 and/or CD8, so they may be included when 478 \n\nanalyzing only the expression of these markers. In this present study, during flow 479 \n\ncytometry analysis, we delimited a positive CD3 expression to define the T lymphocyte 480 \n\npopulation and excluded CD56 positive cells to eliminate any possible presence of NK 481 \n\nand NKT cells. Our results did not show Leishmania-specific cytotoxic activity by CD8+482 \n\nT cells, since these lymphocytes from CL patients at any clinical stage presented no 483 \n\nchange in their degranulation percentages in response to Lb-Ag. Conversely, we found 484 \n\nthat CD4+ T, NK and CD3+CD56+ NKT cells increase their degranulation percentages in 485 \n\nresponse to Lb-Ag, a fact observed in all CL patient groups. Furthermore, we also 486 \n\ndetected expansion of activated antigen-specific CD4+ T, NK and CD3+CD56+ NKT cells 487 \n\nin all CL patient groups. A recent study of our group approached the cellular cytotoxic 488 \n\nprofile in lesions of CL patients from L. braziliensis endemic area. It was shown that 489 \n\nCD3+CD56+ NKT cells, CD4+ T and double-negative (DN) T cells are the most 490 \n\ncompromised cell populations with cytotoxic activity, given their high percentages of 491 \n\nCD107a expression. When the pool of CD107a+ cells was analyzed, it was possible to 492 \n\nobserve high proportions of DN and CD3+CD56+ NKT cells. Surprisingly, NK and CD8+493 \n\nT cells represented only 3% and 4%, respectively, of the total-CD107a+-cell pool [50].494 \n\nTherefore, it seems that the cytotoxicity, hallmark of L. braziliensis infection, is even 495 \n\ndeleterious in the evolution of the disease. Moreover, the cell population responsible for 496 \n\ncytotoxicity should be carefully analyzed, since such results may reflect the discovery of 497 \n\nvaccine targets and immunotherapies.498 \n\nLittle is known about the role of NK cells in CL caused by L. braziliensis. Studies 499 \n\nin experimental models with other species of Leishmania have been discussing that they 500 \n\nare non-essential for the pathology resolution [27] and some authors have proposed that 501 \n\n\n\n20 \n\n \n\nNK cell-mediated cytotoxicity contributes to tissue damage in L. braziliensis infection 502 \n\n[51]. We observed that Lb-Ag induced an expansion of the total, activated and 503 \n\ndegranulating-NK cells in all CL patient groups. In a previous ex vivo study [22], low 504 \n\npercentages of CD107a+ NK cells in CL patients were detected, which was associated 505 \n\nwith a possible suppression of NK cell activity by the parasite, phenomenon noted in L. 506 \n\nmajor infection [52]. These authors also observed that Leishmania reduces the ability of 507 \n\nNK cells to lyse target cells and that direct contact of NK cells with promastigotes results 508 \n\nin the destruction of both cells. In this sense, our results show clearly an expansion of 509 \n\nCD279+ NK cells in all CL patient groups, evidencing an antigen-induced cell exhaustion 510 \n\nstate. A behavior of poor NK cell functionality, characteristic of the exhaustion state, was 511 \n\nobserved in diffuse cutaneous leishmaniasis (DCL) by L. mexicana and it was associated 512 \n\nwith the severity of the disease [53]. In DCL caused by L. mexicana, a correlation of 513 \n\npathological severity with CD279 expression by circulating CD8+ T lymphocytes has 514 \n\nalready been demonstrated [54]. We only observed increased expression of CD279+515 \n\nCD8+ T lymphocytes in DT, group which also showed an increase in activated CD8+ T516 \n\nlymphocytes, suggesting that it may be associated with some effect of the drug therapy 517 \n\nalong with the antigen.518 \n\nThe role of NKT cells in the resistance or susceptibility 519 \n\ntowards Leishmania infections remains to be defined, since controversial data persist 520 \n\n[26]. NKT cells have been better studied in visceral leishmaniasis (VL), their activation 521 \n\nwas demonstrated by a direct pathway where Leishmania-glycocalyx antigens presented 522 \n\nby a CD1d bind to invariant TCR and their participation both in producing cytokines and 523 \n\nwith cytotoxic activity lysing target cells [55\u201357]. Studies in CL are scarce. It has recently 524 \n\nbeen shown that NKT cell activation in CL may also occur through an indirect pathway, 525 \n\nwhere L. mexicana LPG activates dendritic cells which results in the induction of IFN-?526 \n\nproduction by NKT cells [58]; and these cells act as cytotoxic through the externalization 527 \n\nof lithic granules [22]. We observed that Lb-Ag induces CD3+CD56+ NKT cell activation, 528 \n\n\n\n21 \n\n \n\nleading to an increase in the frequency of total and activated-NKT cells in all CL patient 529 \n\ngroups. Furthermore, an expansion of CD107a+ CD3+CD56+ NKT cells was clearly 530 \n\ndemonstrated in CL patients due to the Lb-Ag. Ferraz et al (2017) found high 531 \n\npercentages of total and degranulating-NKT cells in CL patient\u2019s lesions, reinforcing the 532 \n\ninvolvement of NKT cells with cytotoxic activity in CL [50]. It is well known that NKT cells 533 \n\nare sub-divided into two distinct subsets in humans: type I or invariant NKT (iNKT) cells, 534 \n\nwhich express an invariant V?24-J?18 TCR; and a type II or variant NKT cells, which 535 \n\ninclude all other CD1d-dependent T cells [59]. It has been reported that about 70% of 536 \n\nNKT cells had an invariant profile [60], however, such frequency varies in humans and 537 \n\nsome authors point to high percentages of type II NKT cells as well [61,62]. For this 538 \n\nreason, we decided to analyze which proportion of invariant NKT cells was present in 539 \n\nour sampling. Unexpectedly, we found very low frequency of CD3+CD56+ NKT cells 540 \n\nexpressing V?24-J?18 TCR, both in CL patients and HI. It is already established that 541 \n\ntype II NKT cells are reactive to both glycolipids and phospholipids derived from self, as 542 \n\nwell as microbes. Studies focusing on this subset have emerged and suggest that these 543 \n\ncells may impact the biology of diverse parasitic infections and may either promote 544 \n\nprotective innate and adaptive immune responses or contribute to pathogen-mediated 545 \n\ntissue injury [61,63]. Phosphatidylglycerol and diphosphatidylglycerol derived from the 546 \n\nMycobacterium tuberculosis have been reported to be ligands for type II NKT cells [64].547 \n\nIn summary, our work shows with originality a great contribution of type II NKT 548 \n\ncells in CL pathogenesis, since Lb-Ag were able to induce an increase in their frequency, 549 \n\nactivation and degranulation from CL patients. We still observed that Lb-Ag induced 550 \n\nincrease of CD279+CD3+CD56+ NKT cells in healing CL patients. A mechanism of 551 \n\ninhibition of NKT cell activity by CD279 was described in patients with tuberculosis, 552 \n\nwhere it was observed that the blockage of CD279 prevented the apoptosis of IFN-?+NKT 553 \n\ncells and enhanced their lytic degranulation [65]. Further studies are needed to 554 \n\nunderstand why healed CL patients showed increases of exhausted NKT cells in the 555 \n\n\n\n22 \n\n \n\npresence of Lb-Ag and, furthermore, verify whether blockade of  CD279 pathway results 556 \n\nin an increase in the cell activity in CL. In DCL it was possible to restore the effector 557 \n\nmechanisms of exhausted CD8+ T lymphocytes [54].558 \n\nDue to the importance of lymphocyte trafficking in dynamics of infection and their 559 \n\nrelation with the formation of the inflammatory infiltrate and healing process, we also 560 \n\nintended to evaluate the CLA expression, important homing molecule for skin [66], in 561 \n\norder to verify whether Lb-Ag modulates CLA expression, as this may influence the 562 \n\nfunction and migration pattern of effector cells. However, we did not observe modulation 563 \n\nof CLA expression by Lb-Ag in CD8+ T, CD4+ T, NK and CD3+CD56+ NKT cells neither564 \n\nin CL patient groups nor in HI (data not shown). Otherwise, Mendes-Aguiar et al (2009) 565 \n\nsuggested that L. braziliensis antigens up-regulate CLA expression in T lymphocytes 566 \n\nduring active CL [67]. Such divergence of the results may be due to the difference in the 567 \n\nanalysis strategy, where we compared the CLA expression results of the Lb-Ag-568 \n\nstimulated cells with the non-stimulated cells under the same culture conditions; while 569 \n\nthe other authors compared the stimulated T lymphocytes with ex vivo results. We 570 \n\nbelieve that this non-modulation in CLA expression may be due to the fact that soluble 571 \n\nchemotactic factors tissue-derived are required for T cell tracking into the inflamed 572 \n\ntissues [68].573 \n\n574 \n\nConclusions 575 \n\nIn summary, we show that specific cytotoxic response in CL is exerted by different 576 \n\ncell populations, highlighting the role of CD4+ T lymphocytes as the most expressive 577 \n\npopulation in activation, degranulation process and exhaustion receptor expression. The 578 \n\nspecific response to L. braziliensis antigen resulted in expansion of activated and 579 \n\ndegranulating-CD4+ T lymphocytes, NK and CD3+CD56+NKT cells from CL patients, 580 \n\nbesides exhaustion of NK cells. Such increase of cytotoxic activity and cellular activation 581 \n\nmay be related to the tissue damage observed due to the strong inflammatory response 582 \n\n\n\n23 \n\n \n\ncharacteristic of the disease. However, CD8+ T lymphocytes surprisingly did not show 583 \n\nspecific cytotoxic activity to L. braziliensis antigens, indicating that these cells participate 584 \n\nin the CL immunopathogenesis, they are able to expand in response to the antigens, but 585 \n\nare not responsible for the deleterious cytotoxicity in CL.586 \n\n587 \n\nReferences 588 \n\n1.  Gramiccia M, Gradoni L. The current status of zoonotic leishmaniases and 589 \napproaches to disease control. Int J Parasitol. 2005;35: 1169\u20131180. 590 \ndoi:10.1016/j.ijpara.2005.07.001591 \n\n2.  Pace D. Leishmaniasis. J Infect. 2014;69 Suppl 1: S10-18. 592 \ndoi:10.1016/j.jinf.2014.07.016593 \n\n3.  Gupta G, Oghumu S, Satoskar AR. Mechanisms of immune evasion in 594 \nleishmaniasis. Adv Appl Microbiol. 2013;82: 155\u2013184. doi:10.1016/B978-0-12-595 \n407679-2.00005-3596 \n\n4.  WHO | Brazil. In: WHO [Internet]. [cited 17 Jan 2017]. Available: 597 \nhttp://www.who.int/gho/countries/bra/en/598 \n\n5.  Brasil, 2010. Manual de Vigi\u00e2ncia da Leishmaniose tegumentar Americana, 3rd Ed. 599 \nMinist\u00e9rio da Sa\u00fade, Bras\u00edlia (DF).;  600 \n\n6.  Mendon\u00e7a MG, de Brito MEF, Rodrigues EHG, Bandeira V, Jardim ML, Abath FGC. 601 \nPersistence of leishmania parasites in scars after clinical cure of American 602 \ncutaneous leishmaniasis: is there a sterile cure? J Infect Dis. 2004;189: 1018\u20131023. 603 \ndoi:10.1086/382135604 \n\n7.  Schubach A, Haddad F, Oliveira-Neto MP, Degrave W, Pirmez C, Grimaldi G Jr, et 605 \nal. Detection of Leishmania DNA by polymerase chain reaction in scars of treated 606 \nhuman patients. J Infect Dis. 1998;178: 911\u2013914. 607 \n\n8.  Scott P, Natovitz P, Coffman RL, Pearce E, Sher A. Immunoregulation of cutaneous 608 \nleishmaniasis. T cell lines that transfer protective immunity or exacerbation belong 609 \nto different T helper subsets and respond to distinct parasite antigens. J Exp Med. 610 \n1988;168: 1675\u20131684. 611 \n\n9.  Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal 612 \nexpression of interferon gamma or interleukin 4 during the resolution or progression 613 \nof murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J 614 \nExp Med. 1989;169: 59\u201372. 615 \n\n10.  De Luca PM, Macedo ABB. Cutaneous Leishmaniasis Vaccination: A Matter of 616 \nQuality. Front Immunol. 2016;7: 151. doi:10.3389/fimmu.2016.00151617 \n\n11.  Scott P, Novais FO. Cutaneous leishmaniasis: immune responses in protection and 618 \npathogenesis. Nat Rev Immunol. 2016;16: 581\u2013592. doi:10.1038/nri.2016.72619 \n\n\n\n24 \n\n \n\n12.  da Silva Santos C, Brodskyn CI. The Role of CD4 and CD8?T Cells in Human 620 \nCutaneous Leishmaniasis. Front Public Health. 2014;2: 165. 621 \ndoi:10.3389/fpubh.2014.00165622 \n\n13.  Antonelli LRV, Dutra WO, Almeida RP, Bacellar O, Carvalho EM, Gollob KJ. 623 \nActivated inflammatory T cells correlate with lesion size in human cutaneous 624 \nleishmaniasis. Immunol Lett. 2005;101: 226\u2013230. doi:10.1016/j.imlet.2005.06.004625 \n\n14.  Oliveira WN, Ribeiro LE, Schrieffer A, Machado P, Carvalho EM, Bacellar O. The 626 \nrole of inflammatory and anti-inflammatory cytokines in the pathogenesis of human 627 \ntegumentary leishmaniasis. Cytokine. 2014;66: 127\u2013132. 628 \ndoi:10.1016/j.cyto.2013.12.016629 \n\n15.  Da-Cruz AM, Concei\u00e7\u00e3o-Silva F, Bertho AL, Coutinho SG. Leishmania-reactive 630 \nCD4+ and CD8+ T cells associated with cure of human cutaneous leishmaniasis. 631 \nInfect Immun. 1994;62: 2614\u20132618. 632 \n\n16.  Da-Cruz AM, Bittar R, Mattos M, Oliveira-Neto MP, Nogueira R, Pinho-Ribeiro V, 633 \net al. T-cell-mediated immune responses in patients with cutaneous or mucosal 634 \nleishmaniasis: long-term evaluation after therapy. Clin Diagn Lab Immunol. 2002;9: 635 \n251\u2013256. 636 \n\n17.  Da-Cruz AM, Bertho AL, Oliveira-Neto MP, Coutinho SG. Flow cytometric analysis 637 \nof cellular infiltrate from American tegumentary leishmaniasis lesions. Br J 638 \nDermatol. 2005;153: 537\u2013543. doi:10.1111/j.1365-2133.2005.06647.x639 \n\n18.  Coutinho SG, Da-Cruz AM, Bertho AL, Santiago MA, De-Luca P. Immunologic 640 \npatterns associated with cure in human American cutaneous leishmaniasis. Braz J 641 \nMed Biol Res Rev Bras Pesqui M\u00e9dicas E Biol\u00f3gicas Soc Bras Biof\u00edsica Al. 642 \n1998;31: 139\u2013142. 643 \n\n19.  Bittar RC, Nogueira RS, Vieira-Gon\u00e7alves R, Pinho-Ribeiro V, Mattos MS, Oliveira-644 \nNeto MP, et al. T-cell responses associated with resistance to Leishmania infection 645 \nin individuals from endemic areas for Leishmania (Viannia) braziliensis. Mem Inst 646 \nOswaldo Cruz. 2007;102: 625\u2013630. 647 \n\n20.  Bertho AL, Santiago MA, Da-Cruz AM, Coutinho SG. Detection of early apoptosis 648 \nand cell death in T CD4+ and CD8+ cells from lesions of patients with localized 649 \ncutaneous leishmaniasis. Braz J Med Biol Res Rev Bras Pesqui Medicas E Biol. 650 \n2000;33: 317\u2013325. 651 \n\n21.  Ferraz R, Cunha CF, Gomes-Silva A, Schubach AO, Pimentel MIF, Lyra MR, et al. 652 \nApoptosis and frequency of total and effector CD8+ T lymphocytes from cutaneous 653 \nleishmaniasis patients during antimonial therapy. BMC Infect Dis. 2015;15: 74. 654 \ndoi:10.1186/s12879-015-0799-x655 \n\n22.  Cunha CF, Ferraz R, Pimentel MIF, Lyra MR, Schubach AO, Da-Cruz AM, et al. 656 \nCytotoxic cell involvement in human cutaneous leishmaniasis: assessments in 657 \nactive disease, under therapy and after clinical cure. Parasite Immunol. 2016;38: 658 \n244\u2013254. doi:10.1111/pim.12312659 \n\n23.  Juno JA, van Bockel D, Kent SJ, Kelleher AD, Zaunders JJ, Munier CML. Cytotoxic 660 \nCD4 T Cells\u2014Friend or Foe during Viral Infection? Front Immunol. 2017;8. 661 \ndoi:10.3389/fimmu.2017.00019662 \n\n\n\n25 \n\n \n\n24.  Sallusto F. Heterogeneity of Human CD4(+) T Cells Against Microbes. Annu Rev 663 \nImmunol. 2016;34: 317\u2013334. doi:10.1146/annurev-immunol-032414-112056664 \n\n25.  Naouar I, Boussoffara T, Ben Ahmed M, Belhaj Hmida N, Gharbi A, Gritli S, et al. 665 \nInvolvement of different CD4(+) T cell subsets producing granzyme B in the immune 666 \nresponse to Leishmania major antigens. Mediators Inflamm. 2014;2014: 636039. 667 \ndoi:10.1155/2014/636039668 \n\n26.  Zamora-Chimal J, Hern\u00e1ndez-Ruiz J, Becker I. NKT cells in leishmaniasis. 669 \nImmunobiology. 2016; doi:10.1016/j.imbio.2016.11.014670 \n\n27.  Bogdan C. Natural killer cells in experimental and human leishmaniasis. Front Cell 671 \nInfect Microbiol. 2012;2. doi:10.3389/fcimb.2012.00069672 \n\n28.  Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12: 492\u2013499.  673 \n\n29.  Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, et al. 674 \nSensitive and viable identification of antigen-specific CD8+ T cells by a flow 675 \ncytometric assay for degranulation. J Immunol Methods. 2003;281: 65\u201378. 676 \n\n30.  Coutinho SG, Oliveira MP, Da-Cruz AM, De Luca PM, Mendon\u00e7a SC, Bertho AL, 677 \net al. T-cell responsiveness of American cutaneous leishmaniasis patients to 678 \npurified Leishmania pifanoi amastigote antigens and Leishmania braziliensis 679 \npromastigote antigens: immunologic patterns associated with cure. Exp Parasitol. 680 \n1996;84: 144\u2013155. doi:10.1006/expr.1996.0100681 \n\n31.  Bomfim G, Nascimento C, Costa J, Carvalho EM, Barral-Netto M, Barral A. 682 \nVariation of cytokine patterns related to therapeutic response in diffuse cutaneous 683 \nleishmaniasis. Exp Parasitol. 1996;84: 188\u2013194. doi:10.1006/expr.1996.0104684 \n\n32.  Carvalho EM, Johnson WD, Barreto E, Marsden PD, Costa JL, Reed S, et al. Cell 685 \nmediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol 686 \nBaltim Md 1950. 1985;135: 4144\u20134148. 687 \n\n33.  Ribeiro-de-Jesus A, Almeida RP, Lessa H, Bacellar O, Carvalho EM. Cytokine 688 \nprofile and pathology in human leishmaniasis. Braz J Med Biol Res Rev Bras 689 \nPesqui M\u00e9dicas E Biol\u00f3gicas Soc Bras Biof\u00edsica Al. 1998;31: 143\u2013148. 690 \n\n34.  Mendonca SC, De Luca PM, Mayrink W, Restom TG, Conceicao-Silva F, Da-Cruz 691 \nAM, et al. Characterization of human T lymphocyte-mediated immune responses 692 \ninduced by a vaccine against American tegumentary leishmaniasis. Am J Trop Med 693 \nHyg. 1995;53: 195\u2013201. 694 \n\n35.  Macedo ABB, S\u00e1nchez-Arcila JC, Schubach AO, Mendon\u00e7a SCF, Marins-Dos-695 \nSantos A, de Fatima Madeira M, et al. Multifunctional CD4+ T cells in patients with 696 \nAmerican cutaneous leishmaniasis. Clin Exp Immunol. 2012;167: 505\u2013513. 697 \ndoi:10.1111/j.1365-2249.2011.04536.x698 \n\n36.  Hirahara K, Nakayama T. CD4+ T-cell subsets in inflammatory diseases: beyond 699 \nthe Th1/Th2 paradigm. Int Immunol. 2016;28: 163\u2013171. 700 \ndoi:10.1093/intimm/dxw006701 \n\n37.  Soghoian DZ, Streeck H. Cytolytic CD4(+) T cells in viral immunity. Expert Rev 702 \nVaccines. 2010;9: 1453\u20131463. doi:10.1586/erv.10.132703 \n\n\n\n26 \n\n \n\n38.  Mou Z, Muleme HM, Liu D, Jia P, Okwor IB, Kuriakose SM, et al. Parasite-derived 704 \narginase influences secondary anti-Leishmania immunity by regulating 705 \nprogrammed cell death-1-mediated CD4+ T cell exhaustion. J Immunol Baltim Md 706 \n1950. 2013;190: 3380\u20133389. doi:10.4049/jimmunol.1202537707 \n\n39.  Novais FO, Scott P. CD8(+) T cells in cutaneous leishmaniasis: the good, the bad, 708 \nand the ugly. Semin Immunopathol. 2015; doi:10.1007/s00281-015-0475-7709 \n\n40.  Uzonna JE, Joyce KL, Scott P. Low dose Leishmania major promotes a transient T 710 \nhelper cell type 2 response that is down-regulated by interferon gamma-producing 711 \nCD8+ T cells. J Exp Med. 2004;199: 1559\u20131566. doi:10.1084/jem.20040172712 \n\n41.  M\u00fcller I, Kropf P, Louis JA, Milon G. Expansion of gamma interferon-producing 713 \nCD8+ T cells following secondary infection of mice immune to Leishmania major. 714 \nInfect Immun. 1994;62: 2575\u20132581. 715 \n\n42.  Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, et al. 716 \nVaccination with DNA encoding the immunodominant LACK parasite antigen 717 \nconfers protective immunity to mice infected with Leishmania major. J Exp Med. 718 \n1997;186: 1137\u20131147. 719 \n\n43.  Bertholet S, Debrabant A, Afrin F, Caler E, Mendez S, Tabbara KS, et al. Antigen720 \nrequirements for efficient priming of CD8+ T cells by Leishmania major-infected 721 \ndendritic cells. Infect Immun. 2005;73: 6620\u20136628. doi:10.1128/IAI.73.10.6620-722 \n6628.2005723 \n\n44.  Rhee EG, Mendez S, Shah JA, Wu C, Kirman JR, Turon TN, et al. Vaccination with 724 \nheat-killed leishmania antigen or recombinant leishmanial protein and CpG 725 \noligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell 726 \nresponses and protection against leishmania major infection. J Exp Med. 2002;195: 727 \n1565\u20131573. 728 \n\n45.  da Concei\u00e7\u00e3o-Silva F, Perlaza BL, Louis JA, Romero P. Leishmania major infection 729 \nin mice primes for specific major histocompatibility complex class I-restricted CD8+ 730 \ncytotoxic T cell responses. Eur J Immunol. 1994;24: 2813\u20132817. 731 \ndoi:10.1002/eji.1830241135732 \n\n46.  Santos C da S, Boaventura V, Ribeiro Cardoso C, Tavares N, Lordelo MJ, Noronha 733 \nA, et al. CD8(+) granzyme B(+)-mediated tissue injury vs. CD4(+)IFN?(+)-mediated 734 \nparasite killing in human cutaneous leishmaniasis. J Invest Dermatol. 2013;133: 735 \n1533\u20131540. doi:10.1038/jid.2013.4736 \n\n47.  Cardoso TM, Machado \u00c1, Costa DL, Carvalho LP, Queiroz A, Machado P, et al. 737 \nProtective and pathological functions of CD8+ T cells in Leishmania braziliensis 738 \ninfection. Infect Immun. 2015;83: 898\u2013906. doi:10.1128/IAI.02404-14739 \n\n48.  Faria DR, Souza PEA, Dur\u00e3es FV, Carvalho EM, Gollob KJ, Machado PR, et al. 740 \nRecruitment of CD8(+) T cells expressing granzyme A is associated with lesion 741 \nprogression in human cutaneous leishmaniasis. Parasite Immunol. 2009;31: 432\u2013742 \n439. doi:10.1111/j.1365-3024.2009.01125.x743 \n\n49.  de Oliveira Mendes-Aguiar C, Vieira-Gon\u00e7alves R, Guimar\u00e3es LH, de Oliveira-Neto 744 \nMP, Carvalho EM, Da-Cruz AM. Effector memory CD4+ T cells differentially 745 \nexpress activation associated molecules depending on the duration of American 746 \n\n\n\n27 \n\n \n\ncutaneous leishmaniasis lesions. Clin Exp Immunol. 2016;185: 202\u2013209. 747 \ndoi:10.1111/cei.12798748 \n\n50.  Ferraz R, Cunha CF, Pimentel MIF, Lyra MR, Pereira-da-Silva T, Da-Cruz AM, et 749 \nal. CD3+CD4negCD8neg (double negative) T lymphocytes and NKT cells as the 750 \nmain cytotoxic-related-CD107a+ cells in lesions of cutaneous leishmaniasis caused 751 \nby Leishmania (Viannia) braziliensis. Parasit Vectors. 2017; Forthcoming. 752 \n\n51.  Machado P, Kanitakis J, Almeida R, Chalon A, Ara\u00fajo C, Carvalho EM. Evidence 753 \nof in situ cytotoxicity in American cutaneous leishmaniasis. Eur J Dermatol EJD. 754 \n2002;12: 449\u2013451. 755 \n\n52.  Lieke T, Nyl\u00e9n S, Eidsmo L, Schmetz C, Berg L, Akuffo H. The interplay between 756 \nLeishmania promastigotes and human Natural Killer cells in vitro leads to direct 757 \nlysis of Leishmania by NK cells and modulation of NK cell activity by Leishmania 758 \npromastigotes. Parasitology. 2011; 1\u201312. doi:10.1017/S0031182011001363759 \n\n53.  Ca\u00f1eda-Guzm\u00e1n IC, Salaiza-Suazo N, Fern\u00e1ndez-Figueroa EA, Carrada-Figueroa 760 \nG, Aguirre-Garc\u00eda M, Becker I. NK cell activity differs between patients with 761 \nlocalized and diffuse cutaneous leishmaniasis infected with Leishmania mexicana: 762 \na comparative study of TLRs and cytokines. PloS One. 2014;9: e112410. 763 \ndoi:10.1371/journal.pone.0112410764 \n\n54.  Hern\u00e1ndez-Ruiz J, Salaiza-Suazo N, Carrada G, Escoto S, Ruiz-Remigio A, 765 \nRosenstein Y, et al. CD8 cells of patients with diffuse cutaneous leishmaniasis 766 \ndisplay functional exhaustion: the latter is reversed, in vitro, by TLR2 agonists. 767 \nPLoS Negl Trop Dis. 2010;4: e871. doi:10.1371/journal.pntd.0000871768 \n\n55.  Amprey JL, Im JS, Turco SJ, Murray HW, Illarionov PA, Besra GS, et al. A subset 769 \nof liver NK T cells is activated during Leishmania donovani infection by CD1d-bound 770 \nlipophosphoglycan. J Exp Med. 2004;200: 895\u2013904. doi:10.1084/jem.20040704771 \n\n56.  Karmakar S, Paul J, De T. Leishmania donovani glycosphingolipid facilitates 772 \nantigen presentation by inducing relocation of CD1d into lipid rafts in infected 773 \nmacrophages. Eur J Immunol. 2011;41: 1376\u20131387. doi:10.1002/eji.201040981774 \n\n57.  Campos-Mart\u00edn Y, Colmenares M, Gozalbo-L\u00f3pez B, L\u00f3pez-N\u00fa\u00f1ez M, Savage PB, 775 \nMart\u00ednez-Naves E. Immature human dendritic cells infected with Leishmania 776 \ninfantum are resistant to NK-mediated cytolysis but are efficiently recognized by 777 \nNKT cells. J Immunol Baltim Md 1950. 2006;176: 6172\u20136179.778 \n\n58.  Zamora-Chimal J, Fern\u00e1ndez-Figueroa EA, Ruiz-Remigio A, Wilkins-Rodr\u00edguez 779 \nAA, Delgado-Dom\u00ednguez J, Salaiza-Suazo N, et al. NKT cell activation by 780 \nLeishmania mexicana LPG: Description of a novel pathway. Immunobiology. 781 \n2017;222: 454\u2013462. doi:10.1016/j.imbio.2016.08.003782 \n\n59.  Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: 783 \nwhat\u2019s in a name? Nat Rev Immunol. 2004;4: 231\u2013237. doi:10.1038/nri1309784 \n\n60.  Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 785 \n2007;25: 297\u2013336. doi:10.1146/annurev.immunol.25.022106.141711786 \n\n61.  Dhodapkar MV, Kumar V. Type II NKT Cells and Their Emerging Role in Health 787 \nand Disease. J Immunol Baltim Md 1950. 2017;198: 1015\u20131021. 788 \ndoi:10.4049/jimmunol.1601399789 \n\n\n\n28 \n\n \n\n62.  Exley MA, Tahir SM, Cheng O, Shaulov A, Joyce R, Avigan D, et al. A major fraction 790 \nof human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can 791 \nsuppress mixed lymphocyte responses. J Immunol Baltim Md 1950. 2001;167: 792 \n5531\u20135534. 793 \n\n63.  Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention of 794 \nautoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population 795 \nreactive to sulfatide. J Exp Med. 2004;199: 947\u2013957. doi:10.1084/jem.20031389796 \n\n64.  Tatituri RVV, Watts GFM, Bhowruth V, Barton N, Rothchild A, Hsu F-F, et al. 797 \nRecognition of microbial and mammalian phospholipid antigens by NKT cells with 798 \ndiverse TCRs. Proc Natl Acad Sci U S A. 2013;110: 1827\u20131832. 799 \ndoi:10.1073/pnas.1220601110800 \n\n65.  Singh A, Dey AB, Mohan A, Mitra DK. Programmed death-1 receptor suppresses 801 \n?-IFN producing NKT cells in human tuberculosis. Tuberc Edinb Scotl. 2014;94: 802 \n197\u2013206. doi:10.1016/j.tube.2014.01.005803 \n\n66.  Santamaria-Bab\u00ed LF. CLA(+) T cells in cutaneous diseases. Eur J Dermatol EJD. 804 \n2004;14: 13\u201318. 805 \n\n67.  Mendes-Aguiar C de O, Gomes-Silva A, Nunes E, Pereira-Carvalho R, Nogueira 806 \nRS, Oliveira-Neto M de P, et al. The skin homing receptor cutaneous leucocyte-807 \nassociated antigen (CLA) is up-regulated by Leishmania antigens in T lymphocytes 808 \nduring active cutaneous leishmaniasis. Clin Exp Immunol. 2009;157: 377\u2013384. 809 \ndoi:10.1111/j.1365-2249.2009.03970.x810 \n\n68.  Sch\u00f6n MP, Zollner TM, Boehncke W-H. The Molecular Basis of Lymphocyte 811 \nRecruitment to the Skin: Clues for Pathogenesis and Selective Therapies of 812 \nInflammatory Disorders. J Invest Dermatol. 2003;121: 951\u2013962. 813 \ndoi:10.1046/j.1523-1747.2003.12563.x814 \n\n815 \n\nConflict of Interest Disclosure 816 \n\nAll the authors have declared that no competing interest exists. 817 \n\n818 \n\nAcknowledgments 819 \n\nThe authors would like to thank the Flow Cytometry Sorting Core, Oswaldo Cruz 820 \n\nInstitute, FIOCRUZ for availability to flow cytometry acquisitions (MoFlo ASTRIOS Cell 821 \n\nSorter, Beckman Coulter, FL, USA). This research was supported in part by an internal 822 \n\nfunding from IOC-FIOCRUZ and PROEP-CNPq-IOC (402557/2011-5); FAPERJ APQ1 823 \n\nE-26/110332/2014; FIOTEC IOC-008-FIO-15-47. 824 \n\n 825 \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n178 \n\n9.4. ANEXO 4 \n\nArtigo publicado: CD3\n+\nCD4\n\nneg\nCD8\n\nneg\n (double negative) T lymphocytes and NKT \n\ncells as the main cytotoxic-related-CD107a\n+\n cells in lesions of cutaneous \n\nleishmaniasis caused by Leishmania (Viannia) braziliensis. (2017) \n\n \n\n\n\nRESEARCH Open Access\n\nCD3\n+\nCD4\n\nneg\nCD8\n\nneg\n(double negative)\n\nT lymphocytes and NKT cells as the main\ncytotoxic-related-CD107a\n\n+\ncells in lesions\n\nof cutaneous leishmaniasis caused by\nLeishmania (Viannia) braziliensis\nRaquel Ferraz1,2, Clarissa F. Cunha1, Maria In\u00eas F. Pimentel3, Marcelo R. Lyra3, Tatiana Pereira-Da-Silva4,\nArmando O. Schubach3, Alda Maria Da-Cruz5 and Alvaro Luiz Bertho1,2*\n\nAbstract\n\nBackground: Cutaneous leishmaniasis (CL) is caused by Leishmania (Viannia) braziliensis, which infects dermal\nmacrophages and dendritic cells, causing an intense immune-mediated-tissue inflammation and a skin ulcer with\nelevated borders that can heal spontaneously or after antimonial therapy. The resolution of lesions depends on\nan adaptive immune response, and cytotoxic cells seem to have a fundamental role in this process. The aim of\nthis study is to better understand the role of cytotoxicity mediated mechanisms that occur during the immune\nresponse in the CL lesion milieu, considering distinct cytotoxic-related CD107a+ cells, such as CD8+, CD4+, CD4neg\n\nCD8neg (double-negative, DN) and CD4+CD8+ (double-positive, DP) T lymphocytes, as well as NK and NKT cells.\n\nMethods: Lesion derived cells were assessed for T cell subpopulations and NK cells, as well as CD107a expression\nby flow cytometry. In addition, cytometric bead array (CBA) was used to quantify cytokines and granzyme B\nconcentrations in supernatants from macerated lesions.\n\nResults: Flow cytometry analyses revealed that NKT cells are the major CD107a-expressing cell population\ncommitted to cytotoxicity in CL lesion, although we also observed high frequencies of CD4+ and DN T cells\nexpressing CD107a. Analysing the pool of CD107a+-cell populations, we found a higher distribution of DN T cells\n(44%), followed by approximately 25% of NKT cells. Interestingly, NK and CD8+ T cells represented only 3 and 4%\nof the total-CD107a+-cell pool, respectively.\n\nConclusions: The cytotoxicity activity that occurs in the lesion milieu of CL patients seems to be dominated by DN\nT and NKT cells. These findings suggest the need for a reevaluation of the role of classical-cytotoxic NK and CD8+ T\ncells in the pathogenesis of CL, implicating an important role for other T cell subpopulations.\n\nKeywords: Flow cytometry, Cytotoxicity, CD107a, Double-negative T lymphocytes, NKT cells, Lesion, Human\ncutaneous leishmaniasis, Leishmania (Viannia) braziliensis\n\n* Correspondence: alvaro.bertho@ioc.fiocruz.br\n1Laboratory of Immunoparasitology, Oswaldo Cruz Institute, FIOCRUZ, Rio de\nJaneiro, RJ, Brazil\n2Flow Cytometry Sorting Core Facility, Oswaldo Cruz Institute, FIOCRUZ, Rio\nde Janeiro, RJ, Brazil\nFull list of author information is available at the end of the article\n\n\u00a9 The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0\nInternational License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and\nreproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to\nthe Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver\n(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.\n\nFerraz et al. Parasites &amp; Vectors  (2017) 10:219 \n\nDOI 10.1186/s13071-017-2152-2\n\nhttp://crossmark.crossref.org/dialog/?doi=10.1186/s13071-017-2152-2&amp;domain=pdf\nmailto:alvaro.bertho@ioc.fiocruz.br\nhttp://creativecommons.org/licenses/by/4.0/\nhttp://creativecommons.org/publicdomain/zero/1.0/\n\n\nBackground\n\nLeishmaniasis is a group of diseases caused by different\n\nspecies of protozoan parasites from the genus Leish-\n\nmania and is a major neglected tropical disease affecting\n\nhumans globally [1]. In Brazil, American tegumentary\n\nleishmaniasis (ATL) is caused mainly by Leishmania\n\n(Viannia) braziliensis and is present in all states, includ-\n\ning Rio de Janeiro, where it is endemic. The disease\n\npresents a broad spectrum of clinical, immunological\n\nand histopathological manifestations, ranging from self-\n\nhealing localised cutaneous leishmaniasis (CL) to destruc-\n\ntive mucosal leishmaniasis (ML). CL is the most frequent\n\nclinical form of ATL and is characterised by the parasitic\n\ninfection of derma, which results in an intense immune-\n\nmediated tissue inflammation and a skin ulcer with elevated\n\nborders that can heal spontaneously or after antimonial\n\ntherapy. Leishmania induces a chronic granulomatous in-\n\nflammatory disease, given it involves the recruitment of\n\nlymphocytes, plasmocytes and macrophages to the skin\n\n[2]. Several authors have demonstrated that the pathogen-\n\nesis of ATL is dependent on the cellular immune response\n\nand it seems to affect the clinical outcome of the disease\n\nby T-lymphocyte effector functions and cytokine profiles\n\n[3\u20135]. Thus, even though the host immune response con-\n\ntributes to protection, it may also be deleterious favouring\n\nthe establishment and persistence of the disease. Studying\n\nthe cellular immune response in ATL lesions allows us to\n\npropose mechanism involved in the formation, persistence\n\nor healing of leishmaniasis lesions.\n\nAlthough CD4\n+\nT cells are clearly an important source\n\nof cytokines to activate leishmanicidal activities, it is\n\nequally evident that several other cell types are essential\n\nfor an efficient immune response in the lesion microenvir-\n\nonment of leishmaniasis. In this context, some reports\n\nhave shown that CD8\n+\nT cells may have an imperative role\n\nin the immune response in this disease, mainly acting as\n\nIFN-? producers, as well as cytotoxic cells. However, their\n\nrole as a beneficial or deleterious subpopulation is contro-\n\nversial, depending on their functional status.\n\nIt is worthy to highlight that the majority of studies\n\nabout the immune response in ATL were performed with\n\nsamples obtained from peripheral blood of patients; how-\n\never, the immunopathogenic events take place in situ,\n\nwhich highlights the importance of studying the lesion\n\nmicroenvironment. Previous observations from our group\n\nhave shown an expansion of CD8\n+\nT lymphocytes in the\n\ninflammatory infiltrate, suggesting that they are recruited\n\nto the site of infection, and therefore committed to the\n\nhealing process of the CL lesion [6\u201312]. In contrast, other\n\nauthors have associated CD8\n+\nT lymphocytes with tissue\n\ninjury in CL and ML [12\u201317]. Observing cell subpopula-\n\ntions in CL lesions, the cell infiltration and pathology\n\nsuggest that tissue damage is a consequence of the\n\nimmune response, mostly related to T-cell-mediated\n\ncytotoxicity, rather than the parasite itself [18]. More-\n\nover, other authors have shown that the production of\n\ngranzyme A is associated with lesion progression, while\n\ngranzyme B is necessary for cytolysis of L. braziliensis-\n\ninfected monocytes, but also induces tissue damage in\n\nCL patients [16, 17].\n\nAside from CD8\n+\nT lymphocytes, other cell populations,\n\nlike NK and NKT cells, are known as cytotoxic cells and\n\nhave a crucial influence on the development of the disease\n\nor cure. Furthermore, other two T-lymphocyte populations,\n\nCD4\nneg\n\nCD8\nneg\n\ndouble-negative (DN) and CD4\n+\nCD8\n\n+\n\ndouble-positive (DP), can also contribute to the cytotoxic\n\nactivity. Hence, the controversy about the cytotoxicity in\n\nthe immunopathogenesis of ATL needs further study.\n\nCytotoxic T lymphocytes and NK cells share the same\n\nroute of cytotoxicity, by exocytosis of lytic granules.\n\nThis activity is performed by perforin and granzyme,\n\nwhich are stored in lipid bilayer vesicles, containing\n\nlysosomal-associated membrane protein (LAMP), includ-\n\ning CD107a (LAMP-1). This vesicle fuses with the plasma\n\nmembrane at the time of exocytosis, thus mobilising\n\nCD107a to the cell surface, indicating a functional\n\ndegranulation and this phenomenon has been exploited in\n\ncytotoxicity studies [19\u201321].\n\nSince lesions of CL patients are the hallmarks of the\n\nclinical course of the disease, it is fundamental to explore\n\nhow the cytotoxic activity might be involved in the lesion\n\nenvironment. Some authors have previously reported a\n\nheterogeneity in the distribution of T-cell subsets in the\n\nlesion milieu [8, 9, 21], while other reports concerning in\n\nsitu immunopathological analysis, have helped understand\n\nthe local immune response, although the histopathological\n\npatterns may differ within the same lesion, depending on\n\nthe site of ulcer or the duration of the disease [22\u201324].\n\nThus, it is imperative to determine which cell subset\n\neffectively prevails in the lesion environment and their\n\ncytotoxic profiles.\n\nThe results shown here were based on the investiga-\n\ntion of the frequency and distribution of T lymphocyte\n\nsubpopulations, NK and NKT cells in lesions of patients\n\nwith their first manifestation of CL. Moreover, cell sub-\n\npopulation cytotoxic activity through CD107a staining\n\nand granzyme B quantification was determined using\n\nflow cytometry. We also investigated correlations be-\n\ntween the immunological findings and clinical features,\n\nto determine protective or inflammatory profiles, estab-\n\nlished at lesion milieu.\n\nMethods\n\nSubjects\n\nEighteen patients were selected according to the inclusion\n\ncriteria of a clinical and epidemiological history compatible\n\nwith CL. All of the 18 patients enrolled in the study\n\nwere diagnosed for leishmaniasis and were known to\n\nFerraz et al. Parasites &amp; Vectors  (2017) 10:219 Page 2 of 12\n\n\n\nhave acquired the disease in L. braziliensis-endemic\n\nareas of Rio de Janeiro, Brazil [2]. All of them were\n\nrecruited at Leishmaniasis Surveillance Laboratory,\n\nEvandro Chagas National Institute of Infectology (INI),\n\nOswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro,\n\nBrazil. The main clinical features of the studied patients\n\nare described in Table 1. The following criteria were\n\nused for diagnosis: (i) positive Montenegro skin test\n\n(MST); (ii) direct detection of parasites by light micros-\n\ncopy observation; (iii) isolation of Leishmania parasites\n\nby culture fragment in Nicolle-Nevy-McNeal (NNN)\n\nmedium; and histopathologic analysis of the inflammatory\n\ninfiltrate. We maintained the fragments of lesion biopsy in\n\nPBS supplemented with antimicrobials (penicillin and\n\nstreptomycin) for a maximum of 4 hours before process-\n\ning. The species of isolated parasites were characterised by\n\nisoenzyme electrophoresis profiles [25]. All patients were\n\nsubmitted to meglumine antimoniate treatment according\n\nto the guidelines of the Brazilian Ministry of Health.\n\nCollection and processing of tissue sample\n\nIncisional skin biopsy was performed for diagnosis pur-\n\nposes and experimental procedures. Cells were obtained\n\nfrom lesions as described elsewhere [7]. Briefly, after local\n\nanaesthesia with lidocaine, the biopsy was performed\n\nusing a 6 mm punch including 1/3 edge of the lesion. The\n\nobtained fragment was immediately stored in RPMI 1640\n\n(Gibco, Carlsbad, CA, USA), supplemented with HEPES\n\n(10 mM), L-glutamine (1.5 mM), 2-mercapto-ethanol\n\n(1 mM), penicillin (200 UI), and streptomycin (200 ?g/ml)\n\nenriched with 20% of fetal calf serum (all reagents from\n\nSigma-Aldrich Co (St Louis, MO, USA) for up to 4 hours\n\nat 4 \u00b0C. We placed the skin specimen onto a cell dissoci-\n\nation sieve (Tissue Grinder kit, Sigma-Aldrich), stripped\n\noff the subcutaneous fat, and macerated it on a 64 ?m-\n\nstainless steel mesh in Petri dish, containing supplemented\n\nRPMI 1640 medium. After that, we transferred the cell\n\nsuspension with macerated tissue to a 15 ml Falcon tube\n\nand let it rest for five minutes to decant large epithelial\n\ncells, dermal cells and fat tissue. Afterwards, we collected\n\nthe cell-containing supernatant, centrifuged to pellet cells\n\nand separate the supernatant for cytometric bead array\n\n(CBA). To obtain a more pure-cell sample, we resus-\n\npended the cell pellet and filtered the cell suspension into\n\nFalcon\u00ae 12 \u00d7 75 mm tube with cell strainer cap with\n\n35 ?m nylon mesh (BD Biosciences, San Jose, USA). Add-\n\nitionally, we resuspended the cells in PBS supplemented\n\nwith 0.1% sodium azide and 2% fetal calf serum (PBSaz,\n\nSigma-Aldrich) and adjusted to 1 \u00d7 10\n6\ncells per 50 ?l, for\n\n6-color flow cytometry staining, described below.\n\nFlow cytometry\n\nFlow cytometry staining protocol was performed as previ-\n\nously described [11]. Briefly, after collection and process-\n\ning of tissue specimen, cells were stained for surface\n\nmarkers with a panel of monoclonal antibodies (MAbs),\n\nas follow: anti-CD3; anti-CD56; anti-CD8 (Beckman\n\nCoulter, Kendon, FL, USA); anti-CD4 and anti-CD107a\n\n(BD, Bioscience, San Jose, CA, USA). The cells were also\n\nstained with 7-aminoactinomycin D (7-AAD; Beckman\n\nCoulter) for cell viability determination. After 20 min on\n\nice and protected from light, we washed cells once and\n\nincubated with BD FACS lysing solution (BD Biosciences)\n\nto lyse erythrocytes.\n\nIn each sample, 500,000 events were acquired using\n\nMoFlo Astrios Cell Sorter Flow Cytometer (Beckman\n\nCoulter) in a low-flow rate (max 800 eps) to avoid\n\nclogging. Single stained controls were used to set\n\ncompensation parameters, as well as fluorescence-\n\nminus-one (FMO) and isotype controls were used to\n\nset analysis gates.\n\nAfter the acquisition, this staining panel and gate strat-\n\negies allowed us to evaluate the distributions of DN; DP T\n\nlymphocytes; NK cells; NKT cells; and cytotoxic-related\n\nCD107a expression, through a 7-parameter flow cytome-\n\ntry protocol using Kaluza analysis 1.5A software (Beckman\n\nCoulter) (Fig. 1a-f). The limits for the regions in dot plots\n\nand histograms were set based on non-staining cells,\n\nisotype controls and FMO control for CD107a.\n\nCytometric Bead Array (CBA)\n\nThe cytokines measured were TNF, IL-8, IL-10 and\n\nIFN?. The Cytometric Bead Array (CBA) Human Flex\n\nSet system (BD Biosciences) provides a method of\n\ncapturing a soluble analyte or set of analytes with beads\n\nof a known size and fluorescence, enabling the detection\n\nof analytes using flow cytometry. The detection reagent\n\nsupplied in the kit is a mixture of phycoerythrin (PE)-\n\nconjugated antibodies, which emits a fluorescent signal\n\nproportionally to the amount of bound analyte. When\n\nthe capture beads and detectors reagents are incubated\n\nwith an unknown sample containing identified analytes,\n\nsandwich complexes are formed. Granzyme B, IFN-?\n\nand TNF-? levels were quantified in culture media from\n\nmacerated lesions from ten patients. Thirty microliters\n\nof all samples were prepared following CBA multiplex\n\nTable 1 Demographic and clinical information of patients\nincluded in the study\n\nNumber of volunteers 18\n\nSex: Male/Female 17/1\n\nAge (years)a 39.5 \u00b1 6.0\n\nNumber of lesionsa 1.0 \u00b1 0.4\n\nDiameter of lesions (mm)a 41.3 \u00b1 5.0\n\nMontenegro Skin Test (MST) (mm)a 19 \u00b1 2.8\n\nDuration of disease (months)a 57.9 \u00b1 15.0\na\nMean \u00b1 Standard deviation\n\nFerraz et al. Parasites &amp; Vectors  (2017) 10:219 Page 3 of 12\n\n\n\nFig. 1 Frequencies of NK and NKT cells; CD4+, CD8+, double positive (DP) and double negative (DN) CD3+ T-lymphocyte subpopulations. a-f Flow\ncytometry-representative protocol: Cells obtained from cutaneous leishmaniasis lesions were stained with anti-CD3, anti-CD4, anti-CD8, anti-CD56,\nanti-CD107a and 7-AAD. Lymphocytes region was created on forward (FSC) vs side (SSC) scatter dot-plot (a). Cells gated on [Lymphs.1] were\nanalyzed through dot-plots SSC-Height vs SSC-Area (b) and SSC-Height vs SSC-Width (c) to exclude doublets and debris. d Dead cells (7-AAD+)\nwere excluded from the analysis and a gate encompassing 7-AADneg cells was performed. e Based on this gate, NK cells (CD56+CD3neg), NKT\n(CD56+CD3+) and T lymphocytes (CD56negCD3+) were identified. f Based on T lymphocyte gate (T Lymph), CD4, CD8, double-negative (DN) and\ndouble-positive (DP) T lymphocytes were determined. g Bar graphs representing the mean \u00b1 SEM of percentages of NKT and NK cells; CD4+, DP,\nCD8+ and DN T lymphocytes obtained from cutaneous leishmaniasis lesions of 18 patients. Statistical analyses were performed using ANOVA test\nand Dunn\u2019s post-hoc test. Results were considered significant with P &lt;0.05 (*P &lt;0.05; **P &lt;0.01; ***P &lt;0.001)\n\nFerraz et al. Parasites &amp; Vectors  (2017) 10:219 Page 4 of 12\n\n\n\nkit manual, and the cytokines were detected within a\n\nrange of 10\u20132,500 pg/ml. The assays were performed\n\naccording to the manufacturer\u2019s instructions, and sam-\n\nples were acquired in an FACSCallibur flow cytometer\n\n(BD Biosciences). The data were analysed with FCAP\n\nArray Software version 1-01 (Soft Flow, Inc., St. Louis\n\nPark, MN, USA).\n\nStatistical analysis\n\nFor statistical analyses between two groups at a time, we\n\napplied Mann-Whitney U test. For statistical analyses\n\namong more than two groups, we used one-way ANOVA\n\ntest and Dunn\u2019s posttest. We also used a Spearman\u2019s rank\n\ncorrelation test. Correlations and intergroup differences\n\nwere statistically significant when P &lt;0.05. We used\n\nGraphPad Prism 5.0 software (GraphPad Software Inc., La\n\nJolla, CA, USA) for all statistical calculations and graphical\n\nrepresentations.\n\nResults\n\nFrequencies of cell subsets in lesions of cutaneous\n\nleishmaniasis patients\n\nWe focused on determining the cytotoxic profile of\n\ncellular populations obtained directly from active cuta-\n\nneous leishmaniasis lesions. A flow cytometry approach\n\nallowed us to evaluate the frequency of six populations:\n\nCD8\n+\nand CD4\n\n+\nT lymphocytes; CD4\n\nneg\nCD8\n\nneg\ndouble-\n\nnegative T lymphocytes (DN); CD4\n+\nCD8\n\n+\ndouble-positive\n\n(DP) T lymphocytes; NK cells; and NKT cells (Fig. 1), as\n\nwell as cells expressing cytotoxic-related CD107a bio-\n\nmarker. Our gating strategy was performed as follow: a\n\nForward Scatter (FSC) vs Side Scatter (SSC) region was\n\ncreated using a density plot (Fig. 1a) to encompass the\n\nlymphocyte population. We also created height, area and\n\nwidth side-scatter dot plots, to remove doublets and\n\ndebris from analysis (Fig. 1b, c). In addition, we included\n\nonly live cells in analysis considering the gate comprising\n\n7-AAD\nneg\n\n(Fig. 1d) cells. Then, we defined the frequencies\n\nof T lymphocytes, NKT and NK cells based on CD56 vs\n\nCD3 dot plot (Fig. 1e). CD4\n+\n, CD8\n\n+\n, DN and DP cells\n\nwere determined using a CD3\n+\nT cell gate (Fig. 1f).\n\nRegarding T lymphocyte populations, we observed\n\nthat DN T lymphocytes showed the highest frequency\n\n(31.4 \u00b1 4.6%), followed by CD4\n+\n(21.4 \u00b1 2.8%), CD8\n\n+\nT\n\nlymphocytes (14 \u00b1 3.3%) and DP T cells (7.0 \u00b1 2.5%). NKT\n\ncells represented 11.5 \u00b1 3.4% of total cell population and\n\nNK cells 9.4 \u00b1 2.3%. The frequency of DN T cells was\n\nsignificantly higher than NK (U = 25.00, P &lt;0.0001), NKT\n\n(U = 42.00, P = 0.0003) and DP T cells (U = 50.00, P =\n\n0.0007), while the frequency of CD4\n+\nT lymphocytes was\n\nhigher than NK (U = 45.00, P = 0.0004) and DP T cells\n\n(U = 66.00, P = 0.0043) (Fig. 1g).\n\nFrequencies of cell subsets expressing CD107a from\n\nlesions of cutaneous leishmaniasis patients\n\nTo assess the profile of CD107a\n+\n-degranulating-cell pop-\n\nulations from the lesion site, we first evaluated their\n\nfrequency within each cell-population studied. For this,\n\nwe performed flow cytometric protocol to determine the\n\nfrequencies of CD107a\n+\ncells from gated total DN; NKT;\n\nCD4\n+\n; NK; DP; CD8\n\n+\ncells (Fig. 2a-f, respectively).\n\nFigure 2i shows that CD107a\n+\nNKT cells (mean \u00b1 standard\n\nerror: 27.9 \u00b1 5.3%) displayed the highest frequency of\n\npositive cytotoxic cells within the pool of their population.\n\nIn turn, CD107a\n+\nDN T (15.4 \u00b1 2.8%) and CD107a\n\n+\nCD4\n\n+\n\nT lymphocytes (13.5 \u00b1 2.8%) showed similar frequencies to\n\neach other, but lower than that seen by CD107a\n+\nNKT cells\n\n(U = 114.0, P = 0.1329; U = 100.0, P = 0.05, respectively).\n\nCD107a\n+\nNK (5.2 \u00b1 2.2%) showed lower frequencies in re-\n\nlation to NKT, CD4 and DN T cells (U = 40.0, P = 0.0001;\n\nU = 751.00, P = 0.0060; U = 61.00, P = 0.0014, respectively),\n\nas well as CD107a\n+\nDP T cells (3.04 \u00b1 0.8%) (U = 17.50 P&lt;\n\n0.0001; U = 49.00, P = 0.0006; U = 42.5, P = 0.0003, re-\n\nspectively). Interestingly, CD107a\n+\nCD8\n\n+\nT lymphocytes\n\nwere found at the lowest frequency (1.8 \u00b1 0.7%) and\n\nshowed lower statistic difference when compared to NKT,\n\nDN and CD4\n+\nT lymphocytes (U = 16.00, P &lt;0.0001; U =\n\n27.00, P &lt;0.0001; U = 38.00, P &lt;0.0001, respectively)\n\n(Fig. 2i). It is important to note that based on this analysis\n\nwe are not evaluating the total number of cytotoxic\n\ncells in lesion environment, but the percentages of\n\nCD107a\n+\n-degranulating cells considering the pool of\n\neach cell population as 100%.\n\nContribution of cell subsets from the overall pool of\n\nCD107a\n+\ncells\n\nTo determine the contribution of specific cell popula-\n\ntions to the overall pool of CD107a\n+\n-degranulating\n\ncells in lesion environment, we also performed\n\nanother flow cytometry approach, gating all CD107a\n+\n\ncells (Fig. 3a), and then determine the percentages of\n\neach cell population studied from 100%-gated CD107a\n+\n\ncells (Fig. 3b c). Thus, we observed that DN T cells were\n\nthe major contributing cell population to the\n\nCD107a\n+\n-cell pool (40 \u00b1 4%). NKT cells represented\n\nthe second most prevalent population (25.0 \u00b1 4.1%),\n\nfollowed by CD4\n+\nT lymphocytes (14 \u00b1 3.1%) and NK\n\ncells (8 \u00b1 4%). DP and CD8\n+\nT lymphocytes showed\n\nthe lowest percentages inside the CD107a\n+\n-cell pool\n\n(4.0 \u00b1 1.6 and 4.0 \u00b1 2.3%, respectively) (Fig. 3d). In\n\nthis context, comparing the distributions among the\n\nsix different cell populations, based on the pool of\n\nCD107a\n+\n-degranulating cells, we observed that DN T\n\ncells were the major contributors to cytotoxic/de-\n\ngranulating cells at the lesion site, while the DP and\n\nCD8\n+\nT lymphocytes were the lowest contributors.\n\nFerraz et al. Parasites &amp; Vectors  (2017) 10:219 Page 5 of 12\n\n\n\nFig. 2 Frequencies of CD8+; CD4+; DP; DN lymphocytes; NK and NKT cells expressing CD107a from lesions of cutaneous leishmaniasis patients.\nFlow cytometry-representative analysis: a CD107a+DN T; b CD107a+NKT; c CD107a+CD4+ T; d CD107a+NK; e CD107a+DP T; f CD107a+CD8+ T cells.\nIsotype control (g) and fluorescence minus one (FMO) for CD107a staining (h). Electronic gates were created surrounding NKT, NK, CD4, DP, CD8\nand DN cell populations (see Fig. 1). i The bars graph representing the mean \u00b1 SEM of percentages of NKT and NK cells; CD4+, DP, CD8+ and DN\nT lymphocytes expressing CD107a obtained from cutaneous leishmaniasis lesions of 18 patients. Statistical analyses between two groups were\nperformed using Mann Whitney non-parametric t-test. Results were considered significant with P &lt;0.05 (*P &lt;0.05; **P &lt;0.01; ***P &lt;0.001)\n\nFerraz et al. Parasites &amp; Vectors  (2017) 10:219 Page 6 of 12\n\n\n\nCorrelation analysis of frequencies of CD107a\n+\ncells with\n\nproduction of granzyme B, IFN-?, TNF and clinical features\n\nTo ascertain if there was a relationship between cytotox-\n\nicity/degranulation and clinical features, correlation ana-\n\nlyses were carried out with the total frequency of cells\n\nexpressing CD107a, granzyme B production and lesion\n\nsize. Furthermore, we evaluated a possible interconnec-\n\ntion between pro-inflammatory cytokines (IFN-? and\n\nTNF-? - evaluated in culture media after the macerated-\n\nlesion process) with lesion size. We observed a positive\n\ncorrelation between the frequency of cytotoxic-CD107a\n+\n\ncells and the production of granzyme B at the lesion site\n\n(r = 0.79; P = 0.01) (Fig. 4a). We also demonstrated that\n\nlesion size was positively correlated with; granzyme B\n\nproduction (r = 0.80; P = 0.005) (Fig. 4b); the frequency of\n\nCD107a\n+\ncells (r = 0.67; P = 0.02) (Fig. 4c); IFN-? levels\n\n(r = 0.86; P = 0.001) and TNF-? levels (r = 0.83; P = 0.003)\n\n(Fig. 4d, e, respectively). The other T cell subpopulations\n\ndid not show any correlation with lesion size.\n\nDiscussion\n\nLymphocytes are predominant mononuclear cell popu-\n\nlations in leishmaniasis lesions and have been a focus of\n\nstudies regarding the immunopathogenesis of CL. The\n\nliterature-described role of CD8\n+\nT lymphocytes in pro-\n\ntective and pathological responses is still controversial.\n\nPrevious observations from our group have shown an\n\nincrease in the number of CD8\n+\nT lymphocytes in the\n\nFig. 3 Distribution of CD8+; CD4+; DP; DN lymphocytes; NK and NKT cells evaluated from the pool of CD107a+ cells. Flow cytometry-representative\nanalysis to determine the distribution of cell populations in pool of CD107a+ cells. a FSC vs CD107a density-plot represents total percent-\nage of CD107a+ cells based on [Live cells] gate (Fig. 1d). b CD3 vs CD56 density-plot gated on CD107a+ cells to define NK, NKT and T\ncells. c CD4 vs CD8 gated on CD3+ lymphocytes to define CD4, CD8, DP and DN T cells. d Overlay of CD8+; CD4+; DP; DN lymphocytes;\nNK and NKT cell histograms gated on CD107a+ cells. e Pie graph showing the mean data of NK and NKT cells; CD4+; DP, CD8+ and DN\nT lymphocytes (n = 18 CL lesions)\n\nFerraz et al. Parasites &amp; Vectors  (2017) 10:219 Page 7 of 12\n\n\n\ninflammatory infiltrate, suggesting cell recruitment to\n\nthe CL lesion environment and a commitment to this\n\ncell population to lesion resolution [6\u201312]. In contrast,\n\nother authors have associated CD8\n+\n\nT lymphocytes\n\nwith tissue damage in CL and ML [12\u201317]. In murine\n\nmodels, CD8\n+\nT cells are important for pathogen con-\n\ntrol but also are implicated in dermal pathology [25].\n\nApart from CD8\n+\nT lymphocytes, other cell popula-\n\ntions, such as NK and NKT cells, DN, DP and CD4\n+\nT\n\nlymphocytes exhibit cytotoxic functions and could\n\ninfluence disease progression or healing.\n\nPrevious in situ immunopathological studies using con-\n\nfocal or fluorescent microscopy techniques in leishmania-\n\nsis have improved our expertise with the description of\n\nthe cellular composition of the skin inflammatory infiltrate\n\n[18, 23, 24, 26, 27]. Flow cytometry (FCM) has been exten-\n\nsively applied as a key method to address these issues, and\n\nthe majority of the reports are based on peripheral-blood-\n\nsample analysis [6, 11, 28\u201330]. However, it is known that\n\nlymphocytes are recruited from blood to lymph nodes,\n\nprimed with antigens and then migrate to lesion sites; con-\n\nsequently, frequencies of antigen-specific T cells are higher\n\nin leishmaniasis lesions than in blood [7, 17, 31, 32]. For\n\nthat reason, we assessed, using FCM, the cellular immune\n\nresponse in the CL-lesion environment, focusing on six\n\ndistinct cytotoxic cell populations. Since tissue samples\n\nfrom CL lesions have a limited cellularity of lymphocytes\n\ncompared to blood samples, interfering in the multigate-\n\nstrategy FCM analysis, we standardised an enhanced\n\nprotocol to obtain high-concentration-lymphocyte sam-\n\nples. Regarding another critical issue found in the lit-\n\nerature, in which FCM protocols determine CD8\n+\nT\n\nlymphocytes based only on CD8 expression, without\n\nNK and NKT exclusion, we added CD3 and CD56 to\n\nthe analysis, allowing for exclusion of NK and NKT\n\ncells when analysing CD8\n+\nor CD4\n\n+\nT cells. Our data\n\nshowed that the frequencies of CD4\n+\n\nand CD8\n+\n\nT\n\nlymphocytes are similar in the lesion-inflammatory in-\n\nfiltrate, though this similarity depends on the clinical\n\nprofiles of the patients. Even with this resemblance, we\n\nobserved that CD4\n+\nand CD8\n\n+\nT lymphocytes displayed\n\ndifferent frequencies of CD107a\n+\n\ncells, indicative of\n\ncytotoxic activity.\n\nTo investigate the participation of cytotoxic cell popula-\n\ntions at the lesion site, we used two different FCM analysis\n\napproaches within the same sample. In one, we analysed\n\nthe frequencies of each cell population expressing CD107a\n\n(degranulating cells indicative of cytotoxic activity). In the\n\nother, we evaluated the distribution of each cell population\n\nbased on all (100%) CD107a\n+\n\ncells. Interpreting data\n\nFig. 4 Correlation analysis of granzyme B, IFN-? and TNF-? production, frequency of CD107+ cells and lesion size from lesions of CL patients (n = 10).\nGranzyme B, IFN-? and TNF-? levels were quantified in culture media from macerated lesions biopsied from ten patients. All samples were prepared\nfollowing CBA multiplex kit manual and the cytokines were detected within a range of 10\u20132500 pg/ml. We observed positive correlations between\nfrequency of CD107a+ cells and granzyme B production (a); lesion size and granzyme B production (b); lesion size and frequency of CD107a+ cells in\nCL lesions (c); lesion size and IFN-? production (d); and lesion size and TNF-? production (e). The central line represents median values and the graph\nshow best fitted lines with 95% confidence interval. Statistical analyses were performed using Spearman\u2019s test (r: correlation coefficient). Results were\nconsidered significant with P &lt;0.05. Each point represents one CL patient\n\nFerraz et al. Parasites &amp; Vectors  (2017) 10:219 Page 8 of 12\n\n\n\nobtained from these two analyses led us to suggest that\n\nthe NKT-cell pool had the largest portion of their cells\n\ndedicated to cytotoxicity, while DN T lymphocytes repre-\n\nsent the most prevalent cell population looking to all\n\nCD107a\n+\n, degranulating cells. DP T cells with regulatory\n\nfunctions were observed in normal tissue and multiple\n\nsclerosis skin lesion [33, 34]. However, the recruitment of\n\nthese cells to the skin is not fully elucidated, and in the\n\nperiphery, these cells seem to exist as a mature popula-\n\ntion. It has been suggested that these cells originate from\n\na CD8\n+\nT cell precursor and then further express CD4\n\n[35, 36]. Herein we noticed that this cell population is\n\nsparse in the CL lesion and their presence suggests their\n\nparticipation in the local immune response, and thus their\n\nrecruitment to an inflammatory microenvironment.\n\nFurthermore, we showed that these cells are present in CL\n\nlesion with few participating as cytotoxic cells.\n\nWe also observed an overall low frequency of NK cells\n\nas compared to frequencies of CD4\n+\nand DN T lympho-\n\ncytes. This feature was already demonstrated in ML le-\n\nsions were higher frequencies of NK cells in relapse\n\ncases in comparison to cured ones, suggested that high\n\nfrequencies of NK cells could be a suitable protection/\n\npreventive prognostic marker [37]. Some studies have\n\ninvestigated the behaviour of NK and CD8\n+\nT lympho-\n\ncytes in CL, assuming that these cells are the main cyto-\n\ntoxic populations. The role of NK cells in CL has been\n\nassociated with both pathology and protection. Some\n\nauthors propose a protective function through lysis of\n\nextracellular promastigotes and infected macrophages\n\n[37, 38]. Nevertheless, there is evidence that cytotoxic\n\nNK cells contribute to exacerbation of tissue damage\n\n[39]. According to our investigations, only 5% of NK\n\ncells express CD107a, demonstrating a weak commit-\n\nment of NK cell population to cytotoxicity and we\n\nobserved a low frequency of cytotoxic NK cell in lesions\n\n(8% of all CD107a\n+\n-cytotoxic cells). These findings\n\nsuggested that these cells have little influence on the\n\ncytotoxicity that occurs in the lesion environment, based\n\non the distribution of total cytotoxic cells.\n\nRegarding NKT cells, some reports showed that at\n\nleast in CL murine models, these cells seem to block\n\nparasite expansion and also drive the immune response\n\nbased on the cytokines produced [40, 41]. In humans,\n\nNKT cells play a role in several situations, for instance:\n\nshowing either protective or pathogenic role against\n\nmalaria; preventing autoimmunity; protecting against\n\nneoplasia, and having a direct pathogenic role against\n\nmany opportunistic infections common in end-stage\n\nAIDS [42, 43]. In visceral leishmaniasis, NKT cells\n\nseem to have a dual behaviour, depending on their sub-\n\nset: CD4\n+\nNKT cells show a pathogenic activity and\n\ntend to accumulate at the infection site, while CD8\n+\nNKT cells may be protective when in contact with the\n\ntarget cells [44]. Our group has recently portrayed\n\nstrong evidence about the involvement of CD8\n+\nT and\n\nCD4\n+\nT lymphocytes, NK and NKT cells (and their sub-\n\nsets) in the cytotoxic response analysing peripheral blood\n\nfrom CL patients before, during and after antimonial ther-\n\napy. We reported an involvement of different NKT subsets\n\nin CL immunopathogenesis, showing CD8\n+\nNKT cells as\n\nthe main subset involved in cytotoxicity and suggesting a\n\nprotective role of DP NKT subset in CL [45]. There is no\n\npublished report concerning the distribution of NKT cells\n\nin CL lesions. Results observed in our current study\n\nrevealed that NKT cells were distributed as the fourth cell\n\npopulation found in CL lesions and they are the most\n\ncommitted to cytotoxicity, representing the second most\n\ncytotoxic-cell population in the CL lesion environment,\n\npointing to them as an important component of the\n\nlocalised immune response.\n\nAnother important cell population observed in CL\n\nlesions is the CD4\nneg\n\nCD8\nneg\n\n(double-negative - DN) T\n\nlymphocytes. DN T cells represent a minority subpopu-\n\nlation of mature post-thymic T lymphocytes that express\n\nCD3/TCR?/? or ?/? receptor but lack CD4/CD8. These\n\ncells could play an inflammatory and regulatory role in\n\nimmune response [46]. Other authors found that DN ?/\n\n? T lymphocytes could be simultaneously both helper\n\nand cytotoxic activities [46\u201348]. Despite DN T cells\n\nrepresenting a minority subpopulation in peripheral\n\nblood, this T cells subpopulation was also identified in\n\nthe skin. Groh and cols. showed that CD3/TCR ?/?\n\ncomplexes were functionally competent as evidenced by\n\ntheir capacity to transduce activation signals resulting in\n\ncell proliferation, cytokine secretion, and cytotoxic activ-\n\nity [49]. Here, we observed that, in addition to represent-\n\ning the greatest frequency of cells in the lesion (data not\n\nshown), DN T cells showed an important expression of\n\nthe cytotoxic-related-CD107a\n+\nphenotype.\n\nIn an experimental model, DN T cells seem to be key\n\nplayers in protective primary and secondary anti-L.\n\nmajor immunity [50]. In humans, some authors de-\n\nscribed the immunoregulatory potential of DN T cells\n\nin CL and reinforced their role in both protection and\n\npathology. These cells exhibit a highly activated profile\n\nin active CL, being the second most prevalent pro-\n\nducers of inflammatory cytokines, such as IFN-? and\n\nTNF-? [46]. Furthermore, DN T cells could be subdi-\n\nvided into T cells expressing ?/?TCR, which may be\n\ninvolved in an inflammatory response and T cells ex-\n\npressing ??TCR, which produces a biased regulatory\n\nenvironment [4, 46, 51]. We should consider that ?/? DN\n\nT cells are associated with negative regulatory nature as\n\nwell as with several autoimmune disorders. These DN\n\nsubpopulations are restricted to CD1 presenting antigens,\n\ndespite some cells express a restricted TCR and often rec-\n\nognise lipid antigens [46]. Given DN T cells are the\n\nFerraz et al. Parasites &amp; Vectors  (2017) 10:219 Page 9 of 12\n\n\n\npredominant cytotoxic cells observed in CL lesions, we\n\nmay hypothesise that, if the cytotoxicity mediated mecha-\n\nnisms lead to tissue injury, this might be due to a nonspe-\n\ncific lysis orchestrated by DN T cells.\n\nEven with the high amount of DN cytotoxic cells in the\n\nlesion site, a great number of them are non-cytotoxic DN\n\ncells. For this reason, it is possible that DN T cells play a\n\ndual role, one as cytokine producers - inflammatory or\n\nregulatory - and another as a cytotoxic population. Our\n\nanalyses showed that cytotoxic DN cells account for over\n\n40% of all cytotoxic cells, ten times greater than CD8\n+\nT\n\nlymphocytes. Thus, we show, for the first time, that DN T\n\nlymphocytes are present in CL lesion as the most frequent\n\nlymphocyte population and the largest subset of cytotoxic\n\ncells, emphasising a participation in the CL lesion milieu,\n\nlikely related to a cytotoxic activity.\n\nInterestingly, CD8\n+\nT lymphocytes exhibited the low-\n\nest frequency of cytotoxic cells in CL lesions and did not\n\nseem to have a major participation in local cytotoxicity.\n\nFaria et al. [27] suggested that the frequency of CD8\n+\nT\n\nlymphocytes expressing granzyme B was directly associ-\n\nated with the intensity of the inflammatory reaction of\n\nulcerated lesions of CL. Other authors [13] described a\n\nlymphocyte recruitment and persistence of memory\n\nCD8\n+\nT cells to the injury caused by L. braziliensis. It is\n\nimportant to remark that using flow cytometry; some\n\nauthors did not evaluate CD8\n+\nT lymphocytes gated on\n\nCD3\n+\nand CD56\n\nneg\npopulations, which could allow the\n\ninclusion of other lymphocyte populations in the ana-\n\nlysis, such as NK, NKT and gamma/delta + CD8+ T cells.\n\nBesides, NK cell expression of CD8 is significantly lower\n\nthan CD8 expression by T cells and should be concerned\n\nby authors to gate on CD8 T cells (high-CD8 gating strat-\n\negy). These procedures could avoid a misinterpretation of\n\nthe flow cytometric data regarding the frequency of CD8\n+\n\nT lymphocyte in CL lesions.\n\nThe role of CD4\n+\nT lymphocytes in CL is well estab-\n\nlished as driving the immune response based on anti-\n\ngen presentation and cytokine profiles; nevertheless,\n\nfew authors have concentrated efforts on studying cyto-\n\ntoxic functions of this lymphocyte subset. Recently, our\n\ngroup observed in peripheral blood, that the cytotoxic\n\nCD107a\n+\nCD4\n\n+\nT cell might be involved in the healing\n\nprocess of CL patients [45]. Corroborating these find-\n\nings, we observed in the current study a significantly\n\nhigh frequency of CD107a\n+\nCD4\n\n+\nT-cell lymphocytes in\n\nthe CL lesion milieu, surprisingly higher than classical-\n\ncytotoxic NK and CD8\n+\nT cells. Others suggested CD4\n\n+\n\nT cell-mediated cytotoxicity as a mechanism that assists\n\nviral control [52] and induction by Trypanosoma cruzi\n\ninfection [53]. Thus, we may hypothesise that cytotoxic\n\nCD4\n+\nT cells could take part in the immune response\n\nand contribute to parasite control in CL lesion through\n\ncytotoxic-related mechanisms.\n\nIt is important to note that a positive correlation among\n\nfrequencies of CD107a\n+\ncells, granzyme B production and\n\nlesion size provides evidence that cytotoxicity could be as-\n\nsociated with tissue damage. In addition to cytotoxicity,\n\ntissue damage seems to be related to other pro-\n\ninflammatory factors, given larger lesion sizes are\n\nstrictly associated with higher IFN-? and TNF-?. Simi-\n\nlar observations were seen by others, in which larger\n\nlesions were also correlated with a higher frequency of\n\nLeishmania-antigen-specific-inflammatory-cytokine\n\n(IFN-? or TNF-?)-producing lymphocytes [54]\n\nIn summary, although several reports emphasise the key\n\nrole of cytotoxic CD8\n+\nT lymphocytes in CL tissue dam-\n\nage, we are unable to reinforce this hypothesis. This is\n\nreflected by the finding that CD8\n+\nT cells represent the\n\npopulation with the least commitment to cytotoxicity (the\n\nlowest percentages of cytotoxic-related CD107a\n+\ncells) in\n\nthe lesions. Furthermore, CD107a\n+\ncell pool. Nevertheless,\n\nbased on our results, we are not able to affirm that CD8\n+\n\nT lymphocytes do not have an immunomodulatory role,\n\nbut we propose that cytotoxicity-mediated tissue damage\n\nobserved in CL lesions seems to be more influenced by\n\nCD4\n+\n\nT lymphocytes, NKT cells and mostly DN T\n\nlymphocytes.\n\nConclusions\n\nWe focused our investigation on cytotoxicity-mediated\n\nmechanisms, which would occur in cutaneous lesions of\n\nCL patients and we showed, for the first time, the distribu-\n\ntion and commitment of six distinct cytotoxic populations\n\nat the lesion site. From our findings, we suggest that cyto-\n\ntoxicity could have an important participation in the tissue\n\ndamage observed in the lesion. However, we did not find\n\nevidence that CD8\n+\n\nT cells are the main population\n\nresponsible for this damage. Moreover, we may postulate\n\nthat the major sources of cytotoxic activity are DN T\n\nlymphocytes, NKT cells and CD4\n+\nT lymphocytes, which\n\ncomprise 80% of all cytotoxic cells, although cytotoxic\n\nNK, DP and CD8\n+\nT cell are detected in these lesions.\n\nThese findings encourage us to look at cytotoxicity as a\n\nphenomenon that should be better explored, not only by\n\nclassical-cytotoxic NK and CD8\n+\nT cells but also by cyto-\n\ntoxic DN and NKT cells. Due to controversial statements\n\nregarding the actual role of these cell populations in the\n\ncytotoxicity and the complexity of the interaction between\n\nthe human host and Leishmania, the study of the immu-\n\nnopathological mechanisms in humans naturally infected\n\nby Leishmania is of utmost importance, if we hope to\n\ndevelop effective vaccines and alternative immunothera-\n\npeutic treatments in the near future.\n\nAbbreviations\n\nATL: American tegumentary leishmaniasis; CBA: Cytometric bead array;\nCL: Cutaneous leishmaniasis; DN: Double negative; DP: Double positive;\nFCM: Flow cytometry; LAMP: Lysosomal-associated membrane protein\n\nFerraz et al. Parasites &amp; Vectors  (2017) 10:219 Page 10 of 12\n\n\n\nAcknowledgements\n\nThe authors would like to thank the Flow Cytometry Sorting Core, Oswaldo\nCruz Institute, FIOCRUZ for availability to flow cytometry acquisitions (MoFlo\nASTRIOS Cell Sorter, Beckman Coulter, FL, USA) and Dr. Kenneth Gollob for\nvaluable contribution in reviewing this manuscript. This research was supported\nin part by an internal funding from IOC-FIOCRUZ and PROEP-CNPq-IOC\n(402557/2011-5); FAPERJ APQ1 E-26/110332/2014; FIOTEC IOC-008-FIO-15-47.\n\nFunding\n\nNot applicable.\n\nAvailability of data and materials\n\nSince our research is under Brazilian government policy we did not share data.\n\nAuthors\u2019 contributions\n\nALB and RF conceived and designed the study and performed statistical\nanalysis. RF performed the experiments. RF and ALB performed all flow\ncytometry acquisition and analysis. RF and ALB analyzed and compiled\nthe data. AOS, MRL, MIFP took patient care and performed lesion\nbiopsies. AMDC contributed reagents and drafted the manuscript. TPDS\ncontributed in CBA experiments. RF and ALB wrote the final version of\nmanuscript. All authors read and approved the final manuscript.\n\nCompeting interests\n\nThe authors declare that they have no competing interest.\n\nConsent for publication\n\nNot applicable.\n\nEthics approval and consent to participate\n\nThis study was approved by the National Ethical Clearance Committee of\nBrazil (CONEP) as well as by the Evandro Chagas Clinical Research Institute\n(CEP-INI/FIOCRUZ 029/2012), Brazil. They are in accordance to the Declaration\nof Helsinki on human subject research. Before blood collection and lesion\nbiopsies, all volunteers read and signed the informed consent.\n\nPublisher\u2019s Note\nSpringer Nature remains neutral with regard to jurisdictional claims in\npublished maps and institutional affiliations.\n\nAuthor details\n1Laboratory of Immunoparasitology, Oswaldo Cruz Institute, FIOCRUZ, Rio de\nJaneiro, RJ, Brazil. 2Flow Cytometry Sorting Core Facility, Oswaldo Cruz\nInstitute, FIOCRUZ, Rio de Janeiro, RJ, Brazil. 3Laboratory of Surveillance for\nLeishmaniasis, Evandro Chagas National Institute of Infectology, FIOCRUZ, Rio\nde Janeiro, RJ, Brazil. 4Laboratory of AIDS and Molecular Immunology,\nOswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, RJ, Brazil. 5Laboratory of\nInterdisciplinary Medical Research, Oswaldo Cruz Institute, FIOCRUZ, Rio de\nJaneiro, RJ, Brazil.\n\nReceived: 24 December 2016 Accepted: 21 April 2017\n\nReferences\n\n1. WHO | Leishmaniasis. WHO. [cited 2015 Mar 25]. Available from: http://www.\nwho.int/mediacentre/factsheets/fs375/en/\n\n2. De Oliveira-Neto MP, Mattos MS, Perez MA, Da-Cruz AM, Fernandes O,\nMoreira J, et al. American tegumentary leishmaniasis (ATL) in Rio de Janeiro\nState, Brazil: main clinical and epidemiologic characteristics. Int J Dermatol.\n2000;39:506\u201314.\n\n3. Brelaz-de-Castro MCA, de Almeida AF, de Oliveira AP, de Assis-Souza M, da\nRocha LF, Pereira VRA. Cellular immune response evaluation of cutaneous\nleishmaniasis patient cells stimulated with Leishmania (Viannia) braziliensis\nantigenic fractions before and after clinical cure. Cell Immunol. 2012;279:180\u20136.\n\n4. Bottrel RL, Dutra WO, Martins FA, Gontijo B, Carvalho E, Barral-Netto M, et al.\nFlow cytometric determination of cellular sources and frequencies of key\ncytokine-producing lymphocytes directed against recombinant LACK and\nsoluble Leishmania antigen in human cutaneous leishmaniasis. Infect\nImmun. 2001;69:3232\u20139.\n\n5. Bacellar O, Lessa H, Schriefer A, Machado P. Ribeiro de Jesus A, Dutra WO,\net al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients.\nInfect Immun. 2002;70:6734\u201340.\n\n6. Coutinho SG, Da-Cruz AM, Bertho AL, Santiago MA, De-Luca P.\nImmunologic patterns associated with cure in human American cutaneous\nleishmaniasis. Braz J Med Biol Res. 1998;31:139\u201342.\n\n7. Bertho AL, Santiago MA, Da-Cruz AM, Coutinho SG. Detection of early\napoptosis and cell death in T CD4+ and CD8+ cells from lesions of\npatients with localized cutaneous leishmaniasis. Braz J Med Biol Res.\n2000;33:317\u201325.\n\n8. Da-Cruz AM, Bittar R, Mattos M, Oliveira-Neto MP, Nogueira R, Pinho-Ribeiro\nV, et al. T-cell-mediated immune responses in patients with cutaneous or\nmucosal leishmaniasis: long-term evaluation after therapy. Clin Diag Lab\nImmunol. 2002;9:251\u20136.\n\n9. Da-Cruz AM, Bertho AL, Oliveira-Neto MP, Coutinho SG. Flow cytometric\nanalysis of cellular infiltrate from American tegumentary leishmaniasis\nlesions. Br J Dermatol. 2005;153:537\u201343.\n\n10. Bittar RC, Nogueira RS, Vieira-Gon\u00e7alves R, Pinho-Ribeiro V, Mattos MS,\nOliveira-Neto MP, et al. T-cell responses associated with resistance to\nLeishmania infection in individuals from endemic areas for Leishmania\n(Viannia) braziliensis. Mem Inst Oswaldo Cruz. 2007;102:625\u201330.\n\n11. Ferraz R, Cunha CF, Gomes-Silva A, Schubach AO, Pimentel MIF, Lyra MR, et\nal. Apoptosis and frequency of total and effector CD8+ T lymphocytes from\ncutaneous leishmaniasis patients during antimonial therapy. BMC Infect Dis.\n2015;15:74.\n\n12. Cardoso TM, Machado \u00c1, Costa DL, Carvalho LP, Queiroz A, Machado P, et\nal. Protective and pathological functions of CD8+ T cells in Leishmania\nbraziliensis infection. Infect Immun. 2015;83:898\u2013906.\n\n13. Brodskyn CI, Barral A, Boaventura V, Carvalho E, Barral-Netto M. Parasite-\ndriven in vitro human lymphocyte cytotoxicity against autologous infected\nmacrophages from mucosal leishmaniasis. J Immunol. 1997;159:4467\u201373.\n\n14. Barral-Netto M, Barral A, Brodskyn C, Carvalho EM, Reed SG. Cytotoxicity\nin human mucosal and cutaneous leishmaniasis. Parasite Immunol.\n1995;17:21\u20138.\n\n15. Santos Cda S, Boaventura V, Ribeiro Cardoso C, Tavares N, Lordelo MJ,\nNoronha A, et al. CD8(+) Granzyme B(+)-mediated tissue injury versus\nCD4(+)IFN?(+)-mediated parasite killing in human cutaneous leishmaniasis. J\nInvest Dermatol. 2013;33:1533\u201340.\n\n16. Bousoffara T, Louzir H, Ben Salah A, Dellagi K. Analysis of granzyme B activity as\na surrogate marker of Leishmania-specific cell-mediated cytotoxicity in\nzoonotic cutaneous leishmaniasis. J Infect Dis. 2004;189:1265\u201373.\n\n17. Faria DR, Souza PEA, Dur\u00e3es FV, Carvalho EM, Gollob KJ, Machado PR, et al.\nRecruitment of CD8(+) T cells expressing granzyme A is associated with\nlesion progression in human cutaneous leishmaniasis. Parasite Immunol.\n2009;31:432\u20139.\n\n18. Esterre P, Dedet JP, Frenay C, Chevallier M, Grimaud JA. Cell populations in\nthe lesion of human cutaneous leishmaniasis: a light microscopical,\nimmunohistochemical and ultrastructural study. Virchows Arch A Pathol\nAnat Histopathol. 1992;421:239\u201347.\n\n19. Betts MR, Koup RA. Detection of T-cell degranulation: CD107a and b.\nMethods Cell Biol. 2004;75:497\u2013512.\n\n20. Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G. Relationship between\nCD107a expression and cytotoxic activity. Cell Immunol. 2009;254:149\u201354.\n\n21. Zaritskaya L, Shurin MR, Sayers TJ, Malyguine AM. New flow cytometric\nassays for monitoring cell-mediated cytotoxicity. Expert Rev Vaccines.\n2010;9:601\u201316.\n\n22. Palma GI, Saravia NG. In situ characterization of the human host response to\nLeishmania panamensis. Am J Dermatopathol. 1997;19:585\u201390.\n\n23. Palmeiro MR, Morgado FN, Valete-Rosalino CM, Martins AC, Moreira J,\nQuintella LP, et al. Comparative study of the in situ immune response in\noral and nasal mucosal leishmaniasis. Parasite Immunol.\n2012;34:23\u201331.\n\n24. Morgado FN, Schubach A, Rosalino CMV, Quintella LP, Santos G, Salgueiro M,\net al. Is the in situ inflammatory reaction an important tool to understand\nthe cellular immune response in American tegumentary leishmaniasis?\nBr J Dermatol. 2008;158:50\u20138.\n\n25. Cupolillo E, Grimaldi Jr G, Momen H. A general classification of New\nWorld Leishmania using numerical zymotaxonomy. Am J Trop Med Hyg.\n1994;50:296\u2013311.\n\n26. Novais FO, Scott P. CD8(+) T cells in cutaneous leishmaniasis: the good, the\nbad, and the ugly. Semin Immunopathol. 2015;37:251\u20139.\n\nFerraz et al. Parasites &amp; Vectors  (2017) 10:219 Page 11 of 12\n\nhttp://www.who.int/mediacentre/factsheets/fs375/en/\nhttp://www.who.int/mediacentre/factsheets/fs375/en/\n\n\n27. Faria DR, Gollob KJ, Barbosa J, Schriefer A, Machado PRL, Lessa H, et al.\nDecreased in situ expression of interleukin-10 receptor is correlated with the\nexacerbated inflammatory and cytotoxic responses observed in mucosal\nleishmaniasis. Infect Immun. 2005;73:7853\u20139.\n\n28. Da-Cruz AM, Oliveira-Neto MP, Bertho AL, Mendes-Aguiar CO, Coutinho SG. T\ncells specific to Leishmania and other nonrelated microbial antigens can migrate\nto human leishmaniasis skin lesions. J Invest Dermatol. 2010;130:1329\u201336.\n\n29. Clar\u00eancio J, de Oliveira CI, Bomfim G, Pompeu MM, Teixeira MJ, Barbosa TC, et al.\nCharacterization of the T-cell receptor Vbeta repertoire in the human immune\nresponse against Leishmania parasites. Infect Immun. 2006;74:4757\u201365.\n\n30. Ferraz R, Cunha CF, Pimentel MI, Lyra MR, Schubach AO, de Mendon\u00e7a SCF,\net al. T-cell receptor V? repertoire of CD8+ T-lymphocyte subpopulations in\ncutaneous leishmaniasis patients from the state of Rio de Janeiro, Brazil.\nMem Inst Oswaldo Cruz. 2015;110:596\u2013605.\n\n31. Morgado FN, Nascimento MTC, Saraiva EM, de Oliveira-Ribeiro C, Madeira\nMde F, da Costa-Santos M, et al. Are neutrophil extracellular traps playing a\nrole in the parasite control in active American tegumentary leishmaniasis\nlesions? PLoS ONE. 2015;10:e0133063.\n\n32. Tuon FF, Gomes-Silva A, Da-Cruz AM, Duarte MIS, Neto VA, Amato VS. Local\nimmunological factors associated with recurrence of mucosal leishmaniasis.\nClin Immunol. 2008;128:442\u20136.\n\n33. Eljaafari A, Yuruker O, Ferrand C, Farre A, Addey C, Tartelin M-L, et al. Isolation\nof human CD4/CD8 double-positive, graft-versus-host disease-protective,\nminor histocompatibility antigen-specific regulatory T cells and of a novel\nHLA-DR7-restricted HY-specific CD4 clone. J Immunol. 2013;190:184\u201394.\n\n34. Parel Y, Aurrand-Lions M, Scheja A, Dayer J-M, Roosnek E, Chizzolini C.\nPresence of CD4 + CD8+ double-positive T cells with very high interleukin-4\nproduction potential in lesional skin of patients with systemic sclerosis.\nArthritis Rheum. 2007;56:3459\u201367.\n\n35. Kitchen SG, Jones NR, LaForge S, Whitmire JK, Vu B-A, Galic Z, et al. CD4 on\nCD8(+) T cells directly enhances effector function and is a target for HIV\ninfection. Proc Natl Acad Sci U S A. 2004;101:8727\u201332.\n\n36. Overgaard NH, Jung J-W, Steptoe RJ, Wells JW. CD4+/CD8+ double-positive\nT cells: more than just a developmental stage? J Leukoc Biol. 2015;97:31\u20138.\n\n37. Aranha FCS, Ribeiro Jr U, Basse P, Corbett CEP, Laurenti MD. Interleukin-2-\nactivated natural killer cells may have a direct role in the control of\nLeishmania (Leishmania) amazonensis promastigote and macrophage\ninfection. Scand J Immunol. 2005;62:334\u201341.\n\n38. Lieke T, Nyl\u00e9n S, Eidsmo L, Schmetz C, Berg L, Akuffo H. The interplay\nbetween Leishmania promastigotes and human Natural Killer cells in vitro\nleads to direct lysis of Leishmania by NK cells and modulation of NK cell\nactivity by Leishmania promastigotes. Parasitol. 2011;138:1898\u2013909.\n\n39. Machado P, Kanitakis J, Almeida R, Chalon A, Ara\u00fajo C, Carvalho EM.\nEvidence of in situ cytotoxicity in American cutaneous leishmaniasis. Eur J\nDermatol. 2002;12:449\u201351.\n\n40. Joyee AG, Uzonna J, Yang X. Invariant NKT cells preferentially modulate the\nfunction of CD8 alpha + dendritic cell subset in inducing type 1 immunity\nagainst infection. J Immunol. 2010;184:2095\u2013106.\n\n41. Ishikawa H, Hisaeda H, Taniguchi M, Nakayama T, Sakai T, Maekawa Y, et al.\nCD4(+) v(alpha)14 NKT cells play a crucial role in an early stage of protective\nimmunity against infection with Leishmania major. Int Immunol. 2000;12:1267\u201374.\n\n42. Vasan S, Tsuji M. A double-edged sword: the role of NKT cells in malaria\nand HIV infection and immunity. Semin Immunol. 2010;22:87\u201396.\n\n43. Wu L, Van Kaer L. Natural killer T cells and autoimmune disease. Curr Mol\nMed. 2009;9:4\u201314.\n\n44. Kumari S, Jamal F, Shivam P, Thakur A, Kumar M, Bimal S, et al. Leishmania\ndonovani skews the CD56(+) Natural Killer T cell response during human\nvisceral leishmaniasis. Cytokine. 2015;73:53\u201360.\n\n45. Cunha CF, Ferraz R, Pimentel MIF, Lyra MR, Schubach AO, Da-Cruz AM, Bertho AL.\nCytotoxic cell involvment in human cutaneous leishmaniasis: assessments in\nactive disease, under therapy and after clinical cure. Par Immunol. 2016;38:244\u201354.\n\n46. Gollob KJ, Antonelli LRV, Faria DR, Keesen TSL, Dutra WO. Immunoregulatory\nmechanisms and CD4-CD8- (double negative) T cell subpopulations in\nhuman cutaneous leishmaniasis: a balancing act between protection and\npathology. Int Immunopharmacol. 2008;8:1338\u201343.\n\n48. Chapman JC, Chapman FM, Michael SD. The production of alpha/beta and\ngamma/delta double negative (DN) T-cells and their role in the\nmaintenance of pregnancy. Reprod Biol Endocrinol. 2015;13:73.\n\n47. Matsumoto M, Yasukawa M, Inatsuki A, Kobayashi Y. Human double-\nnegative (CD4-CD8-) T cells bearing alpha beta T cell receptor possess both\nhelper and cytotoxic activities. Clin Exp Immunol. 1991;85(3):525\u201330.\n\n49. Groh V, Fabbi M, Hochstenbach F, Maziarz RT, Strominger JL. Double-\nnegative (CD4-CD8-) lymphocytes bearing T-cell receptor alpha and beta\nchains in normal human skin. Proc Natl Acad Sci USA. 1989;86(13):5059\u201363.\n\n50. Mou Z, Liu D, Okwor I, Jia P, Orihara K, Uzonna JE. MHC Class II Restricted\ninnate-like double negative T cells contribute to optimal primary and\nsecondary immunity to Leishmania major. PLoS Pathog. 2014;10:e1004396.\n\n51. Antonelli LRV, Dutra WO, Oliveira RR, Torres KCL, Guimar\u00e3es LH, Bacellar O, et al.\nDisparate immunoregulatory potentials for double-negative (CD4? CD8?) ??\nand ?? T cells from human patients with cutaneous leishmaniasis. Infect Immun.\n2006;74:6317\u201323.\n\n52. Marshall NB, Swain SL. Cytotoxic CD4 T cells in antiviral immunity. J Biomed\nBiotechnol. 2011;2011:954602.\n\n53. Keesen TSL, Gomes JAS, Fares RCG, de Ara\u00fajo FF, Ferreira KS, Chaves AT, et al.\nCharacterization of CD4(+) cytotoxic lymphocytes and apoptosis markers\ninduced by Trypanossoma cruzi infection. Scand J Immunol. 2012;76:311\u20139.\n\n54. Antonelli LRV, Dutra WO, Almeida RP, Bacellar O, Carvalho EM, Gollob KJ.\nActivated inflammatory T cells correlate with lesion size in human\ncutaneous leishmaniasis. Immunol Lett. 2005;101:226\u201330.\n\n\u2022  We accept pre-submission inquiries \n\n\u2022  Our selector tool helps you to find the most relevant journal\n\n\u2022  We provide round the clock customer support \n\n\u2022  Convenient online submission\n\n\u2022  Thorough peer review\n\n\u2022  Inclusion in PubMed and all major indexing services \n\n\u2022  Maximum visibility for your research\n\nSubmit your manuscript at\nwww.biomedcentral.com/submit\n\nSubmit your next manuscript to BioMed Central \nand we will help you at every step:\n\nFerraz et al. Parasites &amp; Vectors  (2017) 10:219 Page 12 of 12\n\n\n\n191 \n\n9.5. ANEXO 5  \n\nArtigo publicado: Apoptosis and frequency of total and effector CD8\n+\n T \n\nlymphocytes from cutaneous leishmaniasis patients during antimonial therapy. \n\n(2015) \n\n \n\n \n\n\n\nRESEARCH ARTICLE Open Access\n\nApoptosis and frequency of total and effector\nCD8\n\n+\nT lymphocytes from cutaneous\n\nleishmaniasis patients during antimonial therapy\nRaquel Ferraz1,2, Clarissa F Cunha1, Adriano Gomes-Silva3, Armando O Schubach4, Maria In\u00eas F Pimentel4,\nMarcelo Rosandiski Lyra4, Sergio CF Mendon\u00e7a1, Cl\u00e1udia M Valete-Rosalino4,5, Alda Maria Da-Cruz3\n\nand \u00c1lvaro Luiz Bertho1,2,6*\n\nAbstract\n\nBackground: Leishmaniasis is an important parasitic disease affecting millions worldwide. Human cutaneous\nleishmaniasis (CL) is endemic in Rio de Janeiro, Brazil, where is caused by Leishmania braziliensis. The adaptive immune\nresponse is accountable for the healing of CL and despite of key role of CD8+ T cells in this immune response little is\nknown about the CD8+ T lymphocytes frequencies, apoptosis and antigen-responsive CD8+ T lymphocytes of CL patients\nduring antimonial therapy.\n\nMethods: Using flow cytometry, we examined total and effector CD8+ T cells from CL patients before (PBT), during\n(PDT) and after (PAT) treatment for apoptosis and frequencies upon isolation and after in vitro L. braziliensis antigens\n(LbAg)-stimulation culture. Besides, a correlation study between immunological findings and lesion size was done.\n\nResults: PDT showed lower frequencies of total CD8+ T lymphocytes and higher levels of apoptosis of these cells,\nwhich were also observed following LbAg-stimulation culture. Regarding effector CD8+ T cells, high frequencies were\nobserved in PDT, while lower frequencies were observed in PAT. Interestingly, PDT showed higher frequencies of\napoptotic-effector CD8+ T lymphocytes. Similar results were seen after in vitro antigenic-stimulation assays. Correlation\nanalysis showed that the greater the size of lesion, the smaller the frequency of effector CD8+ T lymphocytes in PDT\nand PAT, as well as a positive correlation between apoptotic-effector CD8+ T cells frequency and lesion size of PDT.\n\nConclusions: Changes in effector CD8+ T\u2013lymphocyte frequencies, during and after treatment, seem to represent a critical\nstage to generate an efficient immune response and suggest that these cells would be evolved in the triggering or in the\nresolution of lesion, under the influence of therapy. This hypothesis opens new perspectives to clarify controversial\nstatements about the protective or deleterious role of CD8+ T cells in the cure or aggravation of CL and the new approach\nof evaluating patients during treatment proved to be of utmost importance for understanding the immune response in\nthe healing process of human CL.\n\nKeywords: Flow cytometry, Effector CD8+ T lymphocytes, Apoptosis, Human cutaneous leishmaniasis, During antimonial\ntreatment, Leishmania braziliensis\n\n* Correspondence: alvaro.bertho@ioc.fiocruz.br\n1Laboratory of Immunoparasitology, Oswaldo Cruz Institute, FIOCRUZ, Rio de\nJaneiro, RJ, Brazil\n2Flow Cytometry Sorting Core, Oswaldo Cruz Institute, FIOCRUZ, Rio de\nJaneiro, RJ, Brazil\nFull list of author information is available at the end of the article\n\n\u00a9 2015 Ferraz et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative\nCommons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and\nreproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain\nDedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,\nunless otherwise stated.\n\nFerraz et al. BMC Infectious Diseases  (2015) 15:74 \n\nDOI 10.1186/s12879-015-0799-x\n\nmailto:alvaro.bertho@ioc.fiocruz.br\nhttp://creativecommons.org/licenses/by/4.0\nhttp://creativecommons.org/publicdomain/zero/1.0/\n\n\nBackground\nLeishmaniasis is a group of diseases caused by different\n\nspecies of protozoan parasites from the genus Leishmania\n\nand is ranked as the sixth major neglected tropical disease\n\nin the world. In Brazil, American tegumentary leishmania-\n\nsis (ATL) was registered in all states and is endemic in Rio\n\nde Janeiro, where it is caused mainly by Leishmania\n\n(Viannia) braziliensis, leading to a spectrum of clinical,\n\nimmunological and histopathological manifestations, ran-\n\nging from self-healing localized cutaneous leishmaniasis\n\n(CL) to destructive mucosal leishmaniasis [1,2]. CL is the\n\nmost frequent clinical form of ATL and is characterized\n\nby the presence of a skin ulcer, which heals spontaneously\n\nor after antimonial therapy [2,3]. While spontaneous heal-\n\ning appears to be associated with natural resistance, the\n\nimmunological mechanisms of resistance have not been\n\nclearly defined. It was shown that early treatment fails to\n\nprevent ulcer formation in CL [4].\n\nDespite the CD4\n+\n\nT-cell-mediated immune response\n\nplay a pivotal role in the processes either for cure or aggra-\n\nvation of the disease, some reports highlighted that CD8\n+\n\nT lymphocytes may also play important role in the mecha-\n\nnisms for cure of and resistance to Leishmania infection\n\n[5-10]. Although the role of CD8\n+\nT cells has been well\n\nestablished in these studies, there is a controversial state-\n\nments about protective or deleterious function of effector\n\nsubpopulation which has not been elucidated so far\n\n[7,11-17]. Previous researches have focused mostly on im-\n\nmune responses during active phase and at the clinical\n\ncure of disease, thus the investigation of immunological\n\npatterns of patients during the antimonial therapy is crit-\n\nical for better understanding the establishment of path-\n\nology and for determine beneficial parameters of the\n\nimmune responses associated with clinical cure.\n\nCD8\n+\nT lymphocytes are functionally heterogeneous and\n\nthe involvement of effector, na\u00efve and memory CD8\n+\nT-cell\n\nsubsets has already been described in antitumor immune\n\nresponses [18]. It is well established that human-effector\n\nCD8\n+\nT cells have the CD45RA\n\n+\nCD27\n\n?\n\nphenotype and\n\nthese subset is thought to result from CD8\n+\nCD27\n\n+\nprecur-\n\nsors in response to antigenic stimulation [19-22]. To date\n\nthere are few reports about the role of CD8\n+\nT-cell subpop-\n\nulations in the modulation of CL immune response and\n\ntheir functional activity should be better investigated.\n\nSome authors have shown that apoptosis is involved\n\nin modulation of the immune response and may be dir-\n\nectly related to the immunopathogenesis of some dis-\n\neases including leishmaniasis [7,23-26]. Our previous\n\nresults suggest that active disease and spontaneous cure\n\nof CL patients have been associated with higher or\n\nlower percentages of apoptotic CD8\n+\nT cells, respect-\n\nively [7]. Nevertheless, the association between apop-\n\ntosis and functionally-defined CD8\n+\n\nT-lymphocyte\n\nsubsets in CL patients still remains undefined.\n\nThe present study investigates frequency and apoptosis\n\nof total and effector CD8\n+\n\nT lymphocytes, in blood\n\nsmears from CL patients before, during and after treat-\n\nment, as well as evaluates antigen-specific effector CD8\n+\n\nT-lymphocyte frequency and correlating immunological\n\nfeatures with lesion size.\n\nMethods\nStudy Groups\n\nAll CL patients enrolled in this study live in Leishmania\n\nbraziliensis-endemic areas in Rio de Janeiro, Brazil [2]\n\nand were recruited at Leishmaniasis Surveillance La-\n\nboratory, Evandro Chagas Clinical Research Institute\n\n(IPEC), Oswaldo Cruz Foundation (FIOCRUZ), Rio de\n\nJaneiro, Brazil. All patients are volunteers and informed\n\nconsent was obtained from all individuals prior to col-\n\nlection of blood samples. Diagnosis of leishmaniasis was\n\nbased on clinical, laboratorial and epidemiological cri-\n\nteria. Ulcerated cutaneous lesions were associated with\n\npositive Montenegro skin test (MST) and positive para-\n\nsitological exams to confirm a diagnosis of CL. All pa-\n\ntients were submitted to meglumine antimoniate\n\ntreatment according to the guidelines of the Brazilian\n\nMinistry of Health and sub-divided in three cohorts: Pa-\n\ntients before treatment (PBT, n = 8, 36 \u00b1 9 years old),\n\nevaluated after confirmed diagnosis and before begin-\n\nning of anti-Leishmania treatment; patients during\n\ntreatment (PDT, n = 14, 35.7 \u00b1 13.4 years old), evaluated\n\nat the tenth day after beginning anti-Leishmania treat-\n\nment, still showing ulcerated skin lesions; and patients\n\nafter treatment (PAT, n = 11, 41 \u00b1 15,19 years old), at the\n\neighty day after the beginning of treatment. After treat-\n\nment, all patients presented clinical cure, which was de-\n\nfined as full epithelialization of ulcerated lesions,\n\nregression of crusts, desquamation and infiltration.\n\nHealthy subjects (HS, n = 18, 29 \u00b1 9.7 years old), from\n\nnon-endemic areas, showing neither previous history of\n\nleishmaniasis nor any other co-morbidity, such as in-\n\nflammatory diseases, diabetes or cardiologic disease,\n\nwas analyzed similarly. The duration of lesion ranged\n\nfrom one month (less than 30 days) to six months and\n\nthe larger diameter measured of the ulcers varied from\n\n15 to 60 mm (PBT: 40 \u00b1 5.3 mm; PDT: 42 \u00b1 12.5 mm;\n\nPAT: 41.4 \u00b1 13.9 mm). Basic demographic information\n\nof the studied groups is summarized in Table 1.\n\nEthics statement\n\nThis study was approved by National Ethical Clearance\n\nCommittee of Brazil (CONEP) as well as by the Ethical\n\nCommittee for Human Research from Oswaldo Cruz\n\nFoundation (CEP-FIOCRUZ) and Evandro Chagas Clinical\n\nResearch Institute (CEP-IPEC/FIOCRUZ), Brazil. All of\n\nthem adhere to the principles established in the Declar-\n\nation of Helsinki on human subject research. Written\n\nFerraz et al. BMC Infectious Diseases  (2015) 15:74 Page 2 of 11\n\n\n\ninformed consent was taken from all volunteers prior to\n\nblood collection.\n\nEx vivo and in vitro phenotypic and apoptotic assays\n\nHeparinized venous blood was obtained from CL pa-\n\ntients and HS and peripheral blood mononuclear cells\n\n(PBMC) were obtained by Ficoll-Hypaque density gradi-\n\nent centrifugation (Sigma Aldrich, St. Louis, MO, USA)\n\nseparation. A fraction of these cells was stained ex vivo\n\nand another was submitted to in vitro stimulation assay,\n\nwhere PBMC were adjusted (3x10\n5\n/well) in RPMI\n\nmedium supplemented with 10% of AB Rh\n+\ninactivated\n\nhuman serum (Sigma Aldrich) and then distributed in\n\ntriplicate in a 96-well, flat-bottomed plate (Becton Dick-\n\ninson, San Jose, CA, USA), as described previously [27].\n\nCells were stimulated with particulate antigens of L. bra-\n\nziliensis (LbAg) (disrupted in repeated freeze/thaw cycles\n\nand a final 5-minutes ultrasonication). Non-stimulated\n\nand 1 ?g/well-concanavalin A (ConA)-stimulated cells\n\n(Sigma Aldrich) were used as negative and positive con-\n\ntrols of proliferation, respectively. Cultures were carried\n\nout in a humidified atmosphere of 5% CO2 at 37\u00b0C. The\n\ntime of incubation of ConA-stimulated cells was three\n\ndays, while non-stimulated and LbAg-stimulated cells\n\nwere five days. After that, cells were harvested and pre-\n\npared for staining protocols.\n\nCell surface and apoptosis staining protocol\n\nStaining protocol was performed as previously described\n\n[7]. Briefly, ex vivo or in vitro assay\u2019s cells were stained\n\nfor surface markers with a panel of monoclonal anti-\n\nbodies, as follows: FITC-conjugated anti-CD3; APC-\n\nconjugated anti-CD8; PECy7-conjugated anti-CD27;\n\nECD-conjugated anti-CD45 (all Beckman Coulter,\n\nMiami, FL, USA) in PBS containing 0.1% sodium azide\n\n(NaN3; Sigma Aldrich) and 2% fetal calf serum (Sigma\n\nAldrich) and incubated for 20 minutes on ice. After-\n\nwards, these samples were incubated with 20 ?g/mL of\n\n7-aminoactinomycin D (7-AAD; Sigma Aldrich) for\n\n30 minutes at 4\u00b0C, for apoptosis evaluation, as described\n\nin elsewhere. The samples were kept on 7-AAD solution,\n\nprotected from light, until the flow cytometry acquisition.\n\nFlow cytometry\n\nFifty thousand-event acquisitions were performed on\n\nBeckman Coulter Cyan ADP and on BD FACSAria II\n\nflow cytometers. The limits for the quadrant markers\n\nand histograms were always set based on non-staining\n\ncells and isotypic controls and color compensations\n\nwere made based on simple labeling samples. A multi-\n\nparameter flow cytometric protocol to determine the\n\nfrequencies of total and effector CD8\n+\nT lymphocytes\n\nand apoptosis was done in Kaluza 1.2 software (Beck-\n\nman Coulter, Inc., Brea, CA, USA). In this manner, the\n\nfrequency of total CD8\n+\nT lymphocytes was determined\n\nin a CD3 vs. CD8 dot plot (Figure 1C) created from a\n\nregion encompassing lymphocyte population in a SSC\n\nvs. FSC density plot (Figure 1A), excluding doublets\n\n(Figure 1B). To evaluate the frequency of effector CD8\n+\n\nT-lymphocyte subsets a CD27 vs. CD45RA dot plot\n\ngated on CD3\n+\nCD8\n\n+\nregion was created and data\n\nCD27\n+\nCD45RA\n\n?\n\nwas recorded (Figure 1D; Q ? +).\n\nSimultaneously, for apoptosis determination in total\n\n(Figure 1E) and effector (Figure 1F) CD8\n+\nT cells a FSC\n\nvs. 7AAD dot plot was created gated on dot plots repre-\n\nsented in Figure 1C and Figure 1D, respectively.\n\nStatistical analysis\n\nFor statistical analyses between two groups at a time,\n\nMann\u2013Whitney U test was used. For comparison between\n\nnonstimulated and stimulated CD8\n+\nT-lymphocyte sub-\n\nsets, we used a paired nonparametric Wilcoxon test. These\n\nresults were reported as mean \u00b1 standard error (SEM). We\n\nalso used a Spearman\u2019s rank correlation test. Correlations\n\nand intergroup differences were considered statistically\n\nsignificant when P &lt;0.05. All statistical calculations and\n\ngraphical representations of data were obtained using the\n\nGraphPad Prism version 5.0 software (GraphPad Software\n\nInc., La Jolla, CA, USA).\n\nTable 1 Demographic and clinical information of groups included in the study\n\nHS PBT PDT PAT\n\nNumber of volunteers 18 8 14 11\n\nSex: M/F 11/7 7/1 9/5 8/3\n\nAge 29 \u00b1 9.7 36.1 \u00b1 9 35.71 \u00b1 13.4 41 \u00b1 15.1\n\nNumber of lesions NA 1 1 1\n\nDiameter of lesion (mm) (BF) NA 40 \u00b1 5.3 42 \u00b1 12.5 41.4 \u00b1 13.9\n\nMontenegro Skin Test (MST) (mm) (BF) NA 11.3 \u00b1 1.8 11.7 \u00b1 3.6 12.3 \u00b1 3.6\n\nDuration of disease (months) NA 2 (1\u20136) 2 (1\u20136) 2 (1\u20135)\n\nAge; Diameter of lesions; and MST: mean \u00b1 Standard Deviation.\n\nDuration of disease: median (range).\n\nBF = measured Before Treatment.\n\nNA = Not Applicable.\n\nFerraz et al. BMC Infectious Diseases  (2015) 15:74 Page 3 of 11\n\n\n\nResults\nFrequency of total and effector CD8\n\n+\nT cells\n\nWe performed comparative analysis of the frequency of\n\ntotal CD8\n+\nT cells from patients before treatment (PBT),\n\npatients during treatment (PDT) and patients after treat-\n\nment (PAT), as well healthy subjects (HS). The mean\n\nfrequency of total CD8\n+\nT cells was significantly lower in\n\nPDT (15.3 \u00b1 1.5) compared to PBT (23 \u00b1 2; P &lt;0.05) and\n\nto HS (23.6 \u00b1 1.2; P &lt;0.001). These lower frequency also\n\nwere seen when comparing PDT with in PAT (21.5 \u00b1 1.6;\n\nP = 0.07), although these difference was not statistically\n\nsignificant (Figure 2A).\n\nDue to the heterogeneity of the peripheral CD8\n+\nT-cell\n\npool, we performed a dichotomized analysis in order to\n\ndiscriminate the differential distribution of their subsets.\n\nThus, in order to highlight the importance of effector\n\nCD8\n+\nT lymphocytes in the parasitic immune responses,\n\nwe analyzed the CD8\n+\nCD45RA\n\n+\nCD27\n\n?\n\nT cells, an effector\n\nphenotype. We observed a higher frequency of these cells\n\nin PDT (31.2 \u00b1 2.2) compared to other three groups, HS\n\n(12 \u00b1 1.4; P &lt;0.001), PBT (25 \u00b1 2.7; P &lt;0.05) and PAT\n\n(16.9 \u00b1 2.7; P &lt;0.001) (Figure 2B). PBT also showed higher\n\nfrequency of these cells when compared to HS and PAT. It\n\nis important to note that PBT and PDT showed lower per-\n\ncentages of CD8\n+\nCD45RA\n\n+\nCD27\n\n+\nna\u00efve T-cell subset\n\nwhen compared to HS and to PAT, which could be a con-\n\nsequence of differentiation of na\u00efve in effector CD8\n+\nT\n\ncells, during active disease (data not shown).\n\nApoptosis of total and effector CD8\n+\nT cells\n\nPrevious report of our group showed that there was a higher\n\nrate of apoptotic-total CD8\n+\n-T lymphocytes in non-healing\n\nlesions of CL when compared to lesions that progress to\n\nspontaneous cure [7], suggesting a modulate role of apop-\n\ntosis on these cells in CL lesion environment. Following this\n\nhypothesis, we investigated the role of apoptosis in blood\n\nFigure 1 Representative flow cytometry protocol to determine the frequencies of CD8\n+\nT-lymphocyte subsets and apoptosis. Peripheral blood\n\nmononuclear cells (PBMC) from cutaneous leishmaniasis patients were stained ex vivo and after antigenic-stimulated cultures with CD3-FITC, CD8-APC,\nCD45RA-ECD, CD27-PE-Cy7 and 7-AAD. The lymphocytes were gated on forward (FSC) vs side (SSC) scatter dot-plot (A), backgated from CD3+ histogram\nand doublets were excluded by a density plot of FSC Area vs FSC Width (B). CD27 vs CD45RA dot plot (D) gated on CD3+CD8+ region (C) was used to define\nthe frequencies of effector and na\u00efve CD8+ T lymphocytes. Frequency of apoptotic cells (7AADlow) was determined by FSC vs 7AAD dot-plot gated on\nCD3+CD8+ cells (total CD8+ T lymphocytes) (E) and on CD45RA+CD27neg cells (effector CD8+ T lymphocytes) (F).\n\nFerraz et al. BMC Infectious Diseases  (2015) 15:74 Page 4 of 11\n\n\n\ncompartment, through the 7-AAD staining and flow cytom-\n\netry. The results of ex vivo analyses showed higher frequen-\n\ncies of apoptotic-total (14.9 \u00b1 2.8) and apoptotic-effector\n\nCD8\n+\nT cells from PDT (18.6 \u00b1 2.8) when compared to:\n\nPBT (apoptotic-total, 2 \u00b1 0.6; P &lt;0.001; apoptotic-effector,\n\n2.3 \u00b1 1.4; P &lt;0.001); PAT (apoptotic-total, 6.2 \u00b1 1.7; P &lt;0.05;\n\napoptotic-effector, 4.3 \u00b1 1.5; P &lt;0.001); and HS (apoptotic-\n\ntotal, 1.8 \u00b1 0.4; P &lt;0.001; apoptotic-effector, 0.4 \u00b1 0.2; P&lt;\n\n0.001) (Figure 2C and D). These results showed pronounced\n\npercentages of apoptotic CD8\n+\nT lymphocytes only on pa-\n\ntients during treatment, which tend to decrease after the\n\nend of treatment indicating that this phenomenon could be\n\nassociated to the glucantime therapy and the immune re-\n\nsponse triggering.\n\nLeishmania braziliensis-reactive CD8\n+\nT lymphocytes\n\nIn order to determine an expansion of CD8\n+\nT cells in-\n\nvolved in a specific anti-Leishmania T-cell response,\n\nPBMC were cultured in the absence and in the presence\n\nof L. braziliensis antigens (LbAg). Frequencies of LbAg-\n\nreactive-total CD8\n+\nT cells were compared among the four\n\nstudied groups. PDT showed lower mean frequencies\n\nof Leishmania braziliensis-reactive CD8\n+\n\nT lymphocytes\n\n(13.8 \u00b1 1.0) when compared to PAT (24.7 \u00b1 3.9; P &lt;0.05)\n\n(Figure 3A); to HS (20.2 \u00b1 1.6; P &lt;0.01); and to PBT (17.5 \u00b1\n\n2.5), although the difference between the frequencies of PBT\n\nand PDT was not statistically significant (P = 0.2) (Figure 3A).\n\nTo evaluate the modulation in the frequencies of LbAg-\n\nreactive CD8\n+\n-T cells, we performed paired analyses be-\n\ntween the percentage of nonstimulated-total CD8\n+\nT cells\n\n(background - BG) and those of LbAg-stimulated CD8\n+\nT\n\ncells. Both PBT (BG, 21.4 \u00b1 2.8; LbAg, 17.5 \u00b1 2.5; P &lt;0.05)\n\nand PDT (BG, 16.9 \u00b1 1; LbAg, 13.8 \u00b1 1; P &lt;0.01) showed\n\nlower frequencies of LbAg-reactive total CD8\n+\nT cells, more\n\npronounced in PDT (Figure 3C and D, respectively). On the\n\nother hand, PAT showed a higher frequency of these cells\n\n(BG \u2013 17.7 \u00b1 3.7; LbAg \u2013 24.7 \u00b1 3.9; P &lt;0.05) (Figure 3E),\n\nshowing that LbAg down-modulate CD8\n+\nT cells during\n\nin vitro assays with cells obtained from PBT and PDT. In\n\nthe opposite manner, LbAg up-modulate these cells in as-\n\nsays performed with cells from patients after treatment and\n\nclinical cure. No changes on frequency of these cells were\n\nFigure 2 Ex vivo analysis of total CD8\n+\nT-lymphocyte frequency and apoptosis in human cutaneous leishmaniasis. (A) Total CD8+ T lymphocytes;\n\n(B) Effector CD8+ T lymphocytes; (C) Apoptotic-total CD8+ T lymphocytes; (D) Apoptotic-effector CD8+ T lymphocytes. HS - healthy subjects (n = 18);\nPBT \u2013 patients before treatment (n = 8); PDT - patients during treatment (n = 14); PAT - patients after treatment (n = 11). Statistical analyses were performed\nby Mann Whitney Test. The bars represent the mean \u00b1 standard error. Results were considered significant with P &lt;0.05 - *(P &lt;0.05) **(P &lt;0.01) ***(P &lt;0.001).\n\nFerraz et al. BMC Infectious Diseases  (2015) 15:74 Page 5 of 11\n\n\n\nseen in experiments with cells from HS (BG, 18.1 \u00b1 1.6;\n\nLbAg, 20.2 \u00b1 1.6) (Figure 3B).\n\nCorroborating the results showed in ex vivo findings, we\n\nobserved higher rates of apoptotic-CD8\n+\nT cell in cultures\n\nwith LbAg-stimulated cells from PDT (12.8 \u00b1 1.5) compared\n\nto PBT (4.9 \u00b1 0.6; P &lt;0.01); PAT (2.9 \u00b1 0.8; P &lt;0.01); and HS\n\n(5.2 \u00b1 1.2; P &lt;0.001) (Figure 3F). The paired analysis con-\n\nfirmed that the higher frequency of apoptotic-total CD8\n+\nT\n\nlymphocytes from PDT (BG, 6.4 \u00b1 1.5; LbAg, 12.8 \u00b1 1.5; P&lt;\n\n0.001) is antigen-dependent (Figure 3I), and could not be\n\nseen in HS- (BG, 3.7 \u00b1 0.7; LbAg, 5.2 \u00b1 1.2), in PBT- (BG,\n\n5.6 \u00b1 0.9; LbAg, 4.9 \u00b1 0.6) neither in PAT-in vitro experi-\n\nments (BG, 2.7 \u00b1 0.6; LbAg, 2.9 \u00b1 0.8) (Figure 3G, H and J,\n\nrespectively).\n\nRegarding frequency of LbAg-reactive-effector CD8\n+\nT\n\ncells during in vitro assays, it was observed higher frequen-\n\ncies of these cells in experiments with cells from PDT (41.8\n\n\u00b1 3.1) and from PAT (35.8 \u00b1 4.6) when compared to experi-\n\nments with cells from PBT (15.9 \u00b1 1.3; P &lt;0.01) and also to\n\nHS (13.4 \u00b1 1.3; P &lt;0.01 and P &lt;0.001) (Figure 4A). The\n\nmodulation of frequency of these cells in the presence of\n\nthese antigens was confirmed by the paired test in which we\n\ndetected higher frequencies in PDT (BG, 33.1 \u00b1 4; LbAg,\n\n41.8 \u00b1 3.1; P &lt;0.001) and PAT (BG, 29.8 \u00b1 4.3; LbAg, 35.8 \u00b1\n\n4.6; P &lt;0.05) (Figure 4D and E, respectively), while PBT\n\n(BG, 14.6 \u00b1 1.5; LbAg, 15.9 \u00b1 1.3; P &lt;0.01) and HS showed\n\nsimilar frequencies among stimulated and nonstimulated\n\ncells (BG, 11.3 \u00b1 0.7; LbAg, 13.4 \u00b1 1.3) (Figure 4C and B,\n\nrespectively).\n\nConcerning the apoptotic-effector CD8\n+\nT cells, a com-\n\nparison among the four studied groups showed higher\n\npercentages in PDT (28.1 \u00b1 1.5) when compared to HS (3 \u00b1\n\n1.1, P &lt;0.001) and PBT (3.8 \u00b1 0.7, P &lt;0.01). We also\n\nobserved higher frequencies in PAT (12.3 \u00b1 1.1) when com-\n\npared to HS (P &lt;0.001) and PBT (P &lt;0.01) (Figure 4F). The\n\npaired analysis have shown significant differences of\n\napoptotic-effector CD8\n+\nT cells between BG and LbAg in\n\nPDT (BG, 21.2 \u00b1 0.9; LbAg, 28.1 \u00b1 1.5; P &lt;0.001) and PAT\n\n(BG, 9.6 \u00b1 1; LbAg, 12.3 \u00b1 1.1; P &lt;0.05) (Figure 4I and J, re-\n\nspectively), while no significant difference was observed in\n\nHS (BG, 1.7 \u00b1 0.4; LbAg, 3 \u00b1 1.1) and PBT (BG, 3.2 \u00b1 0.7;\n\nLbAg, 3.8 \u00b1 0.7) (Figure 4G and Figure 4H, respectively).\n\nCorrelation analysis of effector and apoptotic-effector\n\nCD8\n+\nT lymphocytes with lesion size\n\nTaking account the relationship between clinical features\n\nand immune response in CL, we correlated the frequencies\n\nof effector and apoptotic-effector CD8\n+\nT lymphocytes with\n\nlesion size. Results showed an inverse correlation between\n\nfrequencies of effector CD8\n+\nT lymphocytes and lesion size\n\nin PDT (r = ?0.79; P &lt;0.001) as well as in PAT (r = ?0.79;\n\nP &lt;0.01). The lower the frequency of effector CD8\n+\nT cells,\n\nthe larger the size of lesion (Figure 5B and C, respectively).\n\nIn contrary, no statistical correlation was observed between\n\nthe frequencies of effector CD8\n+\nT lymphocytes and lesion\n\nsize in PBT (Figure 5A). These results suggest that a greater\n\ninduction of effector CD8\n+\nT cells after the beginning of\n\ntreatment would be associated with small lesions, less\n\ninflammatory process and minor tissue destruction. Correl-\n\nation analyses between lesion size and antigen-specific\n\nCD8\n+\nT cell were done but no statistically significant result\n\ncould be observed (data not shown).\n\nFigure 3 In vitro analyses of total (A \u2013 E) and apoptotic (F \u2013 J) CD8\n+\nT-lymphocyte frequency. (A and F): comparison among the percentages of\n\nLeishmania braziliensis antigen (LbAg)-stimulated cells from HS - healthy subjects (n = 8); PBT \u2013 patients before treatment (n = 8); PDT - patients during\ntreatment (n = 11); and PAT - patients after treatment (n = 6). Statistical analyses were performed by Mann Whitney Test and the bars represent the mean \u00b1\nstandard error. (B, C, D, E, G, H, I, J): comparison between stimulated (Lb-Ag) and nonstimulated cells (BG \u2013 background) from HS; PBT; PDT and PAT,\nrespectively. Solid lines connect the results for the same individual. Statistical analyses were performed by paired, nonparametric Wilcoxon test. Results were\nconsidered significant with P &lt;0.05. *(P &lt;0.05) **(P &lt;0.01) ***(P &lt;0.001).\n\nFerraz et al. BMC Infectious Diseases  (2015) 15:74 Page 6 of 11\n\n\n\nFigure 4 In vitro analysis of effector (A \u2013 E) and apoptotic-effector (F - J) CD8\n+\nT-lymphocyte frequencies. (A and F): comparison among the\n\npercentages of Leishmania braziliensis antigen (LbAg)-stimulated cells from HS - healthy subjects (n = 8); PBT \u2013 patients before treatment (n = 8);\nPDT - patients during treatment (n = 12); and PAT - patients after treatment (n = 6). Statistical analyses were performed by Mann Whitney Test and the\nbars represent the mean \u00b1 standard error. (B, C, D, E, G, H, I, J): comparison between antigen-stimulated (Lb-Ag) and nonstimulated cells (BG \u2013\nbackground) from HS; PBT; PDT and PAT, respectively. Solid lines connect the results for the same individual. Statistical analyses were performed by\npaired, nonparametric Wilcoxon test. Results were considered significant with P &lt;0.05. *(P &lt;0.05) **(P &lt;0.01) ***(P &lt;0.001).\n\nFigure 5 Clinical characteristics correlated with immunological parameters from cutaneous leishmaniasis patients. Correlation between\nthe percentage of effector CD8+ T-lymphocytes (A, B, C) and apoptotic-effector CD8+ T-lymphocytes (D, E, F) with diameter of lesion (mm).\n(A, D) PBT - patients before treatment (n = 8); (B, E) PDT \u2013 patients during treatment (n = 14); (C, F) PAT - patients after treatment (n = 11).\nThe graphics show fit lines with confidence curves. Statistical analyses were performed by Spearman\u2019s correlation test. Results were considered\nsignificant with P &lt;0.05.\n\nFerraz et al. BMC Infectious Diseases  (2015) 15:74 Page 7 of 11\n\n\n\nEarlier report of our group showed high frequencies of\n\napoptotic-total CD8\n+\nTcells in lesions of patients with active\n\nCL compared with patients evolved to spontaneous cure [7].\n\nHence, became noteworthy to correlate the frequencies of\n\ncirculating-apoptotic-effector CD8\n+\nT cells to lesion sizes in\n\norder to identify a T cell subset implicated either protective\n\nor deleterious role during the treatment or after clinical cure\n\nof CL. It was observed a positive correlation between higher\n\nfrequencies of apoptotic-effector CD8\n+\nT cells and larger le-\n\nsion areas in PDT (r = 0.62; P &lt;0.05) (Figure 5E), although\n\nthere were no correlation between these parameters in PBT\n\nand in PAT (Figure 5D and C, respectively).\n\nDiscussion\nThe host immune response to Leishmania is mainly medi-\n\nated by T cells [28]. The study of immunopathogenesis in\n\nhuman CL has been based on the determination of the fre-\n\nquency of CD4\n+\nand CD8\n\n+\nT lymphocytes and cytokine\n\nproduction [13,27,29]. Earlier observations from our group\n\nhave shown that CD8\n+\nT lymphocytes have a role in the\n\ncure process in CL patients [7,8,10,27,30] and other reports\n\nreinforces this hypothesis [14,31]. Conversely, some authors\n\nhave associated the CD8\n+\nT lymphocytes to tissue injury in\n\nCL [15] and in mucocutaneous leishmaniasis [11,12]. It is\n\nimportant to note that, in all of these reports, patients were\n\nevaluated before and after antimonial therapy not taking\n\ninto account the immunological events that happen during\n\ntreatment. In order to assess the characteristics of the im-\n\nmune response involved in the healing process of CL pa-\n\ntients, it is of utmost importance the evaluation of patients\n\nduring antimonial therapy. Our results showed important\n\ndifferences in the CD8\n+\nT-cell frequencies, characterizing\n\nearly and final phases of clinical cure, which seems to be\n\nlinked to antimonial therapy.\n\nThe frequency of apoptotic CD8\n+\nT cells in HS is in ac-\n\ncordance to the normal apoptotic rate (1\u20134%) as reported\n\nelsewhere [32]. Because PDT showed higher frequencies\n\nof apoptotic CD8\n+\nT cells than PBT and HS, we suggest\n\nthat apoptosis of these cells could be related to the begin-\n\nning of therapy. The highest frequency of apoptotic CD8\n+\n\nT lymphocytes observed during the antimonial treatment\n\ncould be associated to lower rate of total CD8\n+\nT cells in\n\nPDT, suggesting an association between apoptosis and a\n\ndown-modulation of the total CD8\n+\nT cells. It is in accord-\n\nance with a previous report of our group, which have\n\nshown that high rates of apoptotic-total CD8\n+\nT cells was\n\nrelated to active disease, while a lower frequency of\n\napoptotic-total CD8\n+\nT cells is related to spontaneous cure\n\n[7]. Brelaz et al. [27] related the key role of CD8\n+\nT cells in\n\nthe process of healing with a significantly higher propor-\n\ntion of circulating CD8\n+\nT lymphocytes in spontaneously\n\nhealed patients when compared to patients before treat-\n\nment. Elevated frequencies of total CD8\n+\nT cells in PAT\n\ncompared to PDT, may represent a tendency of these cells\n\nto reestablish levels of normality at the end of treatment\n\nand could be associated to clinical cure.\n\nWe observed an increase of apoptotic-total CD8\n+\nT cells\n\nand a decrease of total CD8\n+\nT-cell frequencies in LbAg-\n\nstimulated cultures with cells from PDT as well as from\n\nPBT. Inversely we observed an increase of total CD8\n+\nT-cell\n\nfrequencies in LbAg-stimulated cultures with cells from\n\nPAT, showing that at the end of treatment, total CD8\n+\nT\n\nlymphocytes could expand in response to LbAg. Based in\n\nthese findings we may hypothesize that the high rates of\n\napoptosis observed in ex vivo total CD8\n+\nT cells from PDT\n\ncould be triggered by expressive amount of circulating anti-\n\ngen derived from parasite destruction caused by the\n\nantimony.\n\nThe high frequency of LbAg-reactive total CD8\n+\nT\n\nlymphocytes observed after therapy corroborates data\n\nfound by Da-Cruz et al. [10,23] who suggested that the\n\nincreased levels of these cells at the end of treatment\n\nwould be associated with resolution of lesion. It is worth\n\nto note that these studies compared patients before and\n\nafter treatment and there was a need to supplement this\n\ninformation, evaluating patients during treatment. So,\n\nthe increased levels of LbAg-reactive total CD8\n+\nT lym-\n\nphocytes observed at the end of therapy indicate that\n\nprobably an expansion of this cell population was not\n\nperceived at early phases of healing process. It is in ac-\n\ncordance with others [33,34] who reported a later devel-\n\nopment of an efficient immune response, i.e., when there\n\nis a balanced response with control of parasite replica-\n\ntion without tissue injury.\n\nDespite the knowledge about the key role of CD8\n+\nT\n\nlymphocytes in the immune response, the evaluation of ef-\n\nfector CD8\n+\nT-cell subset became an imperative approach\n\nfor better understanding the specific role of these cells, in\n\nhealing process in patients under treatment [19,20,35]. Be-\n\nsides, the relationship between frequencies of effector\n\nCD8\n+\nT cells and the different stages of treatment is un-\n\nknown. Taking into account that effector CD8\n+\nT lympho-\n\ncytes represent 10 to 40% of total-circulating CD8\n+\nT cells\n\nand this pool includes a variety of functionally distinct\n\nsubpopulations, an analysis of effector population can pro-\n\nvide information about some functional characteristics of\n\nthis subset, which would be imperceptible when the ana-\n\nlysis of total CD8\n+\nT lymphocytes was performed.\n\nConcerning ex vivo analysis of effector CD8\n+\nT cell, the\n\nhighest percentage observed in PDT seems to indicate a\n\ngreater induction of this subset during the treatment. Con-\n\nsidering that Glucantime\u00ae is a leishmanicidal drug, a higher\n\namount of circulating antigen during treatment might in-\n\nduce effector CD8\n+\nT lymphocytes and explain the higher\n\nfrequency of these cells in PDT. Some reports corroborates\n\nthis statement, as demonstrated by Meymandi et al. [36]\n\nwhere clearly showed that, at their histological findings,\n\nthere was a reduction in aggregations of histiocytes,\n\nFerraz et al. BMC Infectious Diseases  (2015) 15:74 Page 8 of 11\n\n\n\ndecreased cellular parasitic load and an important in-\n\ncreased numbers of CD3\n+\nT cells in response to combin-\n\ning antimonial treatment. In another study there was an\n\nincrease in the percentage of CD8\n+\nT cells in peripheral\n\nblood from patients with leishmaniasis under treatment\n\nwith meglumine antimoniate [37]. Moreover, the lower\n\nfrequency of CD8\n+\nT cells observed in PAT may be related\n\nto a reduced antigenic stimulation, which could depict\n\nwhat is happening in vivo after clinical cure.\n\nBecause effector CD8\n+\nT lymphocytes from PDT and\n\nPAT expanded in response to LbAg while PBT did not,\n\nour study indicated that antimonial treatment might not\n\ninfluence the involvement of effector CD8\n+\nT lymphocytes\n\nin the antigen-specific immune response to parasite.\n\nApoptosis is a physiological process of immune re-\n\nsponses, however this phenomenon of death can also be a\n\nmodulating factor of immunopathogenesis of some disor-\n\nders such as Dengue, Chagas\u2019 disease and AIDS [21,31,32].\n\nIn the present report, high apoptosis rates observed in\n\nLbAg-stimulated effector CD8\n+\nT cells in PDT point to\n\nthe occurrence of activation-induced cell death (AICD),\n\nsuggesting that this death phenomenon may be happening\n\nin vivo during treatment [33]. Although PAT showed low\n\nfrequencies of effector CD8\n+\nT lymphocytes, when com-\n\npared to PDT, the small rates of apoptotic-effector CD8\n+\n\nT lymphocytes seem to favor to clinical cure. Moreover, in\n\nparasitic infections the cross-talk between apoptosis of T\n\nlymphocytes and cytokine production was associated to a\n\ndeleterious role of this death phenomenon [26].\n\nSome authors considered that the severity of disease\n\ncould be characterized by lesion size, which is considered\n\nas the most significant clinical feature in CL [38]. Herein,\n\nwe showed that the smaller the size of lesion, the greater\n\nthe frequency of effector CD8\n+\nT lymphocytes in PDT and\n\nPAT. Some authors [34] reported that the size of lesion\n\nfound in patients evaluated before therapy was directly re-\n\nlated to activated T lymphocytes. Thus, we may postulate\n\nthat after the beginning of antimonial therapy there is a\n\ngreater induction of effector CD8\n+\nT cells, which is in-\n\nversely proportional to the lesion size, suggesting that a\n\nsmall frequency of effector CD8\n+\nT lymphocytes can favor\n\nto the tissue damage. Agreeing this data, we showed that\n\nthe greater the size of lesion, the higher the frequency of\n\napoptotic-effector CD8\n+\nT lymphocytes in PDT, suggest-\n\ning a deleterious role of this death phenomenon. This\n\nobservation corroborates with our previous report [7]\n\nwhere we observed that patients evolved to spontaneous\n\ncure were associated to small frequencies of apoptotic\n\nCD8\n+\nT lymphocytes. This data emphasize the protective\n\nrole of CD8\n+\nT cells considering the severity of lesions.\n\nFurther studies are underway to determine what func-\n\ntional characteristics these effector cells have, since they\n\ncan present cytotoxic and/or pro-inflammatory-cytokine-\n\nproducer profiles.\n\nConclusions\nTaking together, our results showed an evident expansion\n\nof effector CD8\n+\nT lymphocytes in response to LbAg,\n\nmore pronounced in PDT. Changes in effector CD8\n+\nT\u2013\n\nlymphocyte frequencies, during and after treatment, seem\n\nto represent a critical stage to generate an efficient im-\n\nmune response and suggest that these cells would be\n\nevolved in the triggering or in the resolution of lesion,\n\nwhen under the influence of therapy. Although this work\n\ndo not define the effective role of CD8\n+\nT cells in the CL\n\nimmunopathogenesis, our findings put forth the notion\n\nthat the evolution to cure induced by antimonial therapy\n\nimplicate the effector CD8\n+\nT lymphocytes. Moreover, our\n\nresults emphasize the protective role of CD8\n+\nT cells con-\n\nsidering the severity of lesions. Further studies are under-\n\nway to determine what functional characteristics these\n\neffector cells have, since they can present cytotoxic and/or\n\npro-inflammatory-cytokine-producer profiles. This new\n\napproach of evaluating patients during treatment proved\n\nto be very important for understanding the healing\n\nprocess. Furthermore, this report might be used as a basis\n\nfor further investigations concerning antimonial therapy\n\nand to guide vaccine investigations based on the develop-\n\nment of an effective cellular immune response that regu-\n\nlates tissue damage in human cutaneous leishmaniasis.\n\nAbbreviations\n\n7-AAD: 7 aminoactinomycin D; AICD: Activated-induced cell death;\nAIDS: Acquired immunodeficiency syndrome; APC: Allophycocyanin;\nATL: American tegumentary leishmaniasis; BD: Becton &amp; Dickinson;\nBF: Measured before treatment; BG: Background; CD: Cluster of\ndifferentiation; CL: Cutaneous leishmaniasis; ConA: Concanavalin A;\nCONEP: National Ethical Clearance Committee of Brazil; ECD: Energy couple\ndye; FIOCRUZ: Oswaldo Cruz Foundation; FSC: Forward scatter;\nFITC: Fluorescein Isothiocyanate; HS: Health subjects; IPEC: Evandro Chagas\nClinical Research Institute; LbAg: Leishmania braziliensis antigen;\nMST: Montenegro skin test; NA: Not applicable; PAT: Patients after treatment;\nPBMC: Peripheral blood mononuclear cells; PBT: Patients before treatment;\nPDT: Patients during treatment; PECy7: Phycoerythrin Cyanin 7; SSC: Side\nscatter.\n\nCompeting interests\n\nThe authors declare that they have no competing interest.\n\nAuthors\u2019 contributions\n\nALB and RF conceived and designed the study and performed statistical\nanalysis. RF, CFC and ALB performed the experiments. RF and ALB performed\nall flow cytometry acquisition and analysis. RF and ALB analyzed and\ncompiled the data. AOS, MRL, MIFP and CMVR took patient care. SCFM, AGS\nand AMDC contributed reagents and drafted the manuscript. RF and ALB\nwrote the final version of manuscript. All authors read and approved the\nfinal manuscript.\n\nAuthors\u2019 informations\n\nALB is Senior Scientist, PhD, Vice-Head at Lab. of Immunoparasitology,\nOswaldo Cruz Institute, FIOCRUZ and Coordinator of Flow Cytometry Core\nFacility at Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil; Member of\nISAC \u2013 International Society for Advancement of Cytometry. RF is PhD\nstudent received scholarship from CAPES (Coordena\u00e7\u00e3o de Aperfei\u00e7oamento\nde Pessoal de N\u00edvel Superior); Supervisor at Flow Cytometry Core Facility at\nOswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil.\nCFC is PhD student and received scholarship from CNPq (Conselho Nacional\nde Pesquisa). AMDC is Senior Scientist, PhD, investigators from CNPq. AOS is\n\nFerraz et al. BMC Infectious Diseases  (2015) 15:74 Page 9 of 11\n\n\n\ninvestigator from FAPERJ (Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio\nde Janeiro). SCFM is Senior Scientist, PhD and Head of Lab. of\nImmunoparasitology, Oswaldo Cruz Institute, FIOCRUZ. AGS is postdoctoral\nstudent.\n\nAcknowledgements\n\nThe authors would like to thank Platform of Flow Cytometry, IOC-FIOCRUZ and\nPlatform of Flow Cytometry, PDTIS-FIOCRUZ for flow cytometry acquisitions; to\nDr. Marise Nunes (IOC-FIOCRUZ, Rio de Janeiro, Brazil) and Dr. Paula De-Luca\n(IOC-FIOCRUZ, Rio de Janeiro, Brazil) for donation of some reagents.\nThis research was supported by an internal funding from IOC-FIOCRUZ and\nPROEP-CNPq-IOC (402557/211-5). The funding agencies had no role in study\ndesign, data collection and analysis, decision to publish, or preparation of\nthe manuscript.\n\nAuthor details\n1Laboratory of Immunoparasitology, Oswaldo Cruz Institute, FIOCRUZ, Rio de\nJaneiro, RJ, Brazil. 2Flow Cytometry Sorting Core, Oswaldo Cruz Institute,\nFIOCRUZ, Rio de Janeiro, RJ, Brazil. 3Laboratory of Interdisciplinary Medical\nResearch, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, RJ, Brazil.\n4Laboratory of Surveillance for Leishmaniasis, Evandro Chagas National\nInfectology Institute, FIOCRUZ, Rio de Janeiro, RJ, Brazil. 5Department of\nOtolaryngology and Ophthalmology, Medicine College, Federal University of\nRio de Janeiro, Rio de Janeiro, RJ, Brazil. 6Laboratory of Immunoparasitology\nand Flow Cytometry Sorting Core, Oswaldo Cruz Institute, FIOCRUZ, Av.\nBrasil, 4365, Manguinhos, Pavilh\u00e3o Le\u00f4nidas Deane, sala 408-A, CEP:\n21040-900 Rio de Janeiro, RJ, Brasil.\n\nReceived: 7 August 2014 Accepted: 4 February 2015\n\nReferences\n\n1. WHO. WHO Technical Report Series 949. Control of Leishmaniases. [internet].\nWHO. Available from: http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf?ua=1\n\n2. De Oliveira-Neto MP, Mattos MS, Perez MA, Da-Cruz AM, Fernandes O,\nMoreira J, et al. American tegumentary leishmaniasis (ATL) in Rio de Janeiro\nState, Brazil: main clinical and epidemiologic characteristics. Int J Dermatol.\n2000;39(7):506\u201314.\n\n3. Convit J, Ulrich M, Fern\u00e1ndez CT, Tapia FJ, C\u00e1ceres-Dittmar G, Cast\u00e9s M,\net al. The clinical and immunological spectrum of American cutaneous\nleishmaniasis. Trans R Soc Trop Med Hyg. 1993;87(4):444\u20138.\n\n4. Machado P, Ara\u00fajo C, Da Silva AT, Almeida RP, D\u2019Oliveira Jr A, Bittencourt A,\net al. Failure of early treatment of cutaneous leishmaniasis in preventing the\ndevelopment of an ulcer. Clin Infect Dis Off Publ Infect Dis Soc Am.\n2002;34(12):E69\u201373.\n\n5. Mendonca SC, De Luca PM, Mayrink W, Restom TG, Conceicao-Silva F,\nDa-Cruz AM, et al. Characterization of human T lymphocyte-mediated\nimmune responses induced by a vaccine against American tegumentary\nleishmaniasis. Am J Trop Med Hyg. 1995;53(2):195\u2013201.\n\n6. De Luca PM, Mayrink W, Alves CR, Coutinho SG, Oliveira MP, Bertho AL,\net al. Evaluation of the stability and immunogenicity of autoclaved and\nnonautoclaved preparations of a vaccine against American tegumentary\nleishmaniasis. Vaccine. 1999;17(9\u201310):1179\u201385.\n\n7. Bertho AL, Santiago MA, Da-Cruz AM, Coutinho SG. Detection of early\napoptosis and cell death in T CD4+ and CD8+ cells from lesions of patients\nwith localized cutaneous leishmaniasis. Braz J Med Biol Res Rev Bras Pesqui\nM\u00e9dicas E Biol\u00f3gicas Soc Bras Biof\u00edsica Al. 2000;33(3):317\u201325.\n\n8. Da-Cruz AM, Bertho AL, Oliveira-Neto MP, Coutinho SG. Flow cytometric\nanalysis of cellular infiltrate from American tegumentary leishmaniasis\nlesions. Br J Dermatol. 2005;153(3):537\u201343.\n\n9. Hern\u00e1ndez-Ruiz J, Salaiza-Suazo N, Carrada G, Escoto S, Ruiz-Remigio A,\nRosenstein Y, et al. CD8 cells of patients with diffuse cutaneous leishmania-\nsis display functional exhaustion: the latter is reversed, in vitro, by TLR2\nagonists. PLoS Negl Trop Dis. 2010;4(11):e871.\n\n10. Da-Cruz AM, Bittar R, Mattos M, Oliveira-Neto MP, Nogueira R, Pinho-Ribeiro\nV, et al. T-cell-mediated immune responses in patients with cutaneous or\nmucosal leishmaniasis: long-term evaluation after therapy. Clin Diagn Lab\nImmunol. 2002;9(2):251\u20136.\n\n11. Barral-Netto M, Barral A, Brodskyn C, Carvalho EM, Reed SG. Cytotoxicity in\nhuman mucosal and cutaneous leishmaniasis. Parasite Immunol.\n1995;17(1):21\u20138.\n\n12. Brodskyn CI, Barral A, Boaventura V, Carvalho E, Barral-Netto M. Parasite-\ndriven in vitro human lymphocyte cytotoxicity against autologous infected\nmacrophages from mucosal leishmaniasis. J Immunol Baltim Md 1950.\n1997;159(9):4467\u201373.\n\n13. Coutinho SG, Pirmez C, Da-Cruz AM. Parasitological and immunological\nfollow-up of American tegumentary leishmaniasis patients. Trans R Soc Trop\nMed Hyg. 2002;96 Suppl 1:S173\u20138.\n\n14. Toledo VP, Mayrink W, Gollob KJ, Oliveira MA, Costa CA, Genaro O, et al.\nImmunochemotherapy in American cutaneous leishmaniasis:\nimmunological aspects before and after treatment. Mem\u00f3rias Inst Oswaldo\nCruz. 2001;96(1):89\u201398.\n\n15. da Santos C. S, Boaventura V, Ribeiro Cardoso C, Tavares N, Lordelo MJ,\nNoronha A, et al. CD8(+) Granzyme B(+)-Mediated Tissue Injury Versus CD4\n(+)IFN?(+)-Mediated Parasite Killing in Human Cutaneous Leishmaniasis.\nJ Invest Dermatol. 2013;133(6):1533\u201340.\n\n16. Gautam S, Kumar R, Singh N, Singh AK, Rai M, Sacks D, et al. CD8 T cell\nexhaustion in human visceral leishmaniasis. J Infect Dis. 2014;209(2):290\u20139.\n\n17. Nyl\u00e9n S, Gautam S. Immunological perspectives of leishmaniasis. J Glob\nInfect Dis. 2010;2(2):135\u201346.\n\n18. Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, et al. New\ngeneration vaccine induces effective melanoma-specific CD8+ T cells in the\ncirculation but not in the tumor site. J Immunol Baltim Md 1950.\n2006;177(3):1670\u20138.\n\n19. Hamann D, Kostense S, Wolthers KC, Otto SA, Baars PA, Miedema F, et al.\nEvidence that human CD8 + CD45RA + CD27- cells are induced by antigen\nand evolve through extensive rounds of division. Int Immunol.\n1999;11(7):1027\u201333.\n\n20. Hamann D, Baars PA, Rep MHG, Hooibrink B, Kerkhof-Garde SR, Klein MR,\net al. Phenotypic and functional separation of memory and effector human\nCD8+ T cells. J Exp Med. 1997;186(9):1407\u201318.\n\n21. Bretschneider I, Clemente MJ, Meisel C, Guerreiro M, Streitz M, Hopfenm\u00fcller\nW, et al. Discrimination of T-cell subsets and T-cell receptor repertoire\ndistribution. Immunol Res. 2014;58(1):20\u20137.\n\n22. Nakamura R, La Rosa C, Tsai W, Lacey SF, Srivastava T, Seidel A, et al. Ex vivo\ndetection of CD8 T cells specific for H-Y minor histocompatibility antigens\nin allogeneic hematopoietic stem cell transplant recipients.\nTranspl Immunol. 2014;30(4):128\u201335.\n\n23. Lopes MF, da Veiga VF, Santos AR, Fonseca ME, DosReis GA. Activation-\ninduced CD4+ T cell death by apoptosis in experimental Chagas\u2019 disease.\nJ Immunol Baltim Md 1950. 1995;154(2):744\u201352.\n\n24. Nunes MP, Andrade RM, Lopes MF, DosReis GA. Activation-induced T cell\ndeath exacerbates Trypanosoma cruzi replication in macrophages\ncocultured with CD4+ T lymphocytes from infected hosts. J Immunol Baltim\nMd 1950. 1998;160(3):1313\u20139.\n\n25. DosReis GA, Lopes MF. The importance of apoptosis for immune regulation\nin Chagas disease. Mem\u00f3rias Inst Oswaldo Cruz. 2009;104 Suppl 1:259\u201362.\n\n26. DosReis GA, Ribeiro-Gomes FL, Guillermo LVC, Lopes MF. Cross-talk between\napoptosis and cytokines in the regulation of parasitic infection.\nCytokine Growth Factor Rev. 2007;18(1\u20132):97\u2013105.\n\n27. Da-Cruz AM, Concei\u00e7\u00e3o-Silva F, Bertho AL, Coutinho SG. Leishmania-reactive\nCD4+ and CD8+ T cells associated with cure of human cutaneous\nleishmaniasis. Infect Immun. 1994;62(6):2614\u20138.\n\n28. Liew FY, Xu D, Chan WL. Immune effector mechanism in parasitic infections.\nImmunol Lett. 1999;65(1\u20132):101\u20134.\n\n29. Pereira-Carvalho R, Mendes-Aguiar CO, Oliveira-Neto MP, Covas CJF, Bertho\nAL, Da-Cruz AM, et al. Leishmania braziliensis-reactive T cells Are down-\nregulated in long-term cured cutaneous leishmaniasis, but the renewal\ncapacity of T effector memory compartments is preserved. PloS One.\n2013;8(11):e81529.\n\n30. Coutinho SG, Da-Cruz AM, Bertho AL, Santiago MA, De-Luca P. Immunologic\npatterns associated with cure in human American cutaneous leishmaniasis.\nBraz J Med Biol Res Rev Bras Pesqui M\u00e9dicas E Biol\u00f3gicas Soc Bras Biof\u00edsica\nAl. 1998;31(1):139\u201342.\n\n31. Brelaz-de-Castro MCA, de Almeida AF, de Oliveira AP, de Assis-Souza M, da\nRocha LF, Pereira VRA. Cellular immune response evaluation of cutaneous\nleishmaniasis patients cells stimulated with Leishmania (Viannia) braziliensis\nantigenic fractions before and after clinical cure. Cell Immunol.\n2012;279(2):180\u20136.\n\n32. Herbein G, Mahlknecht U, Batliwalla F, Gregersen P, Pappas T, Butler J, et al.\nApoptosis of CD8+ T cells is mediated by macrophages through interaction of\nHIV gp120 with chemokine receptor CXCR4. Nature. 1998;395(6698):189\u201394.\n\nFerraz et al. BMC Infectious Diseases  (2015) 15:74 Page 10 of 11\n\nhttp://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf?ua=1\n\n\n33. Bittar RC, Nogueira RS, Vieira-Gon\u00e7alves R, Pinho-Ribeiro V, Mattos MS,\nOliveira-Neto MP, et al. T-cell responses associated with resistance to\nLeishmania infection in individuals from endemic areas for Leishmania\n(Viannia) braziliensis. Mem\u00f3rias Inst Oswaldo Cruz. 2007;102(5):625\u201330.\n\n34. Schriefer A, Wilson ME, Carvalho EM. Recent developments leading toward\na paradigm switch in the diagnostic and therapeutic approach to human\nleishmaniasis. Curr Opin Infect Dis. 2008;21(5):483\u20138.\n\n35. Baars PA, Sierro S, Arens R, Tesselaar K, Hooibrink B, Klenerman P, et al.\nProperties of murine (CD8+)CD27- T cells. Eur J Immunol. 2005;35(11):3131\u201341.\n\n36. Meymandi SS, Javadi A, Dabiri Shahriar S, Meymandi MS, Nadji M. Comparative\nhistological and immunohistochemical changes of Dry type cutaneous\nleishmaniasis after administration of meglumine antimoniate, imiquimod or\ncombination therapy. Archives of Iranian Medicine. 2011;14:238\u201343.\n\n37. Mohajery M, Shamsian A, Mahmoodi M. Tc1 cells percentage in patients\nwith cutaneous leishmaniasis before and after treatment with glucantime.\nIranian J Publ Health. 2007;36:55\u201361.\n\n38. Oliveira F, Bafica A, Rosato AB, Favali CBF, Costa JM, Cafe V, et al. Lesion size\ncorrelates with leishmania antigen-stimulated TNF-levels in human cutaneous\nleishmaniasis. Am J Trop Med Hyg. 2011;85(1):70\u20133.\n\nSubmit your next manuscript to BioMed Central\nand take full advantage of: \n\n\u2022 Convenient online submission\n\n\u2022 Thorough peer review\n\n\u2022 No space constraints or color figure charges\n\n\u2022 Immediate publication on acceptance\n\n\u2022 Inclusion in PubMed, CAS, Scopus and Google Scholar\n\n\u2022 Research which is freely available for redistribution\n\nSubmit your manuscript at \nwww.biomedcentral.com/submit\n\nFerraz et al. BMC Infectious Diseases  (2015) 15:74 Page 11 of 11\n\n\n\n \n\n\n\tAbstract\n\tBackground\n\tMethods\n\tResults\n\tConclusions\n\n\tBackground\n\tMethods\n\tSubjects\n\tCollection and processing of tissue sample\n\tFlow cytometry\n\tCytometric Bead Array (CBA)\n\tStatistical analysis\n\n\tResults\n\tFrequencies of cell subsets in lesions of cutaneous leishmaniasis patients\n\tFrequencies of cell subsets expressing CD107a from lesions of cutaneous leishmaniasis patients\n\tContribution of cell subsets from the overall pool of CD107a+ cells\n\tCorrelation analysis of frequencies of CD107a+ cells with production of granzyme B, IFN-?, TNF and clinical features\n\n\tDiscussion\n\tConclusions\n\tAbbreviations\n\tAcknowledgements\n\tFunding\n\tAvailability of data and materials\n\tAuthors\u2019 contributions\n\tCompeting interests\n\tConsent for publication\n\tEthics approval and consent to participate\n\tPublisher\u2019s Note\n\tAuthor details\n\tReferences\n\tAbstract\n\tBackground\n\tMethods\n\tResults\n\tConclusions\n\n\tBackground\n\tMethods\n\tStudy Groups\n\tEthics statement\n\tEx vivo and in?vitro phenotypic and apoptotic assays\n\tCell surface and apoptosis staining protocol\n\tFlow cytometry\n\tStatistical analysis\n\n\tResults\n\tFrequency of total and effector CD8+ T cells\n\tApoptosis of total and effector CD8+ T cells\n\tLeishmania braziliensis-reactive CD8+ T lymphocytes\n\tCorrelation analysis of effector and apoptotic-effector CD8+ T lymphocytes with lesion size\n\n\tDiscussion\n\tConclusions\n\tAbbreviations\n\tCompeting interests\n\tAuthors\u2019 contributions\n\tAuthors\u2019 informations\n\tAcknowledgements\n\tAuthor details\n\tReferences"}]}}}